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SUMMARY 
The incidence of kidney stones amongst South Africa's black population is rare. This is in 
contrast to the white population, whose stone rate is similar to that in Western society. Urine 
composition alone does not account for these differences. This thesis presents a study of the 
inhibitory role of the protein, urinary prothrombin fragment 1 (UPTFI ), and its biochemical 
characterisation in both population groups. 
In a preliminary study, the urine composition and inhibitory activity of urine and 
urinary macromolecules from healthy white and black subjects was compared using a 
spectrophotometric sedimentation assay, zeta potential measurements and particle size 
analysis. Results suggested greater inhibition by urinary macromolecules in the black group. 
UPTFI was isolated from calcium oxalate (CaOx) crystals and purified by reverse 
phase (RP)-high performance liquid chromatography (HPLC) from the urine of healthy white 
(WFl) and black (BFl) subjects. The identity of the purified proteins was confrrmed by 
Western blotting, N-terminal protein sequencing, matrix-assisted laser desorption ionisation 
time-of-flight (MALDI-TOF) mass spectrometry (MS), amino acid analysis and 2D sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE); these analyses did not 
indicate differences in the protein backbone from the two groups. However, alkaline amino 
acid analysis showed the presence of more y-carboxyglutamic acid (Gla) residues in BFI. The 
N-and 0-linked glycans were released by enzymatic and chemical reactions, respectively, and 
sequenced using exoglycosidase digestions in tandem with RP and weak anion exchange 
HPLC, as well as MS. These analyses demonstrated a high proportion of sialylated glycans on 
UPTFl and a greater number of sialic acid residues on BFI. Molecular modeling located the 
glycans on the protein's kringle domain and identified a potential mode by which 
crystallisation could be inhibited. 
The inhibitory activity of crystal matrix extract (CME) from healthy white and black 
subjects, of which UPTFI is the major component, was compared in synthetic urine. Using 
Coulter Counter and e4C]-oxalate deposition analysis, and scanning electron microscopy 
(SEM), CME was shown to inhibit CaOx crystal nucleation, growth and aggregation. These 
effects were greatest in the presence of the black group's CME. The activity of the purified 
proteins, WFI and BFI, were compared in a similar study and were shown to inhibit CaOx 
crystal growth and aggregation. The inhibitory effects were greatest in the presence of BFI. 
The activities of WFI and BFI were also compared in crystal slurries, prepared with either 
exogenous CaOx monohydrate (COM) or dihydrate (COD) crystals, using a 
spectrophotometric sedimentation assay and zeta potential measurements. The relative effects 
v 
of WFI and BFI were similar, but the potential of UPTFI to inhibit COM rather than COD 
aggregation was significantly greater. 
The activities of WFI and BFl were also compared in urine. A cross-over design was 
employed in which ultrafiltered urine from both population groups was dosed with WFI and 
BFI (at physiological concentrations). Coulter Counter and [14C]-oxalate deposition analyses, 
in conjunction with SEM, showed that both proteins promoted CaOx crystal nucleation, but 
inhibited its growth and aggregation. A synergistic relationship between UPTFI activity and 
urine composition was demonstrated, and BFI was found to be a more efficient inhibitor than 
WFI in their endogenous urines. 
Possible differences in urine crystal morphology and the proteins included therein were 
investigated in healthy white and black subjects, as well as in white stone-formers. Urinary 
CaOx crystals were precipitated and examined using SEM, and their hydrate compositions 
were determined by x-ray powder diffraction (XRD). The protein and UPTFI content of the 
urines and crystals were analysed by SDS-PAGE and Western blotting. A higher proportion of 
COM crystals were observed in the black subjects, compared with mainly COD in the white 
group. More of the black subjects' crystals included UPTFI than amongst the whites. 
Pure COM and COD crystals were precipitated from same urine of healthy white and 
black subjects, and similarly characterised and analysed for their protein content. COM 
crystals from black subjects contained mainly UPI'Fl but also osteopontin (OPN), whereas the 
same CaOx hydrate from white subjects included only UPTFI . COD crystals from both 
population groups included mainly OPN. The total amount of intracrystalline protein (per mg 
CaOx) was greater in the black subjects. 
In order to compare their response to dissolution and proteolysis, CaOx crystals from 
healthy white and black subjects were incubated in saturated and unsaturated CaOx buffers 
along with proteases. Crystals were examined by field emission SEM. Differences in the 
response of the typical CaOx hydrates from the two population groups were observed and 
these were consistent with a greater protective role in the black population. 
In this thesis, differences in the activity and structure of UPTFI from black subjects 
compared with whites were demonstrated. Different CaOx hydrates typically predominated in 
the two groups and these were associated with differences in the nature and amount of urinary 
proteins included therein, as well as their susceptibility to dissolution and proteolysis. All of 
these trends implicated UPTFl either directly or indirectly, and were consistent with the rarity 
of stones amongst the black population. Thus UPTF 1 appears to be a potential role-player in 
the protection of the black population from CaOx kidney stone disease. 
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CHAPTER I 
CHAPTER 1: INTRODUCTION 
Approximately 12 % of males in the Western world will have at least one kidney stone 
episode during their lifetime. The figure is only 5% amongst females (Blacklock 1982). 
The incidence of urolithiasis is similar in South Africa's white population. However, in the 
black population it is extremely rare (Modlin 1967, Whalley et a/. 1998). The 
exceptionally low incidence of stones in this group is well recognised and recent studies 
suggest that, while it may have increased slightly (Beukes eta/. 1987), the average figure 
is still below 1 % (Whalley et a/. 1998). The juxtaposition of a stone-prone and virtually 
stone-free population group provides a model scenario for the study of stone formation. 
1.1 Stone formation in South Africa 
The first recorded case of renal calculi in a black South Mrican was in 1927. Vermooten 
(1937) reviewed the Johannesburg General Hospital records for the period 1922 - 1935 
and reported that of 217 000 admissions, 273 white patients were treated for renal calculi 
compared with only one black patient. An x-ray of the black patient, a 30-year-old female, 
indicated the presence of a shadow in her ureter. The physician suspected that this was due 
to a ureteral calculus; however, further examination was refused and thus the diagnosis 
could not be conftrmed. Analysis of the typical diet ingested by the black population 
revealed that the diet was acid-ash based and contained high amounts of vitamin A and low 
levels of calcium (Vermooten 1937). This finding was of interest since a previous study 
reported a significant reduction in stone incidence following an intervention with a similar 
diet (Higgins 1935, cited by Vermooten 1937). 
Subsequently, a few proven cases of renal calculi in members of the black 
population were reported. The first such case was in 1948 (Lopis and Kaplan 1948) and a 
further two cases were reported three years later (Muskat 1951 ). However, the black 
patients afflicted in these cases were all born north of the South African border. Wise and 
Kark (1961) observed that calculi appeared to be more common in these areas than in 
South Africa itself, suggesting that geographical as well as racial factors may be implicated 
in the black South African's protection from stone disease. 
Data obtained from a Durban hospital between 1951 and 1959 conftrmed previous 
reports of the remarkably low incidence of stones amongst the black population in South 
Africa. Of the nearly half a million patients affected, only seven were locally-born blacks 
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(Wise and Kark 1961). This corresponds to an incidence ofO.OOl %. Even more striking is 
that only one of these cases involved a diagnosis as a primary calculus. Although 
predisposing factors such as urinary obstruction and bilharzia were equally common 
amongst South Africa' s Indian and black populations, primary and secondary calculi were 
still a hundred times less prevalent amongst blacks (Wise and Kark 1961 ). 
Modlin (1967) recorded the first comprehensive study of renal calculi amongst 
South African blacks. He hypothesised that urine composition may be responsible for the 
disparate stone incidences amongst the white and black populations. Comparison of their 
average twenty-four hour urine excretions indicated a significantly higher volume, 
osmolality, ionised calcium and sodium level in this group, while their total calcium, 
phosphate and citric acid levels and urinary pH were lower than the white population. 
Modlin (1 967) suggested that the higher sodium/calcium ratio in blacks might be an 
important factor in their protection from stone disease. He argued that sodium competed 
successfully with calcium ions in hydroxyapatite, thus preventing further growth by 
epitaxy and aggregation. A more recent study reported the same sodium/calcium trend in 
white and black subjects (Meyers et al. 1994 ). 
No further studies investigated the intriguing rarity of kidney stones amongst the 
black population until nearly twenty years later. Rodgers and De Klerk (1986) analysed 
urine specimens from four black stone-formers and detected a considerably lower 
sodium/calcium ratio for this group than that which has been reported by Modlin (1967) in 
black control subjects. This supported Modlin's hypothesis that a high sodium/calcium 
ratio may play a protective role in the black population. Crystalluria studies showed similar 
particle size distributions in white and black (male) control subjects (Rodgers and De 
Klerk 1986). However, interesting qualitative differences were observed with the aid of 
scanning electron microscopy. While conventional crystalluria such as calcium oxalate 
dihydrate (COD) crystals was observed in the urine of white subjects, black control 
subjects' urines were composed of copious crystalline salt deposits. These deposits were 
composed mainly of NaCl and KCl along with some mixed deposits containing Na, P, S, 
Cl, K and Ca ions. With the exception of KCl, these deposits were not observed amongst 
the black stone-formers. These observations were in agreement with the black control 
group's higher sodium/calcium ratio (Modlin 1967, Rodgers and De Klerk 1986, Meyers et 
al. 1994) and suggested a direct or indirect protective role for urinary salts in the black 
population. 
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The ultrastructure (Rodgers and De Klerk 1986) and composition (Beukes et a/. 
1987) of stones from black patients is similar to that of white stone-formers. Thus similar 
mechanisms of stone formation probably apply to the black population as to other ethnic 
groups. In a study of 1002 stones collected in the Bloemfontein area over a 15-year period, 
10 % of which were from black patients, Beukes and co-workers reported that the only 
difference in the stone composition of white and black patients was in the percentage of 
COD and struvite (Beukes eta/. 1987). The incidence of COD stones was three-fold higher 
amongst white stone-formers, whereas struvite had a five-fold higher incidence amongst 
blacks. 
Several studies have compared urine composition data of white and black subjects 
in order to identify differences which might account for the latter's lower stone incidence. 
The two most consistently reported differences are the black population' s lower calcium 
(Meyers eta/. 1994, Whalley eta/. 1998, Craig eta/. 2000, Rodgers and Lewandowski 
2002) and citrate excretions (Meyers eta/. 1994, Whalley eta/. 1998, Lewandowski eta/. 
2001, Craig eta/. 2000), followed by their lower sodium (Meyers eta/. 1994, Whalley et 
a/. 1998) and phosphate levels (Whalley et a/. 1998, Rodgers and Lewandowski 2002). 
Paradoxically, a low citrate excretion is associated with an increased risk of stone 
formation and thus urine composition alone does not appear to adequately account for the 
rarity of stones amongst South Africa's black population. However, several intrinsic 
factors have been reported in black subjects that may account for their relative protection 
from stone disease. These factors are: a lack of correlation between sodium and 
calcium/cystine excretions since the black population's higher urinary sodium is not 
associated with unfavourably high levels of urinary calcium and cystine (Whalley et a/. 
1998)~ a possibly lower oxalate absorption rate than the white population (Whalley et a/. 
1998, Lewandowski et a/. 2001 )~ and a possible different renal handling mechanism with 
respect to calcium and oxalate (Rodgers and Lewandowski 2002). 
A recent comparative study of white and black stone-formers demonstrated that 
while their urine compositions were similar, lithogenic risk factors such as metabolic 
disorders were less common and less severe amongst the black group (Whalley et a/. 
1999), thereby adding further intrigue to the phenomenon. In addition, the observation that 
none of the black stone-formers had a family history of urolithiasis suggested that genetic 
factors were less important in this population group. It is worth mentioning that the clinic 
at which the study was conducted attended only twenty-two black patients during the 
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ten-year period of the study, illustrating the remarkably low incidence of stones amongst this 
group. Despite the fact that health care is less accessible to South Africa's poorer black 
communities, the rarity of stone episodes amongst this group is sufficiently noteworthy to 
warrant interest and attention. 
1.2 Epidemiological factors 
In order to understand the processes involved in stone formation and thus appropriately address 
its study, a brief summary of its epidemiology is required. The difference in stone incidef:Ice in 
South Africa's two population groups suggests that race may be a factor. In addition to the 
black population in South Africa, several other groups have also been reported to show stone 
rarity, namely the Indians of Mexico, Peru, Ecuador and Bolivia (Finlayson 1974), Eskimoes 
(cited by Rodgers and Spector 1981) and Australia's aboriginal population (Scott 1990). 
Although they do not show the rarity to stone formation as the afore-mentioned groups, 
African Americans also show a lower incidence of kidney stones than the white population 
(Finlayson 1974, Soucie et al. 1994). It is surprising that, with the exception of the South 
African studies already mentioned, none of these populations have been the subject of intense 
investigation. 
Diet has frequently been cited as a possible explanation for the remarkably low stone 
incidence amongst South African blacks, and is an obviously important epidemiological factor. 
Thus, although a detailed discussion of diet is beyond the scope of this thesis, a brief summary 
of some of the key issues concerning diet is warranted. The increased consumption of animal 
protein in modern society (Blacklock 1982, Robertson and Peacock 1983) has been cited as a 
potential factor contributing to stone formation. However, most studies have focused on the 
role of dietary calcium and oxalate, both of which have an important role to play in 
determining CaOx. stone-forming potential. The most recent evidence suggests that an increase 
in dietary calcium (e.g. from dairy products) should be advised since it reduces urinary oxalate 
levels by binding oxalate in the gut (Curhan et al. 1993, 1997). Conversely, it appears that 
dietary oxalate should be reduced since the ingestion of oxalate-rich foods, such as rhubarb, 
spinach and beets, is associated with an unfavourable increase in urinary oxalate excretion 
(Massey et al. 1993). 
A factor related to dietary advice is that of fluid intake. Many scientists and clinicians 
regard this as the most important factor in controlling stone formation (Pak et al. 1980, 
V ahlensieck 1986). It is apparent that an increase in urine volume will decrease the 
concentration of stone-forming salts. Mineral water containing calcium and magnesium has 
been shown to have both therapeutic and prophylactic merit (Rodgers 1997). This is consistent 
with an earlier proposal that soft water, which contains low levels of 
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magnesium, may be associated with increased rates of stone formation in the south-eastern 
United States (Rodgers and Spector 1981 ). 
Blacklock (1982) proposed that dietary factors may be related to familial trends, 
and other authors have cited the possible role of genetic factors too. This is supported by a 
study in which a significantly higher frequency of renal calculi was observed amongst 
first-degree relatives of stone-formers than their more distant relatives (Resnick et a/. 
1968). However, Finlayson (1974) proposed that environmental factors might mediate 
genetic ones. Subsequently, comparisons of stone incidence based on geographical location 
have been extensively reported. It is likely that differences between stone rates amongst 
countries are related, in part, to their levels of development and economy (Blacklock 
1982). 
Variations in stone patterns within countries suggest that other factors, such as 
climatic variation, play a role. Increases in heat and humidity are often associated with an 
increase in stone risk (Blacklock 1982, Robertson and Peacock 1983, Scott 1990), possibly 
due to increased exposure to ultraviolet radiation and dehydration (Blacklock 1982). The 
south-eastern United States is an example of a so-called stone belt where the incidence of 
stones is significantly greater than elsewhere in the country. This is probably due to the 
region's excessive heat (Scott 1990), but also a lifestyle favouring the ingestion of large 
amounts of oxalate-rich iced tea (Rodgers and Spector 1981 ). Other epidemiological 
factors include infection, metabolic disorders and occupation, since higher rates of stone 
formation are found amongst those involved in less active occupations (Finlayson 1974). 
1.3 Physical chemistry of stone formation and inhibitors 
According to Robertson and Peacock (1983), most epidemiological factors induce changes 
in one or more urinary risk factors. These workers identified six important CaOx stone risk 
indicators on the basis of their ability to distinguish stone-formers from controls: increased 
calcium, oxalate and uric acid excretions; elevated pH; decreased volume; and decreased 
excretion of a group of inhibitors. The result of such changes would be an increase in 
urinary CaOx supersaturation, a prerequisite for crystalluria and thus CaOx stone 
formation (Robertson and Nordin 1982). 
However, while urinary supersaturation IS undoubtedly required for stone 
formation, it is insufficient in itself since both healthy and stone-forming subjects' urines 
are supersaturated and contain crystals (Werness eta/. 1981). Even in the unlikely event of 
the precipitation of all urinary oxalate and extremely rapid crystal growth, renal stone 
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disease is unlikely to occur via free crystalluria (Finlayson and Reid 1978). Thus particle 
retention, perpetuated by injury of the renal epithelium and the subsequent adhesion of 
crystals to the sticky glycocalyx, is both necessary and sufficient for stone formation 
(Finlayson et al. 1984 ). 
Crystallisation begins with the formation of nuclei in a supersaturated solution. 
This is a mechanism by which such a solution sheds its free energy as solid material (Hess 
and Kok 1996). Since urine is seldom sufficiently concentrated to ensure a reasonable rate 
of spontaneous or homogeneous nucleation, it is probable that nucleation usually takes 
place on a foreign surface, i.e. heterogeneous nucleation (Finlayson et al. 1984; Hess and 
Kok 1996). Once a crystal nucleus has reached a critical size, new crystal components are 
added to reduce the overall free energy. This mechanism is known as crystal growth. A 
third mechanism of crystal formation is the rapid sticking together of existing crystals to 
form larger particles, referred to as aggregation (Hess and Kok 1996). The latter 
mechanism is likely to be the more decisive one since growth is usually slow (Robertson 
and Nordin 1982) and thus aggregation is required to form crystals of a clinically relevant 
size (Kok et al. 1990). Furthermore, calculations based on nephron dimensions, 
supersaturation and growth rates, and the size increasing effects of crystal aggregation, 
indicate that the crystal size required for particle retention (as described above) is largely 
dependent on aggregation (Kok and Khan 1994 ). 
Three major theories have been expounded to explain the physical processes of 
stone formation . The first is the heterogeneous nucleation and epitaxy theory. As explained 
earlier, heterogeneous nucleation occurs in urine. This process can occur via epitaxial 
growth. Evidence for the latter mechanism is found in the characteristic mixture of 
crystalline salts detected in kidney stones due to the close fit of their crystal lattices, e.g. 
calcium oxalate (CaOx) and uric acid (Lonsdale 1968). Secondly, the matrix theory 
proposes that, similar to the organic matrix of all stones, the secretion of a matrix 
substance into urine provides a surface for mineralisation (Robertson and Nordin 1982, 
Ryall 1989). However, the growth of stones in ultrafiltered urine suggests that a matrix 
substance is not required for stone development (Ryall 1989), although it may still be 
important in determining the stone's physical properties. 
A third theory of stone formation draws on the discovery that urine from healthy 
subjects retarded the calcification of rat cartilage, whereas stone-formers' urine did not 
(Howard and Thomas 1958). The premise of the inhibitor theory is that inhibitory 
substances in normal urine prevent or reduce crystallisation. The corollary to this 
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hypothesis is that stones occur due to the absence of such ions in the stone-formers· urine 
(Robertson and Nordin 1982, Ryalll989). 
The study of small molecules such as pyrophosphate, citrate and magnesium as 
well as macromolecules, which include glycosaminoglycans and proteins (Worcester 
1996 ), are of considerable interest in view of their possible role in the inhibition of 
physical processes which direct stone formation. It is believed that inhibitors reduce crystal 
nucleation by chelating to calcium or oxalate ions, thereby reducing their supersaturation 
and thus the precipitation of CaOx crystals (Ryall 1997). Inhibition of growth is more 
likely to occur via the binding of inhibitor molecules to crystal surfaces, thus blocking 
growth in this direction (Fleisch 1990). Crystal aggregation may be inhibited by a change 
in the electrical surface charge of crystals which in turn alters their attractive and repulsive 
forces (Fleisch 1990), or by steric hinderance in the case of large molecules (Ryalll997). 
1.4 Urinary proteins 
Of the classes of inhibitors described, macromolecules are the most widely investigated 
today. Indeed, they may be responsible for most of the inhibitory activity measured in 
urine (Worcester 1996). Interest in the role of proteins in the pathogenesis of stones 
originated with the discovery that the organic matrix of kidney stones constitutes 2.5 % of 
its dry weight and is distributed throughout its structure (Boyce and Garvey 1956). A 
significant proportion of the matrix (about 64 %) is protein (King and Boyce 1959). Any 
material associated with a stone, and particularly in such a large proportion, is likely to 
have participated in its formation. However, while this finding may offer valuable insight 
into the mechanisms involved, analysis of the matrix has been problematic due to its poor 
solubility (Boyce et al. 1962). Another difficulty associated with the study of the stone 
matrix has been the uncertainty of its origin. The proteins and macromolecules included 
may be those usually present in urine or they may have been released from the urinary 
tract's epithelial lining as a results of injury caused by the stone itself (Doyle et al. 1991 ). 
Leal and Finlayson ( 1977) reported that physical adsorption alone could not 
account for the association of macromolecules with CaOx stones, implying that a specific 
mechanism must be involved. This finding provided support for the importance of 
accessing information on the role of these molecules in stone formation. Fortuitously, 
Morse and Resnick (1988) proposed a novel approach to the matrix dilemma. studying 
CaOx crystals which they precipitated from urine by adding calcium chloride and sodium 
oxalate (NaOx). The proteins associated with these crystals, which were visualised by 
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two-dimensional gel electrophoresis, were representative of normal urinary 
macromolecules and not those derived from secondary processes. Of particular interest was 
the finding that only a few of the numerous urinary proteins observed in urine was 
included in the CaOx crystals derived from the sample (Morse and Resnick 1988). 
Recent technological advancements in the fields of protein biochemistry and 
molecular biology have greatly increased scientists' ability to address the role of proteins 
in kidney stone formation. A summary of some of the important findings to date is 
presented here. 
Tamm-Horsfall Mucoprotein (THM), the most abundant protein in human urine, is 
synthesised in the kidney and excreted at between 20 and 200 mg per day. Monomeric 
THM has a molecular weight of 80 kDa, but the protein tends to self-associate (Worcester 
1996), a property to which its dual functionality has been attributed (Ryall 1997). The 
effect of THM on CaOx crystallisation has been extensively studied and a variety of 
conclusions reached, depending on the solution characteristics of the test media. At low 
ionic strength and high pH conditions, the protein is an effective inhibitor of aggregation, 
however, the inhibition decreases as these conditions are reversed (Hess et al. 1989). Its 
effect on aggregation is enhanced by the presence of citrate ions, but an increase in calcium 
concentration results in the promotion of aggregation by THM (Hess 1991 ). It has little 
effect on nucleation (Worcester 1996) or growth (Yoshioka et al. 1989, Grover et al. 
1998), and can actually promote nucleation at high ionic strength and low pH (Worcester 
1996). All of the afore-mentioned studies used inorganic solutions or seeded systems. 
However, THM' s ability to inhibit aggregation has been confmned in ultrafiltered urine at 
a concentration in its physiological range (Ryall et al. 1991). The small amount of THM 
present in calcium stones (Hess 1991) and its absence from CaOx crystals suggests that the 
protein does not adsorb to crystal surfaces (Doyle et al. 1991). In fact, steric hinderance 
has been proposed as the mechanism by which it reduces crystal aggregation (Ryall et al. 
1991). Molecular abnormalities in THM from stone-formers have been reported due to its 
polymerization and decreased solubility (Hess 1991) and yet, surprisingly, the same 
urinary concentration of THM has been reported in healthy and stone-forming subjects 
(Ryall 1997). A recent study demonstrated THM' s ability to coat exogenous CaOx 
monohydrate (COM) crystals incubated in whole urine, and thereby prevent their adhesion 
to renal cells (Kumar et al. 2003). THM also reduces COM crystal endocytosis by its 
action on renal epithelial cells (Lieske et al. 1999). Thus along with its ability to retard 
crystal aggregation, THM may play an important role in the prevention of stone formation. 
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Nephrocalcin was named in recognition of its analogy with the bone protein 
osteocalcin. Analogous to THM, it is known to polymerise and thus ranges in size from 
14 kDa, the monomeric form, to 60-68 kDa as a tetramer (Ryall 1997). Approximately 
1-20 mg is excreted in urine each day (Worcester 1996). Inhibition of nucleation, growth 
(Worcester 1996) and aggregation (Hess et al. 1989) has been shown to result from the 
presence of nephrocalcin in inorganic test solutions. Its effect on crystal growth is 
reportedly due to the blocking of potential growth sites via its binding to crystal surfaces 
(Worcester 1996); aggregation is reduced by induction of a negative charge on crystal 
surfaces (Hess et al. 1989). The protein's crystal binding ability also facilitates its role in 
the prevention of COM crystal adhesion to renal cells (Lieske et al. 1999). Nephrocalcin 
contains two to three y-carboxyglutamic acid (Gla) residues per molecule (Ryall 1997). 
These residues are probably responsible for its inhibitory activity since nephrocalcin 
isolated from stone-formers' urine and CaOx stones lacks Gla and exhibits diminished 
activity (Hess et al. 1989). Post-translational modifications such as phosphorylation and 
glycosylation may also be involved (Worcester 1996). Nephrocalcin's activity in urine has 
yet to be demonstrated. 
Another protein that has not yet been tested in urine is osteopontin. It was first 
named uropontin in recognition of its analogy with the bone mineral protein osteopontin 
(Shiraga et al. 1992). However, many subsequent authors have preferred the name 
osteopontin (OPN) and thus this trend will be followed in the present thesis. Urinary OPN 
presents as multiple bands by gel electrophoresis, probably ·due to its degradation by 
urinary proteases (Ryall et al. 2001a); the major band has been observed alternatively at 50 
(Hoyer 1994) and 67 kDa (Ryall et al. 2001a) by different workers using gel 
electrophoresis. Its urinary concentration has been reported at 3 mg/1, assuming a 
molecular weight of 50 kDa (Ryall 1997). Inhibition of COM crystal nucleation and 
growth has been effected by OPN in an inorganic system. This activity is reduced after 
dephosphorylation, suggesting that this post-translational modification may be important 
for its activity (Worcester 1996). OPN also acts as an inhibitor of COM crystal aggregation 
(Asplin et al. 1998) and its presence results in a phase transition from COM to COD 
crystals (Worcester 1996). In addition to its inhibition of crystallisation, OPN appears to 
reduce COM crystal adhesion to renal cells by coating the crystal surface (Lieske et al. 
1999). This was confirmed recently when OPN was detected on the surface of exogenous 
COM crystals incubated in whole urine (Kumar et al. 2003). The binding ability of OPN is 
presumably also responsible for its inclusion in CaOx crystals, where it is found 
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preferentially in COD (Ryall et al. 2001a). Surprisingly though, greater amounts of OPN 
have been observed in COD stones compared with those composed principally of COM 
(Hoyer 1994). 
A complex urinary protein that has received much attention is inter-a-inhibitor, a 
220 kDa protein (Atmani et al. 1996a) composed of two heavy chains covalently linked by 
the glycosaminog1ycan chondroitin sulphate to a light chain (Dawson et al. 1998b ). Most 
studies have focused on the 35 kDa light chain known as bikunin, previously referred to as 
uronic-acid-rich protein in view of its composition (Atmani et al. 1993). The inclusion of 
bikunin and its fragments in urine and CaOx crystals has been reported (Dawson et al. 
1998b); however, it was only detected in one of ten CaOx stones analysed (Dawson et al. 
1998a). Bikunin inhibits crystal nucleation, growth (Worcester 1996) and aggregation in 
inorganic systems (Atmani and Khan 1999), and the protein isolated from stone-formers' 
urine exhibits reduced activity to that obtained from control subjects (Atmani et al. 1996a). 
Of further interest is the demonstration that bikunin reduces the adhesion of COM crystals 
to renal cells (Ebisuno et al. 1999). This was recently confirmed when exogenous COM 
crystals were incubated in whole urine and bikunin was detected on the crystal surface 
(Kumar et al. 2003). Much less has been reported on bikunin's parent molecule, 
inter-a-inhibitor. However, crystallisation studies in inorganic systems indicate 
inter-a-inhibitor's ability to inhibit both crystal growth (Atmani et al. 1996a) and 
aggregation (Dean et al. 1999). Recently, the inclusion of its two heavy chains has been 
demonstrated in urine, CaOx crystals (Dawson et al. 1998b) and CaOx stones (Dawson et 
al. 1998a). Crystallisation studies using a seeded inorganic system also demonstrated that 
the lighter of the two heavy chains inhibit crystal growth and aggregation, although these 
effects were small (Dean et al. 1999). 
The final protein discussed, albumin, is also the second most abundant in urine. 
Albumin resolves as a 67 kDa protein by gel electrophoresis and is excreted at an average 
concentration of 2.40 and 2.66 mg per day in control and stone-forming subjects, 
respectively (Cerini et al. 1999). Urinary albumin has been shown to be a powerful 
nucleator in an inorganic test solution and results in a phase transition from COM to 
principally COD crystals. Promotion of nucleation, regarded as a protective mechanism 
due to its reduction in urinary supersaturation, was more pronounced in control subjects· 
urine. Polymeric forms of albumin were observed more frequently in control subjects than 
stone-formers; the 67 kDa monomeric form was observed in both groups (Cerini et al. 
1999). The effect of serum-derived albumin has also been tested in inorganic systems 
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where it appears to inhibit crystal aggregation (Ryall et al. 1991 ), but demonstrates no 
effect on growth (Grover et al. 1998). Albumin is included in CaOx crystals (Atmani et al. 
1996b), where it is found in greater quantities amongst stone-formers (Atmani and Khan 
2002), and in CaOx stones (Hoyer 1994). Unlike the other proteins described above, 
albumin does not affect COM crystal binding to renal cells (Lieske et al. 1999). 
Finally, the protein urinary prothrombin fragment 1 has received much attention 
and has attracted considerable interest. Since this protein was ultimately selected for 
rigorous investigation in the project described in this thesis, a detailed description of its 
properties follows. 
1.5 Urinary prothrombin fragment 1 
With the intention of studying proteins associated with the early stages of urinary 
crystallisation, Doyle and co-workers precipitated CaOx crystals from urine as described 
previously (page 7; Morse and Resnick 1988) using one-dimensional (instead of two 
dimensional) gel electrophoresis (Doyle et al. 1991). They, too, observed the selective 
inclusion of urinary proteins into CaOx crystals, and demonstrated that a 31 kDa protein 
was predominant. Believing that this protein had not been previously described, it was 
named crystal matrix protein (or CMP) in recognition of its origin. Although CMP 
appeared to be a minor constituent of urine, it clearly exhibited a remarkable a.ffiirity for 
CaOx crystals. Furthermore, higher levels of CMP were found in crystals from female 
subjects when compared with male subjects (Doyle et al. 1991). However, the same 
concentration was detected in the urine of males and females, probably reflecting 
differences in the crystal binding affinity of CMP in men and women (Dawson and Ryall 
1994 ). The possibility that CMP may be associated with the female population's lower 
stone incidence and the manifest potential of a urinary protein directly involved in the 
crystallisation process to influence the course of stone formation, led to further intensive 
scrutiny of CMP. 
Crystallisation studies of the crystal matrix extract (CME), of which CMP is the 
principal component, demonstrated this potential. In an inorganic solution and ultrafiltered 
urine, CME inhibited CaOx crystal growth and aggregation; the greater effect was on the 
latter mechanism (Doyle et al. 1995). The reduction in crystallisation induced by CME in 
the range 0.08 - 1.25 mg/1 for the inorganic solution and 1.25- 10.0 mg/1 for the 
ultrafiltered urine was dose dependent. One of the most noteworthy features of this study 
was the considerable reduction in crystal growth (65 %) measured in the inorganic solution 
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at the highest CME concentration. Under comparable conditions, previous macromolecule 
studies reported growth inhibition of less than 5% (Edyvane et al. 1986). The highly 
efficient inhibition of both crystal growth and aggregation by CME could not be accounted 
for by the cumulative effects of other previously reported proteins likely to be associated 
with the matrix extract. Thus, this observation suggested that the activity of CME might be 
largely attributable to its principal component, CMP (Doyle et al. 1995). 
In order to clarify the identity of the 31 kDa protein, CMP was isolated and purified 
from CaOx crystals by column chromatography and reverse phase (RP)-high performance 
liquid chromatography (HPLC) (Stapleton et al. 1993b). Protein sequencing of the first 
eleven N-tenninal amino acids by Edman degradation showed an 82 % sequence 
homology with the N-terminus of human prothrombin (PT). The relationship between 
CMP and PT was confirmed by Western blotting with a commercial PT antibody. This 
fmding established the first link between urolithiasis and blood coagulation proteins. 
Suzuki and co-workers independently confirmed CMP' s relationship with PT by amino 
acid composition analysis and Western blotting, but mistakenly identified CMP as the PT 
activation peptide, PT fragment 1+2 (PTF1+2) (Suzuki et al. 1994). However, subsequent 
comparison with a standard preparation containing both PTF1+2 and PT fragment 1 
(PTFl ), clarified the identity of CMP as a urinary form of PTFl (Stapleton and Ryall 
1995a). The protein appeared as a double band by gel electrophoresis in contrast to the 
sharp, single band of serum-derived PTFl, probably due either to alterations in the 
protein's molecular structure in the kidney or the action of other urinary components. 
In order to affirm the role of the Fl fragment of PT in stone formation and its 
possible prevention, the anatomical location (Stapleton et al. 1993a) and gene expression 
(Stapleton et al. 1998) of the protein was investigated. Immunohistochemical studies of 
human renal tissue samples and several other organs showed that its distribution was 
limited to the most lithogenic regions of the kidney, namely the epithelial cells of the thick 
ascending limb of the loop of Henle, the distal convoluted tub~e of the nephron and the 
maculae densae of involved nephrons, where it was found in greater quantities amongst 
stone-formers. PTFl was also observed in the liver although with different characteristics 
to the kidney (Stapleton et al. 1993a). It was initially speculated that urinary PTFl might 
be derived from the glomerular filtrate of plasma PT (Stapleton and Ryall 1995a). 
However, a polymerase chain reaction study demonstrated the presence of PTFl mRNA 
(messenger ribonucleic acid) in human kidney, spleen and liver sections. Expression in the 
liver was greater than in the kidney (Stapleton et al. 1998). This confirmed that PTFl was 
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produced by the human kidney and, along with its precise location within the renal system 
and its abundant and selective incorporation into urinary CaOx crystals, strongly suggested 
that this protein played an important role in determining the course of stone formation. 
Recent studies have demonstrated PT expression in rat kidney and liver, suggesting that in 
the absence of human tissue specimens, rats may be an appropriate choice for the 
investigation of possible therapeutic measures (Grover et al. 1999). In recognition of the 
human protein's identity, yet its subtle differences with the analogous fragment from 
plasma, CMP was renamed urinary prothrombin fragment 1, or UPTFl. 
Another important requirement if a protein is to fulfill a regulatory role in stone 
formation, is that it be present in the end product of this process, namely, the stone itself. 
Any protein involved in the physical process of stone formation, or its inhibition, is likely 
to be associated with it. The presence of UPTF1 in CaOx-containing stones satisfies this 
requirement (Stapleton et al. 1996). The absence of any detectable UPTF1 in struvite 
stones suggests that this association with CaOx stones may be elucidative rather than 
merely a product of injUI)' (and the subsequent release of the plasma protein PT) caused by 
the stone. Furthermore, the higher urinary pH in which struvite stones are usually observed 
suggests that the adsorption of UPTF1 onto the crystal surface may be pH dependent 
(Stapleton et al. 1996). 
Another vital property of UPTF1 provides convincing evidence that this protein 
might play an important role in stone formation. A study on the effect of UPTF1 on CaOx 
crystallisation in ultrafiltered urine demonstrated that it was a powerful inhibitor of both 
crystal growth and aggregation (Ryall et al. 1995). UPTF1 decreased crystal aggregation as 
well as the amount of CaOx deposition in a dose-dependent manner at nanomolar 
concentrations ( 1.25 - 10 mg/1 or 40.3 - 322 nmol/1, assuming a mass of 31 kDa). The 
lowest concentration tested in the crystallisation study equates approximately with the 
highest urinary concentration previously reported in healthy subjects using a 
radioimmunoassay (Bezeaud and Guillin 1984). Using this assay, UPTF1 was detected in 
all thirty-seven urines tested with concentrations in the range 0.9- 35.3 nmol/1. At its 
estimated physiological concentration of 1.25 mg/1, UPTF1 inhibited ccystal growth and 
aggregation by 25 and 22 %, respectively (Ryall et al. 1995). 
In order to gauge the relative activity of UPTF1, inhibition experiments were 
conducted comparing PTF1 with three other urinary proteins: THM, human serum albumin 
(HSA), and <X.t-microglobulin (a.1-m) (Grover et al. 1998). All except THM were derived 
from commercially available sources; THM was purified from urine due to its relative 
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abundance. The proteins were chosen due to their presence in CaOx stones and, except for 
THM, their association with CaOx crystals. Using an inorganic system and final 
concentrations of 32 nmolfl (which equates to 1 mg/1 UPTFl), the proteins reduced crystal 
aggregation in order of decreasing magnitude: PTFl, THM, HSA and a 1-m. Only PTFl 
reduced crystal growth. These results not only confirmed the effectiveness of UPTF 1 as an 
inhibitor of CaOx crystallisation, but also demonstrated its superiority on a molar basis in 
comparison with other potentially important urinary proteins (Grover et al. 1998). 
UPTFl's considerable effect on CaOx crystallisation is of interest in light of the 
elevated levels observed in the kidneys of stone-formers. It is possible that UPTFl is 
produced as a protective response in the stone-formers. UPTFl from this group may also 
be functionally defective, or perhaps not all of the PTFl produced by their kidneys is 
released into their urines (Stapleton and Ryall 1995b). Indeed, the amino acid composition 
of UPTFl from stone-formers is different to the protein from control subjects (Stapleton et 
al. 1998). 
Prior to its identification as UPTFl, amino acid composition analysis of CMP 
suggested the presence of several unusual amino acids referred to as Gla (Stapleton et al. 
1993b, Suzuki et al. 1994). Gla is formed by the addition of an extra carboxyl group to 
glutamic acid during post-translational modification of vitamin K-dependent proteins (of 
which PT is one). The Gla domain of UPTFl contains ten such residues and is located at 
the N-terminal region of the molecule. By way of its calcium binding ability, the Gla 
domain of UPTFl is responsible for its exceptional affmity for CaOx crystals (Stapleton 
and Ryalll995b). 
A study of several Gla-containing proteins by Romberg and co-workers showed the 
necessity of the Gla domain to their activity (Romberg et al. 1986). In order to investigate 
the possibility of such a structure-function relationship in UPTFl, in vitro activity studies 
were carried out using the intact PT molecule as well as several of its activation products 
(Grover and Ryall 1999). PTFl, PT fragment 2 (PTF2) and thrombin were tested in 
parallel with their parent molecule, PT, in an inorganic solution at fmal concentrations of 
16.13 nmolfl (this equates to a final PTFl concentration of 0.50 mg/1). PTFl was the most 
effective inhibitor of crystal growth and aggregation, followed by PT. The two fragments 
that lacked the PT Gla domain, namely PTF2 and thrombin, were the least effective 
inhibitors, suggesting that the inhibitory effects of PT and PTFl could be attributed to their 
Gla domain (Grover and Ryall 1999). The existence of this relationship in (ultrafiltered) 
urine was later confirmed (Grover and Ryall 2002). It has been proposed that the superior 
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activity ofPTF1 compared to PT was due to the former's greater charge/mass ratio (Grover 
and Rya111999, Grover and Ryal12002). 
The extent of y-carboxylation in UPTF 1 from urine and CaOx crystals has been 
investigated by two-dimensional gel electrophoresis and Western blotting (Buccholz eta/. 
1999). Most urine samples analysed in the study contained two isoforms ofUPTF1 in the 
low pi range (2.5 - 3.0), whereas the crystals incorporated these two charged variants as 
well as another three at slightly higher pi values. It is likely that the highly charged 
variants were present at lower concentrations in the urine samples and thus could not be 
detected by Western blotting. These results showed that most UPTF1 is found in a highly 
charged state corresponding to a high degree of y-carboxylation. Another study reported an 
approximate pi value of 4 for UPTFI (Stapleton eta/. 1996). 
Although the Gla domain of UPTF1 imparts its considerable inhibitory properties, 
the domain' s strong binding affinity for CaOx crystals also results in frequent 
underestimation of the protein' s urinary concentration (Ryall et a/. 2000). Crystalluria 
often occurs during urine collection as well as during storage (at 4 °C and -20 °C) prior to 
analysis. Thus, unless these crystals are dissolved before the assay, any UPTF1 associated 
with these crystals will be excluded from the protein determination (Dean et a/. 2000). 
Attempts to address this difficulty with measures such as ten-fold post-void urine dilution 
have been unsuccessful and thus no analytical method is currently available for the 
quantitation ofUPTF1 . 
The pilot study in which UPTF1 (or CMP as it was then known) was discovered 
was the first to suggest that the protein may be closely associated with CaOx crystals 
(Doyle eta/. 1991). Several years later, Fleming and co-workers fractured CaOx crystals 
precipitated from filtered urine, and demonstrated the presence of extensive channeling 
throughout their internal structure by field emission scanning electron microscopy 
(FESEM) (Fleming et a/. 1999). The internal detail was more evident after treatment with 
Proteinase K, but was not observed in the presence of a protease inhibitor cocktail or with 
crystals precipitated from ultrafiltered urine (Fleming et a/. 2000). Thus, it may be 
assumed that the erosion observed with the crystals derived from filtered urine must have 
resulted from the removal of protein, and thus that proteins form part of the internal 
ultrastructure of CaOx crystals, i.e. the proteins, including UPTFI, are intracrystalline 
(Fleming et a/. 1999). Similar FESEM results obtained by incubation of crystals in urine, 
showing the erosion of crystal margins and surface fissures, demonstrated that the 
formation of Cl)'Stals in urine might be a reversible process (Fleming eta/. 2000). 
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The visual evidence obtained by FESEM was recently confirmed by empirical data 
using x-ray synchrotron diffraction (Fleming et al. 2003). Higher nonuniform strain was 
observed in urinary CaOx crystals compared with crystals composed of pure mineral or 
those obtained from ultrafiltered urine. These results conclusively demonstrated the 
presence of intracrystalline proteins in urinary CaOx crystals. 
Studies of intracrystalline proteins in other biomineralisation systems provide 
insight into possible roles of UPTFI. Such proteins have been shown to direct crystal 
composition and shape, as well as to influence physicochemical features such as crystal 
binding ability and aggregability (Ryall et al. 2000). Crystals containing proteins 
distributed in continuous channels may also be more susceptible to digestion and 
degradation by intracellular proteases, thus providing a potential mechanism for their 
disintegration, dissolution and even removal by opsonins (Ryall et al. 2000, 2001b). 
Several studies have reported the rapid binding of COM (Riese et al. 1988, Lieske 
et al. 1995, Verkoelen et al. 1995) and COD (Lieske et al. 1996) crystals to cultured renal 
epithelial cells, and crystal adhesion to the renal epithelium is now widely regarded as a 
possible mechanism of stone formation. A recent study reported the presence of PTF 1 + 2, 
which contains the sequence of PTFl , on the surface of exogenous COM crystals 
incubated in whole urine. This demonstra~d the ability of PTFI to reduce COM crystal 
adhesion to renal cells by coating the crystal surface (Kumar et al. 2003). However, if 
crystals are endocytosed, their possible dissolution within lysosomal bodies (at acidic pH 
levels) may represent a protective mechanism (Lieske et al. 1999). Ryall has proposed that 
crystal binding to the cell surface, and their possible internalisation and disintegration, will 
be influenced by the nature and concentration of intracrystalline proteins (Ryall et al. 
2000). Thus, by implication, UPTFI may have a vital role to play in this process. 
In addition, the different affinity of UPTFl for COM and COD crystals is of 
interest While COM crystals contain mainly UPTFl , the protein' s concentration in COD 
intracrystalline space is reduced considerably (Ryall et a/. 200la). Since COM crystals 
exhibit a greater binding affinity for renal cells than COD (Wesson et al. 1998), the 
differential expression of UPTFl in these crystals may be of relevance to the 
v understanding of the crystal-cell binding mechanism. 
1.6 Urinary protein studies in black South Africans 
Research available to date on urinary proteins, as described, suggests that this field may 
offer insi~t into the pathogenesis of stone formation. The composition of urine and 
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lithogenic risk factors have not been conclusively shown to account for South African 
blacks' relative protection from stone disease, other factors are likely to be involved. The 
role of urinary proteins is an obvious area to be investigated. Indeed, studies involving 
THM and albumin have already commenced. 
THM isolated from the urine of white and black subjects have been shown to 
inhibit CaOx crystal nucleation in the black group· s urine, but had no effect on nucleation 
in the white group's urine (Craig et al. 1999). This suggests that the black population's 
urine milieu may enhance the inhibitory capacity of THM. Zeta potential measurements 
have demonstrated that THM (Craig et al. 2001) and albumin (Mensah eta/. 2003) from 
black subjects carry higher negative charges than the same protein obtained from white 
subjects. Thus these proteins in black subjects will exert stronger repulsive forces, which 
may result in greater inhibition of aggregation. This was confirmed by COM crystal 
sedimentation studies in which THM and albumin derived from black subjects 
demonstrated greater inhibition of COM crystal aggregation than the corresponding protein 
obtained from white subjects (Craig eta/. 2001, Mensah eta/. 2003). Comparison of the 
molecular weight, amino acid composition and tryptic digestion patterns of THM from 
white and black subjects have not revealed differences which might account for their 
distinct activities (Craig eta/. 2000). 
It seems possible that the more potent inhibitory activity of urinary proteins in 
South African blacks may contribute to their lower stone incidence. In particular, UPTFl 
appears to be a likely candidate in this context. The growing body of evidence that has 
emerged over the past twelve years on UPTFl strongly suggests that it may play a key role 
in an understanding of the processes involved in stone formation and, indeed, the 
requirements for its prevention. Thus, in view of the protein's apparent potential and the 
intriguing rarity of kidney stones amongst the black population in South Africa, a unique 
research opportunity presented itself. 
1.7 Objectives 
The hypothesis of this thesis was that differences in the physical structure and/or inhibitory 
properties of UPTFl from the white and black populations in South Africa contribute to 
their disparate incidences of kidney stones, and, specifically, the rarity of stones amongst 









To investigate the urine composition and relative inhibitory activity of urine and 
urinary macromolecules of healthy white and black subjects towards CaOx 
crystallisation; 
To isolate the CME from the urine of healthy white and black subjects; 
To compare the protein composition and inhibitory activity of the CME from healthy 
white and black subjects; 
To isolate and purify UPTFl from the urine of healthy white and black subjects; 
To characterise UPTFl from healthy white and black subjects; and 
To compare the inhibitory activity of UPTFl from healthy white and black subjects in 
both inorganic media and urine. 
In addition to the above-mentioned objectives, several other avenues of investigation 
emerged during the course of the study. Thus the following supplementary objectives were 
identified: 
• To compare the morphology of urinary CaOx crystals in healthy white and black 
subjects and white stone-formers, and the proteins included therein; 
• 
• 
To compare the relationship between urinary crystal morphology and UPTFl in 
healthy white and black subjects; and 
To compare the susceptibility of urinary CaOx crystals from healthy white and black 
subjects to proteolysis and dissolution. 
1.8 Thesis outline 
The results of the urine composition and urine inhibitory activity studies are presented in 
chapter 2. These results suggested that urinary macromolecules might provide insight into 
the rarity of kidney stones in South Africa's black population. Thus a detailed investigation 
of the CME (chapter 3) and its principal protein component, UPTFl (chapters 4- 8), from 
both population groups was conducted. The primacy structure of UPTFl from healthy 
white (WFl) and black (BFl) males was rigorously characterised. In addition, the 
glycosylation of WFl and BFl was compared with UPTFl isolated from white and black 
stone-formers (chapter 4). The inhibitory activities of WFI and BFl were compared in 
inorganic media as well as in ultrafiltered urine (chapter 5). The latter study employed a 
cross-over design in which each protein was tested in both population groups' urine. 
Chapter 6 presented investigations of the apparent differences in morphology of urinary 
crystals between the two population groups, along with the relative amounts of UPTFl and 
other proteins in urine and CaOx crystals precipitated therein. Furthermore, by preparation 
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of pure COM and COD crystals from the same urine, the relationship between crystal 
morphology and UPTFl was explored in both population groups (chapter 7). Finally, the 
possibility that differences in the susceptibility of urinary crystals to proteolysis and 
dissolution was investigated in the white and black populations (chapter 8). A summary of 
the major findings and conclusions drawn from these studies are presented in chapter 9. 
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CHAPTER 2 
CHAPTER 2: COMPOSITION & INHIBITORY PROPERTIES 
OF URINE & URINARY MACROMOLECULES 
2.1 INTRODUCTION 
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The remarkable difference between the incidence of kidney stones amongst South Africa's 
white and black populations is now well recognised. Thus identification of urinary 
parameters or inhibitory properties which distinguish the stone-prone white group from the 
stone-free black group is an intriguing challenge. As outlined in chapter I, studies to date 
have addressed urine composition and have reported several noteworthy findings. 
Examples are the black population's lower urinary calcium (Modlin 1967, Whalley eta/. 
1998, Rodgers and Lewandowski 2002), citrate (Modlin 1967, Meyers et a/. 1994, 
Whalley et a/. 1998, Lewandowski et a/. 2001 ), phosphate and urate excretions (Rodgers 
and Lewandowski 2002), higher urinary oxalate excretion (Lewandowski eta/. 2001) and 
higher urinary pH (Rodgers and Lewandowski 2002). Paradoxically, the low citrate and 
higher oxalate are associated with an increased risk of stone formation. 
Howard and Thomas (1958) first reported the inhibitory properties of human urine 
more than forty years ago. They demonstrated that urine from healthy subjects inhibited 
the calcification of rat cartilage more effectively than that of stone-formers. However, to 
date no studies have compared the inhibitory properties of the white and black populations' 
urine in an attempt to explain the latter group' s low stone incidence. 
Robertson described CaOx urolithiasis as the result of an inequality between the 
opposing forces of supersaturation and inhibitory activity in urine (Robertson et a/. 1976). 
Several workers have suggested that it is inhibitory activity that distinguishes 
stone-forming and healthy individuals (Ryall eta/. 1986, Kok eta/. 1990, Asplin eta/. 
1999) since both groups' urines are supersaturated with calcium salts (Wemess et a/. 
1981 ). A study by Asplin confirmed this postulate, showing that inhibition experiments 
were good discriminators between stone-forming and healthy individuals whereas routine 
urine chemistry and supersaturation data were similar in the two groups (Asplin eta/. 
1999). 
Since crystal aggregation is acknowledged as more important than growth in 
determining stone formation (Kok et a/. 1990, Hess and Kok 1996), adequate control of 
this process would appear to be essential for protection against stone formation. Thus, an 
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objective of this thesis was to investigate the two population groups with respect to urinary 
inhibition of aggregation and then to compare these trends with their urine compositions 
and supersaturation levels. In this chapter, crystallisation experiments involving urine and 
macromolecular urine extracts from black and white subjects are described. 
2.2 METHODS 
Inhibitory activity of urine 
2.2.1 Urine collection and treatment 
Twenty-four hour urine samples were collected in plastic bottles containing a boric acid 
preservative (5 g per 24-hr urine). The subjects were five black and five white males 
(respective ages 21- 25 and 19-27 years) on their free unrestricted diet and with no 
previous history of kidney stones. Urines testing positive for haematuria or nitrite using 
urinalysis test strips (Medi Test Combi 5N, Macherey-Nagel) were excluded. Each urine 
was filtered through a 0.75 11m pre-filter followed by a 0.45 11m nitrocellulose filter paper 
before use. 
Aliquots of each sample were retained for urinalysis. Calcium, magnesium, sodium 
and potassium were analysed using a Varian 1275 Model (Australia) flame atomic 
absorption spectrometer (Willis 1967, Trudeau and Freier 1967, Fernandez and Kahn 
1971 ). Oxalate and citrate were quantified using enzymatic assays: oxalate was analysed 
using oxalate decarboxylase and an ascorbate oxidase spatula was used to remove L-
ascorbic acid (Chiriboga 1963), while citrate was determined by citrate lyase conversions 
to oxaloacetate (Gruber and Mollering 1966). Inorganic phosphorus was determined using 
ammonium molybdate (Dryer and Routh 1963), creatinine was determined using picric 
acid (Rocket a/. 1986) and uric acid using uricase (Fossati eta/. 1980). Analytical kits 
were used for these determinations (Boehringer Mannheim; oxalate kit: Sigma). Chloride 
was determined using a chloride sensitive electrode. 
The urinary relative supersaturations of CaOx, brushite and uric acid were 
calculated using the programme EQUJL2 (Wemess et a/. 1985). The terms relative 
supersaturation and supersaturation are used synonymously in the literature and this 
approach was adopted in the present thesis. Urine composition data was analysed 
statistically by analysis of variance (ANOVA) and the results considered statistically 
significant if p ~ 0.05. Average values and their standard errors (SE) are reported. The 
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reasonable assumption was made that the two groups had equal variances and thus the 
variances were pooled 
2.2.2 Preparation and characterisation of calcium oxalate monohydrate crystals 
COM crystals were prepared according to Pak et al. (1975). Equal volumes ofO.OlO mol/1 
CaCh and 0.010 moVI NaOx solutions were mixed at a constant rate of 1 mVmin using a 
peristaltic pump while stirring. The mixture was then stirred for 7 days at 10 °C after which 
the crystals were collected by filtration (0.22 ~). The crystals were dried at 37 °C for at 
least one hour and then verified by x-ray powder diffraction (XRD) and thermogravimetric 
analysis (TGA). The crystals were also viewed by scanning electron microscopy (SEM). 
2.2.2.1 X-ray powder diffraction 
The crystal powder pattern was measured using a Philips PW1050/25 goniometer with 
nickel filtered CuKa radation (A.= 1.51418 A) produced at 40 kV and 25 rnA. Ideally, the 
specimen should be a homogeneous powder of constant particle size in which the material 
has no preferred orientation as this reduces the likelihood of erroneous relative intensities 
(Jenkins and de Vries n.d., Glasser 1977). Since fine grinding greatly reduces the 
contribution of this factor (Klug and Alexander 1974}, the sample was ground with a pestle 
and mortar prior to analysis. 
The powder was placed in an aluminium holder and a scan of the relative intensity 
of reflected x-rays as a function of the Bragg angle (29) was recorded between angular 
limits of 12-40 ° for each sample. The angle which coincided with the maximum of the 
prominent peaks was converted to its corresponding d-spacing using a standard table for 
Cu Ka radiation (Parrish and Mack 1963). These d-spacings were then compared with 
standard reference values (Table 2.1, page 28) for COM, COD and CaOx trihydrate (COT) 
crystals (Sutor and Scheidt 1968, Deganello et al. 1981). 
Intensities can be influenced by several factors such as crystal motion (Klug and 
Alexander 1974}, the theta angle and the path distance of x-rays (Jenkins and de Vries 
n.d.). A detailed ~alculation of the corrected intensity is possible by taking into account 
many of these factors, but this practice is seldom used for routine analyses such as the 
determination of crystal phases (Jenkins and de Vries n.d.). The accuracy of the method is 
thus limited to no more than 5 % (Glasser 1977). 
In the present study the percentage composition of the crystals was determined 
semi-quantitatively on the basis of calculated d-spacings and estimation of relative peak 
intensities, rather than by detailed calculation. 
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2.2.2.2 Thermogravimetric analysis 
For thermogravimetric analysis, crystals (4 mg) were heated from 40 °C to 200 °C at a rate 
of 10 °C per minute (Perkin Elmer PC7 system). A plot of weight percentage versus 
temperature was obtained from which the percentage change in weight was determined. 
This mass loss was then correlated to the number of water molecules in the original 
compound. 
Table 2.1: lnterplanar spacings and relative intensities of powder patterns of calcium 
oxalates 
5.93 100 8.70 12 7.87 40 
5.79 25 6.31 } 6.70 20 4.64 7 6.15 100 5.50 100 
4.52 6 4.40 45 5.28 40 
3.78 } 3.89 14 4.99 60 3.76 13 3.67 8 4.79 20 
3.65 100 3.58 1 4.02 20 
3.00 10 3.38 2 3.75 20 
2.97 46 3.15 "'I 3 3.67 40 
2.91 12 3.09 3.62 60 
2.89 10 3.07 >- 18 3.58 10 
2.84 14 2.81 • 20 3.43 20 
2.51 2 2.77 3.35 10 
2.48 30 2.75 >- 85 3.26 20 
2.41 5 2.41 .. 14 2.84 100 
2.37 2 2.39 14 2.77 80 




• Sutor and Scheidt 1968; • • Deganel/o et al. 1981 
2.2.2.3 Scanning electron microscopy 
Crystals (0.1 mg) were retrieved on filter papers (0.22 ~m) which were glued onto 
aluminium stubs and coated with a single layer of Au/Pd. The crystals were examined 
using a Leica S440 scanning electron microscope (Leica Cambridge Ltd , Cambridge, 
England) operating at an accelerating voltage of 10 kV, a working distance of 10- 15 mm 
and a probe current of 20 - 30 pA 
2.2.3 Sedimentation rates 
2.2.3.1 Preparation of COM crystal slurries and slurry I urine mixtures 
COM crystal slurries were prepared for sedimentation experiments by the addition of 




aminomethane(Tris).HCl, 0.090 mol/1 NaCl (pH 7.2) (Hess et a/. 1989). Crystal slurries 
were equilibrated overnight (at least 16 hours) at 37 °C with stirring (1100 rpm) to ensure 
that equilibration saturation had been achieved. 
After filtration, urine samples from white and black subjects (referred to as WU and 
BU, respectively) were dialysed (10 kDa membrane cut-oft) extensively against the same 
buffer used to prepare the slurries and passed through a 0.22 ~m filter. The slurries were 
then mixed with the appropriate volume of urine to achieve a fmal dilution of 1:2 (urine to 
crystal volume) and equilibrated for 2 hours at 37 °C at 1100 rpm. 
2.2.3.2 Measurement of COM crystal sedimentation rates 
The equilibrated mixtures were transferred to a 10 mm glass cuvette and placed in a 
spectrophotometer (Unicam Helios, Merck, Johannesburg) fitted with a water circulation 
system and a stirrer attachment. The absorbance was then monitored at 620 nm and 37 °C 
for 10 minutes (Hess et a/. 1989). Such plots will henceforth be referred to as an OD62o 
plot; a typical example is shown in Figure 2.1 below. 
1.0 ~ 
0.8 -t-<...,.,.~---------------l 
0.6 ............. \ 
t ~ M" amorbance slope 
stopped stirring 0.4 \ 
0.2,--,'\~-~-;;;;;t 
0.0 +-----,--->---,r----~-----i 
0 150 300 450 600 
Time (s) 
Figur e 2.1: Typical sedimentation rate plot (or ODno plot) 
Crystal aggregation was induced by slow stirring at 722 rpm until the system was stable 
and equilibrium had been reached again, demonstrated by a stable absorbance for at least 
10 seconds. Stirring was then stopped so that the sedimentation rate of crystals indicated 
by a decrease in absorbance could be monitored. Since no further growth or dissolution 
was possible in the system because it was at equilibrium, the slope of the linear decrease in 
absorbance (shown by a straight line in Figure 2. I and henceforth referred to as the 
absorbance slope) could be directly related to the degree of crystal aggregation of the 
sample. The degree of aggregation of each test mixture {i.e. urine- slurry dilution) was 
calculated by the ratio of the slope of the test sample's (Sr) absorbance vs. time graph and 
the slope of the equivalent graph for the control COM slurry (Sc). The percentage 
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inhibition of aggregation (IA) was determined from the formula: IA = 100- [100 x (Sr/Sc)] 
(Hess et al. 1989). 
2.2.3.3 Verification of sedimentation rates method 
Since the sedimentation method had not been previously employed in the author's 
laboratory, a series of urine: crystal dilutions (1:1, 1:2, 1:4, 1:8, 1:16) was tested using a 
single 24-hour urine obtained from a white male (27 years). These results were compared 
with those published by Hess et al. (1989) in order to verify the methodology. For these 
experiments, a slow stirring speed of 722 rpm was used since the experimental data 
obtained was most similar to published data obtained by Hess and co-workers at 500 rpm 
(Hess et al. 1989). 
2.2.3.4 Statistical analysis 
The slope of each absorbance versus time plot was determined by linear regression 
analysis. The square of the Pearson product moment correlation coefficient (R 2) 
corresponding to the slope is reported for these analyses. The average slopes for the WU 
and BU-dosed COM slurries were compared statistically by ANOV A, and standard errors 
are reported. Results were considered statistically significant ifp :S 0.05. 
2.2.4 Zeta potentials 
2.2.4.1 The concept of zeta potential 
The extent of adhesion between particles can be defined as the difference between the sum 
of the cohesive van der Waals and viscous binding forces and the repulsive electrostatic 
forces between them (Finlayson 1976). The latter is defined as the electrical potential at the 
interface of a layer of chemically adsorbed ions on a crystal surface and the diffuse double 
layer of oppositely charged ions surrounding this, more frequently referred to as zeta 
potential (Scurr and Robertson 1986a). Zeta potential is regarded as the main driving force 
favouring disaggregation (Hess and Kok 1996). Curreri et al. (1979) were the first to 
postulate that small molecular weight molecules that inhibited crystal aggregation may do 
so by modification of the crystal zeta potential. Finlayson (1976) later suggested that 
polyanionic macromolecular inhibitors also employ this mechanism. However, the 
presence of hydrophilic regions in these molecules (for example, proteins) results in 
competition by viscous binding forces and the electrostatic forces, thereby increasing the 
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probability of crystal adhesion rather than repulsion (Scurr and Robertson 1986b ). It has 
been shown that trends towards more negative zeta potentials correlate well with an 
increase in inhibition of aggregation in certain molecules (such as heparin, THM and 
macromolecular extracts isolated from urine) (Scurr and Robertson 1986b ). Practically, 
zeta potential may thus be regarded as an indicator of the potential of a compound to 
reduce aggregation by the action of its repulsive negative charge. 
2.2.4.2 Preparation of COM crystal slurry I urine mixtures 
COM crystal slurries were prepared for zeta potential experiments by the addition of 
0.3 mg/ml COM crystals to a 0.010 mol/l sodium acetate buffer (pH 5.7). The ratio of 
urine to crystal slurry volume used was 1:2. Crystal slurries were then treated in the same 
way as described for the sedimentation experiments (paragraph 2.2.3.2) except that slurries 
were incubated at 25 °C (since the instrument measures zeta potential at this temperature). 
2.2.4.3 Measurement of zeta potentials 
After equilibration, the surface charge of each crystal slurry was determined in triplicate by 
measuring its zeta potential (m V) using a Zetasizer 4 (Malvern, England). The average 
percentage decrease in zeta potential of each test sample (ZT), i.e. slurry I urine mixture, 
relative to its COM slurry control (Zc) was calculated using the following formula: 
100 X [(ZT- Zc)/Zc). 
2.2.4.4 Statistical analysis 
The average zeta potential of the WU and BU-dosed slurries were compared by ANOV A 
and standard errors are reported. The results were considered statistically significant if 
p ~ 0.05. 
Inhibitory activity of macromolecular urine extracts 
2.2.5 Urine collection. preparation and treatment 
Twenty-four hour urine samples were collected from ten black and ten white males 
(respective ages 20-25 and 19-21 years) with no previous history of stone disease and 
were treated as described in paragraph 2.2.1 (page 26). An aliquot of each urine was 
retained for protein determination. Of the 20 urines, ten randomly-chosen urines 
(five black and five white subjects) were used for further experiments. These samples were 
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dialysed (10 kDa membrane cut-oft) extensively against distilled water and freeze-dried to 
yield the macromolecular urine extract (MM). Each MM was reconstituted in a minimum 
volume of distilled water for use in the inhibitory activity study. The protein concentration 
of each MM was redetermined prior to the activity study since protein may have been lost 
during dialysis. 
2.2.6 Determination of urinary protein concentration 
The protein concentration of each urine was determined using the Bradford method 
(Bradford 1976). An aliquot of each sample (800 ~1) was added to a Bio-Rad protein assay 
solution (200 ~1) (Bio-Rad) and incubated at room temperature for 5 minutes. The 
absorbance was measured at 595 nm and compared to a triplicate standard curve obtained 
using bovine serum albumin in the range 1 ~glml - 10 ~glml. The slope of the standard 
curve and R2 value corresponding to the slope were determined by linear regression 
analysis. 
2.2. 7 Preparation of synthetic urine and metastable limit determination 
A synthetic urine (SU) was prepared according to the method of Burns and Finlayson 
(1980) for an inhibitory activity study. Six salts were dissolved in the given sequence in 
distilled water at the following final concentrations: 0.106 mol/l NaCl, 0.0323 mol/l 
NaH2P04, 0.00321 molll Na3CJ!sCh.2H20 , 0.00385 molfl MgS04.1H20, 0.0170 mol/1 
Na2S04 and 0.0637 mol/l KCl. Care was taken to ensure that each salt had dissolved 
completely before the next one was added to the mixture. A separate solution of 
CaCh.2H20 was added to the mixture with stirring at a final concentration of 5. 75 mmol/1 
followed by the slow addition of a NaOx solution at a final concentration of 0.318 mmol/1. 
The pH was adjusted to 6.2 by addition of 0.148 g ~Cl and 716 ~1 of 5 mol/l ~OH 
per 100 ml of SU. The final solution was stored at 4 °C for a maximum of 5 days and 
filtered through a 0.22 ~m filter paper before use. 
Difficulties were encountered with the above preparation. Firstly, the solution 
frequently became (irreversibly) cloudy during the preparation stage if the NaOx solution 
was added too quickly or the pH was allowed to exceed 6.2 while adjusting with ~OH. 
Secondly, the solution remained stable for a maximum period of only 5 days before salts 
began to precipitate (indicated by an opaque appearance). 
The CaOx metastable limit (MSL) of the synthetic urine was determined. This is 
the concentration at which a solution of CaOx is in a state of metastability or 
supersaturation and above which spontaneous crystallisation will occur (Ryall eta/. 1985). 
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A measure of the MSL is obtained by challenging the urine to crystallise with increasing 
doses of NaOx and monitoring the effect on particle number. A low MSL indicates 
relative ease of crystallisation. 
The CaOx MSL of the synthetic urine was measured using a Coulter Counter I 
(Beckmann, Johannesburg) fitted with a 140 11m orifice (2.8- 90.0 11m particle size range) 
according to the method described by Ryall et al. (1985). For this determination, 8 ml 
aliquots of synthetic urine were incubated in plastic Coulter cups in a shaking water bath 
(100 rpm) at 37 °C. The samples were dosed with 80 111 NaOx of increasing concentrations, 
ranging from 15 mmol/1 to 195 mmol/1 in increments of 15 mmol/1. After a 30-minute 
incubation period, the particle number at each concentration was measured in duplicate and 
a plot of particle number versus NaOx concentration was constructed. From this plot, the 
exogenous NaOx concentration above which spontaneous crystallisation occurred 
(indicated by a sudden increase in particle number) was determined and was taken as a 
measure of the urine's MSL. A typical plot is shown in Figure 2.2 below. The MSL is 
equivalent to 120 mmol/1 NaOx and thus a concentration exceeding this value (at 1% of 









E = = 
20000 - -- --- - - ---- -
15000 
10000 
~ equivalent to M~ 
-~ 5000 +--- ----- ---:, .----J-------1 
. g., ' 
15 45 75 105 135 165 195 
[NaOxl (mmol/1) 
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2.2.8 Particle size distribution determination 
Aliquots of synthetic urine (10 ml each) were pipetted into glass conical flasks and dosed 
with 100 111 NaOx at a concentration 30 mmol/1 in excess of the previously determined 
MSL to produce adequate crystallisation (Ryall et al. 1985). Five aliquots were retained as 
control samples, five were dosed with MM obtained from white subjects (referred to as 
WMM) and five were dosed with MM obtained from black subjects (referred to as BMM). 
Control and MM-dosed urines were dosed with the same NaOx concentration. The final 
MM concentration was equivalent to the protein concentration of the filtered urine from 
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which the MM was derived. The control and MM-dosed urines were then incubated at 
37 °C in a shaking water bath (100 rpm) for 120 minutes after which the particle size 
distributions were measured using a Coulter Counter I. 
2.3 RESULTS 
Inhibitory activity of urine 
2.3.1 Characterisation of calcium oxalate monohydrate crystals 
The composition of the CaOx crystals prepared according to the method described by Pak: 
et a/. (1975) was verified by XRD, TGA and SEM. The XRD pattern of the crystals 
together with the d-spacings (A) of prominent peaks is shown in Figure 2.3. The 
assignment of these peaks is shown in Table 2.2. All peaks corresponded with known 
COM reflections (refer to Table 2.1 on page 28 for a standard reference table). 
Figure 2.3: X-ray powder diffraction pattern of CaOx crystals prepared according 
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Table 2.2: X-ray powder diffraction peak assignments and percentage composition of CaOx 
crystals prepared according to Pak et aL (1975) 
d- pacing Assignment 
' 
( ) 
' I • 
5.90 COM 
3.64 COM 






The TGA spectrum of these crystals is shown in Figure 2.4 and indicates the decrease in 
weight (%) of the crystals as a function of temperature. The experimental mass loss of 
12.24% (at an onset temperature of 103.4 °C) corresponded closely with the theoretical 
value of 12.32% for the loss of one water molecule associated with a single CaOx 
molecule. XRD and TGA thus confirmed that the crystals were composed of 100 % COM, 
as required for the slurry studies. 
Figures 2.5.1 - 2.5.2 show scanning electron micrographs of the CaOx crystals at 
different magnifications. Small crystals ( -4 ~m in diameter) of ill-defined morphology 
were observed and were thus inconclusive in demonstrating CaOx hydrate morphology. 
Figure 2.4: Thermogravimetric analysis of CaOx crystals prepared 
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Figure 2.5: Scanning electron micrographs of calcium oxalate crystals prepared according to 
Pak et aL (1975). The photographs were taken at the following magnifications: lOK (Fig 2.5.1) and 
12K (Fig 2.5.2). 
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2.3.2 Sedimentation rates 
Figure 2.6 shows the 00620 plots of a COM crystal slurry before and after the addition of 
urine at various dilutions. A gradual increase in the absorbance slope was observed as the 
urine to crystal ratio was increased from 1: 1 to 1:16. The absorbance slopes and 
corresponding percentage inhibition of aggregation relative to the COM slurry control for 
and corresponding percentage inhibition of aggregation relative to the COM slurry control 
for each dilution are presented in Table 2.3. The data demonstrated that inhibition of 
aggregation CIA) decreased as the ratio of urine to crystal slurry increased. 
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Figure 2.6: ODm plots of COM crystal slurries after 
addition of urine at l'ltrious dilutions 
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Fipre 2.7: % Inhibition of aggregration by urine in 
COM crystal slurries at various urine dilutions 
Table 2.3: Absorbance slopes and inhibition of aggregation (lA %) of COM crystal slurry by 
urine at various dilutions 
Ji:l ··•··.· .. . . ... . 0.97 0.97 0.98 0.97 0.95 0.95 
~~y.{(: + •• ::n)w; ,,. ·.:·:": 40.9 22.1 11.4 -75.o -47.7 
This trend is clearly shown in Figure 2.7. The concentration dependent increase in lA was 
similar to that reported by Hess et al. (1989), except that a sharper decrease in inhibition 
between I: I and I :4 dilutions was observed by Hess (approximate lA: 65 % for I :2 and 
50 % for 1:4 dilutions) than in the present study. However, the trends were sufficiently 
similar to verify that the method provided adequate results using the author' s system. The 
1:8 and 1:16 dilutions were omitted from the lA plot in Figure 2.7 and were not considered 
for use in further experiments since negative inhibition data was obtained (suggesting 
promotion of aggregation). 
Figure 2. 8 shows a plot of the average rate of decrease in absorbance ( 620 nm) of a 
COM crystal slurry in the absence and presence of urine from white and black subjects at a 
urine to crystal dilution of 1:2. The individual experiments from which these averages were 
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obtained are shown in Appendix A (COM: Figure AI. page A4; COM+WU: Figures 
A2.1 - A2.5, page A5; COM+BU: Figures A3.1 - A3.5, page A6). It was apparent from 
Figure 2.8 that the sedimentation rate of the COM crystal slurry was considerably reduced 
by the addition of urine from both white and black subjects (indicated by a more gradual 
slope). while the effect of the two group's urine appeared to be similar in this regard 
(indicated by the equal slopes). The absorbance slope and inhibition of aggregation data for 
each white and black subject is shown in Tables 2.4 and 2.5., respectively. All subject's 
urine reduced the absorbance slope of the COM crystal slurry and thus inhibited crystal 
aggregation. The average inhibition exhibited by the white subjects (83.2 %) did not differ 
significantly from the black subjects (85.4 %) (p > 0.05). No noteworthy inter-group 
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Figure 2.8: A~rage 0])620 ~ot of COM crystal slurries. 
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Table 2.5: Absorbance slopes and inhibition of aggregation (lA %) of COM crystal slurries 
before and after addition of black subjects' urine (BU) at a dilution of 1:2 
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2.3.3 Zeta potentials 
The zeta potentials of a COM crystal slurry before and after addition of urine from white 
and black subjects at a urine to crystal dilution of 1:2 are presented in Tables 2.6 and 2.7, 
respectively. The individual values from which the averages were calculated are shown in 
Appendix A (white subjects: Table ALI, page AI; black subjects: Table A1.2, page Al). 
Table 2.6: Average zeta potential (ZP) of COM crystal slurries before and after addition of 
white subjects' urine (WU) at a dilution of 1:2 
COM+WUl -29.0 ± 0.57 62.5 <0.01 3 
COM+WU2 -29.6 ± 0.25 65.8 <0.01 3 
COM+WU3 -30.0±0.12 67.9 <0.01 3 
*COM+WU4 -17.2±0.74 -3.6 >0.05 3 
COM+WU ave: -29.8 ± 2.89 65.4 
• Excluded from average since no change in ZP wrt COM (p>O. 05) 
Table 2.7: Average zeta potential (ZP) of COM crystal slurries before and after addition of 
black subjects' urine (BU) 
.••. ~·::'c~·~ :':~~ ~,,~~,,.,f~~,~~"~w:~[: i~~~ ;~~:,':' :~~~ ~~~ ~,~i 
COM -17.9±0.14 6 
COM+BU1 -22.9 ± 0.35 28.3 < 0.01 3 
COM+BU2 -23.5 ± 0.088 31.8 < 0.01 3 
COM+BU3 -23.3 ±0.17 30.7 <0.01 3 
COM+BU4 -23.4 ± 0.22 30.9 < 0.01 3 
COM+BU ave: -23.2 ± 2.89 30.4 
All of the subjects' urine (except WU4), significantly decreased the zeta potential of the 
COM slurry from -17.9mV to values ranging from -22.9 to -30.0mV (p<O.Ol). There 
were no intra-group differences. However, there was a significant inter-group difference 
between the average zeta potentials (p < 0.05). The average decrease in zeta potential of 
the COM crystal slurry achieved by the white subjects' urine was 65.4 %, compared with 









Figure 2.9: Comparisoo of o/e decrease in 7P of 
COM crystal slurry after additioo of -..ite (WU) 
and liack (BU) subjects' urine at a lilution ofl:2 
Inhibitory activity of macromolecular urine extracts 
2.3.4 Urine protein concentration 
39 
The absorbance of a series of bovine serum albumin (BSA) concentrations measured using 
the Bradford protein assay are presented in Table 2.8. The standard curve and linear 
regression data corresponding to these results are shown in Figure 2.10. 
Table 2.8: Bradford protein assay standard 
curve data using bovine serum albumin (BSA) 
"'' .8SA : Ab~ma®e .. 
.. '• ,l$11.. ,,. ·y, 
<M'•IIf , ..,. cs9Slini) . ., m : .... :' .. .. ""'' 
1 0.0651 0.0037 
2 0.1150 0.0140 
3 0.1521 0.0018 
4 0.2114 0.0077 
5 0.2610 0.0085 
6 0.3222 0.0061 
7 0.3449 0.0118 
8 0.4083 0.0096 
9 0.4519 0.0165 
10 0.5039 0.0093 
0.6 
...... y = 0.0488x + 0.0152 
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Figure 2.10: Standard cur~ for Bradford protein 
assay using bo"Wne serum albumin 
The urinary protein concentration and corresponding daily urinary protein excretions in 
white and black subjects, calculated using the BSA standard curve, are shown in Table 2.9. 
A large within-group variation was observed in both population groups. The protein 
concentrations ranged from 12.8-69.2 mgll and 15.6-95.2 mgll amongst the white and 
black subjects, respectively. Daily protein excretions ranged from 26.8-85.0 mglday and 
24.1 - ll 0 mglday for the white and black subjects, respectively. Comparison of the 
average values showed that the black subjects' urinary protein concentration tended to be 
higher than the white subjects (38.4 vs. 33.2 mgll). In contrast, the black subjects' daily 
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protein excretion tended to be lower than the white subjects (50.7 vs. 58.3 mglday). 
However, these trends were not statistically significant (p > 0.05). The average protein 
excretion values obtained were within the reported urinary values of 40- 80 mglday (Free 
1986). 
Table 2.9: Protein concentration (mg/1) and excretion (mglday) of white and black subjects' 
urine 
WU6 58.5 67.8 BU6 38.3 55.9 
WU7 24.2 33.9 BU7 51.1 48.0 
WU8 21.2 35.4 BUS 27.4 57.9 
WU9 14.3 38.8 BU9 95.2 50.4 
WU10 19.1 40.7 BUIO 36.3 85.0 
WU11 69.2 110 BUll 37.2 32.2 
WU12 52.5 74.1 BU12 31.9 70.8 
WU13 25.0 52.9 BUB 28.6 34.2 
WU14 12.8 55.2 BU14 15.6 26.8 
WUave ±SE: 33.2±6.69 58.3±7.09 BUave ±SE: 38.4±6.69 50.7±7.09 
Average protein concentration: WUvs. BUp>0.05; average protein excretion: WUvs. BUp>0.05 
2.3.5 Synthetic urine metastable limit 
The average CaOx MSL plot of the synthetic urine, shown as particle number versus NaOx 
concentration, is presented in Figure 2.11. The data for this plot is shown in Appendix A, 
Table A2 (page AI). The MSL was equivalent to 45 mmol/1 NaOx as shown by the 
enlarged data point (final urinary NaOx concentration: 0.45 mmol/1). 
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2.3.6 Particle size distributions 
Figure 2.12 shows the average particle volume-particle size distributions at 120 minutes 
after addition of a NaOx load in excess of the MSL. A decrease in the average particle size 
was observed after addition of macromolecular urine extracts from both white and black 
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subjects as indicated by a shift in the mode of the protein-dosed distributions to smaller 
values relative to the synthetic urine. 
o+-_.....,..1!.:...~----,...---_.!::....l!! 
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Figure 2.12: A...erage pll'ticle size fistributioos. 
Synthetic urine before and after addition of 
macromolecular urine extracts from white (WMM) and 
black (BMM) subjects. SU: 20.2f.Ull, SU+WMM: 13.8f.Ull, 
SU+BMM: 9.32~ 
The size distributions for each subject from which these averages were calculated 
are shown in Appendix A (SU: Figures A4.1-4.5, page A 7; SU+ WMM: Figures AS.l-5.5, 
page A8; SU: Figures A6.1-6.5, page A9). The individual particle size values for the white 
and black subjects (giving rise to the peak of each curve above) are reflected in Table 2.10. 
Table 2.10: Particle size (JIID) of synthetic urine before and after addition ofmacromolecular 
urine extracts from white (WMM) and black (BMM) subjects 
:•••:"rr-;[~jl':;•· ·(r~~ ~::[l1·t''!•-:;~~-,.i~i:I; it:~·,i't'i .. :tt,,;,~~t~f-a~t;::.ru·[';~:· . ~-,•-·~I:' IJI·.::•~~m;.,_:·!: 
su 21.5, 21.1, 20.4, 18.9, 18.9 
SUave± SE: 20.2 ± 0.823 
SU+WMM5 14.6 27.7 
SU+WMM6 9.47 53.1 
SU+WMM7 15.3 24.3 
SU+WMM8 16.8 16.8 
SU+WMM9 13.1 35.2 
SU+WMM ave ±SE: 13.8 ± 0.823 31.7 
SU+BMM5 9.47 53.1 
SU+BMM6 10.2 49.5 
SU+BMM7 8. 74 56.7 
* SU+BMM8 10.2, 21.5 49.5, -6.44 
SU+BMM9 8.01 60.4 
SU+BMM ave ±SE: 9.32± 0.823 53 .9 
• Size distribution was bimodal; smaller size was used for SU+BMkf average calculation. 
SU+WMM ave vs. SU+BMM ave: p<0.05 
All of the macromolecular urine extracts tested, regardless of the population group from 
which they were derived, induced a decrease in the average particle size of the synthetic 
urine. Comparison of the average size values for each population group showed that the 
urine extracts derived from the black subjects resulted in a significantly greater decrease in 
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the average particle size than the white subjects (p < 0.05). After addition of WMM and 
BMM, the average size in the synthetic urine decreased from 20.2 ~m to 13.8 ~m and 
9.32 ~m, respectively. These values correspond to particle size decreases of31.7 and 53.9 
% in the presence ofWMM and BMM, respectively. 
2.3.7 Average urine compositions 
The average composition values (mmoV24 hour) and physicochemical parameters of the 
24-hour urines from white and black subjects (n=l4) are shown in Table 2.11 below (the 
results for the urine and MM inhibitory activity studies have been combined). The 
composition of each subject's urine from which the averages were derived is shown in 
Appendix A (white subjects: Table A3.1, page A2; black subjects: Table A3.2, page A3). It 
was noteworthy that the magnesium, phosphate and uric acid excretions were significantly 
lower in the black population group (p < 0.05). 
Table 2.11: Average composition (mmol/24hour) and physicochemical parameters of white 
(WC) and black(BC) subjects' urine (n=14) 
•• vanabla: ·:.n~• :r:~c · !1 •••  • )!: u:u: ... :swc::, ,.' t:' ::; !: r.i:~t '•·<·•BC,; •c: ::' . HF: , .. SET•> · !t;::· · · 
pH 6.20 6.30 0.0930 
Volume (ml/24hr) 1774 1536 139 
Calcium (mmoV24hr) 3.05 2.20 0.374 
Chloride (mmoV24hr) 151 132 13.6 
Citrate {mmoV24hr) 3.04 3.57 0.358 
Creatinine (mmoV24hr) 15.9 13.7 1.12 
*Magnesium (mmoV24hr) 3.82 2.64 0.397 
Oxalate (mmoV24hr) 0.17 0.15 0.014 
*Phosphate (mmoV24hr) 31.2 18.2 2.46 
Potassium_immoV24hr) 59.9 44.4 5.57 
Sodium (mmoV24hr) 152 142 21.9 
Sulphate (mmoV24hr) 20.1 15.6 1.61 
*Uric acid (mmoV24hr) 3.84 2.76 0.284 
RS Brushite 0.680 0.500 0.150 
RS Calcium oxalate 1.51 1.57 0.273 
RS Uric acid 1.30 0.920 0.231 
RS: Relative supersaturation 
*Difference is statistically significant: p<O. 05 
2.4 DISCUSSION 
The present study investigated whether urine composition and inhibitory activity studies 
would discriminate between South African white subjects who are stone-prone, and black 
subjects in whom stone incidence is extremely rare. The rationale for adopting this 
approach arose from a report which suggested that a combination of such data is required 
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to distinguish between stone-formers and controls rather than using urine composition and 
relative supersaturation values alone (Tiselius eta/. 1995). 
Urine composition trends in the present study were inconclusive. Magnesium, 
phosphate and uric acid excretions were significantly lower in the black population group 
(other trends were not significant). The same phosphate and uric acid trends were reported 
recently by Rodgers and Lewandowski (2002) and are consistent with stone incidence in 
this group. The lower urinary magnesium, however, is inconsistent with a low risk of stone 
formation (Takasaki 1972) and is an example of the contradictory trends in urine 
composition that have been reported amongst the black population (Modlin 1967, Whalley 
et al. 1998, Lewandowski et al. 200 1 ). These results suggest that the extremely low stone 
incidence in South African blacks cannot be explained in terms of urine composition alone. 
In the present study, zeta potential measurements revealed that filtered, dialysed 
urine from white subjects induced a significantly greater negative charge in the COM 
crystal slurry than that from black subjects, implying that stronger repulsive forces will 
operate between crystals in the former, eventually leading to a greater probability of 
disaggregation. However, as has been documented previously, competing cohesive forces 
are also involved (Hess and Kok 1996). These tend to negate the effect of the repulsive 
zeta forces. The results of the sedimentation experiments bear testimony to this. These 
showed that there was no difference in the degree of aggregation inhibition between the 
urines of the two population groups, despite the stronger repulsive forces induced by the 
macromolecules in urines from white subjects. It is thus concluded that the cohesive forces 
associated with macromolecules in the latter were stronger than those arising in the urines 
from black subjects. 
At first glance, these results seem somewhat surprising, given that the incidence of 
stones in the black population is far lower than in the whites. However, attention is drawn 
to the use of dialysed urine as opposed to whole urine. An extrapolation of results and 
interpretations from the one medium to the other is clearly inappropriate. If the hypothesis 
that inhibition of aggregation is greater in the urine of black subjects is valid, then one can 
speculate that the same interplay between cohesive and repulsive forces occurs in whole 
urines, and that the former are stronger in the urinary macromolecules of whites than 
blacks. This would give rise to repulsive forces and disaggregation of greater magnitude in 
black subjects. 
The zeta potential and sedimentation results also suggest fundamental differences 
in the properties of the macromolecules larger than 10 kDa in the urine of the two 
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population groups. It is possible that the macromolecules in white subjects' urine carry 
more negatively charged functional groups, while their suggested stronger cohesive forces 
indicate a greater probability to polymerise. The tendency of THM to self-associate has 
been associated with a decreased effect on crystal aggregation (Hess et al. 1989). Thus, a 
higher degree of polymerisation of macromolecules may induce a lower inhibition of 
aggregation in the white population. 
The addition of macromolecular urine extracts from both white and black subjects 
to the synthetic urine resulted in a considerable decrease in the average particle size. This 
change, which may be ascribed to inhibition of aggregation and/or reduced crystal growth, 
was significantly more pronounced in the black subjects. Further studies are required to 
elucidate the specific mechanisms of crystallisation inhibition. However, since inhibition 
of aggregation was demonstrated in the afore-mentioned zeta potential and sedimentation 
experiments, it seems reasonable to conclude that this was the operative mechanism. 
Indeed, this conclusion would be consistent with the white population's urinary 
macromolecules' greater potential to polymerise, as described above. Similar to the black 
group in the present study, other studies have found that smaller particle sizes are a 
consistent feature of control subjects' urine compared with stone-formers (Robertson and 
Nordin 1982). Thus this may be an important factor in the black population's lower stone 
incidence. It is surprising that only a moderate correlation between protein concentration 
and particle size was observed (0.55). This may suggest that specific macromolecular 
components, rather than the total amount of urinary macromolecules, are important in 
determining inhibition of crystallisation. 
Albeit that small sample sizes were used, the results of these experiments provide 
some evidence to suggest that the inhibitory properties of the urine from white and black 
subjects are indeed different. Further studies are required to study the mechanisms of 
crystallisation in more detail. The interesting fmdings with regard to macromolecules from 
white and black subjects, and specifically the potentially greater inhibition in the black 
subjects, suggest that urinary macromolecules might provide insight into the rarity of 
stones amongst the black population. 
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CHAPTER 3: CRYSTAL MATRIX EXTRACT 
3.1 INTRODUCTION 
Investigators studying the anomaly of black South African's apparent stone immunity have 
focussed considerable attention on urine composition. However, the role of urinary proteins 
has not yet been rigorously investigated. As described in chapter 1, approximately 64 % of the 
organic matrix of kidney stones consists of protein (King and Boyce 1959) and thus 
characterisation of this component and its role in stone formation is of considerable interest. 
The incorporation of proteinaceous material into kidney stones may occur during the primary 
event of crystal formation as well as during cellular trauma resulting from abrasion of the 
renal epithelium by the stone (Doyle et a/. 1991 ). Morse and Resnick (1988) were the frrst to 
study proteins in CaOx crystals freshly precipitated from urine, thus precluding the possibility 
that their presence was due to secondary, injurious events. This mixture of proteins derived 
from CaOx crystals is now commonly referred to as the crystal matrix extract or CME (Doyle 
et al. 1991 ). 
Since then, numerous investigators have identified proteins associated with urme 
crystals and have reported their inhibitory properties, albeit mainly in inorganic solutions. The 
proteins identified are albumin (Ryall eta/. 1991, Cerini eta/. 1999) nephrocalcin (Hess et al. 
1989, Worcester 1996), UPTF1 (Ryall et a/. 1995, chapter 5), inter-a-inhibitor (Atmani eta/. 
1996, Dean eta/. 1999) and OPN (Worcester 1996, Asplin eta/. 1998). 
Doyle and co-workers studied the CME from urine and reported remarkable inhibitory 
activity in both an inorganic solution and undiluted urine compared with previous studies of 
other proteins (Doyle et a/. 1995). They also reported the inclusion of a previously unknown 
protein as the major component of the matrix extract (Doyle et a/. 1991 ). This protein was 
later identified as the urinary form of prothrombin fragment 1 (Stapleton and Ryall 1995). 
This protein is the topic of further discussion in Chapters 4- 8. 
This chapter reports the isolation of the CME from the urme of white and black 
subjects and a comparison of their protein composition and inhibitory activities. This allowed 
an assessment of whether the proteins associated with the respective extracts might contribute 
to the black group' s low stone incidence. 
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3.2 METHODS 
3.2.1 Urine collection and treatment 
Twenty-four hour urine samples were collected from white and black subjects with no 
previous history of kidney stones and pooled according to population group. The nwnber of 
urines that were pooled varied between batches but was usually between 5 and 10. Urines 
were tested for haematuria and infection and filtered as described in paragraph 2.2.1 (page 26). 
They were discarded if the tests were positive. Urine composition data (nunol/l) and 
physicochemical parameters were obtained for the pooled urines as previously described 
(paragraph 2.2.1, page 26); no relative supersaturation values were computed since these are 
not appropriate for pooled urines. Urine composition data was analysed statistically by 
analysis of variance (ANOVA) and the results considered statistically significant if p :S 0.05. 
Average values along with their standard errors (SE) are reported 
The CaOx MSL of each urine pool was determined as outlined in paragraph 2.2.7 
(page 32). Some of the MSL experiments were performed using a turbidimeter instead of a 
Coulter Counter (due to availability). This instrument measures the turbidity or cloudiness of a 
sample, and a sharp increase in this parameter is comparable to a sudden increase in particle 
nwnber. Thus the same analysis as that described for the Coulter Counter experiment is 
applicable in these experiments. 
3.2.2 Isolation ofCME 
The CME was isolated from the pooled urines according to a method previously described (Doyle 
et a/. 1991 ). The urines were incubated in a shaking water bath (I 00 rpm) at 37 °C and CaOx 
crystallisation was induced by the addition of NaOx at 30 mmol/1 in excess of the previously 
determined MSL (0.1 ml NaOx I 100 ml urine). Additional loads of NaOx were added after 1 and 
2 hours. After a total incubation time of 3 hours, the crystals were collected by filtration (0.22 11m 
filters) and washed thoroughly with 0.1 mol/1 sodium hydroxide followed by distilled water. The 
crystals were dried at 37 °C for at least 1 hour and then demineralised by stirring in I 00 ml per 
gram of 0.25 mol/1 ethylenediaminetetraacetic acid (EDTA) (pH 8.0). The solution was filtered 
through a 0.22 11m filter and dialysed extensively against distilled water at 4 °C. The dialysate was 
freeze-dried and stored at -20 °C for later use; it is referred to as the CME. The CME 
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prepared from the urine of white and black subjects are henceforth referred to as WE and BE, 
respectively. 
3.2.3 Characterisation of CME 
Aliquots of the pooled urine samples as well as the CMEs each population group were 
retained for protein analysis by gel electrophoresis and Western blotting. 
3.2.3.1 SDS-PAGE 
Aliquots of filtered urine (1 rnl) and CME (0.5 mg) from each population group were prepared 
for analysis by sodium dodecyl sulphate (SDS)-polyacrylamide electrophoresis (PAGE). The 
urine samples were dialysed against distilled water and freeze-dried for SDS-PAGE. The 
CME were dissolved in a minimum volume of distilled water, diluted 1:4 with five times 
concentrated (5x) SDS reducing buffer [0.147 mol/1 Tris.HCl (pH 6.8), 5% SDS, 
25% glycerol, 0.0025% Bromophenol Blue and 12.5% ~-mercaptoethanol], and heated at 
100 °C for 5 minutes before loading. Proteins were resolved by electrophoresis on 15% 
polyacrylamide mini gels [37% (v/v) of a 40% acrylamide in 0.2% bisacrylamide solution, 
0.373 mol/1 Tris.HCl {pH 8.8), 27% distilled water, 0.10% SDS, 0.1% ammonium 
persulphate (Amps), 0.10% N,N,N'N' -tetramethylethylendiamin (TEMED)] with a 6 % 
stacking gel [16 % (v/v) of a 40% acrylamide in 1.8% bisacrylamide solution, 0.123 mol/1 
Tris {pH 6.8), 46% distilled water, 0.25% SDS, 0.25% Amps, 0.16% TEMED] using a 
Tris-HCl running buffer [15% glycine, 3% Tris, 1% SDS, pH 8.3]. Samples were run at 
50 rnA for 50 - 60 minutes. A low range molecular weight marker was included (Bio-Rad). 
The protein bands were then detected by silver staining. Briefly, gels were fixed for 
45 minutes [50% methanol, 12% acetic acid, 0.05% formaldehyde] and then washed three 
times with 50 % ethanol (10 minutes per wash) before a 1-minute pretreatment step 
[0.02% sodium thiosulphate pentahydrate]. The gels were then rinsed with distilled water and 
incubated in a solution of silver nitrate [0.2 % silver nitrate, 0.075 %formaldehyde] for 
20 minutes. Following further rinsing with distilled water, the gels were developed 
[6% sodium carbonate, 0.05% formaldehyde, 0.008% sodium thiosulphate pentahydrate] and 
then further development was prevented by addition of a stop solution [50% methanol, 
12% acetic acid] . 
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3.2.3.2 Western blotting 
Equal amounts of each sample were used for Western blotting. Following electrophoresis, gels 
were soaked in blotting buffer [24.9 mmol/1 Tris, 0.192 mol/1 glycine, 20% methanol, pH 8.3] 
for 15 minutes prior to assembly in the Bio-Rad Mini Trans-Blot apparatus. Proteins were then 
transferred onto a nitrocellulose membrane in blotting buffer at 100 V for 1 hour, with 
cooling, followed by immunodetection. Non-specific sites on the membranes were blocked 
with blocking buffer [9.97 mmol/1 Tris and 147 mmol/1 NaCl (pH 8.0), 6% fat-free skim milk 
powder, 0.05% Tween-20] for 1 hour. The blot was then probed for UPTF1 using a 1:500 
dilution of a monoclonal UPTF1 antibody (provided by Professor Rosemary Ryall, Flinders 
Medical Centre, South Australia) in the blocking buffer for 90 minutes with agitation, 
followed by four washes with olocking buffer, each for a period of 5 minutes. The monoclonal 
antibody was then probed with a 1:1000 dilution of a rabbit anti-mouse/HRP (horse radish 
peroxidase) conjugated secondary antibody in blocking buffer for 1 hour. After extensive 
washing with blocking buffer, the HRP conjugate was detected with a solution containing 
4-chloro-1-napthol (Sigma) [0.05% (w/v) in 17% ice-cold methanol, 0.042% hydrogen 
peroxide and 83% Tris-buffered saline (9.97 mmol/1 Tris, 147 mmol/1 Naa, pH 8.0)] for 
approximately 15 minutes. 
3.2.4 Synthetic urine study 
3.2.4.1 Urine preparation and treatment 
A synthetic urine was prepared as previously described (paragraph 2.2.7, page 32) and two 
replicate crystallisation studies were conducted independently to assess and compare the effect 
of the CME from both population groups on CaOx crystallisation. The CaOx MSL of the 
synthetic urine was measured (refer to paragraph 2.2.7, page 32) and the urine was divided 
into three equal aliquots that were either left untreated or dosed with WE or BE at final 
concentrations of 5 mg/1. The concentration is greater than the approximate physiological 
value reported (Doyle extracted 24.0 mg CME from 12.51 urine, i.e. 1.9 mg/1) (Doyle et al. 
1995). 
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3.2.4.2 Effect ofCME on particle number, volume and size 
Since it has previously been shown that CME does not alter the MSL (Doyle et al. 1995), and 
the amount of CME was limited, equal NaOx loads (30 mmol/l in excess of the MSL of the 
control urines, 0.1 rn1 NaOx per 100 ml urine) were added to the synthetic urine and 
protein-dosed samples to induce crystallisation. This was followed by incubation at 37 °C in a 
shaking water bath (1 00 rpm) for 60 minutes. The effects of WE and BE on the particle 
number and particle volume were measured at IS-minute intervals using a Coulter Counter I 
(140 11m orifice, 2.8- 90.0 11m particle size range, 64 channels). After 60 minutes, an aliquot 
(2 ml) of each sample from one such experiment was filtered (0.22 11m) and prepared for 
examination by scanning electron microscopy as described elsewhere (paragraph 2.2.2.3, 
page 28). 
In a separate experiment, synthetic urine and protein-dosed urines were incubated at 
37 °C for 120 minutes after which the particle size distributions were measured using the 
Coulter Counter I. 
3.2.4.3 Effect ofCME on t 4C}-oxalate deposition 
Experiments were carried out as described for the kinetics studies above except that 
3.125 11Ci I 100 m1 "hot" C4CJ-oxalic acid (NEN, Boston, USA) was added to each flask prior 
to addition of the "cold" NaOx. The incubation period was 120 minutes. Samples were filtered 
into concentrated HCl (1 0 % vlv) at 30-minute intervals to prevent further crystallisation. 
Thereafter, duplicate 1 ml aliquots of the latter were added to 10 ml scintillation fluid (Zinsser 
Analytic, Frankfurt, Germany). Each sample was counted for 10 minutes in a scintillation 
counter (1900 CA Tri-Carb Liquid Scintillation Analyser, Packard-Instrument Co. Inc., 
Meriden CT, USA). A measure of the percentage precipitated C4CJ-oxalate at each time 
interval was obtained by the following calculation: 100 - 1 OOx (CPM x min I CPM 0 min) where 
CPM is counts per minute (Ryall et al. 1995). 
3.3 RESULTS 
3.3.1 Urine composition 
The average composition of pooled unnes from white and black subjects 1s shown m 
Table 3.1. 
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Table 3.1: Average urine composition (mmol/1) and physicochemical parameters of pooled 
urines from white (WC) and black (BC) subjects (n = 7) 
'VilriP,k'i$:'"'ii: .•. ;;~;:: ... ":W1'?;~f?!h'':i'ri,p : rnm~'<f•:\VCf'''[~_·f-F:['UI'Wi,'.\, ·:H•+t:~.~:"'':fU1f!mJ;'••·:::~~f!'iit!NSE;.;,·;ortN'f';H.''' 
Number ofurines pooled 9.4 10.6 0.96 
pH 6.26 5.91 0.0937 
Volume (ml) 14564 15340 1961 
*Metastable limit (mmoVl) 38.6 87.8 5.32 
*Calcium (mmoVl) 2.74 1.24 0.234 
Chloride (mmoVl) 231 120 90.7 
*Citrate (mmolll) 2.38 1.52 0.215 
Creatinine (mmoVl) 21.1 8.36 7.80 
Magnesium (mmoVl) 3.11 2.59 0.429 
Oxalate (mmoVl) 0.277 0.287 0.080 
*Phosphate (mmol/1) 19.6 12.5 1.05 
*Potassium (mmoVl) 34.9 20.9 64.5 
Sodium (mmolll) 144 187 17.7 
Uric acid (mmoVl) 2.44 2.00 0.150 
*Significant difference: WC v.s. BC, p<0.05 
The data of each pooled urine is shown in Appendix B (white subjects: Table Bl, page All; 
black subjects: Table B2, page Al2) along with the data and plot for each pooled urine's MSL 
determination (white subjects: Tables B3.1 - 3.7, pages Al3 - Al4 and Figures Bl.l- 1.5, 
pageA19; black subjects: TablesB4.1-4.7, pagesA15-Al7 and FiguresB2.1 -2.5, 
page A20). The synthetic urine's MSL was the same as reported in chapter 2 (page 40). The 
black subjects • average urinary calcium, citrate, phosphate and potassium concentrations were 
significantly lower than the white subjects, while their average MSL was significantly higher 
(p < 0.05). 
3.3 .2 Isolation and characterisation of CME 
The entire volume of the pooled urines detailed in paragraph 3.3.1 was used for the isolation 
of CME. A portion of these extracts was then retained for the crystallisation study descnbed in 
the present chapter, while the remainder was used for the isolation and purification of UPTFl 
(described in chapter 4 ). Typical protein patterns of the white and black subjects' pooled urine 
and CME are shown in Figure 3.1. 
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kDa: 
MW l 2 3 4 
Figure 3.1: SDS-PAGE of urine and CMEs from 
white and black subjects. The patterns were obtained 
from MW: low molecular weight marker; 1: white 
subjects' urine (1 ml); 2: WE (0.5 mg); 3: black 
subjects' urine (I ml); 4: BE (0.5 mg). 
l 2 
Figure 3.2: Western blot of CMEs 
from white and black subjects 
immunoblotted for prothrombin. 
The patterns were obtained from 
1: WE (0.5 mg); 2: BE (0.5 mg). 
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The urine samples from white (lane 1) and black subjects (lane 3) both contained 
several bands with molecular weights ranging from 17 kDa to 64 kDa. However, it was 
noteworthy that both population groups' CME samples contained only a few bands, with the 
most prominent one at 42 kDa (lanes 2 and 4). In addition to this major band, WE also 
contained two other prominent bands at lower molecular weights, namely 26 and 37 kDa. In 
contrast, BE had another prominent band at a higher molecular weight, namely 62 kDa. 
A Western blot of the CME samples from both population groups is shown in 
Figure 3.2 above. The blot identified the major band in both samples as UPTFI. The CME 
from black subjects (lane 2) appeared to contain more UPTFI per milligram of CME than that 
from the white subjects (lane I). 
3.3.3 Synthetic urine study 
3.3.2.1 E.ffoct ofCME on particle number and volume 
Figures 3.3 and 3.4 (Appendix H, page A79) show the average increase in particle number and 
particle volume during a 60-minute time course after addition of a NaOx load. These trends 
were demonstrated in two independent experiments. The data from the separate particle 
number experiments and the corresponding plots are shown in Appendix B (Table B5, 
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page A18; Figures B3.1- 3.2, page A21). The analogous particle volume results are also 
shown in Appendix B (Table B6, page A18; Figures B4.1 - 4.2, page A21). 
Two features of the plots are apparent: firstly, CME from both population groups 
caused a notable decrease in particle number and particle volume relative to the control and 
secondly, the extent of the decrease was greater in the urine dosed with BE. The common 
point of maximum inhibition of particle number and volume occurred at 30 minutes. The 
average particle numbers after 30 minutes were 14 094, 9 225 and 8 408 /500~1 in the SU and 
WE and BE-dosed urines, corresponding to decreases of 34.5% and 40.3% in the latter two 
urines, respectively. The average particle volumes after the same time period were 1.862, 
1.482 and 1.123 x 106 ~m3 /500~1 in SU, WE-dosed and BE-dosed urines, respectively. These 
values corresponded to decreases in volume of 20.4% and 39.7% in the WE and BE-dosed 
samples, respectively. 
3.3.2.2 Effect ofCME on particle size 
Figure 3.5 .1 shows the average particle volume- particle size distributions of the synthetic 
urine and extract-dosed urines at 120 minutes after addition of a NaOx load. The plots for the 
two independent experiments are shown in Appendix B (experiment 1: Figures B5 .1.1 - 5 .1.2, 
experiment 2: Figures B5.2.1 - 5.2.2, page A22). A decrease in the average particle size of 
synthetic urine was observed after addition of WE and BE, indicated by a shift in the mode of 
the CME-dosed distributions to significantly smaller values compared to the control sample 
(Figure 3.5.1). A magnified view of the SU+WE and SU+BE curves at lower particle volumes 
indicated the presence of a second, smaller peak in the range 7- 20 ~m (Figure 3.5.2). In this 
range, there was a slight shift towards smaller sizes in the BE-dosed urine compared with the 
WE-dosed one. 
The average particle sizes of the above curves (as well as the values from the two 
independently performed experiments) are presented in Table 3.2 below. The two values listed 
for each CME-dosed curves are indicative of their bimodal distributions. The addition of both 
CMEs induced a decrease in the average particle size from 15.30 to 2.91 ~m, corresponding to 
an 81.0% decrease in size. The second (larger) peak in each extract-dosed urine had an 
average size of 11.29 and 9.84 ~m after addition of WE and BE, respectively. These values 
represent size decreases of 26.2 and 35.7% by WE and BE, respectively, relative to the 
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average particle size in the control synthetic urine. This trend was observed in experiment 1, 
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Figure 3.5.2: Awnge particle size of syndtetic urine 
after adlltion of CME From white (WE) and black (BE) 
subjects at final concentrations of 5 ~n 
Table 3.2: Particle size (I'm) of synthetic urine before and after addition of CME from white 
(WE) and black (BE) subjects at final concentrations of S mg/1 
Sample Experiment! Experiment 2 Average 
su 14.57 16.02 15.30 
SU+WE 2.91, 13.11 2.91, 9.47 2.91, 11.29 
SU+BE 2.91, 10.20 2.91, 9.47 2.91, 9.84 
Figure 3.6 shows scanning electron microgmphs of CaOx crystals precipitated from 
synthetic urine before and after addition of the CME. Diflerences were not observed between 
the synthetic urines dosed with WE and BE. Thus, in the context ofthe microscopy study, the 
two crystal extracts are henceforth collectively referred to as CME. In the control synthetic 
urine, coffin-shaped COM crystals and COM aggregates were typically observed 
(Figure 3.6.1 ). The addition of CME resulted in the formation of bipymmidal COD crystals. 
Single CODs together with a rew COD aggregates were characteristically observed. An 
example of the latter is shown in Figure 3.6.3. Swvey views of the synthetic urine and 
extract--dosed urine illustrated a marked decrease in the number of single and aggregated 
crystals after addition ofCME (Figure 3.6.4) compared to the control urine (Figure 3.6.2). 
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Figure 3.6: Scanaing electron micrographs of CaOx crystals deposited in synthetic urine. The 
crystals were precipitated from synthetic urine: mag 7.7 K (Fig 3.6.1), mag 1.2 K (Fig 3.6.2); and 
synthetic urine dosed with CME at a final concentration of5 mgll: mag 12 K (Fig 3.6.3), mag 1.2 K 
3.3.2.3 Effect ofCME on f 4C]-ox deposition 
Figure 3.7 shows the average increase in the quantity of precipitated [14C]-oxalate during a 
120-minute time course after addition of a NaOx load to synthetic urine. The plots for the two 
independent experiments are shown in Appendix B (experiment I: Figure 86.1, experiment 2: 
Figure 86.2, page A22). The corresponding data are given in Table B7 on page Al8. 
The CMEs from both population groups induced a significant decrease in the amount 
of deposited material relative to the control synthetic urine. The deposition in the BE-dosed 
urine was less than the WE-dosed urine until 60 minutes (in both independent experiments), 
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after which the two samples were not significantly different. Inspection of the data at 
30 minutes, the time point at which the particle number and volume data were analysed, 
showed that the average amount of precipitated material decreased from 29.0% in the 
synthetic urine to 12.4 and 5.0 % after addition of WE and BE, respectively. These values 
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Figure 3.7: A"\erage [
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q-oxdeposition rate in syndtetic 
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In the study described in this chapter, particle numbers, volumes and sizes were measured 
using a Coulter Counter. Interpretation of such data should take into consideration the 
characteristics of"particles", measured in the present study, as opposed to "crystals". Thus the 
particles themselves could be crystals, proteinaceous material or a combination of both. 
However, as discussed below, the [14C]-oxalate deposition and SEM data clearly depicted 
crystal formation. As such, the association of particle formation with crystal formation in the 
discussion below is justified. 
The molar compositions of pooled urines used for the preparation of the CMEs are 
presented for reference purposes. A portion of the CMEs was subsequently used for the 
purification of UPTF 1 (described in chapter 4 ), which was used in several experiments 
throughout this thesis. In the synthetic urine crystallisation study, a decrease in particle 
number was observed after addition ofthe CME from both white and black population groups. 
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This observation could be interpreted as either reduced crystal nucleation or promotion of 
aggregation. However, the observed decrease in particle size is inconsistent with the latter. 
Further evidence supporting a decrease in crystal nucleation is the decreased particle volume 
and amount of CaOx deposition, and the notably fewer crystals after the addition of the CME 
from both population groups revealed by scanning electron microscopy. Furthermore, lower 
particle volumes, in conjunction with the decrease in CaOx deposition, were consistent with 
inhibition of growth. Thus the results collectively suggest the CME from both population 
groups is an inhibitor of crystal nucleation, growth and aggregation in the synthetic urine, 
particularly during the early stages of the crystallisation process, during which time the 
changes in particle parameters were the greatest in comparison to the synthetic urine. The 
greater decrease in the particle number and volume and amount of CaOx deposition by BE 
suggests that the black population's matrix extract may be a more efficient inhibitor than that 
derived from white subjects. Inhibition of nucleation by CME has not been previously 
demonstrated. 
In an earlier study, CME was shown to be an inhibitor of CaOx growth and 
aggregation rather than nucleation (Doyle et al. 1991). However, the study by Doyle and 
co-workers differed substantially from the present one as it was conducted using a seeded 
crystallisation system and undiluted ultrafiltered human urine. Doyle and co-workers 
postulated that the observed inhibitory properties were largely attributable to UPTF1, the 
major component of the extract. The synthetic urine employed in the present study contained 
several more components than Doyle's seeded system, but far fewer than the complex milieu 
of real urine. The disparate complexity of the test solutions and, to a lesser extent, the 
different concentrations of CME used, are likely explanations for the CME' s different 
inhibition mechanisms in these media. A further explanation might be the possible variation in 
the composition of CME from different urines. This possibility is explored in chapter 6 of this 
thesis. 
Despite the shortcomings of synthetic solutions in mimicking real urine, the synthetic 
urine used in the present study satisfied the requirement of a neutral test solution in which to 
compare protein extracts derived from the two population groups. The use of real urine from 
either group may have influenced the relative effects. The important point that emerged, 
however, was that CME appears to have the capacity to inhibit all three crystallisation 
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mechanisms. In addition, the extent of such inhibition is dependent on the choice (and 
therefore chemical composition) of the test solution. 
A noteworthy observation of the present study was the preferred nucleation of COD in 
the presence of the crystal extracts. Another possibility is that COD was preferentially 
stabilised in the presence of CME. This observation is perhaps surprising in light of the fact 
that COM is thermodynamically more stable COM (Wemess eta/. 1979). On the other hand, it 
is consistent with the inhibitory properties demonstrated by both CMEs. According to Cerini 
and co-workers, the higher positive charge of COD (due to a greater number of calcium ions 
per unit cell) leads to repulsive forces between crystals and thus disaggregation (Cerini et a/. 
1999). Furthermore, the concomitant lower negative charge of COD crystals diminishes 
crystal adhesion to the cell surface due to the surface's overall negative charge (Asselman and 
Verkoelen 2002), thereby reducing the retention of COD crystals in the collecting ducts 
(Cerini et a/. 1999). Thus, the formation of COD induced in the presence of CME may be 
regarded as a favourable primary step ultimately leading to secondary inhibitory processes. 
Of significance in the present study was the observation that the crystal extract derived 
from black subjects tended to inhibit crystal nucleation to a greater extent than that from white 
subjects, particularly during the initial stages of crystallisation (i.e. first 30 minutes). Indeed, 
the percentage difference between WE and BE (at 30 minutes) with respect to the inhibition of 
particle numbers, particle volumes and [14C)-oxalate deposition was respectively 6, 19 and 
26% respectively. Furthermore, the BE-dosed synthetic urine contained particles of slightly 
smaller size. This suggested a possible superior inhibitory capability that may be related to the 
black population group's relative stone immunity. 
Differences in the protein composition of the two population groups' CME (shown by 
gel electrophoresis), influenced in part by the different urine compositions from which these 
extracts were derived, are likely contributors to the different activities observed. Recognising 
that UPTFl is the major component of both crystal extracts, it was tempting to speculate that 
the observed inhibitory effects were due to the former. While this is possible in light of 
Ryall' s UPTFl study in which the protein's potent inhibitory activity was demonstrated (Ryall 
et a/. 1995), several other proteins as well as non-proteinaceous material such as lipids could 
contribute to the extracts' inhibitory activity. However, even if the activity of CME could be 
directly attributed to UPTF 1, these results cannot be readily extrapolated to activity in real 
urine or even to a physiological function in actual stone formation. Nevertheless, the present 
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study provided sufficient evidence to suggest that an investigation of UPTFl, rather than the 
crude CMEs tested here, from blacks and whites in real urine was warranted. A crystallisation 
study of UPTFl in real urine, as well a comprehensive structural study of UPTFl from black 
and white subjects, should assist in clarifying the contribution, if any, of this inhibitor to the 
low stone incidence of black South Africans. 
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CHAPTER4: UPTFl ISOLATION & CHARACTERISATION 
4.1 INTRODUCTION 
The inhibitory activity of the CME derived from the urine of black subjects was greater than 
that of the extract from white subjects when tested in an inorganic solution (chapter 3). 
Since UPTF1 is the major protein included in matrix extracts from both population groups, 
and is reported to be a potent inhibitor of CaOx crystallisation (Ryall et al. 1995), further 
study of this protein was required. 
Several studies have compared the expression level (Hedgepeth et al. 2001, Atmani 
and Khan 2002) and/or structure (Nakagawa et al. 1987, Knode et al. 1994) of proteins in 
stone-formers and normals in order to identify key factors in stone formation and its 
prevention. A similar approach in South Africa's stone-prone and stone-free populations 
appears to be prudent. Thus in this chapter, possible structural differences in UPTF1 from 
white and black subjects were investigated. 
The two features of UPTF1 most relevant to a discussion of its activity are the Gla 
domain and its glycosylation. The Gla domain of UPTF1 contains ten Gla residues 
responsible for the protein's exceptional binding affinity for CaOx crystals (Stapleton and 
Ryall 1995) and has already been identified as the region of UPTF1 that determines its 
inhibitory activity (Grover and Ryall 1999). Furthermore, nephrocalcin from stone-formers 
lacks the Gla residues present in the inhibitory protein from healthy subjects' urine 
(Nakagawa et al. 1987), thus supporting the importance of Gla residues in protein activity. 
No detailed characterisation of the glycosylation of UPTF1 has been carried out, 
despite the fact that theN- and 0-linked glycans account for about 45% of the protein's 
molecular weight (based on a comparison of the observed mass of 31 kDa on SDS-PAGE 
with the calculated maSs using the amino acid sequence of 17 kDa). However, two previous 
studies have investigated carbohydrate structures on bovine PT, which has a high percentage 
of homology with human PT. Mizuochi identified three biantennary, complex type 
structures which he noted were highly sialylated (Mizuochi et al. 1979). Harlos later 
produced a model of these oligosaccharides on the bovine protein crystal structure (Harlos 
et al. 1987). 
Co- and post-translational modifications such as glycosylation are known to alter 
protein function and are therefore also important in determining protein activity (Worcester 
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1996, Rudd and Dwek 1997). In a study of THM by Knode, the protein isolated from 
stone-formers' urine, which is also known to be a poor inhibitor of crystallisation, was less 
highly glycosylated than THM from normals (Knode et al. 1994). 
An objective of this thesis was therefore to isolate and purify UPTFl from the urine 
of white and black subjects and compare their biochemical properties. On this basis, an 
assessment could be made as to whether differences in the amino acid sequence and 
structure of UPTFl or post-translational modification might account for the black 
population's low incidence of kidney stones. For the glycosylation study, CaOx 
stone-formers were included for comparison with the control subjects. 
4.2 METHODS 
4.2.1 Purification of UPTFl 
UPTFl was purified from the CME according to methods previously published and 
described in chapter 3 (Ryall et a/.1995; paragraph 3.2.2 on page 48). The CME was 
suspended in a minimum amount of distilled water, centrifuged at 11000 g for 3 minutes 
and the supernatant was loaded onto a P2 BioGel desalting column. Fractions of 
approximately 1 ml each were collected and the absorbance was measured at 280 nm. The 
protein eluted in the void volume and this was freeze-dried prior to HPLC. 
UPTFl was isolated by RP-HPLC with a Vydac C4 column (1.0 rnllmin) using a 
linear gradient of 0-42% acetonitrile (ACN) in 0.1 % trifluoroacetic acid (TFA) over 
62 minutes as detailed below. 
Table 4.1: RP-HPLC gradient used for UPTFl purification 
Time(min) Solvent A (%) Solvent B (%) 
0 100 0 
15 100 0 
50 14 86 
55 14 86 
56 0 100 
61 0 100 
62 100 0 
Solvent A: 0.1% TFA; Solvent B: 0.1% TFA in 70 o/oACN 
The protein peaks were collected (absorbance was monitored at 280 nm) and 
analysed by SDS-PAGE and visualised by silver staining. The fraction containing UPTFl 
was dialysed extensively against a phosphate buffer (145 mmol/1 NaCl, 8.21 mmol/1 
K2HP04, 1.84 mmolll KH2P04, pH 7 .3) at 4 °C and the protein concentration was 
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determined using the Bradford method (Bradford 1976; paragraph 2.3.4, page 39). The 
purity of the dialysed material was confirmed by SDS-PAGE (refer to paragraph 3.2.3.1, 
page 49 for details) after which it was aliquoted into plastic eppendorf tubes and stored at 
-20 °C for later use. UPTF1 purified from white and black subjects' urine is henceforth 
referred to as WF1 and BF1, respectively. 
4.2.2 Western blotting 
The proteins presumed to be WF1 and BF1 were immunoblotted with a monoclonal UPTF1 
antibody as described in paragraph 3.2.3.2 (page 50) to confinn their identity. 
4.2.3 Protein MALDI-TOF mass spectrometry 
Purified WF1 and WF1 were analysed by matrix-assisted laser-desorption-ionisation 
time-of-flight (MALDI-TO F) mass spectrometry according to methods previously described 
(Schwager et al. 1998). The protein samples were reduced and the cysteine residues were 
protected with vinyl pyridine followed by hydrolysis with endoproteinase Lys-C and Asp-N 
(2% w/w) that cleave peptide bonds C- and N-terminally to lysine and aspartic acid, 
respectively. Whole or HPLC fractionated digests were analyzed by MALDI-TOF mass 
spectrometry, and the mass measurements (equivalent to mass/charge or rnlz) were 
correlated with calculated masses of UPTF1 peptide fragments. Mass spectra were 
generated from a sinapinic acid matrix (10 mg/ml) using a PerSeptive Voyager Elite 
Biospectrometry Workstation (PerSeptive Biosystems, Framingham, Massachusetts). 
4.2.4 Protein sequencing 
TheN-terminal protein sequence of WF1 and BF1 were determined by automated Edman 
degradation (Brandt et al. 1984). Only the first five amino acids were identified to confirm 
the identity of the protein as UPTF1. 
4.2.5 Amino acid analysis 
The amino acid composition of WF1 and BF1 was determined by acid hydrolysis using an 
Amino Acid Analyser (Millipore) with a cation exchange resin and post-column 
fluorescence using orthophthaldialdehyde. 
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4.2.6 Gla analysis 
The composition of WF1 and BF1 with respect to Gla was determined by alkaline 
hydrolysis (Price 1983) using the same Amino Acid Analyser described above. The alkaline 
conditions prevented the conversion of Gla to glutamic acid (Glu) residues which occurs 
under the acidic conditions frequently used for amino acid analyses. A DL- y-Gla standard 
(Sigma) was included. 
Since Gla is quantitatively converted to Glu during acid hydrolysis, the sum of Gla 
and Glu in the alkaline hydrolysate equals the Glu content of the acid hydrolysate 
(determined as per paragraph 4.2.5 above). Thus the molar ratio of Gla to Glu residues was 
used to determine the Gla content ofWF1 and BF1 (Price 1983), 
i.e. nwnber of Gla residues= [mols Gla/(mols Glu + mols Gla)] x (nwnber of Glu). 
4.2.7 2D SDS-PAGE 
UPTF1 from white and black subjects (5 1-1g each) was resolved using 2D SDS-PAGE using 
a MultiPhor ll system (Gorget al. 1988). lmmobiline dry strips (pH 3-10 non-linear, 18cm, 
Amersham) were used for the isoelectric focusing separation in the first dimension. These 
were rehydrated in a urea solution [8 moVl urea, 0.5% Triton X-100, 0.5% Pharmalyte 
3-10, 0.2% dithiothreitol (DTT), few grains of bromophenol blue] prior to use. Samples 
were diluted 1:4 in a urea mixture [9 moVl urea, 1% DTT, 2% Pharmalyte 3-10, 0.5% 
Triton X-100, few grains of bromophenol blue] to denature the proteins, prior to loading at 
the acidic end of the strip. The samples were covered with silicone oil and run at 500 V for 
5 hours after which the voltage was increased to 3200 V (maximum setting) for 
18-20 hours (for isoelectric focusing). (The first dimension resolved the proteins according 
to charge.) 
For the second dimension, the strips were then placed in equilibration solution 1 
[0.5 % DTT, 50 mmoVl Tris-HCl (pH 6.8), 6.0 moVl urea, 30 % glycerol, 1 % SDS] for 
10 minutes with agitation followed by a further 10 minutes . in equilibration solution 2 
[4.5 % iodoacetamide (lA), 50 mmoVl Tris-HCl (pH 6.8), 6.0 moVI urea, 30% glycerol, 
1 % SDS, few grains of bromophenol blue] with agitation. The hnmobiline strips containing 
WF1 and BF1 were run on separate gels and resolved by molecular weight using 15 % 
acrylamide gels as previously described (refer to paragraph 3.2.3.1, page 49). The samples 
were electrophoresed at 25 rnA until the dye had run off the strips and then at 80 rnA until 
the dye front had reached the bottom of the gels (approximately 4 hours). A low molecular 
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weight protein standard was included on each geL Protein spots were visualised by silver 
staining (paragraph 3.2.3.1, page 49). 
4.2.8 Glycosylation analysis 
4.2.8.1 Theory of glycosylation 
Glycosylation is a process whereby oligosaccharides are attached to proteins and occurs 
within the endoplasmic reticulum and Golgi apparatus of cells (Rudd and Dwek 1997). 
Proteins usually emerge from the biosynthetic pathway as a mixture of glycosylation 
variants referred to a glycoforms and the profiles are usually characteristic of the tissue in 
which the protein is expressed. There are three main classes of covalently-bonded glycosidic 
linkages to proteins, two of which are explored in the present study. 
N-glycosylation is a co-translational modification that occurs during protein folding 
and is available to all proteins that contain the sequon asparagine-Xaa-serine/threonine 
where Xaa represents any amino acid other than proline. The N-glycosylation process is 
initiated by the transfer of a specific oligosaccharide unit (namely Glc3Man9GlcNAc2 where 
Glc: glucose, Man: mannose, Ac: acetyl) to the nitrogen atom in the side chain of ~ain 
asparagine residues. In contrast, the addition of 0-linked glycans is a post-translational 
process. It is initiated by the transfer of a single monosaccharide (usually GlcNAc) to the 
oxygen atom on appropriate serine or threonine side chains (Rudd and Dwek 1997). 
Monosaccharides may be conveniently represented by geometric symbols 
(Figure 4.1, page 68). A type of line drawing and short-hand notation has also been devised 
to readily communicate complex oligosaccharide structures. An example of a biantennary 
complex type structure is given below to illustrate this scheme (devised by Glycobiology 
Institute, University of Oxford). 
4.2.8.2 Protein preparation 
Previously purified UPTF1 from pooled urines of healthy white and black males was used 
(12 J.Lg each) for extraction of theN-linked glycans. In addition, 24-hour urine samples were 
collected from eight healthy white males (ages 20- 27) and seven healthy black males (ages 
21 - 26) so that possible intra-group differences could be investigated. The CME was 
isolated from these urines as previously descn"bed (paragraph 3.2.2, page 48) and used for 
the analysis of theN-linked glycans on UPTFI. 
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Figure 4.1: Graphical re presentations of monosaccharides and their linkages 
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N-Acetyl glucosamine = GlcNAc or A 
Galactose = Gal or G 
N-Acetyl galactosamine= GalNAc 
Fucose = F (outer arm) or Fe (core) 2 
Sialic acid (5-N-Acetylneuraminic acid= Neu5Ac) = S 





The number in square brackets refers to the 
mannose arm that is most processed. 
Twenty-hour urine samples were collected from six white CaOx stone-formers (ages 
35 - 65) and one black CaOx stone-former (age 35). All of these subjects had either passed a 
stone or had one surgically removed during the nine months prior to commencement of the 
study. The CME was isolated from each of these urines and used for analysis of the N-
linked UPTFl glycans. The purified UPTFl from pooled urines of healthy white and black 
males and white CaOx stone-formers (50 Jlg each) was used for analysis of the 0-linked 
glycans. Glycans from each group are denoted by the following abbreviations: white 
controls = WC; black controls = BC; white stone-formers= WSF; black stone-former = 
BSF. Samples obtained from pooled urine samples are denoted as .. pool''. 
4.2.8.3 Extraction of N-linked glycans 
MilliQ water has been found to contain traces of polymers and organic contaminants that 
give a high background signal on mass spectrometry. All glycan samples were therefore 
prepared in fresh MilliQ water purified by distillation at sub-boiling point (referred to as 
SBPH20). 
All of . the protein samples were resolved by electrophoresis on 12.5 % 
polyacrylamide mini gels after reduction (50 mmolll DTT) and alkylation (10 mmolll IA). 
Up to four wells of each sample were run to provide sufficient glycans for analysis. The 
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protein bands were stained with Coomassie Brilliant Blue and then destained. The band 
corresponding to UPTFl (prominent band at -31 kDa) was excised, cut into 1 mm3 pieces 
and frozen at -20 °C for at least 2 hours before further processing. The gel pieces were then 
washed with sodium hydrogen carbonate (20 mmol/1, pH 7.0) and ACN to remove excess 
SDS, and vacuum dried. The N-linked glycans were released overnight by in situ 
deglycosylation with peptide N-glycanase F (PNGase F) (Roche) at 37 °C. The released 
glycans in the supernatant were combined with several washings of the remaining gel pieces 
(alternate washings with ACN and SBP H20) and desalted using an activated anion 
exchange resin. The glycans were filtered to remove any remaining resin and dried under 
vacuum. The extracted glycans were fluorescently labeled with 2-aminobenzamide (2AB; 
Oxford GlycoSciences, Abingdon, United Kingdom) by reductive amination for 2 hours at 
65 °C and the excess label was removed by ascending paper chromatography. The labeled 
glycans were then washed off the paper, dried and dissolved in 200 Jll SBP H20. Refer to 
Appendix C (pages A23 - A27) for further details of the extraction procedure of N-linked 
glycans (KOster eta/. 1997, Radcliffe eta/. 2002) 
4.2.8.4 Extraction ofO-Iinked glycans 
Proteins were dialysed overnight against a 0.1 % TF A solution, freeze-dried and 
cryogenically dried for 2 nights before manual hydrazinolysis. The 0-linked glycans were 
then chemically released by incubation with anhydrous hydrazine at 60 °C for 6 hours and 
the excess hydrazine removed by evaporation. An acid-washed tube was included from this 
stage of the procedure as a blank sample. Glycans were then re-N-acetylated and cleaned up 
by application to an activated anion exchange resin column followed by descending paper 
chromatography. Finally, the glycans were eluted from the paper and dried under vacuum. 
The 0-linked glycans were then 2AB labeled and dissolved in a final volume of 200 Jll SBP 
H20 as described in paragraph 4.2.8.2 above. Refer to Appendix C (pages A28 - A30) for 
further details on the release of 0-linked glycans (Patel et a/. 1993, Royle eta/. 2002). 
4.2.8.5 Exog/ycosidase digestions 
Aliquots of the N- and 0-linked glycan pools (1 and 2 %, respectively) were vacuum dried 
and incubated overnight with arrays of exoglycosidases at 3 7 °C. The specificity and final 
concentration of the exoglycosidases are presented in Table 4.2 (on the next page). 
Following digestion, exoglycosidases were removed with SBP H20 using Micropure-EZ 
filters, vacuum dried and dissolved in 20 Jll SBP H20 for analysis by normal phase 
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(NP)-HPLC. Control digests were included in which glycans were incubated in the buffer 
and SBP H20. Refer to Appendix C (page A28) for further details. The results were used to 
determine the sequence, monosaccharide type and linkage of glycan residues (in 
conjunction with mass spectrometry). 
4.2.8.6 Normal phase HPLC 
Aliquots (1 % in 20 J1l SBP H20) of the glycan pools before and after exoglycosidase 
digestion were added to 80 J.Ll ACN and analysed by NP-HPLC according to the low salt 
buffer system as previously detailed (Guile eta/. 1996) using a 4.6 x 250 mm GlycoSep-N 
column (Glyko, England) (HPLC details: Appendix C, page A27). A 2AB-labeled dextran 
hydrolysate ladder standard consisting of glucose oligomers was used to calibrate the 
system Since the number of glucose residues (GU units) of the dextran peaks are known, 
these were used to calculate the GU values of the unknown glycan structures. These values 
were then compared with a database so that preliminary assignments on the structure of 
each glycan peak could be made. The area of each glycan peak was calculated and 
expressed as a percentage of the total glycan pool. 
Table 4.2: Specificity and final concentration of exoglycosidases 
, • • WJ.,., - . -- eL uo. ;::;.;;':;; --- ... ,. -. : .SO'Irree::Hh. : .. · Db~)' r ;, r:_3t:W:rif''i~:~:w:TE';;_ ;wo.: ' .. . •. ).~fn:::,; .. _; •. ,,·:·':,.·,x ---,Ct)n~ 
Sialidase Arthrobacter Abs Releases a2-3 and 2-6 linked non-reducing I U/ml 
ureafaciens terminal sialic acids 
Streptococcus Nani Releases a2-3 linked non-reducing terminal sialic I U/ml 
pneumoniae acids. 
sialidase 
Fucosidase Almond meal Amf Releases a.I-3 and I-4 linked non-reducing termina 2mU/ml 
fucose residues. Digests outer arm fucose. 
Bovine kidney Bkf Releases a I-6linked non-reducing terminal fucose I U/ml 
residues more efficiently than ai-2, 1-3 and 1-4 
fucose. Digests core fucose. 
Galactosidase Bovine testes Btg Releases fJ 1-3 and 1-4 linked non-reducing 1 U/ml 
terminal galactose residues more efficiently than 
B1-6linked residues. 
Streptococcus Spg Releases~ 1-4 linked non-reducing terminal 80mU/ml 
pneumoniae galactose residues. 
galactosidase 
Hexosaminidase Streptococcus GtuH Releases ~I-2, 3, 4 and 6linked GtcNAc but not 4.5 U/ml 
pneumoniae GalNAc residues. Does not remove bisecting 
~ucosaminidase GlcNAc residues. 
Jack bean Jbh Releases fJI-2, 3, 4 and 6 linked GlcNAc and SOmU/ml 
GalNAc residues. Does not remove bisecting 
GtcNAc residues. 
Mannosidase Jack bean Jbm Releases a.I-2, 3 and 6linked mannose residues 50 U/ml 
more efficiently than a1-3 linked mannose 
residues. 
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4.2.8.7 Weak anion exchange HPLC 
Glycan pools (1 % in 100 J.L]. SBP H20) were separated according to charge by weak anion 
exchange (WAX)-HPLC using a Vydac 301VHP575 column (7.5 x 50mm) (Anachem 
Limited, Luton, England) (Zamze et al. 1998). A bovine serum fetuin standard was included 
which has previously been characterised (Merry et al. 2002). Fractions were collected, 
washed with SBP H20 to remove the solvents, dried under vacuum and analysed by 
NP-HPLC. These profiles were then compared with the total glycan pool obtained on 
NP-HPLC. An aliquot of the glycan pools were also analysed by W AX-HPLC following 
overnight digestion with Abs (which converts charged sialylated glycans to neutral glycans). 
Refer to Appendix C (page A27) for further details. 
4.2.8.8 MALDI-TOF and Quadropole TOF mass spectrometry 
MALDI-TOF mass spectra were recorded using a Micromass TotS pee 2E reflection 
time-of-flight mass spectrometer (Micromass limited, Manchester, England) with a 
saturated solution of 2,5-dihydroxybenzoic acid in ACN as the matrix. Additional mass data 
was also obtained using a hybrid quadropole TOF (QTOF) mass spectrometer fitted with a 
nanospray source (Waters-Micromass Limited, Manchester, England). 
4.2.8.9 Molecular modeling 
Molecular modeling was performed on a Silicon Graphics Fuel work station using Insightll 
and Discover Software (Acelrys, San Diego). The figures were produced using the 
programme Molscript. Since UPTF 1 is an intracrystalline urinary protein, the Ca-bound 
bovine PTF1 crystal structure (Brookhaven database) was used as the basis for modeling. 
The bovine (SWISSPROT, P00735, residues 44- 199) and human (SWISSPROT, P00734, 
residues 44 - 198) sequences were aligned using BLAST (www.ncbi.nlm.gov/BLAST). 
N-and 0 -linked glycan structures were generated using the database of glycosidic linkage 
conformations and in vacuo energy minimisation to relieve unfavourable steric interactions. 
Predicted glycan sites were used in the model (www.cbs.dtu.dk/Services/NetNGlyc and 
www.cbs.dtu.dk/Services/NetOGlyc). The Asn-GlcNAc linkage conformations were based 
on the observed range of crystallographic values, the torsion angles around the Asn Ca.-Cf3 
and Cf3-Cy bonds then being adjusted to eliminate unfavourable steric interactions between 
the glycans and the protein surface. 
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4.3 RESULTS 
4.3.1 Purification of UPTFl 
Results obtained at various stages of the UPTFl purification process are shown below. The 
first step of protein purification was the desalting of the CME by column chromatography. 
A typical absorbance plot of the fractions collected from the column is shown in Figure 4.2 
below. The first peak eluted corresponded to the protein while the salt peak was eluted later. 
20 
Fraction nmnber 
Figure 4.2: Typical absorbance plot obtained of a CME 
sample on a desalting column 
UPTFl was then separated from the mixture of proteins contained in the desalted 
CME by RP-HPLC as shown in Figure 4.3 below. Typically, a mixture of proteins was 
eluted from 33 to 43 minutes followed by UPTFl at 44 minutes (shown by an asterisk). 
Figure 4.3: Typical HPLC chromatogram of 








4.3.2 SDS-PAGE and Western blotting 
The HPLC purified protein was analysed by SDS-PAGE (Figure 4.4) and Western blotting 
(Figure 4.5). The SDS-P AGE showed that a single band was present in the protein samples 
from both white (lane 1) and black (lane 2) subjects after HPLC with apparent molecular 
weights of 42 kDa Both of these protein bands cross-reacted with the monoclonal UPTF1 
antibody (Figure 4.5) and their identity was thus confirmed as UPTF1. The faint band in 
lane 1 at a slightly higher molecular weight than UPTF1 (indicated by an arrow) indicated 
the presence of a small amount ofPTF1+2 in the WF1 sample. This fragment ofPT is also 






MW 1 2 
Figure 4.4: SDS-PAGE of UPTF1 from white and 
black subjects. The protein patterns ubtained are from 
MW: low molecular weight marker; 1: WF 1 (2p.g); 
2: BFI (2J.lg). 
4.3.3 MALDI-TOF mass SjleCtrometry 
1 2 
Figure 4.5: Western blot of UPTF1 
from white and black subjects. The 
protein patterns obtained are from 
1: WFI (2p.g); 2: BFI (2J.lg). 
The spectra of WF1 and BF1 (Table 4.3) revealed [M+Ht ions at mlz corresponding closely 
with the calculated values of 1207.4 and 1617.8 of the Lys-C derived peptides Ala-1-
Lys-10 and Tyr-44-Lys-56. Ions at 766.2, 2000.4 and 1118.6 corresponding to Lys-C 
derived peptide Asp-38-Lys-43 and Asp-N derived peptides Asp-130-Gln-145 and 
Asp-146-Arg-155 were also observed in BF1 (Asp: aspartic acid; Gin: glutamine; refer to 
Table 4.4 on page 74 for the other abbreviations). Peptide 1-10 contains two potential Gla 
residues, which exist in both the carboxylated and uncarboxylated forms in both WF1 and 
BFI. The high percentage of Glu residues in peptide 11-37 and the glycosylation of 
peptides 57-97 and 97-107 hindered the determination of their masses. The mass spectral 
data were consistent with the reported sequence ofUPTFl. The 14% and 34% ofWF1 and 
BF1, respectively, that was successfully mapped did not reveal any apparent differences. 
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Table 4.3: MALDI-TOF of observed [M+Ht ions of UPTFl generated by endoproteinase 
Lys-C or Asp-N (cysteines were protected with vinyl pyridine) 
Amino acid Calculated Observed m/z 
residues m/z WFJ BFl 
1-10 1207.4 1207.5 1207.7 
1-10 3 1251.4 1252.1 1252.2 
1-10 b 1295.4 12%.1 1296.2 
11-37c 3209.4 
38-43 765.8 766.2 
44-54 1374.6 1375.5 
44-56 1617.8 1618.1 1618.3 
57-97 4791.5 
97-107 1124.2 
130-145 1999.3 2000.4 
146-155 1118.3 1118.6 
a D c Peptldes contams one and carboxylated glutam1c ac1d res1due, H1gh percentage of 
glutamic acid residues (30%); 4 Glycosylated peptide 
4.3.4 Protein sequencing 
The first five amino acids at the N-tenninus of WFl and BFl were 
alanine-asparagine-threonine-phenylalanine-leucine. These results are in agreement with 
Walz et al. (1977) and thus confirmed the identity of the purified proteins as UPTFl and 
that there were no differences at the N termini. 
4.3.5 Amino acid analysis 
The results of an amino acid analysis of WFl and BFl by acid hydrolysis are shown in 
Table4.4. 
Table 4.4: Amino acid composition of WFl and BFl as detennined by acid hydrolysis 
Amino Acid 
Number of residues: 
Calculated value WFI BFI 
Asparagine (Asn) 14 16 16 
Threonine (Thr) 18 18 17 
Serine (Ser) 9 11 12 
Glutamic acid (Glu) 22 23 23 
Proline (Pro) 9 9 9 
Glycine (Gly) 9 10 9 
Alanine (Ala) 12 12 13 
Cystine (Cys) 10 10 10 
Valine (Val) 8 8 8 
Methionine (Met) 1 1 1 
Isoleucine (lle) 4 3 3 
Leucine (Leu) 8 8 8 
Tyrosine (Tyr) 5 4 3 
Phenylalanine (Phe) 4 4 4 
Tryptophan (Trp) 3 3 3 
Histidine (His) 3 5 3 
Lysine (Lys) 4 4 5 
Arginine (Arg) 12 8 8 
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The amino acid composition ofUPTF1 from both population groups was similar to 
the calculated data, thus confirming their identity as UPTF1. These data are similar to the 
amino acid composition obtained by Walz eta/. (1977) of human PT. 
4.3.6 Gla analysis 
The results of alkaline hydrolysis and subsequent amino acid analysis of WF1 and BFl are 
shown in Table 4.5 below. The number of Gla residues in WF1 and BF1 was determined as 
10 and 13, respectively, using the number of Glu residues as 23 (from acid hydrolysis 
treatment). 
Table 4.5: y-Carboxyglutamic acid and glutamic acid composition of WFl and BFl 
determined by alkaline hydrolysis 
6.818915 4.083367 
,,.~~·~-~~;'-;:; 
:: ~: .. :: .... ;;;::;:: ~;: :~· .,.~~~~~·:, ·r--·. 
10.1::::: 10 12.7 ::::: 13 
The same trend was observed in a second experiment although the number of Gla residues 
differed (WF1 : 9, BF1 : 8). Such inter-experimental variation is commonly observed in 
amino acid analyses. 
4.3.7 2D SDS-PAGE 
The 2D map ofUPTF1 from white and black subjects (5 ~g each) is shown in Figures 4.6.1 
and 4.6.2, respectively. Only the region in which protein spots were detected is shown. Both 
WF1 and BF1 were present as three distinct spots (shown in red since they were not clear on 
the gel) at molecular weights of approximately 40 kDa. These spots represent charged 
variants ofUPTF1 at low pi values (near the acidic end of the gel). The relative size of the 
middle spot suggested that this charged variant is the most abundant of the three. 




4.3.8 Glycan analysis 
N-linked glycans 
4. 3. 8.1 NP -HP LC of glycan pools 
The N-linked glycans were enzymatically released from SDS-PAGE purified UPTFI. A 
typical protein pattern is shown in Figure 4.7 (Appendix H, page A79). The four bands at 
31 kDa corresponding to UPTF 1 were combined for glycan extraction. Two of the white 
stone-formers had two bands near 31 kDa; these were excised and processed separately. 
They were later found to have similar profiles on NP-HPLC (suggesting that both bands 
were UPTF 1) and the glycans were thus combined. 
Figures 4.8 (page 77) and 4.9 (page 78) show the NP-HPLC profiles of the pool of 
N-glycans from control and stone-forming subjects, respectively. The GU values, which 
reflect the relative size of the glycans, are shown on the x-axis. The intragroup and 
intergroup similarity of the glycan profiles is apparent by inspection. The peak areas for 
each glycan pool are shown in AppendixC (WC: Table Cl, page A31; BC: Table C2, 
page A32; WSF and BSF: Table C3, page A33). They confirmed the considerable 
correlation between samples. The peak numbers indicated in these tables correspond to 
those shown in Figure 4.16 (page 88). 
Owing to the similarity of the N-linked glycan profiles, WC6 was chosen as a 
representative sample (since it contained the largest glycan pool) and used for further 
characterisation. The WCpool and BCpool glycan profiles were slightly different to those 
obtained from the individuals' profiles for white and black subjects, particularly near the 
GUvalues of7.16 and 7.88. This may be due to the fact that the pooled samples' N-glycans 
were released from purified UPTFl whereas the individuals' samples were obtained from 
the crystal matrix extract by SDS-PAGE. However, since the individuals' samples were so 
similar, this was not regarded as significant. 
Preliminary assignments were made by comparing the GU values of peaks with a 
database of N-linked structures. These were confirmed, and some additional assignments 
were made, by following the progression of each peak with a series of exoglycosidase arrays 
in conjunction with mass spectrometry and W AX-HPLC analyses. 
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Figure 4.8: NP-HPLC p-ofiles of N-Iinked glycans on UPTFl pooled from white (WC pool) and black 
(BC pool) control suiiects as \\ell as from se\eral incividual white (WCI-8) and black (BCI-7) 
suiiects. Refer to Tables 4.6 (WC) and 4. 7 (BC) for peak areas. 








GU 5 6 7 8 9 10 
Figure 4.9: NP-HPLC profiles of N-linked glycans on UYfFl from se~ral white stone-formers 
(WSFl-6) and one black stone-former (BSF). Refer to Table 4.8 for peak areas. WSF3 and WSF6 had 
two bands (shown as "a" and "b") presumed to be UPTFl on SDS-PAGE and thus these were processed 
separately. 
4.3.8.2 E.xoglycosidase digestions 
Table 4.6 (pages 79- 81) shows the peak areas expressed as a percentage of the total WC6 
N-glycan pool before (undig) and after a series of exoglycosidase arrays. One peak present 
in the undigested glycan pool was absent in the control digest (peak 6) while another was 
significantly reduced (peak 18). The most likely explanations would be loss of this glycan 
structure during incubation at 37 °C due to its lability or during filtration following the 
overnight digestion. However, these theories were tested and ruled out by additional 
experiments (data not shown) and thus no plausible explanation can be provided. The 
control digest HPLC profile was therefore used for comparison with the exoglycosidase 
array profiles. Although this could not be confirmed, the structure at peak 6 was 
provisionally assigned as A2 on the basis of its relative elution position and comparison of 
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Table 4.6- Notes: 
a -[M] indicates the loss of a p 1-6 mannose. These structures are indicated on the Ibm digest shown in 
Figure4.13. 
b This could possibly be a bisected A2 structure. Digestion with Sph should be used to test this possibility 
(unavailable at time of study). 
c Ukely to be an A2 structure based on its GU value (5.70) and its relative position in the glycan pool profile. 
However, this could not be confirmed since the peak was absent in the control digest. 
d Ukely to be sialic acid residues other than Neu5Ac (N-Acetyl substitution at C-5) which is the most 
commonly observed. Characterisation of the molecular structures of these sialic acids requires further 
investigation. 
e This structure digests similarly to A2G2 (at peak 17). The difference in structure or linkage which could 
account for the slightly lower GU value is not known. 
f Both structures appear to be FcA2G2 on the basis of their digestions and the difference in GU values could 
be consistent with one of them being bisected. Digestion with Sph should be used to test this possibility 
(unavailable at time of study). 
F, G: These structures could not be fully characterised since they were observed after Abs digestion but could 
not be correlated with peaks present in the undigested glycan pool. It is thus probable that they co-eluted with 
the major peaks observed by NP-HPLC. They are likely to be fucosylated (since peaks moved after Abs+Bkf 
digestion compared with Abs alone) and contain ~1-4 galactose linkages (since peaks moved following 
Abs+Amf+Btg and Abs+Amf+Spg digestion compared with Abs+Amf). 
M: These structures contain mannose glycans since the peaks moved following addition of Ibm 
S: These structures are likely to be sulphated since they remained after the array of exoglycosidases. 
S, G, M: These structures could not be fully characterised however it is apparent that they emerged as 
subsequent digestion products of the peak at GU 8.56 after Abs digestion. It is probable that the peak co-eluted 
with another major peak observed in the undigested glycan pool. It is likely that the structure is sialylated (it 
elutes with the disialylated structures after Abs digestion on W AX-HPLC), galactosylated (peak moved 
following addition of Btg and Spg), mannose-containing (peak moved following addition of Ibm) and 
sulphated (since it remained after the array of exoglycosidases). 
ni: These structures could not be identified. 
Undig: This is likely to be an A2G2 structure that was incompletely digested by the addition of Btg. 
The NP-HPLC profiles of the exoglycosidase arrays are shown in 
Figures 4.10- 4.13. The complete array is shown in Figure 4.10 (page 82). The change in 
elution times of relevant peaks following digestion is shown with arrows. For example, the 
peak corresponding to A2G2FS2 (control digest profile) was digested with a sialidase to 
A2G2F. Addition of a fucosidase, which digests outer arm fucose residues (Amf), produced 
the structure A2G2. This was digested to A2 by a galactosidase (Btg) and finally the 
































Figure 4.10: NP-HPLC profiles of a UPTFl N-glyam pool from 
llhlt.e control subject WC6 before and after treatment with an aJTay 
of exodycosidases. Refer to Table 4.9 for sununary of structures and 
Table 4.6 for peak areas. *These structures may be bisected. **Refer to 
notes with Table 4.6 for discussion. 
The identification of the two 
fucosylated structures (peaks 26 
and 27) was confirmed by 
comparison of a digest with a 
fucosidase alone and in 
combination with a sialidase 
(Figure 4.11). Bkf digested 
FcA2G2S2 (peak 27) to 
A2G2S2, but A2G2FS2 (peak 
26) was unaffected. However, 
Abs+Bkf digested A2G2FS2 to 
A2G2. This confmns the 
presence of outer ann fucose, 
which would be inaccessible to 
the fucosidase due to the 
presence of the sialic acid 
residue, rather than core fucose 
in the structure at peak 26. 
Additional galactosidase 
digestions confirmed the 
linkage of galactose residues 
(Figure 4.12) together with the 
corresponding peak areas 
(Table 4.6). The majority of 
terminal galactose were ~ 1-4 
linked since very similar 
profiles were obtained with Btg 
which digests ~1-3 and ~1-4 
linked galactose more 
efficient! y than ~ 1-6 residues, 
compared with Spg which 
digests only ~ 1-4 linked 
galactose residues. The A2G 1 
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figure 4.11: NP-HPLC p-oflle of a UPTFl N-glycan pool from white control subject WC6 IE fore and after 
treatment 'Mth a fucosida..e, alsoused in combination 'Mth a sialidase. 
by both Btg and Spg and is therefore a mixture of ~1-3 (-20 %), ~1-4 (-50%) and ~1-6 
(-30 %) linked galactose structures. Since A2G1Sl is a derivative of A2Gl, it contains the 






Figure 4.12: NP-HPLC p-ofile of a UPTFl N-glycan pool from 
white control subject WC6 before and after cigestion with two 
galactosida<ies, Btg and Spg, (in combination with other 
exoglycosida<ies) to deternine the galactose linkages. *This may 
be a bisected A2 structure. 
same mixture of galactose linkages. 
Five monoantennary N-linked 
structures were identified by 
preliminary assignments, namely 
Man3, AI, AlGI, A2Gl and 
A 1 G 1 S 1. All of these structures, 
when digested with a mannosidase 
(Figure 4.13), shifted to earlier 
elution times and thus confirmed 
that at least one of the mannose 
residues in their trimannosyl core 
was unprocessed. 
The sialic acid residues 
were found to be a.2-6 linked since 
all of the sialylated structures 
digested with Abs, which is specific 
for a.2-3 and a.2-6 linked terminal 
sialic acids, but the profile 
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following digestion with Nani, which digests only a.2-3 linkages, was identical to the 
undigested glycan pool (data not shown). 
Conttol dig 
(I) (2.3) 







Figure 4.13: NP-HPLC p-ofile of a UPTFl N-glycan pool from 
white control subject WC6 before and after cigestion with a 
mannosidase. 
4.3.8.3 Weak anion exchange HPLC 
W AX-HPLC was used to 
separate the WC6 N-linked 
glycan pool into neutral, mono-
and disialylated fractions, both 
before and after digestion with 
Abs. These HPLC profiles are 
presented alongside a fetuin 
standard (Figure 4.14). The 
undigested glycan profile shows 
that a high proportion of the 
N-linked structures are 
Neutral 
Digestion with the combination 
Abs+Amf+Btg+ Jbh produced 
an identical HPLC profile to 
that with GluH substituted for 
Jbh (the latter is shown in 
Figure 4.6; the Jbh digest 
profile is not shown). Since 
GluH releases GlcNAc but not 
GalNAc residues while Jbh 
releases both, it can be 
concluded that the N-linked 










sialylated, which is consistent 
with the proposed assignments. 
The presence of a small amount 
of charged glycans after Abs 
digestion suggests that there may 
be structures other than the 
Figure 4.14: WAX HPLC p-ofile of N-linked glycans on 
UPTFl from white control subject WC6 before and after 
cigestion \\i th a sialidase. A profile of an N -linked fetuin 
standard is included for COJll>arison. 
sialylated ones which also be 
charged, however further studies 
are required to confirm this 
proposal. It could also indicate 
incomplete sialidase digestion. The 
WAX-HPLC fractions were 
collected and analysed by 
NP-HPLC for comparison with the 
total glycan pool (Figure 4.15). 
This analysis showed that in 
addition to those structures 
previously assigned to each peak. 
other structures had also co-eluted 
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at the same GU values. The fraction 
percentage of neutral, mono- and 
disialylated structures present in 













Figure 4.15: NP-HPLC prordes of UPTFl N-glycan pool from white control subject WC6 before and 
after separation by WAX HPLC. 
Table 4.7: Analysis of W AX-HPLC fractions on NP-HPLC of N-linked glycans on UPTFl 
from white control subject WC6 
%PEAKAREA: 
PeakiD Peak area GU Neutral fraction Monosialylated Disialylated 
(%) fraction fraction 
I 0.2 4 .43 100 
2 0.1 4.95 100 
3 0.1 5.08 100 
7 0.3 5.84 100 
8 0.6 5.92 57.8 42.2 
9 0.8 6.08 100 
II 0.3 6.30 100 
12 0.4 6.40 100 
13 0.8 6.60 100 
14 1.4 6.75 100 
15 1.8 6.84 79.5 20.5 
16 1.0 7.12 8.3 91.7* 
17 5.8 7.19 57.3 30.9* 11.8* 
19 2.1 7.48 83.4 16.6 
20 1.6 7.81 13.4 45.7 40.8 
21 27.3 7.92 0.5 87.2 12.3 
23 3.3 8.29 100 
24 2.1 8.57 44.5 55.5 
25 43.3 8.66 2.0 98.0 
26 1.6 8.96 100 
27 0.4 9.24 100 
*Since these peaks did not move on NP-HPLC followmg Abs drgesnon, they are lllcely to be neutralfracnons whrch 
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4.3.8.4 MAWI-TOF and QTOF mass spectrometry 
Mass spectral data obtained by MALDI-TOF MS and QTOF MS is shown in Table 4.8 
(page 86). Refer to Appendix C for the chromatograms recorded (Figures C1- C2, 
page A34). From the observed masses, the number of hexose (Hex; includes Man, Gal), 
N-Acetyl substituted hexose (includes GlcNAc), Neu5Ac (the most commonly observed 
sialic acid residue) and fucose residues are computed. The most probable structure 
corresponding to this composition is then chosen as the assigned structure, taking into 
consideration the exoglycosidase and W AX-HPLC analyses. The mass data recorded was 
consistent with the previously assigned structures. The fucosylated structures could not be 
differentiated by mass spectrometry since no distinction can be made between outer arm 
(peak 26) and core fucose (peak 27, Figure 4.16) and the composition of the remaining 
residues was the same (Hex: 5, HexNAc: 4, Neu5Ac: 2). 
4.3.8.5 Summary of N-linked glycans 
Table 4.9: Summary of N-linked glycans on UPTFl from white control subject WC6 (refer to 
Figure 4.16 for structures) 
PeakiD GU %Area M~or structure 
1 4.43 0.2 Man3 
2 4.91 0.1 A1[6] 
3 5.06 0.1 A1[3] 
6 5.70 0.5 A2 
7 5.83 0.3 A1G1[6] 
8 5.90 0.6 a A1G1[3] 
9 6.03 0.8 D A1G1S1[3] 
11 6.28 0.3 A2G1[6] 
12 6.37 1.6 A2G1[3] 
13 6.58 0.8 b A1G1S1 
14 6.70 1.4 A1G1S1[6] 
15 6.80 1.8 A1G1S1[3] 
16 7.07 1.0 c A2G2 
17 7.16 5.8 A2G2 
18 7.36 2.3 A2G1S1[6] 
19 7.49 2.1 A2G1S1[3] 
20 7.70 1.6 A2G2S1[6] 
21 7.88 . 27.3 A2G2S1[3] 
23 8.25 3.3 D A2G2S2 
24 8.40 2.1 b A2G2S2 
25 8.56 43.3 A2G2S2 
26 8.91 1.6 b A2G2FS2 
27 9.26 0.4 FCA2G2S2 
"The secondary structure that elutes at th1s GU IS AJGJSJ[6] (42% of peak area as shown by WAX-HPLC). 
6 These structures are likely to have sialic acid residues other than Neu5Ac which is most commonly observed. 
e This structure digests similarly to A2G2 (at peak 17). It could be a bisected A2G2 structure, however a 
further digest with Sph is required to confirm this. 
The final structures assigned to each peak in the total N-linked glycan pool are summarised 
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Figure 4.16: NP HPLC &rofile of an uncigested UPTF1 N-glyc:an pool from white control subject WC6. Italicised 
nunmers on the HPLC profile indicate structures observed in glycan pools other than WCfJ (these were not identified). 
The four-pointed stars used in structures 9, 13, 23 and 24 indicate sialic acid residues other than Neu5Ac which is rmst 
coiJlm)nly observed. *This structure has not been confinred since no exoglycosidase wa<> available to rermve a 
bisecting GlcNAc residue. 
accounted for 76% of theN-linked glycan structures: A2G2 (6 %), A2G2S1[3] (27 %) and 
A2G2S2 (43 %). These structures as well as the remaining N-glycans are listed together 
with their GU values and percentage of the glycan pool in Table 4.9 (page 87). 
Approximately 95 % of the structures were sialylated, 5 % were galactosylated and 3 % 
were fucosylated (Table 4.10). All of the structures were complex type oligosaccharides; 
93 % of these were biantennary and 95 % were charged. 
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Table 4.10: Percentage composition of N-linked glycans on UPTFl from white control subject 
WC6 
PERCENTAGE COMPOSIDON: 
Charge of structures: Antennae: Major structures: 
Charged Uncharged Monoantennary Biantennary Sialylated Galactosylated Fucosylated 
94.5 5.5 6.9 92.9 94.5 5.3 2.6 
Owing to the high proportion of sialylated structures, further analysis of all of the 
N-linked glycan samples was carried out with respect to this monosaccharide. The 
percentage of mono- and disialylated structures for each of the control and stone-forming 
subjects' N-glycan pools is summarised in Table 4.11 
Table 4.11: Percentage of mono- and disialylated N-linked glycans on UPTFl from white and 
black control subjects and white stone-formers 
Sialylation WC1 WC2 WC3 WC4 wcs WC6 WC7 WC8 WCAve 
Mono: 44.0 34.2 29.4 48.9 47.3 40.2 44.7 33.0 40.2 
Di: 45.2 59.6 66.9 43.7 42.5 54.3 44.1 62.1 52.3 
Total: 89.2 93.8 96.3 92.6 89.7 94.5 88.7 95.1 92.5 ±2.0 
BCl BC2 BC3 BC4 BC5 BC6 BC7 BCAve 
Mono: 15.0 11.8 11.2 9.0 15.8 7.5 20.4 15.0 
Di: 78.7 82.9 83.4 87.6 77.8 74.7 63.7 78.4 
Total: 93.7 94.7 94.5 96.6 93.6 82.2 87.7 93.4±2.0 
WSFl WSF2 WSF3 WSF4 WSF5 WSF6 WSFAve 
Mono: 15.3 20.2 16.9 18.6 16.8 16.5 . 17.3 
Di: 77.2 63.8 74.6 70.8 73.6 72.7 72.5 
Total: 92.5 83.9 91.4 89.5 90.3 89.2 89.5 ±2.0 
BSF BSF 
Mono: 15.5 15.5 
Di: 76.9 76.9 
Total: 92.4 92.4±2.0 
Total s~alylatron: We vs. Be p=0.32, We vs. WSF p=0.08 
Mono- and disialylation: we vs. Be p<O.OJ, we vs. WSF p<O.OJ 
The total percentage of sialylated structures was not statistically different for the 
four groups, however the relative proportions of mono- and disialylated structures were of 
interest. The latter constituted 52 % of the white control subjects' N-glycans compared with 
78% amongst black control subjects. The white stone-formers' glycans contained 72% 
disialylated structures. Both the black control and white stone-forming subjects had 
significantly higher proportions of disialylated structures than the white controls. No 
statistical comparison could be made with the black stone-former due to the small sample 




4.3.8.6 NP-HPLC of glycan pools and exoglycosidase digestions 
Figure 4.17 shows NP-HPLC 
profiles from the undigested 
WSF glycan pool followed 
by a series of exoglycosidase 
digestions. The peak areas 
are shown in Table 4.12 
(page 91 ). Several structures 





fetuin standard as well a 
database of 0-linked 
structures (Royle et al. 2002) 
and thus the exoglycosidase 
digestions (as well as 
WAX-HPLC) were used to 
confirm these assignments. 
The structure 
observed at a GU value of 
2.22 in the fetuin and 
WSFpool sample (5.5 %) is 
the product of a base 
catalysed J3-elimination 
reaction referred to as 
peeling. This occurs during 
hydrazinolysis (depending on 
the conditions used) and 
leads to the elimination of 
terminal (core) GalNAc 
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Figure 4.17: NP-HPLC Jrofiles of 0-linked glycam on UPTFI 
pooled from 3 wbite stone-formers follo\\ing arrays of 
exoglycosidase clgestions. An O-lin ked fetuin standard is included 
above for co111>arison. *Contaninant peaks. **Peeled product. The 
peak at GU 4.40 after addition of GluH is an N-linked structure, 
some of which are released during hydrazmolysis. 
oligosaccharides (Merry et al. 2002). 
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PEAK STRUCI'URE GU Undig Abs Abs Abs 
ID Btg Btg 
GluH 
t-~ 0.92 7.9 14.3 
~2AB 1.00 7.9 22.0 22.6 
Contaminant 12.0 12.0 12.0 12.0 
ni 1.21 
ni 1.35 2.9 2.4 2.7 2.9 
ni 1.48 2.8 3.2 3.5 3.0 
ni 1.73 1.3 2.3 1.7 1.2 
.. 216 
1.78 1.2 3.1 
Contaminant 5.5 5.5 5.5 5.5 
1 ~-~IS "Core I" 1.81 8.7 22.9 17.6 11.8 
Contaminant 1.94 3.1 3.9 4.9 4.2 
Contaminant 1.99 18.4 19.5 2.5 1.9 




ni 2.39 2.1 1.8 1.6 1.6 
ni 2.44 3.1 1.6 2.6 1.5 
2 b Sialylated 2.52 2.0 
Contaminant 2.58 5.6 5.9 5.8 5.6 
;.-216 2.72 1.4 2.3 1.1 
Contaminant 2.78 2.8 2.8 3.2 3.0 
3 ./218 2.91 4.7 
4 ... ?-218 3.22 4.5 
5 c-:.-218 3.29 
Contaminant 3.37 1.1 3.0 3.0 1.6 
ni 3.49 1.8 
~ 3.58 2.2 2.6 
Contaminant 3.68 2.8 1.3 
6 ;--218 3.88 2.1 
7, 8 7218 >218 4.38 6.8 
. . 
a ThiS IS a degradation product of the hydrazmolys1s reaction and IS refe"ed to as a "peeled" product . 
b WAX-HPLC showed that this structure is charged and it digests with Abs, suggesting the presence of sialic 
acid. Further studies are required to identify the structure (e.g. liquid chromatography- mass spectrometry). 
c This structure has a slightly higher GU value than peak 5 and digests with Abs, suggesting that it may be 
the same structure as peak 5 but with a modified sialic acid (i.e. not Neu5Ac which is the most commonly 
observed sialic acid residue). 
Contomitulnt: These peaks co"esponded to those observed in the blank 0-linked sample. 
ni: not identified 
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It is not possible to determine the 0-linked structure from which this peeled product 
originated and thus is a limitation of the analysis. In addition, structures corresponding to 
those eluted in the blank sample's NP-HPLC profile were observed in the undigested glycan 
pool. These are unavoidable byproducts of the sample preparation procedure and have been 
indicated by asterisks on the HPLC profiles to prevent their confusion with genuine 
0-linked structures. 
The NP-HPLC profiles of undigested 0-glycan pools from the control subjects 
appeared similar to the WSF sample (Figure 4.18). However, closer inspection showed that 
the core 1 structure (Gal-GalNAc, peak 1) was absent from the control subjects and there 
were larger amounts of the structures from peaks 2 and 5 (P2 and PS) (in fact they were not 
initially identified in the WSF sample due to the small amount in the undigested pool). 
Since the 0-glycan pools from 
white and black control subjects 
contained the same structures, only the 
former was used for exoglycosidase 
digestions. In an attempt to identify the 
additional structures (P2 and P5), 
WC pool was digested with Abs 
followed by Btg. Both structures 
digested with the sialidase and are 
therefore sialylated 0-glycans. 
Structure P5 digested to core 1 with Abs, 
which was further digested to the 
GalNAc monosaccharide with Btg. The 
digestion pattern is therefore the same as 
that of structure 4 and the GU value is 
only slightly higher (GU 3.29 versus 
3.22). It is therefore likely that this 
0-glycan has the same basic structure 
but with a modified sialic acid. Previous 
studies of N-glycans have shown that this 
monosaccharide is the most likely to 




Figure 4.18: NP-HPLC profiles of 0-linked 
glycans on UPTFl pooled from 3 white control 
subjects before and after exoglycosi~e cigestions. 
The nUimers correspond to the sarre structures 
observed in WSF pool Structure 2 has not been 
identified but clearly digests with Abs. Peak 5 
probably corresponds to a core 1 structure with a 
rrodified sialic acid (i.e. not Neu5Ac). The open 
arrows (Abs profile) the GU value at which peaks 2 
and 5 appeared in the undigested SIUJ1>le. 
*Contaminant peaks . **Peeled product. 
show variation in GU values and thus the same may be true of sialylated 0 -glycans (Guile 
et al. 1996). Further characterisation using liquid chromatography-mass spectrometry is 
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required to verify the proposed structure. Structure P2 was characterised further in the 
present study and also does not appear in the existing 0-glycan database. Further studies in 
which the peak is collected during NP-HPLe and analysed may aid identification of this 
structure. 
4.3.8.7 Weak anion exchange HPLC 
W AX.-HPLe was used to separate the 
WSF and We 0-linked glycan pools by 
charge density, both before and after 
digestion with Abs (Figure 4.19). These 
HPLC profiles are presented alongside a 
fetuin standard which has been 
previously characterised (Royle et al. 
2002). Three structures observed in 
both glycan pools correlated with peaks 
in the fetuin standard and thus 
confmned the assignment of the 
sialylated core 1 structures 3, 4 and 8. A 
peak at 8 min in both samples as well as 
two further peaks in we (10, 14 min) 
could not be identified, however 
digestion with Abs confirms that they 
are sialylated structures. The presence 
of a small amount of glycans after Abs 
digestion in both WSF and We samples 
suggested that charged structures other 
than the sialylated ones may be present. 
Two structures (eluted at 12.5 and 
16min) in we were resistant to the 
sialidase (shown by solid arrows in 
Figure 4.19) and one of these ( 12.5 min) 
also remained after Abs digestion in the 
WSF sample. Incomplete digestion by 
the sialidase seemed unlikely here (as 










Figure 4.19: WAX-HPLC profiles of D-linkedglycam 
on UPTFI pooled from white control (W C) subjects 
and white stone-formers (WSF) before and after Abi 
clgestion. An 0-linked fetuin standard is included for 
COJil>arison. Solid arrows indicate structures which did 
not digest with Abs and open arrows indicate structures 
which could not be identified. 
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proposed for the WC6 N-linked glycans) as less material was present before digestion. Thus 
these peaks may represent previously unreported 0-linked glycan structures. 
4.3.8.8 Summary of 0-linked glycans 
The final structures assigned to each peak in the total 0-linked glycan pools are summarised 
in Figure 4.20. These structures are listed together with their GU values and the percentage 
of the total glycan pool in Table 4.13. All of the fully characterised 0-links in the two 
control groups· samples were core 1 structures and all of these were sialylated. Of these 
structures, two had a GlcNAc residue ~1-6-linked to the GalNAc core. In addition, the white 
stone-formers· sample also had a large proportion of the core 1 structure (28 %) and thus 
we J»01 
7,8 
1 2 3 4 
Figure 4.20: NP-HPLC profiles of 0-linked glycans on UPTFI pooled from white (WC) and Hack (BC) 
control suijects and white stone-formers (WSF). The solid arrows indicate structures present at 
significantly higher higher proportions in the control SaJ11>les. The open arrow indicates a structure only 
present in the stone-fonners' satq>le. Refer to paragraph 4.3.8.6 for a discussion on the structures 2 and 5. 
*Contarrinant peaks. **Peeled product. 
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had a lower percentage of sialylation (72 %) than the control groups' 0-glycans. 
Table 4.13: NP-HPLC analysis of 0-linked glycans on UPTFl pooled from white control 
(WC), black control (BC) and white stone-formers (WSF) 
PeakiD GU WCpool 
%AREA: • 
Structure BCpool WSFpool 
1 1.81 28.3 b rAB 
2 2.52 11.8 12.2 9.2 • Sialy1ated 
3 2.91 16.4 15.3 15.2 y .!AJS 
'* 4 3.22 10.1 18.9 14.7 ')-2AB 
5 3.29 7.0 10.0 3.5 d~2AB 
6 3.88 7.3 8.2 6.9 72~ 
7 4.38 47.3 35.4 22.1 ~2AB 
* -8 ? 2AB 
* • Contaminant and peeled product peaks were excluded for these calculations. 
b It is likely that a small amount of this structure was present in the control subjects' samples but was 
hidden by the contaminant peak at GU 1. 78. 
e WAX-HPLC showed that this structure is charged and it digests with Abs, suggesting the presence of sialic 
acid. Further studies are required to identify the structure (e.g. liquid chromatography- mass 
r.,ectrometry ). 
This structure has a slightly higher GU value than peak 5 and digests with Abs, suggesting that it may 
be the same structure but with a modified sialic acid (i.e. not Neu5Ac which is the most common sialic cid). 
Molecular modeling 
4.3.8.9 Molecular model of UPTF 1 
The molecular model of UPTF1 (Figure 4.21) was generated using the calcium-bound 
bovine PTF1 crystal structure along with predicted N-and 0-glycan sites. Figure 4.21.1 is a 
side view of the model and indicates the domain-like structure of the protein. Seven calcium 
atoms are bound to Gla residues in the Gla domain and all occupied glycan sites were 
located on the kringle domain. Although the site specificity of the glycans was not 
determined, the sizes of the major N-glycans were similar and the 0-glycans were all core 1 
structures, thus the conclusions drawn would not be significantly different. Both predicted 
N-glycan sites were occupied and an A2G2S2 structure was attached to residues 78 and 100. 
Two of the five possible 0-glycan sites are shown occupied, namely at residues 121 and 
122, and a mono-sialylated core 1 structure is attached to these sites in the model. 0-glycans 
were also predicted at residues 102, 120 and 149, but these were not reasonable due to steric 
interactions with other glycans and the protein itself (SWISSPROT numbering, P00734). An 
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end-on view down the Gla domain (Figure 4.21.2) illustrates the significantly increased 
diameter of the glycoprotein ( 63 A) compared with its unglycosylated form (36 A). The 
distances between adjacent glycan chains are shown, namely 40 and 43 A (O-N) and 60 A 
(N-N). 
Figure 4.21: Molecular model of UPrFl showing N .. and 0-linked glycans 
4.21.1: Side-on view 
'V 
GJadomain 










4.4.1 Primary structure 
A method for the purification of UPTFl to homogeneity was established using column 
chromatography and RP-HPLC in accordance with the protocol described by Ryall et al. 
(1995). Primary structural data obtained by MALDI-TOF MS, N-terminal protein 
sequencing and amino acid composition analysis were consistent with the reported sequence 
of human PTFl. These did not reveal differences between white and black subjects. 
Since the Gla domain ofUPTFl, by virtue of its Gla acid residues and their affinity 
for calcium ions, is reported to determine the protein's inhibitory activity (Grover and Ryall 
1999), the number of Gla residues in WFl and BFl was compared. Gla is formed when 
glutamic acid residues acquire an additional y-carboxyl group during post-translational 
modification. It is noted that WF1 contained ten Gla residues as previously reported for 
UPTFl (Stapleton and Ryall 1995), whereas BF1 contained a further three such residues. 
This suggests that additional glutamic ac~ds were modified on BFl. The greater number of 
Gla residues measured in the black population's UPTF1 may indicate a potentially greater 
inhibitory capacity. This would be consistent with a previous study in which nephrocalcin 
derived from stone-formers contained none of the Gla residues reported on normal 
nephrocalcin which inhibited crystallisation (Nakagawa et al. 1987). 
2D SDS-PAGE indicated that both WF1 and BF1 have three charged variants of 
UPTFl with varying degrees of y-carboxylation, which exist at low pi values. A previous 
study of urinary CaOx crystals immunoblotted for PT fragments reported five charged 
variants in the pattern of a doublet and a triplet (Buccholz et al. 1999). The triplet pattern 
and pi were similar to the present study. Another investigator reported an approximate pi 
value of 4 for UPTFl without any reference to isoforms (Stapleton et al. 1996). It is perhaps 
surprising that the observed differences in Gla from WF 1 and BF 1 were not reflected on 2D 
SDS-PAGE. It is suggested that other unknown effects may have masked these differences. 
While primary structural data on WF1 and BF1 were similar, the difference in the 
number of Gla residues may be indicative of an enhanced inhibitory potential ofBFl which 
could partly account for the black population' s remarkably low rate of stone formation. 
However, since the oligosaccharides on UPTFl account for almost a third of its mass, and 
the importance of glycosylation in understanding the role of glycoproteins and their possible 
structure-function relationships has been shown (Rudd and Dwek 1997), a further study of 
the glycans on UPTF 1 was undertaken. 
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4.4.2 Post-translational modifications 
A comprehensive analysis of the N-linked glycans on UPTFl of white and black subjects 
from both healthy and stone-forming groups was conducted. The same N-linked structures 
were observed in all four groups; only the proportions varied. The majority of the g1ycans 
(93 %) were the complex biantennary type with a high proportion of sialylation (95 % ), all 
of which were a2-6 linked to galactose residues. Most galactose residues had f31-4 linkages, 
and core and outer arm fucosylation was observed. The two major structures sequenced 
were A2G2S1 (27 %) and A2G2S2 (43 %). Exoglycosidase digestions and WAX-HPLC 
both suggested that charged groups other than sialic acid might be present, although these 
appeared to constitute a small percentage (< 5 %) of the total glycan pool. Sulphated 
glycans might account for this observation since they have been reported on other urinary 
proteins (Hard et al. 1992; van Rooijen et al. 1998; Wakabayashi eta/. 1999). 
Two of the sialylated structures were assigned to multiple peaks, namely A1G1S1 
(four peaks) and A2G2S2 (three peaks). Since differences in linkage could not account for 
the observations, it is possible that some of these structures contained modified sialic acid 
residues, i.e. a modification of the most commonly observed Neu5Ac. Considerable 
diversity exists amongst the sialic acid family and modifications can affect the 
hydrophilicity (and therefore the GU value) of the structures (Varki 1999). Nelsestuen 
reported the presence of both N-glycolylneuraminic acid and Neu5Ac on bovine PT 
(Nelsestuen and Suttie 1972), whereas Mizuochi detected only Neu5Ac structures 
(Mizuochi et al. 1979). However, there is evidence from the present study to suggest that 
such diversity may be present on UPTFI. Fraction collection of the relevant peaks followed 
by further characterisation (e.g. liquid chromatography-mass spectrometry) could validate 
this proposal. 
Identification of sialylated A2G2 structures is consistent with a previous study of 
bovine PT which demonstrated extensive sialylation with sialic acids on both Gal and 
GlcNAc residues (Mizuochi et al. 1979). However, whereas all sialic acid residues in the 
present study were a2-6 linked to f31-4 linked galactose, Mizuochi reported a2-6 linked 
sialic acids with f31-4 linked galactose and a2-3 linked sialic acids with f31-3 linked 
galactose. 
WFl and BF1 obtained from pooled urmes (of control subjects) were also 
characterised. These glycan pools were similar to those obtained from the individuals, 
suggesting that pooling is an appropriate strategy when larger amounts of protein (and 
therefore glycans) are required. 
CHAPTER4 99 
The analysis of 0-linked glycans on UPTFl revealed the presence of sialylated 
core 1 structures in both control groups as well as the white stone-formers. In addition, a 
high proportion of the core 1 structure was observed in the white stone-formers' glycan 
pool. The latter glycan pool therefore contained a considerably lower percentage of 
sialylated 0-glycans. No previous studies have reported the presence of, or characterised, 
the 0-glycans on UPTF1. Similar to the N-glycan results, W AX-HPLC indicated that 
charged groups other than sialic acids might be present; sulphated 0-glycans are likely 
candidates for further testing. Additional structures were observed by W AX-HPLC which 
could not be identified due to the infancy of this area of glycobiology (a database of 
0-glycans was only recently published by Royle et a/. 2002), the complexity of 0-glycan 
structures due to the existence of at least eight core structures compared with one for 
N-glycans (Royle eta/. 2002), and the lack of appropriate 0-glycan standards. 
The varying degrees of sialylation amongst the groups investigated are noteworthy. 
The total percentage of sialylated N-glycans were similar, whereas the white stone-formers 
had a considerably lower proportion of 0-glycan sialylation than the two control groups. 
Comparison of the white and black control subjects showed a significantly higher 
percentage of disialylated N-glycans in the latter. Since these two groups had the same 
percentage of 0-glycan sialylation, overall the black control group's glycans present a 
greater number of sialic acid residues than the white controls. It is perhaps surprising that 
this apparent difference in sialylation (and thus negative charge) was not observed by 2D 
SDS-PAGE. It is possible that the differences in sialylation were insufficient to influence 
the overall charge of UPTF 1, or that other factors (which tended to result in a lower 
negative charge) may have opposed these effects. 
Molecular modeling located the highly sialylated N- and 0-glycans on the kringle 
domain of UPTF1. This was notable since it is the Gla domain that binds calcium ions and 
is responsible for the protein's inhibitory activity (Grover and Ryall 1999). It appears at first 
that the distance of the glycan sites to the calcium binding ones prevents the glycans' 
interruption of this process. However, intermolecular interactions between glycans and 
Gla residues/ calcium ions are possible. It is thus feasible that the glycans on UPTF1 affect 
its inhibitory activity. Previous studies of two urinary proteins have demonstrated a 
relationship between post-translational medications and protein activity. In these studies, 
THM from stone-formers' urine, which is a poor inhibitor of crystallisation, was shown to 
be less highly glycosylated than THM from normals (Knorle et a/. 1994), while 
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dephosphorylation of osteopontin reduces its capacity to inhibit CaOx crystallisation 
(Worcester 1996). 
In addition to possibly influencing UPTFl 's inhibitory activity, the glycans, and in 
particular sialic acids (and other charged groups such as sulphates), may play a role in 
mediating crystal interactions with renal epithelial cells. Several studies have reported the 
binding of COM (Riese eta/. 1988, Lieske et al. 1995, Verkoelen eta/. 1995) and COD 
(Lieske et a/. 1996) crystals to renal cell surfaces. Crystal adherence to the renal epithelium 
is now widely regarded as a possible mechanism of stone formation, in addition to blockage 
of the nephron caused by crystal aggregation (Lieske et al. 1999). The subsequent 
internalisation and dissolution of these attached crystals within lysosomal bodies may also 
represent a possible protective mechanism (Lieske et a/. 1999; refer to chapter 8). 
It appears that the renal cell surface presents as a negative charge (Lieske et a/. 
1996) by virtue of anionic surface molecules (Asselman and Verkoelen 2002), whereas 
CaOx crystals present a positively charged surface. Thus interruption of the interaction 
between these two oppositely charged sites is likely to occur by acting on either the cell 
surface and inducing a positive charge, or the crystal surface and inducing a negative 
charge. Either of these mechanisms would reduce crystal adhesion to the renal cell surface 
by way of repulsion (Lieske et al. 1999). A recent study in which the binding of exogenous 
COM crystals to cells was measured in the presence of whole urine, demonstrated that 
PTF 1 + 2 (which contains UPTF 1) reduces crystal adhesion by coating the surface of crystals 
(Kumar et a/. 2003). It is possible that Kumar's observation was directed in part by the 
presence of highly sialy1ated glycans on UPTF1 . 
The negative charge on the renal cell surface is largely due to the presence of 
terminal sialic acids (Asselman and Verkoelen 2002), and thus several studies have focused 
on this monosaccharide. Sialic acid-containing cell surface glycoproteins appear to be 
critical determinants of crystal binding since pretreatment of cells with neuraminidase 
greatly reduce COM crystal binding (Lieske et al. 1999). Sialic acids also direct the face 
selective nucleation of COD crystals onto renal epithelial cell surfaces via the {00 1} face in 
favour of the { 100} face in their absence (Lieske et a!. 2001 ). The linkage of sialic acid also 
appears to be important since a2- 3 linked residues on the surface of a renal cancer cell line 
have been shown to provide protection from COM crystal binding whereas a2--6 linked 
residues did not (Kramer et a/. 2003 ). In another study of human collecting duct cells from 
six CaOx stone-formers, a2--6 linked sialic acids were more highly expressed (Hofbauer et 
a/. 1998). These authors postulated that the a2--6 linkage favours crystal attachment to the 
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cell surface. The fact that UPTFl contained exclusively o2~ linked sialic acids suggests 
that it may mediate stone formation by attachment to the epithelial cell surface. 
Thus it seems possible, and indeed highly probable, that sialic acids have an 
important and possibly directive role to play in the attachment of CaOx crystals to renal cell 
surfaces, and the possible disruption of this process. However, at present, all but one recent 
crystal-cell interaction study (Kumar et al. 2003) have used inorganic crystals, and thus the 
influence of urinary proteins associated with these crystals has not been rigorously 
investigated. Moreover, no studies have investigated protein-associated glycans but have 
instead focused on the role of cell surface glycans. The elucidation of the impact of specific 
glycans attached to the intracrystalline protein UPTFl on crystal attachment is therefore an 
important study that needs to be addressed. However, it seems probable that a greater 
negative charge on the crystal surface of black control subjects, by virtue of an increased 
number of UPTFl ' s sialic acid residues, may provide a greater repulsive force to the 
negatively charged renal cell surface. This would result in diminished crystal adhesion in 
the black population, which could explain their relative protection from stone disease. 
Further studies should address two areas. Firstly, whether the inhibitory activity of 
intact UPTFl is different from the aglyco and asialo forms. And secondly, whether crystals 
that include the intact protein are more or less likely to attach to renal epithelial cell surfaces 
than crystals that contain the aglyco or the asialo forms of UPTFL These studies will help to 
elucidate the role of UPTFl and its glycans in the prevention of urolithiasis, as well as the 
possible protection of black South Africans from stone disease. 
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CHAPTER 5: UPTFl CRYSTALLISATION STUDIES 
IN INORGANIC SOLUTIONS & URINE 
5.1 INTRODUCTION 
105 
In an attempt to identify the potential role of urinary proteins m the black population's 
apparent stone immunity, the CME was isolated from the urine of black and white subjects for 
in vitro activity studies (chapter 3). The results showed that in an inorganic solution, the black 
group· s CME inhibited crystallisation more efficiently than that of the white group. As the 
major protein incorporated into the CME, UPTF1 from black and white subjects was then 
fully characterised. Structural differences in the two group's UPTF1 were observed which 
suggest that their inhibitory activities may be different. Thus a comparative study of the 
inhibitory activity of UPTFl from black and white subjects is required. 
For the purpose of these activity studies, both inorganic media and urine were utilised. 
It has been claimed that aqueous solutions, synthetic urine and dilute urine do not realistically 
reflect the complexity of real urine (Rodgers 1999), and thus the effect of substances in such 
media are unlikely to reflect their activity with respect to CaOx crystallisation under 
physiological conditions (Aeisch 1978). However, the use of simpler inorganic media may 
still provide valuable information for the study of basic crystallisation processes (Ryall in 
Hess et al. 2001 ). Furthermore, it is possible to study the effect of a single inhibitor in 
isolation (Tiselius in Hess et a/. 2001 ), which is not easily achieved in urine. The complexity 
of urine is such that innumerable interactions may interfere with the activity of a single 
molecule. Despite the advantages of using inorganic test solutions, the use of urine (whole or 
minimally diluted) is nevertheless important since it more closely approximates the solution in 
which kidney stones form (Ryall in Hess et a/. 2001 ). Extrapolation of results to physiological 
conditions and thus the potential to prevent actual stone formation is more reasonable, albeit 
not entirely appropriate. 
Thus for the purpose of this thesis, the inhibitory activities of WFl and BFl were 
compared in inorganic solutions as well as in urine in order to assess the possible contribution 
ofUPTF1 to the black population's remarkably low incidence of kidney stones. 
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5.2 METHODS 
5.2.1 Synthetic urine study 
5.2.1.1 Synthetic urine treatment 
A synthetic urine was prepared according to the method of Burns and Finlayson ( 1980a; 
paragraph 2.2.7, page 32). The solution was stored at 4 °C and was stable for a maximum of 
5 days. Aliquots were flltered through a 0.22 fA.m fllter paper immediately before use. The 
CaOx MSL was determined in duplicate according to the method of Ryall and co-workers 
(Ryall et al. 1985; paragraph 2.2.7 on page 32). 
5.2.1.2 Effect ofUPTF1 on particle size 
Since it has previously been shown that macromolecules and urinary proteins including 
UPTFI do not alter the MSL (Ryall et al. 1991, Ryall et al. 1995, Doyle et al. 1995) and since 
the amount of UPTFI was limited, equal NaOx loads (30 mmoVl in excess of the previously 
determined MSL) were added to the control synthetic urine and protein-dosed samples to 
induce crystallisation. Aliquots of 10 m1 were left untreated or dosed with WFI or BFI at final 
concentrations of 1.25 mgll (approximate physiological concentration according to Ryall et al. 
1995). This was followed by incubation at 37 °C in a shaking water bath (100 rpm) for 
120 minutes. The effect of WFI and BFl on the particle size distribution was measured at 
120 minutes using a Coulter Counter I (140 fA.m orifice, 2.8-90.0 fA.m particle size range, 
64 channels). The following number of measurements was made for each sample: SU, n=lO; 
SU+WFI, n=8; SU+BFI, n=IO. 
After completion of two of the experiments, aliquots (2 ml) of the control and 
protein-dosed samples were filtered through a 0.22 fA.m filter paper. The crystals were 
examined using a scanning electron microscope as previously described (paragraph 2.2.2.3 on 
page 28). 
5.2.1.3 Effect ofUPTFJ on [14C]-oxalate deposition 
Aliquots (25 ml) of synthetic urine were left untreated or were dosed with WFI or BFI at fmal 
concentrations of 1.25 mg/1. Experiments were carried out as described in paragraph 3.2.4.3 
(page 51). Two separate experiments were carried out. 
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5.2.1.4 Statistical analysis 
All data were analysed statistically by ANOV A. The results were considered statistically 
significant if p :S 0.05. Average values and standard errors are reported for all experiments. 
P-values are not reported for the e4C]-oxalate deposition experiment due to the small sample 
SIZe. 
5.2.2 Ultrafiltered urine study 
5.2.2.1 Urine collection and treatment 
Independent pooled urines from black and white males, each consisting of equal volumes 
(300 ml) of five 24-hour urine specimens in accordance with the recommendations of a study 
for the optimum pooling of samples (Jappie and Rodgers 2000), were prepared. Each pooled 
urine was filtered (0.75 J.Lm pre-filter, 0.45 J.Lm, 0.22 J.Lm) and divided into two portions. One 
portion was retained for the MSL determination and the residual volume was ultrafiltered 
through a 10 kDa membrane (Millipore) in order to remove all macromolecules larger than 
10 kDa including UPTF 1 and retained for crystallisation studies. The ultrafiltered urine from 
black and white males is henceforth referred to as BUF and WUF respectively. Urine 
composition data (rrunol/1) and physicochemical parameters were computed for each pooled 
urine (paragraph 2.2.1. page 26); no relative supersaturation values were computed since these 
are not appropriate for pooled urines. Urine composition data was analysed statistically by 
ANOVA and the results considered statistically significant if p :S 0.05. Average values and 
standard errors are reported. 
5.2.2.2 Cross-over experiment 
The effects of WF 1 and BF 1 on CaOx crystallisation in ultrafiltered urine were compared 
using a cross-over design previously described (Craig et al. 1999). In this protocol, depicted in 
Figure 5.1 (page 108), BUF and WUF were each divided into three equal aliquots. Two 
aliquots of each ultrafiltrate were dosed with BF 1 and WF 1. at final concentrations of 
1.25 mg/1, while the remaining aliquot was left unaltered and retained as a control sample. 
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Figure 5.1: Cross-over design employed for UPfFl crystal&ation study. WUF: pooled, 
ultrafiltered urine from white males; BUF: pooled, ultrafiltered urine from black males; control: 
untreated ultrafiltered urine; +WFJ: ultrafiltered urine after addition of WFl at a final 
concentration of 1.25 mgll; +BFJ: ultrafiltered urine after addition ofBFl at a final concentration 
of1.25 mgll 
5.2.2.3 Effect ofUPTFJ on particle number, volume and size 
The CaOx MSL of each pooled urine was detennined according to the method of Ryall and 
co·workers (Ryall et a/. 1985; paragraph 2.2.7, page 32). As previously described 
(paragraph 5.2.1.2, page 106), equal NaOx loads (30 mmol/1 in excess ofMSL) were added to 
the control and protein-dosed ultmfiltrates to induce crystallisation. This was followed by 
incubation at 37 °C in a shaking water bath (100 rpm) for 120 minutes. The effect ofBF1 and 
WF1 on the particle number, particle volume and particle size distribution was measured at 
120 minutes using a Coulter Counter! (140 J.lm orifice, 2.8 • 90.0 J.lm particle size range, 
64 channels). The number of independent pooled urines from each population group used for 
the crystallisation studies are as follows: particle number and volume measurements: n=5; size 
measurements: n=4. 
After completion of two experiments from each population group, aliquots (2 ml) of the 
control and protein-dosed sample urines were filtered (0.22 J,lm) and prepared for examination 
by scanning electron microscopy (paragraph 2.2.2.3, page 28). 
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5.2.2.4 Effect of UPTF1 on [14C]-oxalate deposition 
Aliquots (25 ml) of ultrafiltered urine were left untreated or dosed with WFI or BFI at fmal 
concentrations of 1.25 mg/1. Experiments were carried out as described elsewhere 
(paragraph 3.2.4.3, page 51). Three independent pooled urines from each population group 
were used for this experiment. 
5.2.2.5 Statistical analysis 
Urine composition data were analysed statistically by ANOV A and the results considered 
statistically significant ifp ~ 0.05. Average values and standard errors are reported. 
For the particle number, volume and size studies, protein-dosed urines were defined as 
being the same as their control ultrafiltrates if their difference was less than 5 %. In each of 
these studies, experiments that differed to the trend displayed by the majority were excluded 
from the average calculations. Average values and standard errors are reported. No p-values 
were computed since independent urine samples were used for the replicate experiments. 
5.2.3 Sedimentation kinetics 
5.2.3.1 Effect of UPTF1 on COM crystal slurries 
Sedimentation kinetics of COM crystal slurries were tested in the absence and presence of 
UPTFI isolated from the urine of white and black subjects. Crystal slurries were prepared by 
the addition of 1.0 mglml COM crystals to a buffer containing 0.010 mol/1 Tris-HCl, 
0.270 mol/1 NaCl (pH 7.2) (Hess et al. 1989). Crystal slurries were equilibrated overnight (at 
least 16 hours) at 37 °C with stirring (1100 rpm) to ensure that equilibration saturation had 
been achieved after which UPTFI was added at a final concentration of 1.25 mg/1. The slurries 
were then treated as described in paragraph 2.2.3 .2 (page 29). 
5.2.3.2 Effect of UPTF 1 on COD crystal slurries 
Preparation of calcium oxalate dihydrate crystals 
COD crystals were prepared according to Brown et al. ( 1989), with modification to the 
incubation temperature and pH. These modifications were necessary since under the 
conditions prescribed by Brown, small percentages of COT (<10 %) were formed in the 
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present study. Citrate, magnesium and potassium ions were used to stabilise the dihydrate 
morphology. A solution containing 0.0385 mol/1 Na3C6H50 7.2H20, 0.0462 mol/1 
MgS04.7H20 and 0.255 mol/1 KCl was prepared in a final volume of 250 ml distilled water 
(solution 1 ). A 125 ml solution of 0.0251 mol/1 CaCh (solution 2) was then added to solution 
1 with mixing. The pH of the mixture of solutions 1 and 2 was adjusted to 6.5 and left to 
equilibrate at 25 De in a water bath for 10 minutes (solution 3). A 125 ml solution of 
6.40 rnmol/1 NaOx was added to solution 3 and the mixture was left to equilibrate at 25 De in a 
water bath for 10 minutes. The crystals were then collected from the final mixture by filtration 
(0.22 f.A.m filters), washed with methanol and dried at 37 De for at least 1 hour. 
The crystal morphology was identified by XRD analysis (paragraph 2.2.2.1, page 27) 
and confmned by TGA (paragraph 2.2.2.2, page 28). A 0.1 mg sample was also retrieved on 
filter paper (0.22 f.A.m) and prepared for examination using a scanning electron microscope as 
described in paragraph 2.2.2.3 (page 28). 
Measurement of sedimentation rate 
The analogous experiment to that described in section 5.2.3.1 (page 109) was carried out, 
except that COD crystal slurries were used instead of COM crystal slurries. 
5.2.3.3 Statistical analysis 
The slope of each absorbance versus time plot was determined by linear regression analysis. 
The R2 corresponding to the slope is reported for these analyses. The average slopes for the 
WF 1 and BF 1-dosed crystal slurries were compared statistically by ANOV A and considered 
statistically significant if p :S 0.05. 
5.2.4 Zeta potentials 
5.2.4.1 Effect of UPTFJ on COM crystal slurries 
The zeta potential of COM crystal slurries was tested before and after addition of UPTF1 
isolated from the urine of white and black subjects. The experiments were carried out as 
described in paragraph 2.2.4.3 (page 31) except that UPTF1 (at a final concentration of 
1.25 mg/1) was added to the COM crystal slurry instead of urine. 
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5.2.4.2 Effect of UPTF1 on COD crystal slurries 
The zeta potential of COD crystal slurries was tested in the absence and presence of UPTF 1 
isolated from the urine of white and black subjects. The experiments were carried out as 
described for the COM crystal slurries above. 
5.2.4.3 Statistical analysis 
The average zeta potential of the WFl and BFl-dosed crystal slurries were compared by 
ANOVA. The results were considered statistically significant if p :S 0.05. 
5.3 RESULTS 
5.3.1 Synthetic urine study 
5.3.1.1 Metastable limit 
The average CaOx MSL plot of the synthetic urine, shown as particle number versus NaOx 
concentration, is presented in Figure 5.2. The data from which the plot was obtained is 
presented in Appendix D (Table Dl, page A35). The MSL was determined as being equivalent 
to 45 mmol/1 NaOx, as indicated by the enlarged data point below. 
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Figure 5.2: A~rage plot of particle number wrsus sociurn 
oxalate concentration in synthetic urine 
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5.3.1.2 Effect ofUPTFJ on particle size 
Figure 5.3 shows the average particle volume-particle size distributions at 120 minutes after 
addition of a NaOx load. A decrease in the average particle size was observed after addition of 
WF1 and BF1 as indicated by a shift in the mode of the protein-dosed distributions to smaller 
values compared to the synthetic urine. The average particle size values are reflected in 
Table 5.1. The average size in the undo sed synthetic urine was 17.45 J.lm compared with 
12.60 J.lm and 12.09 J.lm after addition ofWF1 and BF1 respectively. These values correspond 
to decreases of27.8 and 30.7% in particle size, respectively. The decrease in average particle 
size caused by both WF1 and BF1 was significant (p < 0.01) but no di:trerence between WF1 
and BF1 was detected (p > 0.05). However, a slight shift in the BF1-dosed curve towards 
smaller particle sizes relative to the WF1-dosed curve was evident. All ofthe average particle 
size distributions and corresponding average particle size values are presented in Appendix D, 
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Figure 5.3: Awnge particle size clstrilutions in syndaetlc: 
urine. Synthetic urine (SU) before and after addition of WFI 
and BF I at fmal concentrations of l.25nWI 
Table 5.1: Particle size of synthetic urine (SU) before and after addition ofWFl and BFl at final 
concentrations of 1.25 mg/1 
Sample Size ave. •;. Deer. p-value n-value 
± SE_{Jun) wrtSU wrtSU 
su 17.45 ± 0.30 10 
SU+WF1 12.60 ±0.30 27.8 < 0.01 8 
SU+BF1 12.09 ±0.30 30.7 < 0.01 10 
SU+WFJ vs. SU+BFJ: p>0.05 
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Figure 5.4 shows scanning electron micrographs of CaOx crystals precipitated in the 
synthetic urine before (Figures 5.4.1 - 5.4.3) and after addition ofWFl (Figures 5.4.4 - 5.4.6) 
and BF1 (Figures 5.4.7 - 5.4.9). The synthetic urine typically consisted of large crystal 
aggregates composed of mainly small, oval-shaped COMs (<4 J.Lm in length) (Figures 
5.4.1 - 5.4.2) along with some single COM crystals. In addition, several long needle-shaped 
crystals (>15 J.Lm) were observed (Figure 5.4.3). After addition of UPTF1 from both 
population groups, typically large bipyramidal COD crystals (1 0 - 15 Jlm in diameter) were 
observed. A few small single, oval-shaped COMs and long, needle-shaped crystals remained 
after addition ofUPTF1 (SU+WF1 : Figure 5.4.6; SU+BF1 : Figure 5.4.9). The crystals in the 
protein-dosed urine were notably less highly aggregated and usually consisted of small 
clusters of COD crystals (SU+ WF 1: Figures 5.4.4 - 5.4.5; SU+BF1 : Figures 5.4. 7 - 5.4.8). 
Figure 5.4: Scanning electron micrographs of CaOx crystals deposited in synthetic urine. The 
crystals were precipitated from synthetic urine: mag 3K (Fig 5.4.1), mag 5K (Fig 5.4.2), mag 8K 
(Fig 5.4.3); synthetic dosed with WFl : mag 8K (Fig 5.4.4), mag lOK (Fig 5.4.5), mag 7K (Fig 5.4.6); 
and synthetic urine dosed with BFl : mag 2.5K (Fig 5.4.7), mag 6K (Fig 5.4.8), mag 8K (Fig 5.4.9). 
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5.3.1.3 Effect ofUPTFJ on t'CJ-oxalate deposition 
Figure 5.5 shows the average increase in the deposition of precipitated [14C]-oxalate during a 
120-minute time course after addition of a NaOx load. It is evident that WF1 and BF1 induced 
a decrease in the amount of precipitated material relative to the synthetic urine control sample. 
After 120 minutes, the percentage precipitated [14C]-oxalate decreased :from 57.6% in the 
synthetic urine to 46.9 and 48.4% in the urines dosed with WF1 and BF1 respectively. These 
decreases correspond to growth inhibition of 18.7 and 16.0 %, respectively. The initial rate of 
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The [14C]-oxalate deposition curves for the two separate experiments, as well as the 
data from which these plots were obtained, are shown in Appendix 0, Figure 02.1 -2.2 
(page A4l) and Table 03 (page A35), respectively. 
5.3.2 Ultrafiltered urine study 
5.3.2.1 Urine composition and metastable limit 
The average urine composition (mmol/l) and physicochemical parameters of the pooled urines 
from black and white subjects are presented in Table 5.2. 
Table 5.2: Average urine composition (mmol/1) and physicochemical parameters of pooled urines 
from white and black sub_iects (n=5) 
Variables White subjects Black subjects p-value 
(ave±SE) (ave±SE) 
pH 6.30±0.090 6.21 ±0.090 NS 
Volume(ml) 7006±703 6437 ±703 NS 
Metastable limit (mmol/1) 48.0±8.21 81.0±8.21 <0.05. 
Calciwn (mmoVI) 2.26±0.334 1.46± 0.334 NS 
Chloride (mmol/1) 105 ± 12.6 104 ± 12.6 NS 
Citrate (mmol/1) 1.73 ± 0.266 1.51 ± 0.266 NS 
Creatinine (mmoVI) 10.6± 1.49 11.0 ± 1.49 NS 
Magnesium (mmol/1) 2.74± 0.392 2.16± 0.392 NS 
Oxalate (mmoVl) 0.150 ± 0.020 0.112 ± 0.020 NS 
Phosphate (mmoVI) 20.3 ± 2.46 16.2 ± 2.46 NS 
Potassiwn (mmoVI) 25.0±4.49 26.3 ± 4.49 NS 
Sodiwn (mmol/1) 142 ± 21.6 146±21.6 NS 
Uric acid (mmolll) 2.27± 0.300 2.23 ± 0.300 NS 
*Significant difference between averages 
116 CHAP1ER5 
The results fur all ten pooled urines are presented in Appendix 0, Tables D4.1- D4.2 
(pages A36- A37). The data from which the MSL was determined is presented in Appendix 
D, Table 05.1 - 05.2 (page A38), and the corresponding plots are shown in Appendix 0, 
Figure 3.1-3.10 (page A42- A43). The NaOx concentration corresponding to the MSL is 
shown by the turning point of the plots. It is noted that the CaOx MSL was significantly higher 
in the black subjects (p < 0.05). This is consistent with a relatively lower risk in this 
population group. 
5.3.2.2 Effect ofUPTFJ on particle number and volume 
Table 5.3 and Table 5.4 show the particle number and volume data respectively measured at 
120 minutes after addition of a NaOx load. For the particle number data (Table 5.3) in the 
white groups' ultrafiltrates, four of five experiments showed a greater increase in particle 
number after addition of WF1 than after addition of BF1 and one experiment showed no 
difference between WF1 and BF1. In the black groups' ultrafiltrates, three offive experiments 
showed a greater increase in particle number after addition ofBF1 than after addition ofWF1, 
one showed no difference between WF1 and BF1 and the final experiment showed a greater 
increase. 
Table 5.3: Particle number (/500J11} of ultrafiltered urine from white (WUF) and black (BUF) 
subjects before and after addition ofWFl and BFl at final concentrations ofl.l5 mg/1 
WUF WUF+WFl WUF+BFl 
Experiment I 9203 19016 18542 
Experiment 2 9202 12414 9194 
Experiment 3 • 12512 14969 ll258 
Experiment 4 10937 19477 18489 
Experiment 5 7101 14668 7928 
Average± SE: 9791 ± 912 16109± 1357 13082 ± 2281 
BUF BUF+WFl BUF+BFl 
Experiment I • 8439 9021 14100 
Experiment 2 6130 12099 12108 
Experiment 3 9189 13836 18968 
Experiment 4 3296 5279 8048 
Experiment 5 • • 12361 22179 18396 
Average±SE: 6763± 1326 10059± 1879 13306±2269 
• Effects of WFJ and BF 1 were the same, 1e. difference between particle numbers < 5% 
• • Excluded from average calculation since trend differed to that of the majority 
For the particle volume data (Table 5.4) in the white groups' ultrafiltrates, four of :five 
experiments showed a greater increase in particle volume after addition ofWFI , while the last 
experiment showed the opposite trend. For the black groups' ultra:filtrates, two of five 
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experiments showed a greater increase in particle volume after addition of BFl, two of five 
experiments showed no difference between WF 1 and BF 1, and one showed a greater increased 
in particle volume after addition ofWF 1. 
Table 5.4: Particle volume (x106 J1m3/500 Jl.l) of ultrafiltered urine from white (WUF) and black 
(BUF) subjects before and after addition ofWFl and BF1 at final concentrations of1.25 mg/1 
WUF WUF+WFl WUF+BFl 
Experiment 1 1.532 2.552 1.972 
Experiment 2 2.473 4.932 2.697 
Experiment 3 8.899 11.510 9.972 
Experiment 4 6.121 8.806 6.953 
E:tg>eriment 5 • 1.394 2.804 3.627 
Average± SE: 4.756 ± 1.699 6.950 ± 1.993 5.399 ± 1.879 
BUF BUF+WFl BUF+BFl 
Experiment 1 • • 0.904 1.614 1.646 
Experiment 2 1.229 1.765 2.321 
E~eriment 3 • • 3.177 4.356 4.165 
Exj>eriment 4 1.569 4.440 5.530 
Experiment 5 • 1.672 2.782 2.377 
Average± SE: 1.720 ± 0.504 3.044 ± 0.783 3.415 ± 0.883 
• Excluded from average calculation smce trend differed to that of the maJority 
•• Effects ofWF I and BFI were the same, ie. difference between particle volumes< 5% 
When considering the avemge particle number and volume data, it is apparent that 
both WFl and BFl induced an increase in particle number and volume relative to the control, 
when tested in both population groups' ultmfiltmte. Furthermore, the greatest change in these 
pammeters resulted from the addition of the UPTF1 which was endogenous to that 
ultmfiltmte, i.e. BF1 increased particle numbers and volume more than WF1 in BUF, whereas 
WF1 increased particle numbers and volume more than BFl in WUF. 
Table 5.5 shows the corresponding avemge percentage change in particle number and 
volume, as well as in other particle pammeters which will be discussed later. The 
afore-mentioned trends for particle numbers are well illustmted by the percentage data. When 
BFl was added to BUF, particle numbers increased by 96.7 %, whereas addition of WF1 
resulted in an increase of only 48.7 %. Similarly, when WF1 was added to WUF, particle 
numbers increased by 64.5 %, whereas addition ofBF1 resulted in an increase of only 33.6 %. 
The same trends were observed for particle volumes. 
Table 5.5 also shows that BF1 's effect on particle number and volume in BUF is 
considembly greater than its e:trect in WUF (particle number and volume increases of96.7 and 
98.6% respectively in BUF, vs. 33.6 and 13.5% respectively in WUF). However, WFI 's 
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effect on WUF is greater than its effect in BUF with respect to particle number (particle 
number increases of 64.5 % in WUF vs. 48.7 % in BUF), but less e:trective than in BUF with 
respect to particle volume (particle volume increases of 46.1 % in WUF vs. 77.0 % in BUF). 
Table 5.5: Percentage change in average particle parameters of ultrafiltered urine from white 
(WUF) and black (BUF) subjects after addition of WFl and BFl at final concentrations of 
1.25 mg/1 
BUF experiment: WUF experiment: 
+WFI +BFI +WFI +BFI 
% Increase particle number 48.7 96.7 64.5 33.6 
% Increase particle volume 77.0 98.6 46.1 13.5 
%Decrease particle size 20.7 37.9 28.0 14.7 
%Decrease [14C)-ox deposition 30.2 43.0 33.8 21.7 
5.3.2.3 Effect ofUPTFJ on particle size 
Table 5.6 shows the particle sizes measured at 120 minutes after addition of an oxalate load. 
For the particle data measured in the white groups' ultrafiltrates, three offour experiments 
showed a greater decrease in particle size after addition ofWF 1, and one experiment showed a 
greater decrease in particle size after addition of BF1. For the black groups' ultra:filtrates, 
three of three experiments showed a greater decrease in particle size after addition ofBF1. The 
particle size distributions corresponding to each experiment is shown in Appendix D, 
Figures D4.1- 4.4 (page A44) and Figures D4.5- 4.7 (page A44), respectively. 
Table 5.6: Particle size (p.m) of ultrafiltered urine from white (WUF) and black (BUF) subjects 
before and after addition ofWFl and BFl at final concentrations of1.25 mg/1 
WUF WUF+WFI WUF+BFI 
Experiment 1 16.96 11.30 14.13 
Experiment2 14.13 10.60 12.72 
Experiment 3 16.96 12.72 14.13 
Experiment 4 * 15.54 12.01 11.30 
Average± SE: 16.02±0.94 11.54 ± 0.62 13.66± 0.47 
BUF BUF+WFl BUF+BFI 
Experiment 1 14.13 11.30 9.89 
Experiment 2 15.54 11.30 8.48 
Experiment 3 11.30 9.89 7.07 
Average± SE: 13.66 ± 1.45 10.83 ± 0.47 8.48 ± 0.81 
*Excluded from average cakulatzon smce trend differed to that of the ma]onty 
Figure 5.6.1 and 5.6.2 shows the average particle volume- particle size distributions 
at 120 minutes after addition of a NaOx load to the white and black groups' ultra:filtrate, 
respectively. A decrease in the average particle size was obsetved after addition ofWF1 and 
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BF 1, indicated by a shift in the mode of the protein-dosed distributions to smaller values 
compared to their respective ultrafiltrate controls. The greatest decrease in particle size 
resulted from the addition of the UPTF1 which was endogenous to that ultrafiltrate. Thus, 
WF 1 induced a decrease in the average size in WUF from 16.02 Jlm (± 0.94) to 11.54 Jlm 
(± 0.62}, while addition of BF1 induced a decrease in the size to only 13.66 f.1m (± 0.47) 
(Figure 5.6.1). Similarly, BF1 decreased the avemge size in BUF from 13.66 Jlm (± 1.45) to 
8.48 Jlm (±0.81}, while addition of WF1 decreased the size to only 10.83 fliD (±0.47) 
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Table 5.5 (page 118) also shows that BF1 's effect on particle size in BUF is 
considembly greater than its effect in WUF (particle size decrease of 37.9 % in BUF vs. 
14.7% in WUF). Similarly, WF1 's effect in WUF is greater than its effect in BUF (particle 
size decrease of 20.7% in BUF vs. 28.0% in WUF). These trends are similar to those 
observed for particle number and volume. 
Figure 5.7 shows scanning electron micrographs of CaOx crystals deposited after 
dosing with NaOx and addition of UPTF1 to each control ultrafiltrate (after 120 minutes). 
These microgmphs are representative of the two ultrafiltrates examined from each population 
group. No differences between BF1 and WF1-dosed ultrafiltrates were observed. Thus in the 
context ofthe microscopy study, BF1 and WF1 will collectively be referred to as UPTF I. 
Crystals deposited in BUF and WUF were typically highly aggregated with only a few single 
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crystals (Figures 5.7.1- 5.7.2 respectively). In contrast, both protein-dosed ultrafiltrates 
showed a notable decrease in the degree of aggregation (Figures 5.7.3- 5.7.4). 
Of interest is the observation that while deposits in BUF consisted ofboth COM and 
COD crystals (Figure 5.7.1), deposits in WUF were composed almost entirely ofdihydrates 
with typically only a few, very small (<1 J.1m diameter) COM crystals (Figure 5.7.2). After 
addition of UPTF1, mainly COM crystals were observed in the blacks' ultrafiltrate 
(Figure 5.7.3) while the hydrate composition in the whites' ultra:filtrate was unaffected, i.e. 
COD were observed (Figure 5.7.4). 
Figure 5.7: Scanning electron micrographs ofCaOx crystals deposited in ultrafiltered urine. The 
crystals were precipitated from: blacks' ultrafiltered urine (Fig 5.7.1), blacks' ultrafiltered urine dosed 
with UPTF1 (final concentration 1.25 mg/1) (Fig 5.7.2), whites' ultrafiltered urine (Fig 5.7.3), whites' 
ultrafiltered urine dosed with UPTF1 (final concentration 125 mg/1) (Fig 5.7.4.). All micrograph 
magnifications are 4.5 K. 
5.2.3.4 Effect ofUPTFJ on f 4C]-oxalate deposition 
Figures 5.8.1 and 5.8.2 show plots ofthe average increase in the deposition rate of precipitated 
[
14C]-oxalate during a 120-minute time course after addition of an oxalate load to the white 
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and black groups' ultra:filtrate, respectively. The average data corresponding to these plots is 
shown in Table 5.7. The plots of each ofthe individual WUF and BUF experiments is shown 
in Appendix 0, Figures 05.1 - 5.3 (page A45) and Figures 05.4-5.6 (page A45), 
respectively. The data from which the WUF and BUF plots were obtained is presented in 
Appendix 0, Table 06.1 (page A39) and Table 06.2 (page A39), respectively. 
For the rt4C]-oxalate deposition measured in the white groups' ultra:filtrates, two of 
three experiments showed a greater decrease in deposition after addition of WF 1 and one 
experiment showed a greater decrease after addition ofBF 1. In the black groups' ultrafiltrates, 
two of three experiments showed a greater decrease in deposition after addition ofBF1 and 
one experiment showed a greater decrease after addition ofWF1 . 
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Table 5.7: Average percentage precipitated (14C)-oulate in ultrafiltered urine from wbite (WUF) 
and black (BUF) subjects before and after addition of WF1 and BF1 at final concentrations of 
1.25 mg/1 
WUF experiment: BUF e:qteriment: 
Time WUF WUF+WFl WUF+BFl BUF BUF+WFl BUF+BFl 
0 0 0 0 0 0 0 
30 41.0 13.0 172 50.3 12.3 10.2 
60 52.4 23.9 26.7 58.6 33.9 16.2 
90 60.3 33.4 37.7 67.4 45.1 28.6 
120 55.5 36.8 43.4 70.9 49.5 40.4 
From the average data plotted in Figures 5.8.1 and 5.8.2 above, it is evident that BF1 
and WF 1 decreased the amount of precipitated material, when tested in both WUF (Figure 
5.8.1) and BUF (Figure 5.8.2). The greatest decrease in precipitate resulted from the addition 
of the UPTF1 which was endogenous to that ultrafiltrate. Thus after 120 minutes, WF1 
decreased the percentage precipitated [14C]-oxalate in WUF from 55.5% to 43.4 %, while 
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addition ofBF1 decreased the amount precipitated to only 36.8 %. These represent decreases 
in CaOx deposition of33.8 and 21.7% by WF1 and BF1 respectively relative to the whites' 
ultrafiltrate control (Table 5.5, page 118). Similarly, the addition of BF 1 decreased the 
percentage precipitated in BUF from 70.9% to 40.4 %, while addition ofWFI decreased the 
amount precipitated to only 49.5 %. These values correspond to decreases in CaOx deposition 
relative to BUF of43.0 and 32.0% by BFI and WF1, respectively (Table 5.5, page II8). 
5.3 .3 Sedimentation rates 
5.3.3.1 EffectofUPTFJ on COM crystal slurries 
Figure 5.9 shows a plot of the average rate of decrease in absorbance (620 nm) of a COM 
crystal slurry before and after addition of WFI and BFl. The individual experiments from 
which these averages were obtained are shown in Appendix 0 (COM: Figures 
06.I.1 - 06.I.6, page A46; COM+WF1: Figures 06.2.1 - 06.2.6, page A47; COM+BF1: 
Figures 06.3.1- 06.3.7, page A48). 
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Figure 5.9: A"\erage ODs2o .. ot ofCOMcrystal slurries. 
Before and after addition of WFl and BFl at final 
concentrations of 1.25~11 
It is apparent from Figure 5.9 that the sedimentation rate ofthe COM crystal slurry is 
greatly reduced by the addition ofboth WFI and BFI while the effect of the two population 
groups' UPTFI appears to be similar in this regard. This is supported by the data presented in 
Table 5.8. Both WF I and BF I significantly reduced the absorbance slope of the COM crystal 
slurry and thus inhibited crystal aggregation, shown by lA indices of 78.3 and 83.I %, 
respectively (p < O.OI). There was no significant difference between the effect ofWFI and 
,. 
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BFl (p > 0.05). The absorbance slopes fur the individual experiments from which the avemge 
slopes were obtained is shown in Appendix D, Table 07.1 (page A40). 
Table 5.8: Average absorbance slope (x-10.&81) and inhibition of aggregation (lA %) of COM 
crystal slurries before and after addition ofWF1 and BF1 at final concentrations of1.25 mg/1 
Sample AbtJOrbuce slope ~ p-value n-value 
ave.:t:SE~} (%) wrtCOM 
COM 336 ± 8.5 (0.981) 6 
COM+WF1 73 ± 8.5 (0.896) 78.3 < 0.01 6 
COM+BF1 57 ± 8.5 (0.909) 83.1 < 0.01 7 
COM+WFJ vs. COM+BFJ: p > 0.05 
5.3.3.2 Characterisation ofCaOx crystals 
The composition ofCaOx crystals prepared according to the method described by Brown et al. 
(1985) was verified by XRD, TGA and SEM. Figure 5.10 shows the XRD pattern of the 
crystals together with the d-spacings (A) of prominent peaks. The assignment of these peaks is 
shown in Table 5.9. All peaks corresponded with known COD reflections (refer to Table 2.1 
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Figure 5.10: X-ray powder diffraction pattern ofCaOI crystals prepared 
according to Brown et aL (1985) 
124 CHAPTERS 




6.32 COD ,...., 
4.44 COD 
3.93 COD 
3.42 could not assign 
3.08 COD 





2.34 COD , .... 
Figure 5.11 shows the decrease in weight (%) of the crystals as a function of 
temperature. The computed mass loss of 18.62% (at an onset temperature of 106.7 °C) 
corresponds closely with the theoretical value of21.96 % for the loss of two water molecules 
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Figure 5.11: Thermogravimetric analysis ofCaOx crystals prepared according 
to Brown etaL (1985) 
Figures 5.12.1- 5.12.2 show scanning electron micrographs of the CaOx crystals at 
different magnifications. Only small, bipyramidal crystals (~5 J..Lm in diameter) were observed 
in the CaOx sample. This morphology is typical of COD crystals. Thus, all three methods used 
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confirmed that the crystals prepared were composed of 100 % COD, as required for the COD 
crystal slurry studies. 
Figure 5.12: Scanning electron micrographs of CaOx crystals prepared according to Brown et aL 
(1985). The photographs were taken at the following magnifications: 9K (Fig 5.12.1) and 6K (Fig 
5.12.2). 
5.3. 3.3 Effect ofUPTFJ on COD crystal slurries 
Figure 5.13 shows a plot of the average rate of decrease in absorbance (620 run) of a COD 
crystal slurry before and after addition of WFI and BFI . The individual experiments from 
'Vhich these averages were obtained are shown in Appendix D (COD: Figures D7.1.1- D7.1.9, 
pagesA49-A50; COD+WFI : FiguresD7.2.1 - D7.2.12, pagesA51 - A52; COD+BFI : 
Figures 07.3.1- D7.3.10, pages A53 - A54). 
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It is apparent from Figure 5.13 that the sedimentation rate of the COD crystal slurry is 
greatly reduced by the addition of both WF1 and BF1, while the effect of the two population 
groups' UPTF1 appears to be similar. This is supported by the data presented in Table 5.10. 
Both WF1 and BF1 significantly reduced the absorbance slope of the COD crystal slurry and 
therefore inhibited crystal aggregation, shown by lA indices of 56.8 and 53.7 %, respectively 
(p < 0.01). There was no significant difference between the effect of WF1 and BF1 (p > 0.05). 
The absorbance slopes for the individual experiments from which the average slopes were 
obtained is shown in Appendix D (Table D7 .2, page A40). 
Table 5.10: Average absorbance slope (x-10~s-1) and inhibition of aggregation (lA %) of COD 
crystal slurries before and afte~ addition ofWF1 and BF1 at final concentrations of 1.25 mg/1 
COD 95 ± 2.9 (0.945) 9 
CODtWFl 41 ± 2.9 (0.954) 56.8 < 0.01 12 
CODtBFI 44 ± 2.9 (0.913) 53 .7 < 0.01 10 
COD+WFJ vs. COD+BFJ: p > 0.05 
5.3.3.4 Comparative ejfoct ofUPTFJ on COM and COD crystal slurries 
The ability of UPTF1 to inhibit aggregation of COM and COD crystal slurries was compared. 
Figure 5.14 shows the lA indices (± SE) of the COM (shown by the solid bars) and COD 
slurries (shown by the open bars) after addition of both WF1 and BF1 . 
COM+UPTFI COD+UPTFI 
COM+WFI COD+WJll COM+BI'l COD+BFl 
Figure 5.15: A\el"age 0/e irililition by lJ>1Fl 
Figure 5-14: Awrage % inhilition by WF1 and BFl in COM COM & COD slunies (final concentration 
& COD slurries (final coocentratioos cll.25mgll). l.25mgfl). 
L-------------------------~ 
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It is apparent that the extent of aggregation inhibition by UPTF 1 from both population 
groups is greater in COM than COD crystals. Since the inhibition by WF1 and BF1 was not 
significantly different in either crystal sluny, the lA indices for the two groups' UPTF 1 were 
averaged with respect to COM and COD. Thus UPTF1 collectively refers to WF1 and BF1 in 
Figure 5.15. The difference in inhibition by UPTF1 in COM and COD crystals is clearly 
shown here (p < 0.01). 
5.3.4 Zeta potentials 
5.3.4.1 Effect ofUPTFJ on COM crystal slurries 
Table 5.11 shows the average zeta potential (mV) values of a COM crystal sluny before and 
after addition of WF1 and BFl. The individual values from which the averages were 
calculated are presented in Appendix D (Table D8.1, page A40). These values are shown 
graphically in Figure5.16 (page 128). It is evident that the addition ofboth WF1 and BF1 
resulted in a decrease in zeta potential towards a more negative value. This is reflected by the 
significant decrease in zeta potential of the COM by WF1 and BF1 of 92.8 and 89.2 %, 
respectively (p < 0.01). The respective effects ofWF1 and BF1 were not significantly different 
(p > 0.05). 
Table 5.11: Average zeta potential of COM crystal slurries before and after addition ofWFl and 
BFl at final concentrations of 1.25 mg/1 
Sample ZPave. %Decrease p-value n-value 
±SE(mV) wrtCOM wrtCOM 
COM -16.7 ±0.55 6 
COM+WFI -32.2 ± 0.55 92.8 < 0.01 6 
COM+BF1 -31.6 ± 0.55 892 < 0.01 6 
COM+WFJ vs. COM+BFJ: p > 0.05 
5.3.4.2 Effect ofUPTFJ on COD crystal slurries 
Table 5.12 below shows the ave~ge zeta potential (mV) values of a COD crystal sluny before 
and after addition of WF1 and BFl. The individual values from which the averages were 
calculated are presented in Appendix D, Table D8.2 (page A40). These values are shown 
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Flgure 5.17: Average zeta p.Cential of COD slurries. 
Before and after addition of WFI and BFI at final 
concentrations of 1.25uWl 
It is evident that the addition of both WF1 and BFl resulted in a decrease in zeta 
potential towards a more negative value. This is reflected by the significant decrease in zeta 
potential of the COD by WFl and BF1 of 70.0 and 66.2 %, respectively (p < 0.01). The 
respective effects ofWFl and BFl were not significantly different (p > 0.05). 
Table 5.12: Average zeta potential of COD crystal slurries before and after addition ofWFl and 
BFl at final concentrations of1.25 mg/1 
Sample 'nave. %Decrease p-value n-value 
±SE(mV) wrtCOD wrtCOD 
COD -16.0 ± 0.62 6 
COD+WFI -27.2 ± 0.62 70.0 < 0.01 6 
COD+BFI -26.6 ± 0.62 66.2 < 0.01 6 
COD+WFJ vs. COD+BFJ:p > 0.05 
5.3.4.3 Comparative effect ofUPTFJ on COM and COD crystal slurries 
The effect ofUPTFl on the zeta potential of COM and COD crystal slurries was compared. 
Figure 5.18 shows the average percentage decrease in zeta potential ofthe COM (shown by 
solid bars) and COD slurries (shown by open bars) after addition of both WFl and BFl. It is 
apparent that the change in zeta potential towards a more negative value in the presence of 
UPTFl from both population groups, indicating a greater potential for inhibition of 
aggregation, is greater in COM compared with COD crystals. Since the inhibition by WF 1 and 
BFI was not significantly different in either crystal slurry, the percentage decrease for the two 
proteins was averaged with respect to COM and COD. Thus UPTF 1 collectively refers to 
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WFI and BFI in Figure 5.19. The difference in UPTFI activity in COM and COD crystal 
slurries is clearly shown here (p < 0.01). 
% 
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Figure 5.18: Alerage % decrease in zeta potential rl COM& 
COD slurries. After addition of WFJ and BF1 at final 
concentrations of 1 
5.4 DISCUSSION 






Figure 5.19: Alerage 0/e decrease in zeta puu:uo•• J 
of COM & COD slurries. After addition ofUYfFJ 
at a fmal concentration of 1.25mg/l 
The particle data obtained in synthetic urine suggests that UPTFI inhibits crystal growth and 
aggregation, regardless of the population group from which it is derived. Growth inhibition is 
shown by the decreased amount of deposited CaOx and smaller particle sizes, while the latter 
observation, along with electron microscopy data, also suggests reduced crystal aggregation in 
the presence of UPTFI. These results represent the first report of UPTFI ' s inhibitory activity 
in an inorganic solution. In addition, when compared with WFI, BFI appeared to result in the 
precipitation of more small crystals and a greater decrease in the initial rate of CaOx 
deposition. The formation of more small crystals is regarded as favourable since it reduces the 
supersaturation of CaOx (Kavanagh 1992). These observations are consistent with greater 
inhibition by BFI in the synthetic urine test solution. 
It is noteworthy that addition of UPTFI derived from both population groups resulted 
in a change in crystal morphology, from mainly COM crystals in undosed synthetic urine to 
almost exclusively COD in the protein-dosed urines. A similar polymorphism has been 
reported previously following the addition of macromolecules to inorganic solutions (Wesson 
et al. 1998). This may be regarded as a favourable response since the higher positive charge on 
130 CHAPTERS 
COD (due to the greater number of calcium ions per unit cell) results in greater repulsive 
forces between crystals, and therefore favours disaggregation (Cerini et a/. 1999). 
Furthermore, COD show a lower binding affmity for epithelial cell surfaces than COM 
crystals (Wesson eta/. 1998), thus reducing crystal retention in the collecting ducts. 
These results demonstrate that BF1 is a more efficacious inhibitor than WF1 in 
synthetic urine. The structural differences in UPTF1 from the two groups, in particular the 
black population's great number of Gla residues and higher number of sialic acid residues 
(chapter 4), are the most likely explanation. 
5.4.2 Ultrafiltered urine study 
Following the synthetic urine experiments, a more comprehensive study of UPTFl activity 
was conducted in urine using a cross-over design described earlier. In this study, an increase in 
particle volume was observed when urine was dosed with UPTF1. An increase in crystal 
volume can occur only if the total mass of deposited crystalline material increases (through 
increased nucleation and/or growth). However, when crystals clump together to form a 
"particle", an increase in total volume can occur through two possible mechanisms. Firstly, if 
imperfect packing of crystals takes place during aggregation, pores containing air or fluid are 
created, thereby generating a larger volume for the particle as a whole. This is an 
inte rcrystalline process. On the other hand, a second possibility is intracrystalline 
incorporation of urinary proteins into the crystal lattice, again generating a larger volume for 
the particle (Ryall et a/. 1995). The Coulter Counter simply measures the total volume of a 
particle, irrespective of whether there are intercrystalline pores or intracrystalline proteins. 
Thus, volume data obtained from this instrument may be incorrectly interpreted as crystal 
volume. This limitation can be overcome by C4CJ-oxalate deposition experiments which 
provide data about the total mass of crystalline material that has formed. 
In the present study, particle volumes increased in the presence of UPTFl, but the 
C4CJ-oxalate experiments showed that the total mass of deposited CaOx did not increase. 
Indeed, to the contrary, the total deposited mass decreased. Thus, the observed increase in 
particle volume cannot be attributed to the deposition of new crystalline material. 
Aggregation, with concommitant generation of pores, may also be eliminated as an 
explanation since particle size decreased and SEM observations revealed that less aggregation 
had in fact occurred. The only other possible explanation for the increase in particle volume is 
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increased nucleation and/or intra-crystalline incorporation of UPTF1 into the CaOx crystal 
lattice. The former is supported by the observed increase in particle numbers, and the latter has 
been demonstrated previously (Fleming eta/. 1999, Ryall eta/. 2000, chapter 8). 
The particle number and size data, [' 4C]-oxalate deposition experiments and SEM 
observations suggest that the presence of UPTF1, irrespective of the population group from 
which it is derived, promotes the nucleation of small crystals of CaOx (increased particle 
numbers; smaller sizes), but inhibits their growth (decreased deposition of [14C]-oxalate; 
smaller sizes). Inclusion of UPTFl into the crystal lattice occurs (increase in particle volume), 
but these inclusions, while increasing the overall volume of the particles, are not of sufficient 
magnitude to increase their size. The particle number (increase) and size data (decrease) as 
well as SEM are also consistent with inhibition of aggregation, or promotion of 
disaggregation. All of these observations suggest that UPTF1 has a protective role in both 
population groups. 
The observation that UPTFl inhibits CaOx crystal growth and aggregation m 
ultrafiltered urine is in agreement with Ryall et a/. (1995) . Of some interest is the further 
observation that the protein promotes nucleation. As mentioned above, this is regarded as a 
protective factor. Cerini and co-workers (Cerini eta/. 1999), in their study of urinary albumin 
in an inorganic solution, reported that an increase in the number of small crystals lowered 
urinary saturation and thus prevented larger crystals and aggregates from forming . 
Electron microscopy results showed a difference in CaOx hydrate composition of the 
urine from black and white subjects. In a study on the formation of stable crystalluria, CODs 
were formed in the presence of a raised urinary calcium excretion (Bums and Finlayson 
1980b, Hennequin et a/. 1998, Ryall et a/. 2001) while COM formation has been reported at 
lower calcium concentrations (Bums and Finlayson 1980b, Ryall et a/. 2001). Thus, the 
observation that the whites' ultrafiltrate consisted of mainly CODs is consistent with their 
relatively higher urinary calcium concentration, while the formation of COD and COM in the 
blacks' urine is consistent with the relatively lower calcium concentration in this population 
group (Modlin 1967, Whalley eta/. 1998, Rodgers and Lewandowski 2002). 
Furthermore, COM crystals were present exclusively after addition of UPTFl to the 
black groups' urine, while COD were present after the white groups' urine was dosed with 
UPTFl . The response of the former group was unexpected in light of previous reports that 
macromolecules result in the formation of mainly COD crystals. Moreover, the presence of 
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COD has been described as more protective than COM crystals (refer to page 130). However, 
given that the black population has a remarkably low incidence of stones, the presence of 
COM rather than COD crystals in their urine (both before and after dosing with UPTFl) is 
evidently not harmful and perhaps even an indicator of a unique protective factor in this 
population group. 
The results of the present study clearly demonstrate a synergistic relationship between 
urine composition and UPTFl activity during in vitro CaOx crystallisation. This relationship 
has not been reported previously. 
A comparison of the activity of UPTFl from the two groups shows that WFl 
demonstrated a greater inhibitory activity than BFl in WUF, while BFl was superior in BUF. 
These trends are open to several interpretations, involving properties of the proteins as well as 
the ultrafiltrates. Factors such as the relatively lower calcium concentration of the blacks' 
urine (Modlin 1967, Whalley et a!. 1998, Rodgers and Lewandowski 2002), which in turn 
determines their higher proportion of COM crystals, the relative binding affinities of the 
proteins for the CaOx hydrates which distinguish blacks and whites, and the possible presence 
of unidentified low molecular weight constituents in the respective ultrafiltered urines, could 
all play a role . 
The present study of UPTFl activity m ultrafiltered unne demonstrated several 
important findings. Firstly, in addition to confirming earlier findings that UPTFl is an 
effective inhibitor of CaOx crystal growth and aggregation in urine, the study showed that 
UPTFl promotes nucleation. The latter result has not been reported previously. Increased 
nucleation may be regarded as a protective mechanism. Secondly, and more importantly, a 
synergistic relationship between UPTFl and urine composition was observed which influences 
the inhibitory capacity of the protein. The lower calcium concentration and relative 
supersaturation of CaOx in the black subjects' urines (Table 5.2) could have contributed to the 
favourable synergistic relationship between UPTFl and urine composition in this group. 
Specifically, it is of considerable interest that in its endogenous urine BFl was found to be a 
superior inhibitor than WFl in its endogenous milieu (Table 5.5). This may indicate that the 
conformation adopted by BFl in BUF is the most efficacious in terms of inhibitory activity. 
5.4.3 Sedimentation rates and zeta potentials 
The results of the ultrafiltered urine study showed the potential importance of crystal 
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morphology with respect to UPTFl activity. Thus a comparative study of the activity of 
UPTFl from both population groups with regard to crystal aggregation in COM and COD 
crystals was conducted. Since crystal morphology can be more readily controlled in an 
inorganic solution, synthetically prepared CaOx crystals composed of either pure COM or 
pure COD were used in these studies. 
Both WFl and BFl strongly inhibited COM and COD crystal aggregation in the 
sedimentation rate study. Differences in the two population groups' UPTFl activity were not 
detected. However, the aggregation inhibition by UPTFl in the COM crystal slurry was 
considerably greater than in the COD slurry (80.7 %in COM vs. 55.2% in COD). 
The trend in zeta potentials was similar. While there were no detectable differences 
between WFl and BFl, the decrease in zeta potential by UPTFl towards more negative values 
in the COM crystal slurry, irrespective of population group, was significantly greater than in 
the COD slurry (90.8 % in COM vs. 68.3 % in COD). The decrease in zeta potential is 
indicative of a greater driving force towards disaggregation by action of the repulsive negative 
charge on the crystals (Hess and Kok 1996). A study of THM has shown that more negative 
zeta potentials correlate well with increased inhibitory activity (Scurr and Robertson 1986). 
The sedimentation rate and zeta potential studies therefore strongly suggest that the 
capability of UPTFl to disaggregate COM crystals is significantly greater than with COD 
crystals. In the inorganic media tested here, the interaction or binding between COM and 
UPTFl therefore appears to enable greater inhibition by UPI'Fl. 
5.4.4 Conclusions 
It is clear from the present study that while UPTFl is an effective inhibitor in both inorganic 
media and urine, its specific role with regard to CaOx crystallisation also varies accordingly. 
By investigating its inhibitory activity in several environments, valuable information was 
obtained on its inhibitory capacity as well as the factors necessary to facilitate and optimise 
this role. 
Three important factors, which both independently and collectively influence UPTFl 's 
inhibitory activity, are its calcium-binding properties (Benarous et al. 1976, Bloom and Mann 
1978), its Gla residues (Benarous et al. 1976, Bloom and Mann 1978, Grover and Ryalll999), 
and pH (Benarous et al. 1976). These factors determine the protein's conformation which, in 
turn, determines inhibitory activity. In a study of human PT, the parent compound from which 
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UPTF1 is derived, Benarous reported that the molecule had a positive affinity for calcium ions 
(related to the presence of Gla residues) resulting in a conformational change in the protein 
(Benarous et al. 1976). Bloom later showed the same results for the Gla-rich fragment of PT, 
namely PTF1 (Bloom and Mann 1978). More recent studies have confirmed that Gla residues 
also facilitate the urinary protein·s exceptional affinity for calcium ions (Grover and Ryall 
1999). Therefore changes in UPTF1·s calcium binding ability and/or the sequence or number 
of Gla residues are likely to influence the protein's conformation and hence its activity. The 
moderately higher activity of BF1 measured in the synthetic urine may therefore be due, in 
part, to its greater number of Gla residues compared with the white group· s UPTF1 
(chapter 4). 
Furthermore, a study of human PT showed optimal calcium binding in the pH range 
7.4- 8.5, with a rapid increase in binding at pH values approaching 7.4 (Benarous et al. 1976). 
The significantly higher urinary pH of blacks previously reported by our laboratory 
(Lewandowski et al. 2001), although not observed in this chapter, therefore suggests that BF1 
may have a superior calcium binding capacity compared to WFl. However, the fact that BF1 
was not a superior inhibitor to WF1 in all test solutions also suggests that factors other than 
pH interact synergistically to determine the protein's activity in urine. 
Ryall's recent report that UPTF1 is preferentially included into COM rather than COD 
crystals (Ryall et al. 2001), and thus presumably binds more strongly to COM, further 
confirms the significance of calcium binding in the role of UPTF 1. This finding may also 
explain the superior activity of UPTFl in COM compared with COD crystal slurries measured 
in the present study. It is possible that the binding of UPTF1 to COM crystals results in a 
protein conformation that is more favourable for inhibition of crystallisation. 
Further investigation of the relationship between CaOx crystal morphology, 
calcium binding and the role of UPTFl in black and white subjects is clearly warranted. This 
is especially important due to the different hydrate composition of urinary CaOx crystals from 
the two population groups reported here. However, it is already evident that t~e greater 
inhibition by BF1 in synthetic urine, and the more favourable synergistic combination of BF1 
in its parent urine compared with WF 1 in its own parent urine, may be important factors in the 
black population·s relative protection from kidney stone disease. 
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CHAPTER 6: URINARY & INTRACRYSTALLINE PROTEINS 
6.1 INTRODUCTION 
Earlier chapters in this thesis have described the isolation of UPTFl from the urine of white 
and black South Africans, and its comprehensive characterisation (chapter 4) and testing in 
inhibitory activity studies (chapter 5). These investigations offered insight into the possible 
contribution of this urinary protein plays in the black population's relative protection from 
kidney stone disease. 
The crystallisation inhibitor theory of stone formation suggests that the presence of 
certain ions, macromolecules or proteins in the urine of healthy individuals prevents the 
formation of stones (Robertson and Nordin 1982, Worcester 1996, Ryall 1997). An adjunct to 
this theory is that an abnormality in one of these inhibitors or its diminished expression may 
contribute to the precipitation of stone-forming salts and the resulting diseased state in 
stone-formers. 
Thus a further area that warranted evaluation was the urinary concentration of UPTF 1, 
and other proteins, as well as the amounts of protein associated with CaOx urine crystals in the 
two population groups. White stone-formers were included as a third group in this 
investigation. 
6.2 METHODS 
6.2.1 Urine treatment 
Twenty-four hour urine samples were collected in plastic bottles containing a boric acid 
preservative from subjects on their free unrestricted diets. Ten subjects were healthy males 
(19- 26 years) with no previous history of kidney stones (five white, five black). A further 
five subjects were white CaOx stone-formers (35- 50 years). All of these had either passed a 
stone or had one surgically removed during the six months prior to commencement of the 
study. The urine samples from these three groups are abbreviated as WC, BC and WSF, 
respectively. Each urine was tested for haematuria and infection, filtered and aliquots retained 
138 CHAPTER6 
for urinalysis as previously described (paragraph 2.2.1, page 26). Urine composition data was 
analysed statistically by ANOVA and the results considered statistically significant if p ~ 0.05. 
Average values and SE are reported. 
6.2.2 Crystal preparation 
The CaOx MSL of each unne was determined as outlined before (Ryall et a!. 1985; 
paragraph 2.2.7, page 32). Urines were then placed in glass beakers covered with parafilm and 
incubated at 37 °C with agitation (100 rpm). Thereafter, CaOx crystallisation was induced by 
the dropwise addition of a NaOx load (30.0 mmol/1 in excess of the MSL, 0.1 ml NaOx per 
1 00 ml urine) at 0 and I hour. After a further hour, the precipitated crystals were collected by 
filtration (0.22 J..Lm) and washed thoroughly with distilled water to remove surface-bound 
proteins and extraneous urine (Ryall eta!. 2001). A glass rod was used to remove crystals that 
had settled on the bottom of the beakers and the rod was rinsed thoroughly with distilled 
water. Crystals were dried at 3 7 °C for at least 30 minutes, collected from the filter paper using 
a metal spatula and stored in glass vials at -20 °C for later use. 
6.2.3 Characterisation of urine crystals 
The hydrate composition of each subject's CaOx unne crystals was identified by XRD 
(described in paragraph 2.2.2.1 on page 27). A sample (0.1 mg) of each was also set aside for 
examination using a scanning electron microscope. In this regard, crystal suspensions 
(0 .1 - I mg) were prepared in plastic eppendorf tubes with distilled water ( 1 J..Lg/J..Ll) and 
immediately filtered onto a 0.22 11m filter paper followed by washing with 2 m1 of distilled 
water. Filter papers were dried at 37 °C for 30 minutes and glued onto aluminium stubs and 
then treated as described previously (paragraph 2.2.2.3, page 28). 
6.2.4 Preparation of urine and crystals for protein analysis 
An aliquot (5 ml) of each urine sample was dialysed (10 kDa cut-off) extensively against 
distilled water and freeze-dried for analysis by SDS-PAGE and Western blotting. A sample of 
the CaOx crystals ( 1 0 - 20 mg) obtained from each subject was demineralised by the addition 
of 0.25 molll EDTA (pH 8.0) (1 ml per 10 mg) with stirring for 30 minutes. The resulting 
solution was then centrifuged at 11 000 g for 2 minutes and the supernatant was loaded onto a 
P2 BioGel desalting column. Fractions were collected at 4-minute intervals and the 
absorbance measured at 280 nm. The first peak eluted from the column corresponded to the 
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protein content of the crystals; this was freeze-dried in a plastic eppendorf tube. Proteins from 
the urine and crystal samples were stored at -20 °C for later use. 
6.2.5 SDS-PAGE 
Protein samples derived from urine (0.3- 0.5 ml) and CaOx crystals (0.9- 2.7 mg) were 
dissolved in the minimum amount of distilled water and diluted 1:4 with 5x SDS reducing 
buffer. The proteins were resolved using 15 % polyacrylamide gels and visualised by silver 
staining (described in paragraph 3.2.3.1, page 49). A lower percentage of bis-acrylamide 
(0.2 %) was used for the WSF gels compared with the WC and BC gels (1.8 %). 
6.2.6 Western blotting 
Protein samples derived from urine (1 ml) and CaOx crystals ( 1.8 - 5.4 mg) were resolved by 
SDS-PAGE and transferred onto nitrocellulose membranes for immunodetection as previously 
described (paragraph 3.2.3.2, page 50). The primary antibody used was a rabbit anti-human PT 
antibody (DakoCytomation, Glostrup, Denmark) at a dilution of 1:500 with a secondary rabbit 
antibody (Amersham Biosciences, New Jersey, USA) at a dilution of 1:1000. 
6.3 RESULTS 
6.3.1 Urine composition 
The average urine composition (mmol/24hr) and physicochemical data of specimens from 
white and black control subjects and white stone-formers are presented in Table 6.1. The 
values for each 24-hour urine are given in Appendix E (WC: Table E1, page A55; BC: 
Table E2, page A55; WSF: Table E3, page A56). Attention is drawn to the significantly lower 
urinary pH, and the higher creatinine and sodium excretions of the white stone-formers 
compared with the white control subjects (p < 0.05). However, the creatinine levels were all 
within the accepted normal range recorded in South Africa (personal communication: 
PathCare, Cape Town, South Africa). 
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Table 6.1: Average urine composition (mmol/24hr) and physicochemical parameters of white 
and black control subjects and white stone-formers (n=5) 
Variables we average BCaverage WSFaverage p-value: p-value: 
±SE ±SE ±SE WCvs.BC WCvs.WSF 
pH 6.40:1::0.120 6.29 ±0.120 5.88:1::0.120 NS <0.05 
Volume (ml/24hr) 1076:1::359 1246:1::359 1877:1::359 NS NS 
Metastable limit (mmoVI) 60±22 63±22 66±22 NS NS 
Calcium (mmol/24hr) 3.73 ±0.585 3.15 ±0.585 5.46 ±0.585 NS NS 
Chloride (mmol/24hr) 122 ±28.0 160 ±28.0 153 :1::28.0 NS NS 
Citrate (mmol/24hr) 2.10 ±0.442 2.32 ±0.442 2.77 ±0.442 NS NS 
Creatinine (mmol/24hr) 14.3 ± 1.73 17.7 :1:: 1.73 18.1 ± 1.73 NS <0.05 
Magnesium (mmol/24hr) 2.79 ±0.629 2.73 ±0.629 3.69:1::0.629 NS NS 
Oxalate (mmol/24hr) 0.17 :1:: 0.0355 0.20 :1:: 0.0355 0.16 :1::0.0355 NS NS 
Phosphate (mmol/24hr) 27.4±6.27 30.4±6.27 33.8 ± 6.27 NS NS 
Potassium (mmol/24hr) 53.3 ±8.84 41.4± 8.84 51.5 ± 8.84 NS NS 
Sodium (mmol/24hr) 62.0 ±38.2 82.4± 38.2 248:1::38.2 NS <0.05 
Sulphate (mmol/24hr) 16.0 ± 3.90 18.0± 3.90 19.3 ± 3.90 NS NS 
Uric acid (mmol/24hr) 3.84 ±0.521 3.6:1::0.521 4.5 ±0.521 NS NS 
RS Brushite 2.03 ±0.300 1.27:1::0.300 1.06:1::0.300 NS NS 
RS Calcium oxalate 4.10 ± 0.867 3.62 ±0.867 2.74±0.867 NS NS 
RS Uric acid 1.10 ±0.627 1.11 ± 0.627 3.09:1::0.627 NS NS 
RS: Relative supersaturation; NS: not significant, i.e. p > 0.05 
6.3.2 X-ray powder diffraction 
The XRD patterns of crystals precipitated from each subject's urine sample along with the 
d-spacings (A) of the prominent peaks is shown in Appendix E (WC: Figure El.l- El.S, 
page A60; BC: Figure E2.1 - E2.5, page A61; WSF: Figure E3.1 - E3.5, page A62). The 
assignment of these peaks to particular CaOx hydrates and the corresponding estimated 
percentage hydrate composition of the crystals is tabulated in Appendix E (WC: Table E4, 
page A57; BC: Table E5, page A58; WSF: Table E6, page A59). 
The CaOx hydrate composition of each subject's crystals is presented in Table 6.2 
Table 6.2: Estimated hydrate composition of CaOx crystals precipitated from the urine of white 
and black control subjects and white stone-formers 
Subject White subjects: Black subjects: White stone-formers: 
number %COM %COD %COM %COD %t:;OM %COD 
1 40 60 0 100 35 65 
2 0 100 50 50 70 30 
3 0 100 100 0 0 100 
4 0 100 60 40 0 100 
5 0 100 30 70 65 35 
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Pure COD crystals precipitated in four of the urines from white control subjects. On 
the other hand, mixtures of COM and COD were the characteristic feature of crystals that 
precipitated from the urines ofblack subjects and white stone-formers. 
6.3.3 Scanning electron microscopy 
Figure 6.1 shows scanning electron micrographs of urine crystals obtained from five white 
control subjects. The predominance of bipyramidal-sbaped COD crystals is clearly evident 
here. In fuct, only one subject' s urine precipitated disc-shaped COM crystals, namely WC1 
(Figures 6.1.1 - 6.1.2). The COD crystals from these subjects typically ranged in diameter 
from 10-25 JUD.; the diameter of COM observed in WC1 was 5- 10 J1l1l. 
Figure 6.1: Scanning electron micrographs of CaOx crystab from the urine of white control 
subjects. The crystals are from the following subjects: WCI, mag 8.0K (Fig 6.1.1) and mag IlK 
(Fig 6.1.2); WC2, mag 3.94K (Fig 6.1.3); WC3, mag 3.0K (Fig 6.1.4); WC4, mag 8.0K (Fig 6.1.5); and 
WCS, mag 4.05K (Fig 6.1.6). 
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The crystals precipitated from the urine offive black control subjects are shown 
in Figure 6.2 below. Attention is drawn to the mixture of disc-shaped COM and bipyramidal 
COD crystals in this control group's urine. The exception to this trend was BCl whose 
crystals were composed almost exclusively of COD (Figure 6.2.1) with a few very large 
plate-like trihydrate crystals (Figure 6.2.2). This CaOx hydrate is seldom obsetVed in urine 
and thus its obsetVation here is noted with interest. The size range of COM crystals typically 
ranged from 5 - 10 J.Ull in diameter compared with an average diameter of 1 0 J.Ull for the COD 
crystals. Only BC5 had larger COD crystals, which averaged 22 J.Ull in diameter (Figure 6.2.6). 
Figure 6.2: Scanning electron micrographs of CaOx crystals from the urine of black control 
subjects. The crystals are from the following subjects: BC 1 at mag 9 .OK (Fig 6.2.1) and mag 4.5K 
(Fig 6.2.2); BC2 at mag 6.0K (Fig 6.2.3 ); BC3 at mag 8.0K (Fig 6.2.4 ); BC4 at mag 6.12K (Fig 6.2.5); 
and BC5 at mag 4.0K (Fig 6.2.6). 
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Scanning electron micrographs of unne crystals obtained from five white 
stone-formers are shown in Figure 6.3 below. The trend observed in these subjects' urines was 
towards the presence of mainly bipyramidal-shaped COD crystals, although a significant 
number of disc-shaped COMs were also observed in WSF1 (Figures 6.3.1 - 6.3.2), WSF2 
(Figures 6.3.3) and WSF5 (Figures 6.3.7- 6.3.8). Several large, tightly packed COD 
aggregates were observed in WSF4's sample as shown in a survey view of the stub 
(Figure 6.3.5). A close-up of these unusual aggregates is shown in Figure 6.3.6. The size of 
COM crystals typically ranged from 6- 8 J.Ull in diameter compared with an average diameter 
of 10- 15 J.Ull for the COD crystals. One stone-former (WSFl) had significantly larger COD 
crystals with an average diameter of22 J.Ull (Figures 6.3.1- 6.3.2). 
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Figure 6.3: Scanning electron micrographs of CaOx crystals from the urine of white 
stone-formers. The crystals are ftom the following subjects: WSFl at mag 7.7K (Fig6.3.1) and 
mag 4.0K (Fig 6.3.2); WSF2 at mag 5.0K (Fig 6.3.3); WSF3 at mag 5.0K (Fig 6.3.4); WSF4 at 
mag l.OK (Fig 6.3.5) and mag 4.0K (Fig 6.3.6); and WSF5 at mag 5.0K (Fig 6.3.7) and mag 6.0K 
(Fig 6.3.8). 
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6.3.4 Protein analysis 
6.3.4.1 White control subjects 
The desalting chromatograms of demineralised crystals prepared from the urine of white 
control subjects are shown in Appendix E (Figures E4.1- E4.5, page A63). The first peak in 
each chromatogram corresponds to the protein content of the crystals (confirmed by 
SDS-PAGE) while the second peak is the salt content (partly from the EDT A solution used for 
demineralisation and partly from the crystals themselves). 
The SDS-PAGE of urine samples from white control subjects and the crystals 
precipitated from each of these samples are shown in Figures 6.4.1 and 6.4.2, respectively. 
The urine samples contained several proteins over a wide range of molecular weights, in 
contrast to the crystals which contained fewer proteins all of which were 31 kDa and larger. 
Figure 6.4: SDS-PAGE of urine and CaOx urinary crystals from white control subjects. 
Samples were sepamted through a 15% polyac.rylamide, 1.8% bisac.rylamide SDS-PAGE. 
Figure 6.4.1. The patterns were obtained from urine samples as shown, MW: low molecular weight 
standard; 1: WCl (0.5 ml); 2: WC2 (0.5 ml); 3: WC3 (0.5 ml); 4: WC4 (0.5 ml); 5: WC5 (0.5 ml). 
Figure 6.4.2. The patterns were obtained from CaOx urina.ry c.rystals as shown, MW: low molecular 
weight standard, 1: WCl (0.9 mg); 2: WC2 (2.7 mg); 3: WC3 (2.7 mg); 4: WC4 (2.7 mg); 5: WC5 
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Six major bands were seen in all the urine samples with molecular weights of 18, 34, 
40, 48, 53 and 58 kDa (lanes 1 - 5). In addition to these, a broad and intense band at 65 kDa 
was observed in WC 1 's urine (lane 1 ), which was very mint in the other control subjects. This 
might correspond to albumin, one of the most abundant urinary proteins. Ditrerent intensities 
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of the six bands were observed amongst the five subjects, with the most intense bands 
observed in WCI (lane I) and the least intense bands in WC3 (lane 3). Two additional and 
very faint bands below 14 kDa were found in all ofthe urines. 
The CaOx crystals precipitated from these urines all contained significant amounts of 
two proteins, one at 57 and the other at 62 kDa with varying intensities (lanes 1 - 5). These 
bands were most prominent in the crystals from WCS (lane 5). A third band at 32 kDa (lane 1) 
was observed in WCl 's crystals, which had the same relative mobility as the UPTFI standard 
in lane Fl . 
Western blots of the urine samples and CaOx crystals with aPT antibody are shown in 
Figure 6.5.1 and Figure 6.5.2, respectively. Four of the five white control subjects (lanes I, 
3 - 5) have a similar amount of a 31 kDa band in their urine. This band corresponds to UPTF 1 
as confirmed by the UPTFI standard (Figure 6.5.2, lane Fl). The fifth subject's urine 
contained considerably less of this band (lane 2). Comparison of the intensity of the UPTFI 
bands in the urine samples with the 0.5 J..Lg UPTFI standard (Figure 6.5.2, lane Fl) suggests 
that the urine samples contain approximately 0.1 J..Lglml UPTFI, although this could not be 
quantified from the gel. 
Figure 6.5: Western blot of urine and CaOx urinary crystals from white control subjects 
immunoblotted for prothrombin. Figure 6.5.1. The patterns were obtained from urine samples as 
shown, 1: WC1 (1 ml); 2: WC2 (1 ml); 3: WC3 (1 ml); 4: WC4 (1 ml); 5: WC5 (1 ml). 
Figure 6.5.2. The patterns were obtained from CaOx urinary crystals as shown, 1: WC 1 (1.8 mg); 
2: WC2 (5.4 mg); 3: WC3 (5.4 mg); 4: WC4 (5.4 mg); 5: WC5 (5.4 mg); F1: 0.25 Jlg UPTF1 . 
Figure 6.5.1 Figure 6.5.2 
I 2 3 4 5 1 2 3 4 5 F1 
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6.3.4.2 Black control subjects 
The desalting chromatograms of demineralised crystals prepared from the urine of black 
control subjects are shown in Appendix E (Figures E5.1 - E5.5, page A64). The frrst peak in 
each chromatogram corresponds to the protein content of the crystals (confirmed by 
SDS-PAGE) while the second peak is the salt content (partly from the EDTA solution used for 
demineralisation and partly from the crystals themselves). 
Figures 6.6.1 and 6.6.2 show the SDS-PAGE of urine samples and their corresponding 
crystals obtained from five black control subjects. As observed in the white control samples, 
fewer proteins were included in the CaOx crystals than were observed in the urine samples, 
although this distinction is less apparent in the black control subjects. 
Figure 6.6: SDS-PAGE of urine and CaOx urinary crystals from black control subjects. 
Samples were separated by 15% polyacrylamide, 1.8% bisacrylamide SDS-PAGE. Figure 6.6.1. 
The patterns were obtained from urine samples as shown, MW: low molecular weight standard, 
1: BC1 (0.5 ml)~ 2: BC2 (0.5 ml)~ 3: BC3 (0.5 ml)~ 4: BC4 (0.5 ml)~ 5: BC5 (0.5 ml). Figure 6.6.2. 
The patterns were obtained from CaOx urinary crystals as shown, MW: low molecular weight 
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The same molecular weight bands were observed in the black controls' urine as for the 
whites, namely at 18, 34, 40, 48, 53, 58 and 65 kDa (lanes 1 - 5). The intensities of all of these 
bands differed considerably amongst the five subjects. The two bands most prominent in all of 
the urine samples were at 34 and 40 kDa. 
The CaOx crystals precipitated from these urines all contained significant amounts of 
three bands at 34, 54 and 60 kDa with varying intensities (Figure 6.6.2, lanes 1 - 5). Very little 
• 
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protein was included in BC5's crystals and it is likely that insufficient crystallisation occurred 
to allow for inclusion of protein. These three bands were most prominent in the crystals from 
WC5 (lane 5). The 34 kDa bands (most prominent in BC3, lane 3, and BC 4, lane 4) had the 
same relative mobility as the UPTF1 standard in lane Fl. 
Western blots of the urine samples and CaOx crystals with aPT antibody are shown in 
Figure 6. 7.1 and Figure 6. 7 .2, respectively. Three of the five black control subjects 
(lanes 3 - 5) had a similar amount of a 31 kDa band in their urine. This band corresponds with 
the UPTF1 standard in lane F1 (Figure 6. 7.1 ). One subject had a considerably higher amount 
of urinary UPTF1 (BC1, lane 1) while another had significantly less (BC2, lane 2). The 
intensity of the UPTF1 bands suggests that the urine samples contain approximately 0.1 J.lg/ml 
UPTF1 (i.e. lanes 3- 5), but two- to three-fold more in some samples (lane 1). These estimates 
could not be quantified from the gel. A second band below UPTF1 was also observed in BC1 
(lane 1) and BC4 (lane 4) probably due to degradation of UPTF1, possibly during sample 
processmg. 
Three of the subjects' crystals contained a 31 kDa band corresponding to UPTF1 
(BC2- 4, lanes 2- 4). The amount in BC3' s crystals was significantly higher than the other 
two subjects. Faint bands at 49 and 73 kDa corresponding to PTF1+2 and PT were also 
observed in BC2 and BC3' s crystals. 
Figure 6.7: Western blot of urine and CaOx urinary crystals from black control subjects 
immunoblotted for prothrombin. Figure 6. 7.1. The patterns were obtained from urine samples as 
shown, I : BCl (l ml); 2: BC2 (l ml); 3: BC3 (l ml); 4: BC4 (l ml); 5: BC5 (1 ml); FI: 0.5 J.lS 
UPTFl . Figure 6. 7.2. The patterns were obtained from CaOx urinary crystals as shown, 1: BCl 
(1.8 mg); 2: BC2 (1.8 mg); 3: BC3 (1 .8 mg); 4: BC4 ( 1.8 mg); 5: BC5 (1 .8 mg). 
Figure 6.7.1 
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6.3.4.3 White stone-formers 
The desalting chromatograms of demineralised crystals prepared from the urine of white 
stone-funners are shown in Appendix E (Figures E6.1 - E6.5, page A65). The first peak in 
each chromatogram corresponds to the protein content of the crystals (confirmed by 
SDS-PAGE) while the second peak is the salt content (partly from the EDT A solution used fur 
demineralisation and partly from the crystals themselves). 
The SDS-P AGE of five white stone-fonners' urine samples and the CaOx crystals 
precipitated from these urines is shown in Figures 6.8.1 and 6.8.2, respectively. As in the 
control subjects' urine, similar patterns were observed amongst the individuals but with 
ditrering intensities of any given band. The major bands were observed at 20, 48, 53 and 
59 kDa with a broad area containing several bands at 28-41 kDa (lanes 1- 4). The most 
noteworthy feature of the urines' protein patterns was the relative abundance of the protein at 
59 kDa which was equally evident in all of the white stone-fonners' samples, possibly 
corresponding to albumin. 
Figure 6.8: SDS-PAGE of urine aad CaOx urinary crystals from white stone-formers. 
Samples were separated through a 15% polyactylamide, 0.2% bisacrylamide SDS-PAGE. 
Fig111~ 6.8.1. The patterns were obtained ftom urine samples as shown, MW: low molecular weight 
standard; 1: WSFI (0.3 ml); 2: WSF2 (0.3 ml); 3: WSF3 (0.3 ml); 4: WSF4 (0.3 ml). Flgw~6.8.2. 
The patterns were obtained ftom CaOx urinary crystals as shown, MW: low molecular weight 
standard; 1: WSFI (1.8 mg); 2: WSF2 (0.9 mg); 3: WSF3 (0.9 mg); 4: WSF4 (1.8 mg); 5: WSFS 













MW 1 2 3 4 S F1 
A significantly fuwer number of proteins were included into the crystals (Figure 6.8.2) 
than their corresponding urine samples. Four of the five subjects' crystals contained bands at 
58 and 68 kDa (WSFl in lane 1, WSF2 in lane 2, WSF3 in lane 3, WSF5 in lane 5). All of 
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these except for WSF1 also had a prominent band at 65 kDa. These were the most prominent 
and characteristic of the white stone-fonners' crystals. A 38 kDa band with the same mobility 
as the UPTF1 standard in lane F1 was observed in two of the subject's crystals (WSF2 in 
lane 2, WSF5 in lane 5). Two subjects had :firlnt bands at 20 and 23 kDa (WSF1 in lane 1, 
WSF5 in lane 5). WSF4 had a ditrerent protein pattern to the other stone-fonners with a single 
band at 41 kDa. 
Figures 6.9.1 and 6.92 show Western blots of the urine samples and CaOx crystals 
using aPT antibody. All four stone-fonners' urine Oanes 1 - 4) contained a similar amount of 
a 31 kDa band which corresponds with the UPTF1 standard Oane F1). Based on the intensity 
of these bands, the quantity or UPTF1 is approximately 0.1 J.t&. A notable feature of the urine 
blot was the presence of intense bands at a high molecular weight. These may indicate the 
presence ofPT aggregates. Three subjects had fuint bands at 73 kDa which correspond to PT 
(WSF2 in lane 2, WSF3 in lane 3, WSF4 in lane 4). WSF1 had a fuint 49 kDa band 
corresponding to PTF1 +2. 
All of the subjects' crystals contained a 31 kDa band corresponding to UPTF 1 except 
for WSFl. The crystals from WSF2 and WSF5 contained approximately 1 J.l8 UPTF1 
(although this could not be quantified from the gel), while WSF3 and WSF4 had considerably 
less. Faint bands at 49 and 73 kDa corresponding to PTF1 +2 and PT were also observed in 
WSF2 and WSF5 's crystals. 
Figure 6.9: Western blot of urine and CaOx urinary crystals from white stone-formers 
immunoblotted for prothrombin. Figure 6.9.1. The patterns were obtained from urine samples 
as shown, I: WSFI (1 ml); 2: WSF2 (1 ml); 3: WSF3 (1 ml); 4: WSF4 (1 ml); FI: 0.25 J,1g 
UPTFI. Figure 6.9.2. The patterns were obtained from CaOx urinary crystals as shown, 1: WSFI 
(3.6 mg); 2: WSF2 (3.6 mg); 3: WSF3 (3.6 mg); 4: WSF4 (3.6 mg); 5: WSFS (3.6 mg). 
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6.4 DISCUSSION 
Many investigators have compared healthy and stone-forming subjects in an attempt to find 
factors that distinguish the two groups and thereby identify potential markers of stone 
formation. These studies have focused on two areas. The first area is that of urinary 
physicochemical parameters and the ability of urine to inhibit crystallisation. Lower urinary 
MSL (Ryall et a/. 1986, Asplin et a/. 1999), higher levels of urinary supersaturation, and 
reduced inhibition of COM aggregation (Tiselius et a/. 1995) have been reported amongst 
male stone-formers compared with control subjects. All of these trends indicate, a relatively 
higher risk in the former group. Growth inhibition appears to be the same in the two groups 
(Porile eta/. 1996, Worcester 1996), although some differences have been reported. However, 
these differences were less consistently observed amongst stone formers than the different 
effects on aggregation inhibition (Tiselius et a/. 1995). Robertson and Nordin (1982) reported 
larger particle sizes in the urine of stone-formers. However, a later study by Ryall and 
co-workers found the same crystals sizes in healthy and stone-forming subjects after addition 
of the same standard oxalate load in excess of their respective MSL (Ryall et a/. 1986). These 
apparent discrepancies may be due to differences in methodology. 
Secondly, studies have investigated the role of urinary proteins and in particular their 
relative concentrations and inhibitory properties. Reduced growth inhibition (Asplin et a/. 
1999) by stone-formers' urine proteins has been reported, as well as reduced inhibitory 
activity by THM (Hess et al. 1989) and nephrocalcin (Hess et al. 1989, Nakagawa eta/. 1987) 
isolated from stone-formers' urine. However, conflicting results with respect to the relative 
amounts of protein in urine and crystal extracts have been reported. These results will be 
discussed in detail later. 
Urine composition data in the present study indicated that the white stone-formers had a 
significantly lower urinary pH and a higher sodium excretion than the white control subjects. The 
stone-formers' lower urinary pH is surprising since an elevated urinary pH is usually regarded as 
risk factor for CaOx stones (Robertson and Nordin 1982). The raised urinary sodium of this group 
is, however, consistent with a report that increased dietary salt resulted in a greater risk of CaOx 
stone formation (Sakhaee et a/. 1993). The concomitant elevation in ionic strength amongst 
stone-formers may have influenced the conformation and binding of urinary proteins in this group. 
The small sample sizes in the present study, however, prescribe that the urine composition results 
not be over interpreted. 
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In the present study, a consistent trend was observed in all urine samples. Six dominant 
proteins were observed in the 14- 70 kDa molecular weight range. However, there was some 
variation in the relative amount of the proteins present. The distinctive major protein 
components amongst the three groups are noteworthy. Amongst the white subjects, no single 
protein was clearly dominant. In contrast, the 34 and 40 kDa bands were markedly more 
intense than the other protein bands in the black subjects. The identity of these proteins is 
unknown and requires further investigation. In the white stone-formers' urines, the 59 kDa 
band was the most prominent and may correspond to albumin. SDS-PAGE suggested that 
more total protein per millilitre of urine was observed in white stone-formers than in their 
control group, although this could not be quantified from the gels. Some black subjects' urine 
appeared to contain more total protein than the white subjects, although there was more 
intra-group variation amongst the former group. It is likely that in all subjects, filtration of 
their urine samples reduced the amount of albumin as well as selectively removing THM 
(Atmani et a/. 1998). These two proteins are usually observed at approximately 66 and 
80 kDa, respectively, on SDS-P AGE. 
Several recent studies have reported comparative urinary protein expressions between 
controls and stone-formers. Hedgepeth et a/. (2001) measured the relative density of 
inter-a-trypsin inhibitor trimer (220 - 240 kDa), OPN and PT -related protein bands on 
Western blots. No difference was found in the expression of UPTF1 from healthy and 
stone-forming males, in agreement with the present study. In fact, only inter-a-trypsin 
inhibitor trimer was differentially expressed, with significantly more of this protein in the 
CaOx stone-formers' urine than the control group. Stapleton reported increased PT expression 
in stone-formers' kidneys (Stapleton et a/. 1993), which is consistent with the probable PT 
aggregation observed in the present study on Western blots of stone-formers' urine. However, 
lower concentrations ofOPN (Yasui et al. 1999, Nishio et al. 2001) and UPTF1 (Nishio et al. 
2001) have also been reported amongst stone-formers. There is thus no clear trend in these 
studies to suggest that a general elevation or lowering of protein expression occurs amongst 
stone-formers. 
The inclination to draw firm conclusions from the urine data is tempered by the 
difficulties reported with the determination of certain urinary proteins. UPTF1 and OPN bind 
strongly to CaOx crystals (Ryall et al. 2001 , Atmani and Khan 2002) and may therefore often 
be underestimated in urine due to their inevitable association with crystals that form in vivo or 
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after urine collection (Dean eta/. 2000). Thus, the reliable quantitation of UPTFl in controls 
and stone-formers, as well as other intracrystalline proteins, will only be possible once an 
analytical method has been developed that addresses these difficulties. This suggests that the 
UPTFl determination reported by Nishio eta/. (2001) may be unreliable. 
The relative quantities of protein in the different groups are puzzling. On the one hand, 
the greater amounts of protein in the white stone-formers' urine compared to the white 
controls suggest a pathogenic role. On the other hand, it is tempting to suggest that higher 
levels of protein in the black control group relative to the white controls could be indicative of 
the inhibitory role of proteins. Perhaps the important factor to address is not the relative 
amounts of total protein, but rather the relative amounts of individual proteins. 
Several conunon features were also noted in the crystal extracts in the present study. 
SDS-PAGE demonstrated that, with the exception of WSF4, the two protein bands near 57 and 
62 kDa were present in all crystal extracts, regardless of the individual or group from which 
they were derived. These bands are likely to correspond to OPN on the basis of their 
approximate molecular weights and the similar appearance of these patterns to those obtained 
in another study in which the protein was identified by Western blotting (chapter 7). Similar 
protein patterns were observed for the white control and stone-forming subjects' crystals. In 
both groups, the 57 and 62 kDa bands were the major components, followed by UPTFL The 
black control subjects' crystals contained notably more protein bands than the white group. In 
particular, more crystal extracts from black as opposed to white subjects contained UPTF1 . 
The prominence of UPTF1 and OPN in CaOx crystal extracts has been reported 
previously. Atmani and co-workers have demonstrated the presence of PT-related proteins, 
OPN and albumin as the major crystal components derived from controls and stone-formers 
(Atmani eta/. 1996, 1998, Atmani and Khan 2002). Recently, PT-related proteins were shown 
to predominate in crystals from control subjects, whereas albumin predominated amongst 
stone-formers' crystals (Atmani and Khan 2002). Whole urine was used for all of these 
studies. Furthermore, Ryall eta/. have reported the inclusion of UPTFI and OPN as the major 
components of COM and COD crystals extracts, respectively (Ryall eta/. 2001). The latter 
study was conducted in filtered urine which explains the absence of albumin reported by 
Atmani. 
Inspection of the relative amounts of the two major intracrystalline protein 
components, UPTF1 and OPN, suggests a possible relationship between crystal morphology 
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and the protein(s) included therein, as Ryall has described previously (Ryall eta/. 2001). For 
example, the crystals composed of 100% COD (WC2 - WC5, BCI, WSF3) contained 
negligible amounts of UPTFl, but relatively large amounts of OPN. In comparison, crystals 
consisting of higher proportions of COM (BC3, WSF2, WSF5) contained a mixture of the two 
proteins. The greatest proportion of COD crystals was observed in the white control subjects, 
followed by the white stone-formers and the black subjects. 
The trends with regard to hydrate composition are interesting in light of recent 
crystal-cell interaction studies in which COM crystals have been shown to attach more readily 
to renal epithelial cells than COD crystals (Wesson eta/. 1998). This attachment process is 
believed to be a possible precursor to stone development since crystals attach to renal cells 
after exposure to CaOx (Lieske et a/. 1999). The presence of mainly COD in the urine of 
white controls as opposed to the presence of COD and COM crystals in white stone-formers is 
therefore consistent with the diseased state in the latter group. However, the higher percentage 
of COM crystals in black subjects is inconsistent with the crystal attachment theory and thus 
does not provide a rational explanation for the black group's apparent immunity. Thus crystal 
morphology may be associated with other factors that influence the stone-forming potential in 
this population group. Such factors may relate to the nature and quantity of the proteins which 
are incorporated into the crystals themselves. 
The present data showed the selective inclusion of proteins into CaOx urine crystals, a 
feature which was first reported by Morse and Resnick (1988) and was also shown in the CME 
study (chapter 3). At least six major proteins were observed in the three group's urines 
compared with only two major protein components in the crystal extracts. In particular, a large 
disparity between the urinary and intracrystalline amounts of UPTFl was demonstrated by 
Western blotting. For example, subject WC4 had no detectable intracrystalline UPTFl 
compared with approximately 0.5 J.Lg UPTFl per milligram of CaOx in WCl. These subjects 
appeared to have comparable urinary concentrations of the protein. This suggests that urinary 
proteins have different binding affinities for CaOx crystals which direct their inclusion. Thus, 
a clear distinction between urinary and intracrystalline proteins appears to be crucial to a 
discussion of the potential role of proteins in stone formation and its possible prevention. 
The present study was the first to investigate urinary and intracrystalline proteins in 
white and black subjects. Urinary levels of UPTFI amongst black and white control subjects 
as well as white stone-formers appear to be similar, although accurate and more reliable 
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quantitation may reveal otherwise. The apparent predominance of different urinary proteins in 
the three groups warrants further investigation as a possible indicator of their relative 
stone-forming potentials. 
The distinctive CaOx crystal compositions amongst white and black subjects were 
noteworthy, with a higher proportion of COM crystals in the latter group. This trend appears 
to correspond to differences in the typical matrix proteins observed and, more specifically, the 
observation that UPTFI is more consistently present in the crystals of black subjects than in 
the urine of white subjects (controls and stone-formers). Since the low stone incidence of 
stones in South African blacks is an a priori fact, it seems reasonable to infer that the 
afore-mentioned trends play a protective role in the black population. However, the role of 
COM is not entirely clear since a higher proportion of this hydrate was also observed amongst 
white stone-formers compared with their control group. Thus, further study of the relationship 
between crystal morphology and urinary proteins, and their role in stone formation, is 
required. 
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CHAPTER 7: UPTFl INCLUSION IN CALCIDM OXALATE 
MONOHYDRATE & DIHYDRATE CRYSTALS 
7.1 INTRODUCTION 
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Urine chemistry studies comparing South Africa's black and white populations have 
revealed a few significant differences, including the former's lower urinary citrate 
concentration (Modlin 1967, Meyers eta/. 1994, Whalley eta/. 1998, Lewandowski eta/. 
2001 ), higher urinary oxalate concentration (Lewandowski et a/ . . 2001) and lower urinary 
calcium concentration (Modlin 1967, Whalley et a/. 1998, Rodgers and Lewandowski 
2002). Of particular interest to the present study is the latter observation. 
As demonstrated previously, urinary crystals precipitated from black subjects are 
composed of a mixture of COM and COD crystals compared with the predominance of 
COD crystals amongst the white population urine (chapter 6). This observation was not 
surprising since lower urinary calcium is known to favour the formation of monohydrate 
crystals while the dihydrate morphology predominates at higher calcium concentrations 
(Burns and Finlayson 1980). Of interest is a recent report by Ryall that differences in 
crystal morphology are associated with the selective inclusion of urinary proteins into these 
crystals (Ryall eta/. 2001a). In particular, UPTF1 is the principal intracrystalline protein in 
COM crystals, whereas the principal intracrystalline protein in COD crystals is OPN. 
An objective of this thesis was therefore to investigate the chemical conditions 
required to precipitate pure COM and COD crystals from the urine of black and white 
subjects, and to qualitatively and semi-quantitatively compares the major proteins included 
in the crystals. 
7.2 METHODS 
7 .2.1 Urine treatment 
Twenty-four hour urine samples were collected in plastic bottles containing a boric acid 
preservative. The subjects were healthy black (ages 20- 25) and white males (ages 
19 - 26) on their free unrestricted diet. Urines were tested for haematuria and infection, 
pooled according to population group and filtered as described in paragraph 2.2.1 
(page 26). For the preliminary studies (black groups 1-3, white groups 1-3), the entire 
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24-hour urine from each subject (between 1 and 7 specimens) was pooled. However, for 
black group 4 and white group 4, an equal volume of the five urines was pooled in 
accordance with the recommendations of a study for the optimum pooling of samples 
(Jappie and Rodgers 2000). Aliquots of the pooled urines were retained for urinalysis 
(paragraph 2.2.1, page 26)~ relative supersaturations were not calculated since these are not 
appropraite for pooled urines. Urine composition data was analysed statistically by 
ANOVA and the results considered statistically significant if p :S 0.05. Average values 
along with their standard errors are reported. 
An aliquot of each pooled urine was not adjusted for its calcium concentration and 
was retained as a control sample, while the reminainder of the pooled sample was divided 
into several equal aliquots. The calcium concentration in these latter aliquots was adjusted 
by titration with a 1 mol/1 solution of calcium chloride or by addition of distilled water to 
give a final range of urinary calcium concentrations between 0.5 mmol/1 and 16 mmol/1. It 
should noted that all urinary constituents would be lowered by dilution and thus results 
could not be ascribed to a lowering of calcium concentration alone. 
7.2.2 Crystal preparation 
The CaOx MSL of each pooled urine was determined according to the method described 
by Ryall and co-workers (Ryall eta/. 1985~ paragraph 2.2.7, page 32). MSL determinations 
were repeated after adjustment of calcium concentrations. Crystals were then precipitated 
from these urines by addition of a standard NaOx load as decribed before (paragraph 6.2.2, 
page 138). 
7.2.3 Characterisation of urine crystals 
The composition of each batch of urine crystals was semi-quantitatively determined by 
XRD analysis as previously described (paragraph 2.2.2. 1, page 27). Crystals (0.1 mg) 
obtained from black group 4 and white group 4 were also examined by scanning electron 
microscopy (paragraph 2.2.2.3, page 28). 
7.2.4 Crystal preparation for protein analysis 
Samples of CaOx crystals ( 10 - 20 mg) obtained from black group 4 and white group 4 
were demineralised by the addition of EDTA, desalted and the resulting protein 
freeze-dried as previously described (paragraph 6.2.4, page 138). The protein was 
dissolved in distilled water to provide a final concentration of 1 mgll 0 J.ll and stored at 
-20 °C in plastic eppendorf tubes for later use. 
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7.2.5 SDS-PAGE 
Protein samples (obtained from 0.9-2.7 mg crystals) were dissolved in distilled water and 
diluted 1:4 with 5x SDS reducing buffer. The proteins were resolved by SDS-PAGE on 
15 % polyacrylamide gels and detected by silver staining as previously described 
(paragraph 3.2.3.1, page 49). 
7.2.6 Western blotting 
Protein samples (obtained from 1.8-5.4 mg crystals) were resolved by SDS-PAGE and 
transferred onto nitrocellulose membranes for irnmunodetection as previously described 
(paragraph 3.2.3.2, page 50). The antibodies used were rabbit anti-human PT 
(DakoCytomation, Glostrup, Denmark) at a dilution of 1 :500 and a rabbit polyclonal OPN 
antibody (Abeam, Cambridge, England) at a dilution of 1:1000. A secondary rabbit 
antibody (Amersham Biosciences, New Jersey, USA) was used at a dilution of 1:1000 
followed by detection with 4-chloro-1-napthol. 
7.3 RESULTS 
7.3.1 Urine composition 
Urine composition (mmol/1) and physicochemical data for pooled samples from the black 
and white groups are given in Tables 7.1.1 and 7.1.2, respectively (page 160). CaOx 
crystals were precipitated from these samples. Attention is drawn to the significantly lower 
urinary calcium and potassium concentrations in the black groups (p < 0.05). 
7 .3.2 X-ray powder diffraction 
XRD patterns of crystals prepared at various calcium concentrations from the urines of 
black group 4 (Figures 7.1.1 - 7.1.4) and white -group_ 4 (Figures 7.1.5 - 7.1.8), together 
with the d-spacing (A) of prominent peaks, are shown below (page 161). 
The assignment of these peaks to particular hydrates as well as the estimated 
percentage composition of the crystals is shown in Table 7.2.1 for black group 4 and 
Table 7.2.2 for white group 4 (page 162). The XRD patterns (black groups: 
Figures F1.1- F1.16, pages A 72- A74; white groups: Figures F2.1- F2.16, 
pages A75- A77), peak assignments and composition (black groups: Tables Fl. I- F1.3, 
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pages A66- A68; white groups: Tables F2.1- F2.3, pages A69- A71) of crystals prepared 
from black and white groups 1-3 are shown in Appendix F. 
Table 7.1.1: Urine composition (mmoVl) and physicochemical parameters of black groups' 
pooled urines 
Variables Black Black Black Black Black group 
~oup1 uoup_2 _group3 group4 ave. ±SE 
Number of urines 3 3 3 5 3.5 
Volume for crystal 50 100 80 300 133 
l'feparation (ml) 
pH 6.20 6.40 6.42 6.38 6.35 ±0.116 
Volume (ml/24hr) 4560 4890 4645 5615 4928 ±953 
Metastable limit(mmolll)* 150 >195 >195 105 >161 ± 15.5 
Calcium (mmolll) * 1.02 0.64 1.23 2.56 1.36± 0.760 
Chloride (mmolll) * 43.0 53.0 88.9 70.0 63.7 ±8.44 
Citrate (mmolll) 1.00 0.947 1.01 1.74 1.17 ± 0.784 
Creatinine (mmolll) 8.20 5.19 6.31 10.5 7.55 ± 1.09 
Magnesium (mmolll) 0.564 0.630 0.719 1.07 0.748 ± 0.716 
Oxalate (mmolll) 0.114 0.108 0.114 0.0873 0.106 ±0.0266 
Phosphate (mmolll) 12.8 4.60 10.3 18.8 11.6 ± 2.90 
Potassium (mmolll) * 10.7 10.2 17.2 17.7 14.0±3.77 
Sodium (mmolll) 216 95.5 76.6 23.2 103 ± 30.8 
Sulphate (mmolll) 10.1 6.30 9.47 6.07 7.98 ± 2.06 
Uric acid (mmolll) * 1.29 0.900 1.68 2.49 1.59 ±0.293 
*Significantly different to the white groups' pooled urine average (p<0.05) 
Table 7.1.2: Urine composition (mmoVl) and physicochemical parameters of white groups' 
pooled urines 
Variables White White White White White group 
~ou~1 uoup2 _group3 group4 ave. ±SE 
Number of urines 7 1 5 5 4.5 
Volume for crystal 50 100 200 400 188 
preparation (ml) 
pH 6.15 5.90 6.52 6.55 6.28 ± 0.116 
Volume (ml/24hr) 8665 2350 6465 6690 6042±953 
Metastable Iimit(mmolll)* 60 60 45 45 53± 15.5 
Calcium (rnmolll) * 6.52 1.67 3.96 4.08 4.06±0.760 
Chloride (mmolll) * 115 119 144 126 126 ± 8.44 
Citrate (mmolll) 5.99 1.07 2.21 1.90 2.79±0.784 
Creatinine (mmolll) 11.9 7.70 11.3 12.0 10.7 ± 1.09 
Magnesium (mmolll) 5.37 0.574 1.98 2.56 2.62 ±0.716 
Oxalate (mmolll) 0.226 0.0979 0.133 0.0508 0.127 ±0.0266 
Phosphate (mmolll) 23.4 13.1 26.4 19.9 20.7 ±2.90 
Potassium (mmolll) * 40.7 19.2 38.2 37.2 33.8 ± 3.77 
Sodium (rnmolll) 137 84.4 112 66.7 100± 30.8 
Sulphate (mmolll) 22.9 11.3 13.1 12.0 14.8 ± 2.06 
Uric acid (mmolll) * 3.09 2.38 3.50 3.20 3.04±0.293 
*Significantly different to the black groups' pooled unne average (p<0.05) 
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Figure 7.1: X-ray powder diffraction patterns of CaOx urine crystals. The crystals were 
precipitated from black group 4' s urine at: 0.50 mmolll Ca (7 .1.1 ), 1.00 mmolll Ca (7 .1.2), 
2.56 mmolll Ca (7.1.3), 12.0 mmolll Ca (7.1.4); and from white group 4's urine at: 0.50 mmolll 
Ca (7.1.5), 1.00 mmolll Ca (7.1.6), 4.08 mmolll Ca (7.1.7), and 12.0 mmolll Ca (7.1.8). 
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Table 7.2.1: X-ray powder diffraction peak assignments and estimated percentage 
composition of CaOx crystals precipitated from the urine of black group 4 
Ca d-spacing Assignment Composition: 
(mmolll) <A> %COM %COD 




2.41 COM 100 0 





2.50 COM 80 20 







2.37 COM 55 45 






2.37 COD 0 100 
* Control unne, 1.e. unadjusted Ca 
Table 7 .2.2: X-ray powder diffraction peak assignments and estimated percentage 
composition of CaOx crystals precipitated from the urine of white group 4 
Ca d-spacing Assignment Composition: 
(mmolll) <A> %COM %COD 
0.50 6.02 COM 
3.69 COM 
3.00 COM 
2.51 COM 100 0 







2.37 COM 70 30 






2.35 COD 0 100 




2.37 COD 0 100 
* Control unne, 1.e. unadjusted Ca 
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The percentage hydrate composition of all the black and white groups· urine 
crystals is summarized in Tables 7.3.1 and 7.3.2, respectively. Inspection of these trends 
indicates that at relatively low final calcium concentrations (0.5 mmol/1), pure COM 
crystals are obtained in both population groups • urine. The results further demonstrate that 
as the fmal calcium concentration increases, COD gradually replaces COM until pure COD 
is obtained in both groups· urine at final calcium concentrations 2:12 mmol/1. It is 
noteworthy that while the white groups· crystals often consisted of large percentages of 
COD at calcium concentrations of 8 mmol/1 or lower, significant amounts of COM 
( 40 - 50 %) were observed in the black groups· urine even at this relatively high calcium 
concentration. 
Table 7.3.1: Estimated hydrate composition of CaOx crystals precipitated from the black 
groups' urine at various calcium concentrations as determined by x-ray powder diffraction 
Ca Black group 1: Black group 2: Black group 3: Black group 4: 
(mM) %COM %COD %COM %COD %COM %COD %COM %COD 
0.50 100 0 100 0 100 0 
0.64 100* 0* 
1.00 55 45 80 20 
1.02 100* 0* 
1.23 60* 40* 
2.00 65 35 55 45 
2.56 55* 45* 
4.00 75 25 70 30 
8.00 40 60 50 50 45 55 
10.0 35 65 
12.0 0 100 0 100 
16.0 0 100 
* Control urine, i.e. unadjusted Ca 
Table 7 .3.2: Estimated hydrate composition of CaOx crystals precipitated from the white 
groups' urine at various calcium concentrations as determined by x-ray powder diffraction 
Ca White group 1: White group 2: White group 3: White group 4: 
(mM) %COM %COD %COM %COD %COM %COD %COM %COD 
0.50 100 0 100 0 100 0 100 0 
1.00 100 0 100 0 70 30 
1.67 100* 0* 
2.00 100 0 
3.96 0* 100* 
4.00 100 0 
4.08 0* 100* 
6.52 75* 25* 
8.00 0 100 40 60 
10.0 0 100 
12.0 0 100 0 100 0 100 
16.0 0 100 
* Control unne, i.e. unadjusted Ca 
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7.3.3 Scanning electron microscopy 
Figure 7.2 shows scanning electron micrographs of urine crystals obtained from black 
group 4 (Figures 7.2.1 -7.2.4) and white group 4 (Figures 7.2.5 -7.2.8) at various calcium 
concentrations. Attention is drawn to the existence of only disc-shaped COM crystals at 
0.5 mmo111 calcium concentration in the urines of both population groups and their gradual 
replacement by bipyramidal COD crystals until only the latter are observed at a calcium 
concentration of 12 mmo111. These micrographs therefore confinn the results obtained by 
x-ray powder diffraction. Thus, crystals prepared at the threshold concentrations of 
0.5 mmo111 and 12 mmo111 were used to precipitate respectively pure COM and COD for 
protein analysis by SDS-PAGE and Western blotting. 
Figure 7.1: Scanning electron micrographs of CaOx urine crystak. The crystals were 
precipitated from black group 4's urine at: 0.50 mmol/1 Ca (mag 7.5K) (Fig 7.2.1), 1.00 mmolll Ca 
(mag IOK) (Fig 7.2.2), 2.56 mmol/1 Ca (mag IlK) (Fig7.2.3), 12.0 mmolll Ca (mag 8K) 
(Fig 7.2.4); and white group 4's urine at: 0.50 mmol/1 Ca (mag 9K) (Fig 7.2.5), 1.00 mmol/1 Ca 
(mag 8K) (Fig 7.2.6), 4.08 mmol/1 Ca (mag 9K) (Fig 7.2.7), and 12.0 mmol/J Ca (mag 13K) 
(Fig 7.2.8). 
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It is also evident that COMs predominate in the black groups' control urine (in 
which calcium was not adjusted) (Figure 7.2.3), while CODs are formed exclusively in the 
white groups' control urine (Figure 7.2.7). Fine lines were apparent on the {101} face of 
COM crystals, most notable in Figure 7 .2.1 and Figure 7 .2.6, which was not evident on the 
surface of CODs. These may be growth lines or due to the inclusion of urinary proteins, 
since these lines are not observed in COM crystals precipitated from ultrafiltered urine 
(Ryall et al. 2001b). The appearance of growth lines on COMs is reminiscent ofy-shaped 
cracks due to growth by cyclic twinning in struvite (magnesium ammonium phosphate 
hexahydrate) crystals (Kim 1982). 
7.3.4 Protein analysis 
The desalting chromatograms of demineralised crystals prepared from black group 4 
(Figures 7.3.1-7.3.3) and white group 4 (Figures 7.3.4 -7.3.6) at various calcium 
concentrations are shown in Figure 7.3. The first peak in each chromatogram corresponds 
to the protein content of the crystals (confirmed by SDS-PAGE) while the second peak is 
the salt content (partly from the EDTA solution used for demineralisation and partly from 
the crystals themselves). 
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Figure 7.3: Desalting chromatograms of demineralised CaOx urine crystals. The 
demineralised crystals were from black group 4's urine: 0.50 mmol/l Ca and 4.3 mg (Fig 7.3.1), 
2.56 mmol/l Ca and 10.9 mg (Fig 7.3.2), 12.0 mmolll Ca and 9.35 mg (Fig 7.3.3); and white 
group 4's urine: 0.50 mmolll Ca and 13.9 mg (Fig 7.3.4), 4.08 mmolll Ca and 18.8 mg (Fig 7.3.5), 
and 12.0 mmolll Ca and 23.5 mg (Fig 7.3.6). 
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Protein patterns of the desalted crystals from black group 4 and white group 4 are 
shown in Figure 7.4 (black subjects: lanes 1-5; white subjects: lanes 6 -10). Since these 
crystals were washed with thoroughly with distilled water to remove surface-bound 
proteins, it can be concluded that the proteins shown by gel electrophoresis are 
intracrystalline. The protein content of CaOx crystals prepared from the black group's 
urine varies markedly with hydrate type (concomitant with calcium concentration). The 
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pure COM crystals (lane I) show five major bands: two low molecular weight proteins at 
I7 and 20 kDa, a protein at 38 kDa whose relative mobility is the same as the UPTFI 
standards in lanes 4 - 5 and two higher molecular weight proteins at 62 and 66 kDa. Two 
faint bands at 48 and 56 kDa are also apparent. In contrast, pure COD crystals (lane 3) do 
not contain the low molecular weight proteins, very little of the 38 kDa band and 
significantly more of the proteins at 62 - 66 kDa. They also show a distinct band at 56 kDa 
and a faint band at 48 kDa. The mixed morphology crystals formed in the control urine (in 
which the calcium was not adjusted) (lane 2) contains both the 38 kDa and the high 
molecular weight proteins as well as a faint band at 56 kDa. 
The protein content of crystals from the white group also varies with respect to 
hydrate type. The COM crystals (lane 6) consist almost exclusively of the 38 kDa protein 
whose relative mobility is the same as the UPTFI standards in lanes 9 - 10. In contrast, the 
COD crystals (lane 8) are composed of higher molecular proteins at 58, 62 and 66 kDa 
with a faint band at 48 kDa. The same protein pattern described for lane 8 was observed in 
the crystals formed in the white group' s control urine (in which the calcium was not 
adjusted) (lane 7) which were also pure CODs. 
Figure 7.4: Protein patterns of CaOx urine crystals (black subjects: lanes 1 - 5; white subjects: 
lanes 6-10). Samples obtained from black group 4's urine are MW: low molecular weight 
standard; / : COM (0.9 mg); 2: control urine's crystals (0.9 mg); 3: COD (0.9 mg); 4: 0.25 Jlg 
UPTFI; 5: 0.5 Jlg UPTFI. Samples obtained from white group 4's urine are MW: low molecular 
weight standard, 6: COM (2.7 mg); 7: control urine's crystals (2.7 mg); 8: COD (2.7 mg); 9: 0.25 Jlg 
UPTFI; 10: 0.5 Jlg UPTFI. 
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A Western blot of the CaOx urine crystals from both population groups for UPTFI 
and other PT fragments is shown in Figure 7.5. Prominent bands with the same mobility as 
the UPTFI standard (lane 7) appear in lanes I , 2 and 4. Additional faint bands at 73 
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(lanes 1, 2 and 4) and 49 kDa (lane 2) correspond to PT and PTF1+2 (Grover and Ryall 
1999), respectively. 
Figure 7.5: Western blot of CaOx urine crystals immunoblotted for prothrombin. The 
patterns obtained from black group 4's urine are J: COM (1.8 mg); 2: control urine's crystals 
(1.8 mg); 3: COD (1.8 mg). Patterns obtained from white group 4's urine are lane 4: COM 
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Figure 7.6 shows a Western blot of both population groups' urine crystals for OPN. 
Figure 7.6: Western blot of CaOx urine crystals immunoblotted for osteopontin. The 
patterns obtained from black group 4's urine are J: COM (1.8 mg), 2: control urine's crystals 
(1.8 mg), 3: COD (1.8 mg). Patterns obtained from white group 4's urine are 4: COM 
(3.6 mg), 5: control urine's crystals (3.6 mg), 6: COD (3.6 mg). Urine was used as a positive 
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Prominent bands at 62 and 66 .kDa were observed in lanes 3, 5, 6 and 7, while faint 
bands at the same molecular weights were observed in lane 2. The 66 kDa band 
corresponds to full length OPN (Atmani et al. 1998) and the 62 kDa band is most likely a 
degradation product since OPN is known to be degraded by urinary proteases (Ryall et al. 
2001a). The higher molecular weight bands (lanes 2-3, 5-6) may be aggregates of the 
protein (Johnson-Tardieu et al. 2000). Since no purified OPN was available, urine was 
concentrated (lane 7) and used as a positive control. 
7.4 DISCUSSION 
Urine composition data confirmed previous reports that the black population has a 
significantly lower urinary calcium concentration than the white population (Modlin 1967, 
Whalley et al. 1998, Rodgers and Lewandowski 2002). In this study, the average urinary 
calcium concentration amongst the black groups' urines was 66 % lower than the white 
groups' urines (1.36 mmol/1 vs. 4.06 mmol/1). The urinary calcium concentration was a 
relatively reliable predictor of CaOx crystal morphology. Mainly COM crystals were 
formed at lower calcium concentrations, but COD crystals gradually replaced these as the 
calcium concentration was increased. However, the actual concentrations required to 
produce the CaOx hydrates differed for the two population groups. Amongst the black 
groups, the calcium concentration required to precipitate pure COD was =::;12 mmol/1, while 
the required concentration was only 8 mmol/1 in three of the four white groups. When 
comparing the hydrate composition of CaOx crystals at equal calcium concentrations (i.e. 
at 8 mmol/1 calcium concentration), the white groups' crystals consistently had a higher 
percentage of COD than those of the black groups. Therefore, it appears that inherently 
different urinary compositions (and not just the calcium concentrations) may play a 
contributory role in determining urine crystal morphology in the two population groups. 
COD crystals are thermodynamically less stable than COM (Burns and Finlayson 1980). 
However, increased stability of the dihydrate crystal structure has been reported in the 
presence of citrate, magnesium and potassium (Brown et al. 1989). Thus, the significantly 
lower potassium concentration amongst the black groups in this study might have 
contributed to the relatively lower percentage of COD crystals in their urines. 
The protein content of CaOx crystals precipitated from the urine of the two 
population groups was of particular interest. The COM crystals from both population 
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groups, formed at relatively lower calcium concentrations, contained UPTF1 (and other PT 
fragments), while COD crystals from both groups formed at relatively higher calcium 
concentrations, contained mainly OPN. These observations are in agreement with a 
previous study (Ryall eta/. 2001a). 
Thus, researchers interested in studying UPTF1 would be advised to adopt a 
modified purification procedure to the one published by Ryall and co-workers (1995). The 
present study showed that the amount of intracrystalline UPTF1 may be altered by 
manipulation of the endogenous urinary calcium concentration. The dilution of urinary 
calcium to lower concentrations favoured COM precipitation rather than COD, thus 
increasing the amount of intracrystalline UPTFl derived per milligram of CaOx crystals 
from a urine sample (despite the dilution of other ions which also occurred). This strategy 
may be employed in a research setting if large amounts of UPTF1 are required for 
inhibitory activity or protein characterisation studies. 
It is apparent that the different crystal structures of COM and COD (arising from 
different calcium concentrations) and the conformations adopted by UPTFl and OPN, are 
key factors in determining the selective inclusion of urinary proteins into the respective 
CaOx hydrates. Indeed, Heuer suggests that intracrystalline proteins ensure that only 
crystals of a particular composition and shape precipitate and determine the 
physicochemical features of the resulting crystals (Heuer et a/. 1992). It is therefore 
speculated that the conformation of UPTFl at relatively low calcium concentrations may 
favour its binding, relative to OPN, to COM, which crystallises in the P2llc group (Tazzoli 
and Domeneghetti 1980). In contrast, the conformation of OPN at relatively higher calcium 
concentrations may favour its binding, relative to UPTFl, to COD, which crystallises in 
the I4/m space group (Sterling 1965). 
Crystals obtained from the black group's control urine (Figure 7.4, lane 2) contained 
at least two proteins with reported inhibitory properties, namely UPTF1 and OPN. In 
comparison, the white group's crystals (Figure 7.4, lane 5) contained only OPN. This may 
be a contributing factor in the black population's lower stone incidence. 
Comparison of the COM crystals from the two groups showed that while both OPN 
and UPTF1 were included in the black group's crystals, only UPTF1 was included in COM 
crystals from the white group's urine. The black group's COM crystals also contained low 
molecular weight proteins ( 17, 20 kDa), which were absent in crystals from the white 
group. 
CHAJ>'IER 7 171 
Western blotting showed that the black group's COM crystals contained two to 
three times more UPTF1 per milligram of CaOx than the white group's COM crystals. 
These observations suggest one of two possible conclusions: either the black group had a 
higher urinary UPTF1 concentration than the white group, or the former group's urine 
composition was more favourable for binding of UPTF 1 to CaOx crystals. Since a 
semi-quantitative study showed that the two groups had relatively similar urinary levels of 
UPTF 1 at their endogenous calcium concentrations (chapter 6), the strength of protein 
binding to CaOx crystals in the black group appeared to be a key factor in determining the 
higher amount of UPTF1 in this group's crystals. 
The COD crystals precipitated from the black and white group's urines also 
differed in their protein content. While the former group's COD contained a large 
proportion of OPN as well as an unidentified 56 kDa protein, the white group's COD 
consisted almost entirely of OPN. 
Although it is recognised that pretreatment of urine such as filtration and washing 
of urine crystals with distilled water or sodium hydroxide affects which proteins are 
incorporated (Atmani et al. 1998), the inclusion of different proteins into the same hydrate 
type derived from the two population groups' urines suggests that urine composition, in 
addition to crystal morphology, directs the capacity of particular urinary proteins to bind to 
CaOx crystals. 
Only a select number of proteins have been found in CaOx urine crystals compared 
with the large number observed in urine samples by SDS-PAGE (Doyle et al. 1991). The 
most prominent crystal-associated proteins found are PT -related proteins and OPN 
(Atmani et al. 1996, 1998; Ryall et al. 2001a; Atrnani and Khan 2002), followed by 
albumin (Atmani et al. 1996, 1998; Atrnani and Khan 2002). Small amounts of 
a 1-microglobulin (Atrnani et al. 1996, 1998; Atmani and Khan 2002) and inter-a-inhibitor 
fragments (Atmani et al. 1996, 1998; Dawson et al. 1998; Atrnani and Khan 2002) have 
also been identified. It is possible that the unidentified proteins observed at 17 - 20 kDa in 
the black group's COM crystals are fragments of bikunin, itself a fragment of inter-a-
inhibitor (Dawson et al. 1998). 
Of note is the observation that SDS-PAGE showed two OPN bands for the black 
group's crystals, while the white group's crystals displayed three bands. Since it is well 
known that OPN is degraded by urinary proteases (Ryall et al. 200la), this observation 
might suggest that less degradation of OPN occurred in the black group's urine; thus the 
protein may be more stable in this group's urine. Western blotting showed two OPN bands 
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in both groups· COD crystals, but it is possible that the lower two bands observed in the 
white group's crystals by SDS-PAGE were combined into one band at 62 kDa on the 
Western blot. 
Significantly more total intracrystalline protein per milligram of CaOx crystals was 
included in the black group·s crystals compared with the white group. This is demonstrated 
by the similar intensities of the two group·s crystals by SDS-PAGE (Figure 7.4) despite a 
three-fold greater crystal load from the white group (2.7 mg vs. 0.9 mg for the black 
group). 
It is widely recognised that crystal attachment to the renal epithelium may play a 
role in stone formation (Lieske et al. 1999). Ryall's studies have shown the potential of 
intracrystalline proteins to facilitate the erosion and dismantling (and possibly even the 
dissolution) of CaOx crystals by allowing urinary and intracellular proteases to penetrate 
the crystalline structure (Ryall et al. 2001b). It is thus proposed that the nature and amount 
of intracrystalline protein influences the probability that crystal attachment will result in 
stone formation (Ryall et al. 2001b). In light of these studies, the incorporation of greater 
amounts of intracrystalline protein into the black group's urine crystals may play a greater 
protective role in this group than the white group. 
The importance of crystal morphology and urine composition to the selective 
inclusion and binding of urinary proteins has been clearly shown. This study has also 
demonstrated for the first time that CaOx crystals freshly precipitated from the black 
population group·s urine contains a greater amount of UPTF1 than the white group (per 
milligram of CaOx). The black group's urine composition also appears to be more 
favourable for binding of UPTF1 than the white group' s urine in the presence of COM 
crystals. Thus, the black group· s urinary milieu may contain components that enhance 
UPTF 1 binding. Further studies to identify and characterise these components are 
warranted. 
The information presented in this chapter regarding the black group· s urine 
composition and their intracrystalline proteins may therefore contribute to an 
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CHAPTER 8: PROTEOLYSIS & PARTIAL DISSOLUTION OF 
CALCIUM OXALATE URINE CRYSTALS 
8.1 INTRODUCTION 
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A few urinary proteins, including UPTFl, are intimately associated with the mineral 
constituent of CaOx crystals (Fleming eta/. 1999, Ryall eta/. 2000), being distributed in 
channels throughout the mineral phase. Ryall has thus hypothesised that in addition to their 
role as inhibitors of crystallisation, proteins may also fulfill another role in the prevention 
of urolithiasis. It has been demonstrated that urinary crystals, rich in protein, are 
susceptible to protease treatment whereas crystals composed of pure mineral are not. 
Recent studies have shown the potential of intracrystalline proteins to facilitate the 
dismantling of urinary crystals by providing proteases with access to their protein core 
(Ryall eta/. 2000, 200lb). Thus, the inclusion of intracrystalline proteins such as UPTFl 
into CaOx urinary crystals may provide an unexpected second line of protection against 
stone formation should such proteins unsuccessfully prevent significant crystal growth and 
aggregation (Ryall eta/. 2001b). 
In addition to the afore-mentioned proteolysis studies, Lieske and co-workers have 
also shown that dissolution of exogenous COM occurs in the acidic lysosome of renal 
monkey cells (Lieske et a/. 1997). The dissolution of exogenous COD crystals incubated in 
urine at various dilutions has previously been reported (Akbarieh et a/. 1987) and 
incubation of urinary COM crystals causes pitting and erosion, demonstrating conclusively 
that crystals are susceptible to attack by endogenous proteases occurring in normal, healthy 
urine. This is not seen in the presence of a protease inhibitor cocktail or with crystals 
precipitated from ultrafiltered urine (Fleming et a/. 2000). It is probable that both 
dissolution and proteolysis will occur in vivo due to the acidic environment of cell 
lysosomes (pH -5) as well as the production of proteases by these organelles. 
Thus the objective of the present study was to investigate the role of both 
proteolysis and dissolution of urinary CaOx crystals in the white and black populations. 
Furthermore, since the urines of the two population groups tend to contain different CaOx 
hydrates (chapters 6 and 7), a comparison of the susceptibility of COM and COD to 
dissolution and proteolysis was warranted. The work reported in this chapter had the 
potential to elucidate whether the black population' s urinary crystals are more susceptible 
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to dissolution and/or degradation, which could offer an explanation for their lower stone 
incidence. 
8.2 METHODS 
8.2.1 Preparation of CaOx urine crystals 
Twenty-four hour urine samples were collected from ten healthy males (five whites, five 
blacks) and equal volumes from each were pooled according to population group. This was 
in accordance with the recommendations of a study for the optimum pooling of samples 
(Jappie and Rodgers 2000). The pooled urines were filtered (0. 75 J.Lm pre-filter, 0.45 J.Lm, 
0.22 JIM) and an aliquot of each was retained as a control sample. The CaOx MSL of both 
pooled urines was determined (paragraph 2.2.7, page 32) and aliquots were retained for 
urinalysis (as described in paragraph 2.2.1, page 26). Relative supersaturations were not 
calculated since this is not appropriate for pooled urines. 
The remaining urine was ultrafiltered through a l 0 kDa membrane to remove all 
macromolecules larger than 10 kDa, including UPTFl . The ultrafiltrates from white and 
black subjects were each divided into three aliquots and either left unaltered, or dosed with 
either WFI or BFl (refer to Table 8.1 below) at final concentrations of 1.25 mg/1. All 
four samples from each population group were incubated at 3 7 °C in a water bath and 
agitated at 100 rpm. Since neither ultrafiltration nor the addition ofUPTFI alters the CaOx 
MSL (Doyle et a/.1995, Ryall et a/.1995), equal NaOx loads in excess of the filtered 
urines' MSL were added to all four samples from each population group. Crystallisation 
was induced by the addition of a NaOx load (30 mmol/l in excess of MSL, 0.1 ml NaOx 
per 100 ml urine) at 0 and 1 hour. After a further hour, the crystals were collected by 
filtration (0.22 J.Lm) and washed briefly with 0.1 mol/1 sodium hydroxide followed by 
thorough washing with distilled water. A shortened incubation period of 2 hours 
(compared with 3 hours for UPTFI isolation) was used to ensure that a minimal layer of 
CaOx mineral was deposited around the intracrystalline proteins, so that they would be 
suitable for protease studies. The precipitated crystals were dried at 3 7 °C for 30 minutes 
and stored at -20 °C for later use. 
Owing to technical difficulties with the ultrafiltration apparatus, large amounts of 
protein were observed (by SDS-PAGE) in the CaOx crystals from ultrafiltered urine. 
Negligible contamination was evident in the UF crystals dosed with UPTF1. Thus in a separate 
experiment, additional urines from five white and five black subjects were collected. The 
urines were pooled, filtered, ultrafiltered and CaOx crystals were prepared 
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as described above. Crystals prepared from the various urine samples are henceforth 
referred to by the abbreviations shown in Table 8.1 below. 
Table 8.1: Abbreviations used to denote crystals prepared from white and black subjects' 
pooled urines before and after dosing with UPTFl from both population groups 
From ultndiltered Urine 
closecl · w.idt'W,Fl! · 
From~urine ·· 






The crystals to be analysed were demineralised and desalted as described elsewhere 
(paragraph 6.2.4, page 138). The protein peaks collected were freeze-dried, dissolved in 
distilled water and diluted 1:4 with SDS reducing buffer [62.5 mmolJI Tris-HCl (pH 8.8), 
2 % SDS, 10 % glycerol, 0.05 % Bromophenol Blue and 5 % P-mercaptoethanol]. Samples 
were heated at 1 00°C for 5 minutes and then electrophoresed on 9 - 18% gradient gels with 
a 4% stacking gel [6.5% of a 30% acrylamide in 0.8% bisacrylamide solution, 
139 mmolJI Tris-HCl (pH 6.8), 0.11 % SDS, 1.8 % Amps, 0.22 % TEMED] using a 
Tris-HCI running buffer [25 mmoVl Tris-HCI (pH 8.3), 192 mmoVI glycine, 0.1 % SDS]. 
Electrophoresis was carried out for I 0 minutes at 10 rnA, followed by 60 minutes at 
15 rnA The protein bands were either detected by silver staining or transferred onto 
nitrocellulose membranes for immunostaining. For silver staining, the gels were fixed for 
30 minutes (or overnight) [40 % ethanol (v/v), 10% acetic acid (v/v)] followed by 
pretreatment in a sodium acetate solution for 10 minutes [0.603 molJI sodium acetate, 
8.06 mmolJI sodium thiosulphate, 30% ethanol, 0.52% glutaraldehyde]. After two rinses 
of 5 minutes each in distilled water, the gels were incubated in a silver solution 
[5.88 mmolJI silver nitrate, 0.008% formaldehyde] for 30 minutes. The silver was then 
washed off with two rinses of 1 minute each with distilled water and the gels were 
developed [0.236 molJI sodium carbonate, 0.01% formaldehyde]. The development was 
stopped by addition of a solution ofEDTA [39.2 mmolJI EDTANa2.H20]. 
8.2.3 Western blotting 
After electrophoresis, gels were soaked in blotting buffer [19.8 mmolJI Tris, 0.150 molJI 
glycine, 16% methanol, pH 8.3] for 15 minutes prior to assembly in the Bio-Rad Mini 
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Trans-Blot apparatus. Proteins were then transferred onto a nitrocellulose membrane in 
blotting buffer at 100 V for 1 hour, with cooling, followed by immunodetection. Non-
specific sites on the membranes were blocked with a phosphate buffer (PBS) [145 mmol/1 
NaCl, 6.26 mmol/1 K2HP04.3H20, 1.84 mmol/1 KH2P04, pH 7.3] for 1 hour. The blot was 
then probed for UPTFl and OPN with antibodies diluted in PBS with 3% fat-free skim 
milk powder and 0.05 % Tween-20. One half of the membrane was equilibrated in a 
3:1000 dilution of 819-1 IgG (Stapleton et al. 1996) and the other was equilibrated in a 
1:2500 dilution of rat anti-human OPN IgG (Chemicon, Temecula, USA) for 1 hour. The 
membranes were washed with PBS (3 washes of 5 minutes each) after which the 
monoclonal antibodies were probed with a 1:250 dilution of goat anti-mouse lgG HRP 
conjugate (Bio-Rad) and 3:4000 goat anti-rat IgG HRP conjugate (Chemicon, Temecula, 
USA), respectively, for 1 hour. The membranes were washed three times with PBS 
(5 minutes per wash) and developed in a 3,3' -diaminobenzidine (DAB) solution [0.06% 
DAB, 0.1 % H20 2] for approximately 4 minutes and washed with distilled water to stop the 
reaction. 
8.2.4 Proteolytic digestion and partial dissolution of crystals 
Prior to digestion, crystals were placed on a glass slide and fractured using a metal spatula. 
Crystals were viewed under a light microscope to confirm that a significant proportion had 
been fractured before further use. Crystals (0.25 mg) were then transferred to a glass 
scintillation vial and incubated at 37 °C with agitation (100 rpm) for 16 hours in a 0.5 ml 
solution containing 12.5 mmol/1 Tris-HCl (pH 6.0) in both a saturated or unsaturated CaOx 
solution, and 2 units/ml of cathepsin D (Sigma), thrombin (CSL Limited) or Proteinase K 
(Roche). Refer to Appendix G (Table 02, page A78) for the preparation of the CaOx 
solutions. 
Crystals before treatment (referred to as the control samples) and those incubated in 
the buffers alone were included. The unsaturated CaOx buffer was used to bring about 
partial dissolution, whereas the saturated buffer ensured minimal crystal dissolution and 
thus facilitated the observation of proteolysis alone. 
After the 16-hour incubation period, an aliquot (0.2 ml) was removed from each 
scintillation vial and filtered onto a 0.22 J..lm filter paper. The filters were washed 
thoroughly with distilled water, dried at 37°C for at least 30 minutes and glued onto 
aluminium stubs. The crystals were coated with Au/C and examined using a field emission 
scanning electron microscope (Philips XL30, University of Adelaide, Australia) operating 
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at an accelerating voltage of 10 kV and a working distance of 10 mm. A summary of the 
treatments for each batch of crystals is shown below (Table 8.2). 
Table 8.2: Summary of treatments used for various crystals 
*Unsat **Sat 
Control 
CaOxbuffe1 CaOx bufl'e1 
WF " " " WUF " " WUF+WFl " " WUF+BFl " " BF " " " BUF " " BUF+WFl " " BUF+BFl " " • Unsaturated CaOx buffer to bring about partial dissolution 
; b Saturated CaOx buffer to ensure minimal crystal dissolution 
8.3 RESULTS 
8.3.1 Urine composition 
CathD Throm 
" " " " " " " " " " " " " " 
ProK 
" 
" " " 
" " 
Urine composition (mmol/l) and physicochemical parameters of the pooled urines from 
white and black subjects used to prepare the CaOx crystals are presented in Appendix G 
(Table G1, page A78). 
8.3.2 SDS-PAGE and Western blotting 
The SDS-PAGE of CaOx crystals prepared for proteolysis and dissolution studies is shown 
below (Figure 8.1). The gel confirmed that the crystals obtained from filtered urine 
contained a range of proteins, whereas no protein was detected in crystals from the 
ultrafiltered urines. A large proportion of the protein from WF and BF (Figure 8.1) was 
identified as UPTF1 and OPN by Western blotting (Figures 8.2.1 and 8.2.2, respectively). 
It is evident that BF included considerably more UPTF1 and OPN per milligram of CaOx 
than WF (Figure 8.2), although this could not be quantified from the gel. 
SDS-PAGE demonstrated that crystals obtained after dosing ultrafiltered urine with 
UPTF1 (-31 kDa) also contained additional bands corresponding to PT-related proteins 
(Figure 8.1). These were observed at 20, 48, 60 and 72 kDa. The band at 48 kDa is 
PTF1+2. The bands at -60 and higher kDa values almost certainly represent the UPTF1 
dimer, and heterodimers of UPTF1, PT and other of its fragments, which are known to 
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form in the presence of calcium ions (Harlos et al. 1987). WUF+WF1 appeared to bind 
more PT (-72 kDa) relative to the amount of UPTF1 than the crystals from BUF dosed 
with UPTF1. 
Multiple bands were observed in the crystals from both population groups blotted 
for OPN (Figure 8.2.2), which is in agreement with a previous report that the molecular 
weight ofOPN varies widely from 20-15 kDa in SDS-PAGE systems (Denhardt and Guo 
1993). The multiple bands observed in the present study would have resulted from 
degradation of OPN by urinary proteases (Ryall et a/. 2001a). Identical OPN protein 
patterns have been observed by Ryall (R Ryall, Flinders Medical Centre, Australia, 
personal communication). 
Figure 8.1: SDS-PAGE of CaOx urine 
crystals. The patterns were obtained from 
MW: low molecular weight standard and the 
following crystals: WF, WUF, WUF+WFl, 
BF, BUF, BUF+WFl and BUF+BFl. 








MW WF WUF WUF BF BUF BUF BUF 
+WFI +WFI +BFI 
8.3.3 FESEM of control c.tystals 
8. 3. 3.1 Crystals from ultra.filtered urine 
Figure 8.2: Western blot of CaOx urine 
crystals. The patterns were obtained from 
MW: pre-stained molecular weight marker, and 
crystals from white (WF) and black (BF) 
subjects' filtered urine immunoblotted for 
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Electron micrographs of the crystals precipitated from ultrafiltered urine of white and black 
subjects were similar and thus representative examples are shown in Figure 8.3. Before 
treatment, the bipyramidal COD crystals had little surface texture (Figure 8.3.1) and 
appeared to be solid (Figure 8.3.2). Most COM crystals were oval-shaped and had smooth 
swfaces (Figure 8.3.1), although a few had swface detail, particularly on the {101} filce 
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(Figure 8.3.3). Crystal shape and texture of COM (Figure 8.3.4) and COD (Figure 8.3.5) 
were unaffected by incubation in the saturated CaOx buffer. Both COM (Figure 8.3.6) and 
COD (Figures 8.3.7- 8.3.8) were resistant to digestion by cathepsin D. 
Technical difficulties were encountered with the first batch of crystals prepared 
from ultrafiltered urine (UF) (described on page 176). As a result the crystals presented in 
Figure 8.3 do not originate from the same urines used in the remainder of the study 
(Figures 8.4- 8.14). However, the appearance of UF crystals both before and after 
protease treatment was similar in ultrastructure to a previous report (Ryall et al. 2001 b). 
Thus, in addition to the absence of protein (> 10 kDa) observed by SDS-PAGE (Figure 8.1, 
lanes WUF and BUF), this confirmed that the UF crystals were appropriate for use as a 
negative control in the present study. 
Figure 8.3: Field emission scanning electron micrographs of UF CaOx crystals before and 
after protease treatment in a saturated Calli butfer. The crystals underwent the following 
treatments: control (8.3.1 - 8.3.3), saturated CaOx buffer (8.3.4- 8.3.5), and Cathepsin D in the 
saturated CaOx buffer (8.3.6- 8.3.8). 
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8.3.3.2 Crystals from filtered urine and ultrafiltered urine dosed with UPTFJ 
Crystals from white subjects 
The micrographs presented in Figure 8.4 are of crystals derived from a pooled urine of 
white subjects. The images obtained from filtered urine and ultrafiltered urine dosed· with 
either WFI or BFI are presented separately, and all are before treatment. However, since 
no differences between the three sets of crystals were observed, the comments are 
applicable to all three sets of crystals from the white subjects. A survey view of WF 
(Figure 8.4.1) showed the predominance of COD crystals from the white subjects, although 
some small COM crystals were also observed. 
Several COM crystals showed the presence of surface detail on the { 0 I 0} face 
(Figure 8.4.2) and the core of COM crystals appeared to be more porous than near the 
periphery (Figures 8.4.4, 8.4.6). In contrast, most COD crystals showed little evidence of 
erosion and were relatively smooth (Figure 8.4.5) and solid (Figures 8.4.3, 8.4.5, 8.4. 7). 
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Figure 8.4: Field emission scanning electron micrograpm of WF, WUF+WFl and WUF+BFl 
CaOx erystab before treatment. The crystals are as follows: WF (8.4.1- 8.4.3), WUF+WFI 
(8.4.4- 8.4.5), and WUF+BFI (8.4.6- 8.4.7). 
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Crystals from black subjects 
Figure 8.5 presents micrographs of crystals derived from a pooled urine of black subjects. 
The images obtained from :filtered urine and ultrafihered urine dosed with either WF I or 
BFI are presented separately, and all are before treatment. However, similarly to the white 
subjects' crystals described above, no differences between the three sets of crystals were 
observed. Thus the comments are applicable all three sets of crystals from the black 
subjects. A survey view of BF (Figure 8.5.1), taken at the same magnification as the WF 
survey image shown above (Figure 8.4.I ), showed the predominance of COM crystals 
from the black subjects, in contrast to COD which was the principal CaOx hydrate in the 
urine of white subjects. 
Fine fissures were observed on the {I OI} fuce (Figure 8.5.2) as well as in the 
interior of COM crystals (Figure 8.5.3). These observations were consistent with the 
binding and inclusion of urinary proteins. The exterior of COM crystals were not as 
smooth and well defined (Figures 8.5.5, 8.5. 7) as those observed from ultrafiltered urine 
(Figure 8.3.6). In contrast to the COMs, most COD crystals appeared to be relatively solid 
(Figures 8.5.4, 8.5.6, 8.5.8). Although this was not common, some surface erosion of COD 
crystals was observed (Figure 8.5.8). 
Figure 8.5: Field emission scanning electron micrographs of BF, BUF+WFl and BUF+BFl 
CaOx crystals before treatment. The crystals are as follows: BF (8.5.1- 8.5.4), BUF+WFl 
(8.5.5- 8.5.6), and BUF+BFl (8.5.7- 8.5.8). 
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8.3.4 FESEM showing proteolysis 
8.3.4.1 Crystals from white subjects 
Crystals from the filtered urine of white subjects (Figure 8.6) were incubated in a saturated 
CaOx buffer along with various proteases in order to demonstrate proteolysis. In the 
presence of the buffer alone, a few COM crystals underwent partial dissolution 
(Figure 8.6.1 ). althoug h most remained intact. The edges of COD crystals were slightly 
eroded (Figure 8.6.2). 
Figure 8.6: Field emission scanning electron micrographs of WF CaOx crystals before 
and after protease treatment in a saturated CaOx buffer. The crystals underwent the 
following treatments: saturated CaOx buffer (8.6.1 - 8.6.2); cathepsin D (8.6.3 - 8.6.4), 
thrombin (8.6.5- 8.6.6) and Proteinase K (8.6.7 - 8.6.8) in the saturated CaOx buffer. 
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Incubation with cathepsin D resulted in varying degrees of proteolysis of COM 
crystals. In the most advanced cases of proteolysis, complete digestion of the core of 
crystals was observed (Figure 8.6.3), with the result that a doughnut-shaped exterior 
remained. COD crystals appeared relatively intact after treatment with cathepsin D 
(Figure 8.6.4). Neither COM (Figure 8.6.5 - 8.6.6) nor COD crystals (Figure 8.6.5) were 
notably affected by treatment with thrombin. After incubation with Proteinase K some, but 
not all, COM crystals showed signs of dissolution (Figure 8.6. 7). The COD crystals were 
relatively intact except for some minor surface pitting (Figure 8.6.8). 
8.3.4.2 Crystals from black subjects 
Crystals from the filtered urine of black subjects after the same protease treatments are 
shown in Figure 8. 7. In the presence of the buffer alone, most COM crystals remained 
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intact (Figure 8.7.1), while COD crystals developed slightly jagged edges and some 
erosion on the { 101} faces (Figure 8. 7 .2). 
Incubation with cathepsin D resulted in varying degrees of proteolysis. COM 
crystals showed evidence of slight erosion (Figure 8.7.3), while COD crystals appeared 
relatively intact after treatment (Figure 8.7.4). Similar to the crystals from white subjects, 
COM (Figure 8.7.5) and COD crystals (Figure 8.7.6) appeared resistant to treatment with 
thrombin. However, some crystal fragments were observed on the COM and COD crystal 
surfaces. COM crystals incubated with Proteinase K were unaffected (Figure 8.7.7), 
whereas significant surface erosion of COD crystals was observed (Figure 8.7.8). The 
{101} face of COD crystals were considerably more eroded then the same sample 
incubated in the buffer alone (Figure 8.7.2). 
Figure 8. 7: Field emission scanning electron micrographs of BF CaOx crystals before 
and after protease treatment in a saturated CaOx buffer. The crystals underwent the 
following treatments: saturated CaOx buffer (8.7.1- 8.7.2); cathepsin D (8.7.3- 8.7.4), thrombin 
(8.7.5- 8.7.6) and Proteinase K (8.7.7 - 8.7.8) in the saturated CaOx buffer. 
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8.3.5 FESEM showing proteolysis and dissolution 
Crystals prepared from filtered urine of white (WF) and black (BF) subjects, as well as 
both population groups' ultrafiltered urine dosed with either WF1 or BF1 (UF+WF1, 
UF+BF1), were treated with proteases in an unsaturated CaOx buffer. No differences were 
observed in crystals containing a mixture of proteins (WF, BF) and those containing 
mostly prothrombin fragments (UF+WF1, UF+BF1). The susceptibility of COM and COD 
crystals to treatment was also the same, whether from white or black subjects, although the 
relative proportion of the two CaOx hydrates differed in the two groups, as described 
before. Thus, in order to present the large number of micrographs in a manageable way, the 
micrographs were grouped according to their protease treatment, rather than the origin of 
the crystals (since these showed no differences). Furthermore, crystals derived from white 
and black subjects are not presented separately; representative examples are included. 
8. 3. 5.1 Effect of cathepsin D 
In the presence of cathepsin D and the unsaturated CaOx buffer, COM crystals were 
eroded and degraded to varying degrees. In some crystals, only surface detail on the { 101 } 
face (Figure 8.8.1) and moderate erosion (Figure 8.8. 7) was evident. A cross-section of a 
COM crystal showed signs of fissures and porosity in the crystal interior (Figure 8.8.12). 
However, in other crystals, disintegration was more significant and sub-crystallites were 
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observed on the {010} face (Figure 8.8.2) as well as in the crystal interior (Figure 8.8.6). 
The COM crystal surface, which was relatively smooth before treatment (refer Figure 8.5.7 
on page 185 for a typical example), was highly eroded in a few crystals and a highly 
porous ultrastructure was evident (Figures 8.8.3, 8.8.8). The effect of cathepsin D appeared 
to be most advanced in the crystal depicted in Figure 8.8.11, where numerous closely 
packed sub-crystalline particles were evident. Most of the core of the crystal appeared to 
have been excavated by the treatment. 
Figure 8.8: Field emission scanning electron micrographs of CaOx crystab after incubation 
with cathepsin D in an unsaturated CaOx buffer. The following crystals were treated: WF/BF 
(8.8.1 - 8.8.5); UF+WF1 (8.8.6 - 8.8.10); UF+BF1 (8.8.11 - 8.8.14). 
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The majority of COD crystals were unaffected and appeared to be relatively smooth 
and solid after treatment (Figures 8.8.5, 8.8.13). However, some surface pitting and 
deformation (Figures 8.8.4, 8.8.10) of COD crystals was observed, along with slightly 
eroded edges (Figure 8.8.9). Minor etching ofthe surface of a few COD crystals was noted 
(Figure 8.8.14). Significant dissolution was not evident when the unsaturated CaOx buffer 
was used along with cathepsin D. 
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8. 3. 5.2 Effect of thrombin 
The interior of COM crystals (Figure 8.9.2, 8.9.7, 8.9.9) appeared to be similar to those 
before treatment (compare Figure 8.5.3 on page 184), although porosity was evident. Some 
COM surfaces showed signs of erosion (Figure 8.9.6), but most were still relatively smooth 
and intact after treatment with thrombin in the unsaturated CaOx buffer. Sticking of crystal 
fragments to the surfuce of COM (Figures 8.9.1, 8.9.7, 8.9.9) and COD (Figure 8.9.3) 
crystals was frequently observed after incubation with thrombin. This may have indicated 
that the crystals were coated with excess protease, and also that the buffer did not dissolve 
these fragments. Several COD crystals had a shiny appearance (Figures 8.9.5), which may 
also have been indicative of a thrombin coating. Etching of COD surfuces was observed 
(Figures 8.9.4, 8.9.8, 8.9.10). 
Figure 8.9: Field emB.sion scanning electron micrographs of CaOI cryst:Ui after incubation 
with thrombin in an unsaturated CaOx buffer. The following crystals were treated: WF/BF 
(8.9.1 - 8.9.5); UF+WFI (8.9.6- 8.9.8); UF+BFI (8.9.9- 8.9.10). 
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8.3.5.3 Effect of Proteinase K 
Crystals incubated with Proteinase K and the unsaturated CaOx buffer showed signs of 
erosion and significant dissolution. While some COM crystals appeared to be unaffected 
(larger COM in Figure 8.1 0.1 ), some were notably deformed (Figure 8.1 0. 7) and had 
apparently dissolved from the interior, being concave in appearance (Figure 8.10.2; COM 
in Figure 8.10.5). In the latter case, a large amount of organic material was evident on the 
filter papers (e.g. around smaller COM in Figure 8.10.1) and fewer crystals were observed 
than in the corresponding control samples. 
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Figure 8.10: Fteld emission scanning electron micrographs of CaOx crystals after incubation 
with Proteinase K in an unsaturated CaOx buffer. The following crystals were treated: WF /BF 
(8.10.1- 8.10.4); UF+WF1 (8.10.5- 8.10.6); UF+BFl (8.10.7- 8.10.8). 
The COD crystals appeared to be relatively solid inside (Figures 8.1 0.3, 8.1 0.6, 
8.1 0.8), but several had jagged edges (an example is shown in Figure 8.1 0.4). Many CODs 
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(Figures 8.1 0.5, 8.1 0.6), but not all (Figure 8.1 0.8), showed evidence of significant erosion 
on the crystal surfuces. 
8.3.6 FESEM showing dissolution 
Crystals incubated in the unsaturated CaOx buffer alone showed evidence of considerable 
dissolution and deformation. Since the most noteworthy feature of this study was the 
different effect on COM and COD crystals, this feature is depicted in the micrographs 
shown. No distinction is made between the batch of crystals or the population group of the 
subjects from which the crystals were derived. 
8.11: Field emission scanning electron micrographs showing stages of COM crystal 
dissolution in an unsaturated CaOx buffer. (8.11.1 is a typical COM crystal before treatment) 
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Figure 8.11 (above) shows a series of COM crystals following incubation in the 
unsaturated CaOx buffer alone, at various stages of dissolution. The arrows indicate the 
proposed pathway of dissolution from a single, intact COM (Figure 8.11.1) crystal to, 
possibly, its smallest fragments (Figure 8.11.6). Apparently single, whole COM crystals 
first showed evidence of dissolution at their inner core, being concave in appearance 
(Figure 8.11.2). Crystals appeared to have an organic "skin" (Figure 8.11.3), which was 
evident as dissolution progressed. Gradual dissolution coincided with the deposition of 
increasing amounts of organic material (Figure 8.11.4 - 8.11.5). Tiny, amorphous 
crystallites were observed and may have been the final stage of dissolution (Figure 8.11.6). 
Figure 8.12: Field emission scanning electron mic:rograpu showing COD crystal dissolution 
in an unsaturated CaOx buffer. (8.12.1 is a typical COD crystal before treatment) 
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A similar series of micrographs represent COD crystals at various stages of 
dissolution (Figure 8.12 above). The arrows indicate the proposed pathway of dissolution 
from a single, intact COD (Figure 8.12.1) to, perhaps, its smallest fragment (Figure 
8.12.6). Apparently single, whole COD fragmented progressively, first at their edges 
(Figure 8.12.2) and then on the { 101} faces (Figures 8.12.3 - 8.12.4 ). Fracturing 
characteristically occurred along a common plane, namely the middle of the { 101 } face as 
depicted in Figure 8.12.3, and revealed tiny and geometrically arranged bipyramidal 
subunits (Figure 8.12.4). These subunits almost certainly represent crystallites. Further 
disruption of the crystal structure was also evident (Figure 8.12.5). Small, bipyramidal 
crystallites (Figure 8.12.6) were observed at, presumably, the most advanced stage of 
dissolution. 
8.4 DISCUSSION 
The proteolytic degradation of urinary CaOx crystals from both white and black subjects 
was demonstrated. In the presence of a saturated CaOx buffer (thus preventing significant 
dissolution), the addition of proteases resulted in the etching, degradation and even 
excavation of crystals to varying degrees. Since the crystals obtained from ultrafiltered 
urine appeared to have almost solid interiors and smooth surfaces, it may be assumed that 
the erosion observed with the crystals derived from filtered urine resulted from the removal 
of intracrystalline proteins. These findings are in agreement with previous reports by Ryall 
and co-workers (Ryall et al. 2000, 2001b). 
Cathepsin D caused the most significant crystal erosion of the three proteases 
tested, and was also notably more effective in degrading COM as opposed to COD 
crystals. This may reflect selectivity by cathepsin D for COM-associated proteins, of which 
UPTF1 is predominant (Ryall et al. 2001a; chapter 7). In the most advanced cases of 
degradation, considerable excavation of the crystal interior was observed, exposing an 
array of tightly-packed subcrystalline particles. The removal of the core of some, but not 
all, COM crystals by protease treatment suggests that the protein was concentrated in the 
central region of the crystal and not near the edges (Ryall et al. 2001). This is consistent 
with the condensation of protein and the subsequent precipitation of mineral around it. As 
the urine is depleted of protein, the proportion of mineral shell surrounding it increases 
(Fleming et al. 1999). 
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Partial dissolution studies of COM and COD crystals permitted the observation of 
their unique ultrastructures, as well as stages of the fragmentation process. Whole, 
disc-shaped COM crystals first began to show signs of dissolution at their inner region. 
This was consistent with the location of protein at the centre of the CaOx crystal structure, 
as described above. In the latter stages of dissolution, tiny COM crystallites were observed 
amongst the organic material that was leached onto the filter paper. These particles may be 
amorphous composites of organic and inorganic material, and have been previously 
reported by Ryall and co-workers in COM and COD crystals (Ryall et al. 2000). Similar 
amorphous sub-units have also been reported by Addadi and co-workers in a study on 
biomineralisation in the marine sponge (Addadi et al. 1999). 
The disintegration of bipyramidal COD crystals was first noted at their periphery 
where jagged edges appeared. Distinct fracture planes were also observed, typically in the 
centre of the { 101} faces, and not along their edges. The strengthening of crystal planes 
against fracturing by proteins has been described previously in the sea urchin spine 
(Addadi et al. 1999}, and would seem to be a plausible explanation in the case of urinary 
crystals too. The newly exposed surfaces revealed tiny, geometrically-arranged 
bipyramidal structures. These are likely to be the crystallites of which the apparently single 
COD crystals are composed. 
A combination of dissolution and proteolysis was observed using an unsaturated 
CaOx buffer in conjunction with protease treatment. Since these two processes are likely to 
occur concurrently in vivo, these observations are probably the most physiologically 
relevant. Indeed, the combined effects of dissolution and proteolysis resulted in more 
significant erosion and degradation of CaOx crystals than in those subjected to either one 
of the processes alone. The effects of both thrombin and Proteinase K were most notable 
on COD crystals. Thrombin appeared to coat the surface of some CODs, and etching of 
crystal surfaces was also observed. The apparent selectivity of thrombin for COD crystals 
is consistent with the fact that the protease cleaves OPN (personal communication: R. 
Ryall, Flinders Medical Centre, South Australia), which is more abundant in COD crystals 
than in COM (Ryall et al. 2001a; chapter 7). Considerable dissolution was observed along 
with surface erosion of COD crystals after incubation with Proteinase K. It is possible that 
dissolution occurred more rapidly than proteolysis in the presence of this protease, and thus 
the former effects were more apparent. Furthermore, the surface erosion of COD crystals 
suggests selectively of Proteinase K for COD-associated proteins, although the reason for 
this is not apparent. 
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In contrast to thrombin and Proteinase K, cathepsin D facilitated considerable 
crystal erosion and disintegration, particularly in the case of COM crystals. Since UPTF1 
is the principal protein component of COM crystals, further proteolysis studies of this 
protein should include cathepsin D. The results obtained in the present study with 
Cathepsin Dare of particular interest since the protease is found in celllysosomes and is 
active throughout the tubules of human nephrons (Hartz and Wilson 1997). Thus, 
cathepsin D could mediate the dismantling of CaOx crystals if they are internalised by 
renal cells in vivo. 
In light of the apparent selectivity of the proteases tested for the different CaOx 
hydrates, thrombin and Proteinase K may be more appropriate for further studies of white 
subjects whose urines contain predominantly COD crystals, while cathepsin D should be 
used with black subjects, whose urines characteristically contain COM crystals. 
No discernible differences in the relative response of crystals from white and black 
subjects to proteolysis were noted. However, in all cases, COM crystals (whether from 
white or black subjects) appeared to be more susceptible to degradation and dissolution 
than COD, possibly reflecting their unique crystal structures. The distinctive CaOx 
hydrates in the two population groups, as well as the relative response of these hydrates to 
proteolytic treatment, are thus important. Consequently, they warranted further analysis as 
presented below. 
A study by Riese and co-workers was one of the first to report the binding of COM 
crystals to renal cell surfaces (Riese et al. 1988), an observation which others have 
confirmed using several renal cell lines (e.g. Ueske et al. 1995, Verkoelen et al. 1995). 
Crystal adherence to the renal epithelium is now widely regarded as a possible mechanism 
of stone formation, in addition to blockage of the nephron caused by crystal aggregation 
(Ueske et al. 1999). Crystal adhesion appears to be stereospecific since the association of 
COM with renal cells is favoured over that of COD crystals (Wesson et al. 1998). 
Although crystal adhesion may at first appear to promote stone formation by 
providing a site for further crystal deposition, it is also possible that the attached crystals 
will be endocytosed, thus facilitating their degradation by intracellular proteases. This 
mechanism has been observed in cultured monkey cells treated with exogenous COM 
(Ueske et al. 1997) and COD (Lieske et al. 1996) crystals. These crystals were internalised 
and dissolved over a period of weeks within the cell lysosomes (Lieske et al. 1999). In 
fact, the proposal has been made that crystal attachment and subsequent dissolution may be 
an unexpected means by which to avert stone formation (Lieske et al. 1999). Studies 
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demonstrating raised lysosomal protease activity in the urine of stone-formers (Bautista et 
a/. 1996) and in cultured renal cells challenged with CaOx crystals (Hackett et al. 1994), 
suggest that these mechanisms occur in vivo. 
The distinctive morphology of urinary CaOx crystals from white and black 
subjects, and in particular the predominance of COM amongst the black population, could 
prove to be a decisive factor in their relative protection from stone disease. Although COM 
crystals are likely to bind more avidly to renal cells, recent evidence suggests that these 
crystals may be endocytosed and degraded by lysosomal proteases. Indeed, it appears, on 
the evidence of the present study, that this process may be more efficient with respect to 
COM crystals. Perhaps the degradation of internalised crystals is more efficient amongst 
the black population. 
Further investigations comparing the attachment and dissolution of urinary crystals 
from white and black subjects using a renal cell culture model are required. These may 
elucidate the contribution of crystal adhesion and intracellular proteolysis to the 
exceptionally low stone incidence amongst the black population. 
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CHAPTER 9: D ISCUSSION, CONCLUSIONS & A FUTURE OUTLOOK 
The hypothesis of this thesis was that differences in the physical structure and/or inhibitory 
properties of UPTF 1 from the white and black populations in South Africa contribute to 
the remarkably low stone incidence of kidney stones amongst the black population. As a 
prelude to exploring this hypothesis, a preliminary investigation of the inhibitory activity 
of urine from white and black subjects was conducted (chapter 2). Urine composition 
trends in the black population were inconclusive when compared with whites, and could 
not account for the former group's protection from stone disease (in fact inconsistent 
trends were observed in the various studies conducted in this thesis). However, urinary 
macromolecules from black subjects induced the formation of smaller particle sizes in 
synthetic urine when the urine was challenged with a sodium oxalate load. These 
macromolecules also demonstrated greater repulsive forces in COM crystal slurry assays, 
suggesting a greater potential to disaggregate the COM crystals. Both of these trends are 
consistent with inhibition of a greater magnitude by urinary macromolecules from the 
black population, which may be related to their lower incidence of stones. 
Expanding on the theme of macromolecules while shifting to the primary focus of 
the thesis, the inhibitory activity of the CME from healthy white and black subjects was 
compared (chapter 3). CME reduced crystal nucleation, growth and aggregation during the 
early stages of CaOx crystallisation in a synthetic urine. These effects were more 
pronounced in the presence of the CME derived from black subjects than whites. In 
addition, the CME from both population groups induced the favourable nucleation or 
stabilisation of COD crystals. It was speculated that the apparently greater inhibition of 
CME from the black population might be due, in part, due to the properties of UPTF 1, its 
principal component. 
Thus, UPTFI was isolated and purified from the urine of healthy white and black 
subjects and rigorously characterised (chapter 4). N-terminal sequencing, amino acid 
analysis and MALDI-TOF MS did not reveal differences between WFl and BFl, and both 
proteins were shown to contain three charged variants with similar pi values according to 
2D SDS-PAGE. However, amino acid analysis by alkaline hydrolysis demonstrated the 
presence of a greater number of Gla residues on BFl than WFI. Oligosaccharide 
sequencing identified a high proportion of sialylated glycans on UPTFI , with a greater 
number of sialic acid residues present on BFI than WFI. The N- and 0-linked glycans 
were located on the kringle domain ofUPTFI by molecular modeling. 
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In addition to investigating possible structural differences, the inhibitory activity of 
WFl and BFl were compared (chapter 5). UPTFl inhibited CaOx crystal growth and 
aggregation in synthetic urine, whether from white or black subjects, and these effects 
were greatest in the presence ofBF1 during the early stages of crystallisation. Furthermore, 
WFl and BFI induced a favourable hydrate transition from COM to COD crystals in the 
synthetic urine. The effect of WFl and BF1 on the crystallisation of exogenous COM and 
COD crystals was also examined. While the relative effects demonstrated by the two 
proteins could not be distinguished, sedimentation rates and zeta potential experiments 
suggested a greater potential for inhibition of COM rather than COD aggregation by 
UPTFI. In ultrafiltered urine, UPTFl from both population groups promoted CaOx crystal 
nucleation, but inhibited its growth and aggregation. All of these mechanisms were 
regarded as protective. In a cross-over design crystallisation study, ultrafiltered urine from 
the two population groups was dosed with both WFl and BFl. A synergistic relationship 
between UPTFl activity and urine composition was demonstrated, and BFl was found to 
be a more effective inhibitor than WF1 in their endogenous urines. 
On the basis of the afore-mentioned findings, it was concluded that the relationship 
between UPTFl and CaOx crystal morphology should be explored. This was motivated by 
the following three key points: the synergy between UPTF 1 and urine; the different CaOx 
hydrates which predominated in the two population groups' urine; and the greater 
inhibition of COM rather than COD aggregation by UPTFl . 
To this end, crystal morphology and the levels of urinary and CaOx 
matrix-associated UPTFl, as well as other urinary proteins, were compared in healthy 
white and black subjects and white stone-formers (chapter 6). The urinary concentrations 
of UPTFl in the three groups appeared to be similar by Western blotting. However, 
UPTF1 and other proteins were selectively incorporated into the CaOx crystals derived 
from these urines. More of the black subjects' crystals contained UPTFl than that of the 
whites (controls and stone-formers). These differences coincided with higher proportions 
of COM crystals in the urine of black subjects, compared with COD crystals which were 
excreted principally amongst the white subjects. 
The protein content of pure COM and COD urinary crystals from healthy white and 
black subjects were compared both qualitatively and semi-quantitatively (chapter 7). COM 
crystals from black subjects contained mainly UPTFl but also OPN, whereas the same 
CaOx hydrate from white subjects included exclusively UPTFl. COD crystals from both 
population groups included mainly OPN. In addition to the hydrate type, urine composition 
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appeared to influence protein binding to CaOx crystals, again drawing attention to a 
relationship between UPTF 1 and urine composition. The total amount of intracrystalline 
protein (per mg CaOx) was greatest in the black subjects. 
Finally, the response of CaOx crystals from healthy white and black subjects to 
dissolution and proteolysis was investigated (chapter 8). COM crystals, whether from 
white or black subjects, were notably more susceptible to dissolution, erosion and 
degradation than COD crystals. This observation was particularly significant in view of the 
predominance of COM crystals amongst the black population. 
A rigorous review of the literature revealed two major pathways by which stone 
formation may be mediated and possibly prevented. The first of these was the long-touted 
mode of crystallisation inhibition. A second, and more recently proposed mode of 
protection was by modulating crystal adhesion to renal epithelial cells. The results and 
discussions presented in this thesis clearly reflected UPTFI 's potential to influence both of 
these mechanisms; in the first instance, by way of its powerful inhibitory capacity in urine 
and, in the second instance, by virtue of its inclusion within the crystalline architecture and 
its consequent susceptibility to proteolysis. 
In the context of this thesis, the important attribute of UPTFI which has been 
identified is its ability to distinguish between the white and black populations. Indeed, 
UPTFI derived from the urine of black subjects exhibited enhanced inhibition of CaOx 
crystallisation in synthetic urine and in synergy with its parent urine, in comparison with 
UPTFI from the urine of white subjects. These properties are likely to be related to the 
greater number of Gla residues on BFI and, possibly, the greater number of sialic acid 
residues on BFI, as well as a conformation in the black population's urine that is more 
favourable for inhibition. The greater inhibition of COM compared with COD aggregation 
by UPTFI suggested that the binding affinity ofUPTFl for the CaOx hydrates may also be 
involved in its activity. 
The abundance of urinary COM crystals amongst the black population and the 
concomitant higher levels of UPTFI were noteworthy. In addition, the total amount of 
intracrystalline protein in this group was greater. The latter finding was particularly 
striking given recent findings that intracrystalline proteins may provide a natural defense 
against kidney stone formation by way of their susceptibility to intracellular proteolysis 
following crystal attachment and endocytosis. 
Previous studies reporting the binding of COM and COD crystals to renal epithelial 
cells have all used crystals composed of pure mineral. However, it is now recognised that 
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the inclusion of proteins such as UPTFI into CaOx crystals in vivo is likely to affect their 
physicochemical features and thus binding properties. As the major component of COM 
crystals from the black population, UPTF I is likely to exert the greatest influence on the 
surface charge of these crystals. Thus, the larger number of sialic acid and Gla residues on 
BFl compared with WFl may provide a greater negative charge to the black population's 
urinary crystals. This would provide a greater repulsive force to the negatively charged 
renal cell surface, resulting in diminished crystal adhesion in the black population. 
Consideration of all of the afore-mentioned results show that the objectives of this 
thesis have been met and that the original hypothesis has been validated. However, while 
this thesis has unearthed several new areas that allow a more enlightened understanding of 
the black population's remarkably low stone incidence, the present study is perhaps only 
the beginning. Future investigations should aim to clarify and further investigate the role of 
UPTFl in the two mechanisms described above, as well as the unique properties of BFl 
and its role with respect to these mechanisms. Firstly, the contribution of the glycans, and 
in particular sialic acids, to the inhibitory activity of UPTF 1 should be investigated. This 
could be achieved by comparison of the aglyco and asialo forms of UPTF 1 with the intact 
protein in an in vitro crystallisation study. Secondly, the role of UPTFI 's glycans as 
possible mediators of crystal binding to renal cells should be examined by quantifying the 
extent of adhesion of crystals containing UPTFI and its aglyco and asialo forms in 
comparison with crystals composed of pure mineral. And thirdly, the attachment and 
dissolution of urinary crystals from white and black subjects should be compared using a 
renal cell culture model. These studies have the potential to clarify the function of 
UPTFl 's glycans and the contribution of crystal adhesion and intracellular proteolysis to 
the exceptionally low stone incidence amongst the black population. 
The elucidation of the precise reasons for the rarity of stones amongst South 
Africa' s black population is likely to confirm the vital role of urinary proteins in the 
formation of, and protection from, kidney stones. However, the complex nature of stone 
disease suggests that it is necessary to examine the role of proteins in conjunction with 
several other factors, of which diet is likely to be one. The key contribution of this thesis 
has been to demonstrate that, amongst these other possible factors, UPTF 1 is indeed a 
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TABLES & FIGURES 
Interplanar spacings and relative intensities of powder patterns of calcium oxalates 
X-ray powder diffraction peak assignments and percentage composition of CaOx 
crystals prepared according to Pak eta!. ( 197 5) 
Absorbance slopes and inhibition of aggregation (IA %) of COM crystal slurry by urine 
at various dilutions 
Absorbance slopes and inhibition of aggregation (IA %) of COM crystal slurries before 
and after addition of white subjects' urine (WU) at a dilution of 1 :2 
Absorbance slopes and inhibition of aggregation (IA %) of COM crystal slurries before 
and after addition of black subjects' urine (BU) at a dilution of 1:2 
Average zeta potential (ZP) of COM crystal slurries before and after addition of white 
subjects' urine (WU) at a dilution of 1:2 
Average zeta potential (ZP) of COM crystal slurries before and after addition of black 
subjects' urine (BU) at a dilution of 1 :2 
Bradford protein assay standard curve data using bovine serum albumin (BSA) 
Protein concentration (~-tg/ml) and excretion (mg/day) of black and white subjects' 
urine 
Particle size ( ~-tm) of synthetic urine before and after addition of macromolecular urine 
extracts from white (WMM) and black (BMM) subjects 
Average composition (mmol/24hr) and physicochemical parameters of white (WC) 
and black (BC) subjects' urine 
Typical sedimentation rate plot (or OD620 plot) 
Typical plot of particle number versus sodium oxalate concentration to determine 
metastable limit (MSL) 
X-ray powder diffraction pattern of CaOx crystals prepared according to Pak et a!. 
(1979) 
Thermogravimetric analysis of CaOx crystals prepared according to Pak eta/. ( 1979) 
Scanning electron micrographs of CaOx crystals prepared according to Pak et a!. 
(1975) 
OD620 plots of COM crystal slurries after addition of urine at various dilutions 
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Average particle number of synthetic urine as a function of time 
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Average particle size of synthetic urine (3.5.1- 3.5.2) 
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HPLC gradient used for UPTF1 purification 
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white control subject WC6 
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Western blot ofUPTF1 from white and black subjects 
20 SDS-PAGE ofUPTF1 from white (4.6.1 ) and black subjects (4.6.2) 
SDS-PAGE of crystal matrix extract from white control subject WC6 
NP-HPLC profiles of N-linked glycans on UPTF1 pooled from white (WC pool) and 
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black (BC 1-7) subjects 
NP-HPLC profiles of N-linked glycans on UPTF1 from several white stone-formers 
(WSFl-6) and one black stone-former (BSF) 
NP-HPLC profiles of a UPTFl N-glycan pool from white control subject WC6 before 
and after treatment with an array of exoglycosidases 
NP-HPLC profile of a UPTF1 N-glycan pool from white control subject WC6 before 
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NP-HPLC profile of a UPTFl N-glycan pool from white control subject WC6 before 
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NP-HPLC profiles of 0-linked glycans on UPTFl pooled from 3 white control 
subjects before and after exoglycosidase digestions 
W AX-HPLC profiles of 0-linked glycans on UPTFI pooled from white control (WC) 
subjects and white stone-formers (WSF) before and after Abs digestion 
NP-HPLC profiles of 0-linked glycans on UPTFI pooled from white (WC) and black 
(BC) control subjects and white stone-formers (WSF). 
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Average urine composition (mmol/1) and physicochemical parameters of pooled urines 
from white and black subjects (n=5) 
Particle number (/500~-tl) of ultrafiltered urine from white (WUF) and black (BUF) 
subjects before and after addition of WFI and BFI at final concentrations of 1.25 mg/1 
Particle volume (xl03 ~-tm3/500 ~-tl) of ultrafiltered urine from white (WUF) and black 
(BUF) subjects before and after addition of WFl and BFI at final concentrations of 
1.25 mg/1 
Percentage change in average particle parameters of ultrafiltered urine from white 
(WUF) and black (BUF) subjects after addition of WFI and BFI at final 
concentrations of 1.25 mg/1 
Particle size ( J.tm) of ultrafiltered urine from white (WUF) and black (BUF) subjects 
before and after addition of WFI and BFI at final concentrations of 1.25 mg/1 
Percentage precipitated C4CJ-oxalate in ultrafiltered urine from white (WUF) and 
black (BUF) subjects before and after addition ofWFI and BFI at final concentrations 
of 1.25 mg/1 
Average absorbance slope (x-10·\-1) and inhibition of aggregation (IA %) of COM 
crystal slurries before and after addition of WF1 and BFI at final concentrations of 
1.25 mg/1 
X-ray powder diffraction peak assignments of CaOx crystals prepared according to 
Brown eta/. ( 1985) 
Average absorbance slope (x-10-ss- 1) and inhibition of aggregation (IA %) of COD 
crystal slurries before and after addition of WFI and BFI at final concentrations of 
1.25 mg/1 
Average zeta potential (m V) of COM crystal slurries before and after addition of WF I 
and BF1 at final concentrations of 1.25 mg/1 
Average zeta potential (m V) of COD crystal slurries before and after addition of WFI 
and BFl at final concentrations of 1.25 mg/1 
Cross-over design employed for UPTFl crystallisation study 
Average plot of particle number versus sodium oxalate concentration in synthetic urine 
Average particle size distributions in synthetic urine. Synthetic urine (SU) before and 
after addition ofWF1 and BFl at final concentrations of 1.25 mg/1 
Scanning electron micrographs of CaOx crystals deposited in synthetic urine 
Average [14C]-ox deposition rate in synthetic urine. Synthetic urine (SU) before and 
after addition ofWF1 and BF1 at final concentrations of 1.25 mg/1 
Average particle size distributions in WUF. Ultrafiltered urine from white subjects 
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Average particle size distributions in BUF. Ultrafiltered urine from black subjects 
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Scanning electron micrographs of CaOx crystals deposited in ultrafiltered urine 
Average [14C]-ox deposition rate in WUF. Ultrafiltered urine from white subjects 
(WUF) before and after addition of WF I and BF1 at final concentrations of 1.25 mg/1 
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Figure 5.8.2 Average [14C]-ox deposition rate in BUF. Ultrafiltered urine from black subjects 
(BUF) before and after addition ofWF1 and BFl at final concentrations of 1.25 mg/1 
Figure 5.9 Average OD62o plot of COM crystal slurries. Before and after addition of WFl and 
BF 1 at final concentrations of 1.25 mg/1 
Figure 5.10 X-ray powder diffraction pattern of CaOx crystals prepared according to Brown eta/ 
(1985). 
Figure 5.11 Thermogravimetric analysis of CaOx crystals prepared according to Brown et a/. 
(1985). 
Figure 5.12 Scanning electron micrographs of CaOx crystals prepared according to Brown eta/. 
(1985). 
Figure 5.13 Average OD620 plots of COD crystal slurries. Before and after addition of WF1 and 
BF1 at final concentrations of 1.25 mg/1 
Figure 5.14 Average % inhibition by WFl and BF1 in COM & COD crystal slurries (final 
concentrations of 1.25 mg/1) 
Figure 5.15 Average% inhibition by UPTFl in COM & COD crystal slurries (final concentration 
of 1.25 mg/1) 
Figure 5.16 Average zeta potential of COM crystal slurries. Before and after addition of WF1 and 
BF1 at final concentrations of 1.25 mg/1 
Figure 5.17 Average zeta potential of COD crystal slurries. Before and after addition of WFl and 
BF1 at final concentrations of 1.25 mg/1 
Figure 5.18 Average% decrease in zeta potential of COM & COD crystal slurries. After addition 
of WF1 and BF1 at final concentrations of 1.25 mg/1 
Figure 5.19 Average % decrease in zeta potential of COM & COD slurries. After addition of 
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Western blot of urine and CaOx urinary crystals from black control subjects 
immunoblotted for prothrombin 
Western blot of urine and CaOx urinary crystals from white stone-formers 
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Table 7.1.1 Urine composition (mmol/1) and physicochemical parameters of black groups• pooled 
unnes 
Table 7.1.2 Urine composition (mmol/1) and physicochemical parameters of white groups• pooled 
urines 
Table 7.2.1 X-ray powder diffraction peak assignments and percentage composition of CaOx 
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X-ray powder diffraction peak assignments and percentage composition of CaOx 
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Composition of black groups' CaOx urine crystals as determined by x-ray powder 
diffraction 
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diffraction 
X-ray powder diffraction patterns of CaOx urine crystals 
Scanning electron micrographs of CaOx urine crystals 
Desalting chromatograms of demineralised CaOx urine crystals 
Protein patterns of CaOx urine crystals (black subjects: lanes I - 5; white subjects: 
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Western blot of CaOx urine crystals immunoblotted for prothrombin. 
Western blot of CaOx urine crystals immunoblotted for osteopontin. 
Abbreviations used to denote crystals prepared from white and black subjects' pooled 
urines before and after dosing with UPTFI from both population groups 
Summary of treatments used for various crystals 
SDS-PAGE ofCaOx urine crystals 
Western blot ofCaOx urine crystals 
Field emission scanning electron micrographs of UF CaOx crystals before and after 
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Field emission scanning electron micrographs of WF, WUF+WF1 and WUF+BF1 
CaOx crystals before treatment 
Field emission scanning electron micrographs of BF, BUF+WF1 and BUF+BF1 CaOx 
crysta1s before treatment 
Field emission scanning electron micrographs of WF CaOx crystals before and after 
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Field emission scanning electron micrographs of CaOx crystals after incubation with 
thrombin in an unsaturated CaOx buffer 
Field emission scanning electron micrographs of CaOx crystals after incubation with 
Proteinase K in an unsaturated CaOx buffer 
Field emission scanning electron micrographs showing stages of COM crysta1 
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Field emission scanning electron micrographs showing stages of COD crysta1 
dissolution in an unsaturated CaOx buffer 
Zeta potential (ZP) of COM crystal slurries before and after addition of white subjects' 
urine (WU) at a dilution of 1 :2 
Zeta potential (ZP) of COM crystal slurries before and after addition of black subjects' 
urine (BU) at a dilution of 1:2 
Particle number as a function of sodium oxalate concentration in synthetic urine 
Composition (mmol/24hr) and physicochemical parameters of white subjects' urine 
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OD62o plot of COM crystal slurries 
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00620 plot of COM crystal slurries after addition of black subjects' urine at a dilution 
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pooled urines ( 1.1 - B 1. 7) 
Particle number as a function of sodium oxalate concentration in black subjects: 
pooled urines (2.1 - B2.7) 
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Particle volume of synthetic urine before and after addition of CME from white (WE) 
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Particle size of synthetic urine before and after addition of CME from white (WE) and 
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Particle number as a function of sodium oxalate concentration in synthetic urine 
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[
14C]-oxalate deposition in synthetic urine before and after addition ofWFl and BFl at 
final concentrations of 1.25 mgll. 
MSL plots of white (3.1-3.5) and black (3.6-3.10) subjects' pooled urines 
Particle size distributions in white (4.1-4.4) and black (4.5 -4.7) subjects' 
ultrafiltered urine before and after addition of WFl and BFl at final concentrations of 
1.25 mgll. e4C]-oxalate deposition in ultrafiltered urine from white (5.1- 5.3) and black 
(5.4- 5.6) subjects 
00620 plots of COM crystal slurries (6.1.1- 6.1.6). 
00620 plots of COM crystal slurries after addition of WFI (final concentration 
1.25 mgll) (6.2.1 - 6.2.6). 
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1.25 mgll) (6.3.1-6.3.7). 
0062o plots of COD crystal slurries (7 .1.1 - 7 .1.9). 
OD620 plots of COD crystal slurries after addition of WFl (final concentration 
1.25 mgll) (7.2.1-7.2.12). 
0062o plots of COD crystal slurry after addition of BF1 (final concentration 1.25 mgll) 
(7.3.1 -7.3.10) 
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Desalting chromatograms of demineralised CaOx crystals precipitated from white 
control subjects' urine 
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X-ray powder diffraction peak assignments and percentage composition of CaOx 
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X-ray powder diffraction peak assignments and percentage composition of CaOx 
crystals precipitated from the urine of black group 3 
X-ray powder diffraction peak assignments and percentage composition of CaOx 
crystals precipitated from the urine of white group 1 
X-ray powder diffraction peak assignments and percentage composition of CaOx 
crystals precipitated from the urine of white group 2 
X-ray powder diffraction peak assignments and percentage composition of CaOx 
crystals precipitated from the urine of white group 3 
X-ray powder diffraction patterns of CaOx crystals precipitated from black males' 
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APPENDIX A: TABLES 
Table A1.1: Zeta potential (ZP) of COM crystal slurries before and after addition of white 
subjects' urine (WU) at a dilution of 1:2 
Sample Zeta potential (mV) ~±SE(mV) 
COM -17.9, -17.8, -17.3, -18.4, -17.9,-17.8 -17.9 ± 0.14 
COM+WU1 -30.8, -30.5, -30.4 -30.6±0.12 
COM+WU2 -27.9, -29.8, -29.3 -29.0 ± 0.57 
COM+WU3 -29.1, -29.9, -29.8 -29.6±0.25 
COM+WU4 -29.8, -30.2, -29.9 -30.0 ± 0.12 
COM+WU5 -18.6, -16.9. -16.1 -17.2 ± 0.74 
Table A1.2: Zeta potential results of COM crystal slurries before and after addition of black 
subjects' urine (BU) at a dilution of 1:2 
Sample Zeta potential (mV) ~±SE(mV) 
COM -17.9, -17.8, -17.3, -18.4, -17.9,-17.8 -17.9 ± 0.14 
COM+BU1 -22.2, -23.2, -23.3 -22.9 ±0.35 
COM+BU2 -23.5, -23.4, -23.7 -23.5 ± 0.088 
COM+BU3 -23.5, -23.0, -23.5 -23.3 ±0.17 
COM+BU4 -23.1, -23.2, -23.8 -23.4 ± 0.22 
COM+BU5 -22.7, -22.5, -23.3 -22.8 ±0.24 
Table A2: Particle number as a function of sodium oxalate concentration in synthetic urine 
[NaOx] Particle number (/500 pl): 
(mmolll) Experiment I Experiment 2 AvenJge±SE 
15 3525 2902 3214 ± 312 
30 1986 2002 1994 ± 8 
45 * 1846 1919 1882 ± 36 
60 16176 15905 16040± 136 
75 10893 10725 10809 ±84 
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APPENDIX A: FIGURES 
Figure Al: 00620 plot of COM crystal slurry 
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APPENDIX A A5 
Figure A2: 00620 plots of COM crystal slurries after addition of white subjects' urine at a 
dilution of 1:2. 
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APPENDIX A 
Figure A4: Particle size distributions of synthetic urine (4.1- 4.5). 
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Figure A5: Particle size distributions of synthetic urine after addition of macromolecular 
extracts from white subjects' urine. 
Figure AS.l: SU+WMMS particle size distribution 
750 ..---------------
~ Q 




1: = 250 +---~--------\-----1 
l! E 
0 I 0 20 30 
Size (pm) 





= 8 = U'l 900 ....... -~ c 
"C ::s.. 600 
~ ... ~ 
cf ~ 300 
0+-~--~-----r--~~ 
() J() 20 30 
Size (pm) 
Figure AS.S: SU+WMM9 particle size distribution 1 
250 ,.-----------------: 
() J() 20 30 
Size (pm) 
Figure A5.2: SU+WMM6 particle size distribution 
1200 ..---------------, 
o+--------r-------,~~~~~ 
() I 0 20 30 
Size (pm) 
Figure A5.4: SU+ WMM8 particle size distribution 
!!00 -r--------1:""""%--------, 
0+-----r----~-----~ 
() 10 20 30 
Size (pm) 
APPENDIX A A9 
Figure A6: Particle size distributions of synthetic urine after addition of macromolecular extracts 
from black subjects' urine. 
Figure A6.1: SU+BMMS particle size distribution 
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Table B3.1: Particle number as a function of sodium oxalate concentration in white males' 
pooled urine 1 
[NaOx] Particle number: 
(mM) Experiment 1 Experiment 2 Average 
15 390 397 394 
30 308 357 332 
45 421 444 432 
60 * 593 652 622 
75 5921 6076 5998 
90 14420 14718 14569 
* NaOx concentration corresponding to metastable limit 
Table B3.2: Particle number as a function of sodium oxalate concentration in white males' 
pooled urine 2 
[NaOx] Turbidity: 
(mM) Experiment 1 Experiment 2 Average 
15 0.54 0.50 0.52 
30 0.47 0.48 0.475 
45 * 1.02 1.00 1.01 
60 5.5 6.0 5.75 
75 8.2 9.2 8.7 
90 15.6 16.6 16.1 
* NaOx concentratiOn corresponding to metastable limit 
Table B3.3: Particle number as a function of sodium oxalate concentration in white males' 
pooled urine 3 
[NaOx] Particle number: 
(mM) Experiment 1 Experiment 2 Average 
15 124 
30 758 
45 * 946 
60 12021 
75 20250 
* NaOx concentration corresponding to metastable limit 
Table B3.4: Particle number as a function of sodium oxalate concentration in white males' 
pooled urine 4 
[NaOx] Particle number: 
(mM) Experiment 1 Experiment 2 Average 
15 0.38 0.35 0.365 
30 0.45 0.48 0.465 
45 * 0.97 0.95 0.96 
60 4.0 4.2 4.1 
75 13.7 13.8 13.75 
90 13.2 13.1 13.15 
105 16.0 17.1 16.55 




Table B3.5: Particle number as a function of sodium oxalate concentration in white males' 




























Table B3.6: Particle number as a function of sodium oxalate concentration in white males' 
pooled urine 6 
[NaOx] Particle number: 
(mM) Experiment 1 Experiment 2 Average 
15 1783 1699 1743 
30 * 431 420 426 
45 6631 6942 6787 
60 18861 18577 18719 
75 20459 20410 20435 
90 20666 20573 20620 
* NaOx concentration corresponding to metastable limit 
Table B3.7: Particle number as a function of sodium oxalate concentration in white males' 
pooled urine 7 
[NaOx] Particle number: 
(mM) Experiment 1 Experiment 2 Aver3le 
15 * 1128 1118 1123 
30 8062 7912 7987 
45 17870 17893 17882 
60 17649 17367 17508 














Table B4.1: Particle number as a function of sodium oxalate concentration in black males' 
pooled urine 1 
[NaOx] Turbidity: 
(mM) Experiment 1 Experiment 2 Average 
15 0.77 0.72 0.74 
30 1.50 1.00 1.25 
45 0.90 0.85 0.88 
60 1.2 l.l l.l5 
75 * 1.6 1.7 1.65 
90 4.1 4.0 4.05 
105 7.5 7.1 7.3 
120 17.2 17.1 17.2 
* NaOx concentration corresponding to metastable limit 
Table B4.2: Particle number as a function of sodium oxalate concentration in black males' 
pooled urine 2 
[NaOx] Particle number: 
(mM) Experiment 1 Experiment 2 Aver32e 
15 818 917 868 
30 553 639 596 
45 530 580 555 
60 * 632 626 629 
75 6210 6477 6344 
90 14819 14359 14589 
105 19783 18111 18947 .. * NaOx concentration corresponding to metastable ilm1t 
Table B4.3: Particle number as a function of sodium oxalate concentration in black males' 
pooled urine 3 
[NaOx] Turbidity: 
(mM) Experiment 1 Experiment 2 Average 
15 0.66 0.63 0.64 
30 0.44 0.42 0.43 
45 0.69 0.70 0.695 
60 0.75 0.79 0.77 
75 0.52 0.54 0.53 
90 1.61 1.7 1.65 
105 * 1.95 2.02 1.98 
120 6.8 7.4 7.1 
150 28 29 28.5 






Table B4.4: Particle number as a function of sodium oxalate concentration in black males' 
pooled urine 4 
[NaOx] Particle number: 
(mM) Experiment 1 Experiment 2 Average 
15 508 572 540 
30 538 535 536 
45 * 902 1005 953 
60 2003 2070 2036 ~ 
75 3585 4127 3856 ; 
90 1621 2421 2021 
105 7147 9528 8338 
120 8128 9761 8944 
150 7391 8726 8058 
* NaOx concentration corresponding to metastable limit 
~ 
Table B4.5: Particle number as a function of sodium oxalate concentration in black males' 
pooled urine 5 
[NaOx] Particle number: • 
(mM) Experiment 1 Experiment 2 Aver32e ~ 
15 531 662 5% 
30 
45 807 874 840 
60 1596 1246 1421 
75 680 636 658 
90 * 843 865 854 
105 3753 4138 3946 
120 4002 4442 4222 
* NaOx concentration corresponding to metastable limit 
Table B4.6: Particle number as a function of sodium oxalate concentration in black males' 
poc:>led urine 6 
[NaOx] Turbidity: 
(mM) Experiment 1 Experiment 2 Aver32e 
15 0.62 0.56 0.59 
30 0.68 0.58 0.63 
45 1.00 0.94 0.97 
60 1.08 1.03 1.06 
75 1.09 1.19 1.14 
90 * 1.68 1.72 1.70 
105 7.4 8.1 7.75 
120 27 28 27.5 
* NaOx concentration corresponding to metastable limit 
I 
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Table B4.7: Particle number as a function of sodium oxalate concentration in black males' 
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Table B5: Particle number (/500pl) of synthetic urine before and after addition of CME from 
white (WE) and black (BE) subjects at final concentrations of 5 mg/1 
Time Experiment I: Experiment 2: Average: 
su SU+WE SU+BE su SU+WE SU+BE su SU+WE SU+BE 
0 169 98 182 177 128 42 173 113 112 
15 14754 11052 8034 13630 4206 3292 14192 7629 5663 
30 15676 12193 11652 12513 6257 5164 14094 9225 8408 
45 12990 11303 11848 11006 8018 6576 11998 9660 9212 
60 12572 9762 11898 9028 8230 9297 10800 8996 10598 
Table B6: Particle volume (106 pm3/500pl) of synthetic urine before and after addition of 
CME from white (WE) and black (BE) subjects at final concentrations of 5 mg/1 
Time Experiment I: Experiment 2: Average: 
su SU+WE SU+BE su SU+WE SU+BE su SU+WE SU+BE 
0 0.037 0.036 0.032 0.025 0.042 0.015 0.019 0.039 0.024 
15 1.637 1.266 0.590 0.928 0.556 0.556 1.283 0.911 0.573 
30 1.928 1.736 1.305 1.796 1.228 0.940 1.862 1.482 1.123 
45 2.08 2.500 1.654 2.333 1.972 1.559 2.207 2.236 1.607 
60 2.343 2.694 2.200 2.721 2.345 2.185 2.532 2.520 2.193 
Table B7: [14C]-oxalate deposition expressed as a percentage precipitated [14C]-oxalate in 
synthetic urine before and after addition of CME from white (WE) and black (BE) subjects 
at final concentrations of 5 mg/1 
Time Experiment I: Experiment 2: Average: 
su SU+WE SU+BE su SU+WE SU+BE su SU+WE SU+BE 
0 0 0 0 0 0 0 0 0 0 
30 16.2 11.9 5.0 41.7 12.8 7.0 29.0 12.4 5.0 
60 38.5 24.2 26.4 61.2 32.7 30.9 49.9 28.5 28.7 
90 51.0 32.9 33.0 69.7 48.0 54.2 60.4 40.5 43.6 
120 58.7 39.8 38.6 74.6 59.6 64.7 66.7 49.7 51.7 
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APPENDIX B: FIGURES 
Figure Bl: Particle number as a function of sodium oxalate concentration in white subjects' 
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Figure 81.2: MSL plot of \\bite males' 




Figure 81.4: M5L plot of \\bite males' 









Figure 81.6: MiL plot of white males' 
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Figure 82.1: M'iL ~ot of ~jack males ' 
!!!Qled urine I 
45 75 105 135 
[NaOx] (mM) 
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H~:ure 82.7: MSLpiQt of Hack males ' 
pooled urine 7 
















Figure 82.2: MSL ~ot of black males' 
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Figure B3: Particle number as a function of time of synthetic urine before and after addition of 
CME from white {WE) and black {BE) subjects at final concentrations of 5 mg/1 (3.1: experiment 
1, 3.2: experiment 2). 
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Figure B4: Particle volume of synthetic urine before and after addition of CME from white {WE) 
and black {BE) subjects at final concentrations of 5 mg/1 (4.1: experiment 1, 4.2: experiment 2). 
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Figure B5: Particle size of synthetic urine before and after addition of CME from white (WE) and 
black (BE) subjects at final concentrations of 5 mg/1 (5. 1.1 - 5.I .2: experiment I, 5.2.1 - 5.2.2: 
experiment 2). 
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Figure B6: [14C]-oxalate deposition rate in synthetic urine before and after addition of CME from 
white (WE) and black (BE) subjects at final concentrations of 5 mg/1 (6.1 : experiment , I, 6.2: 
experiment 2). 
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APPENDIX C: METHODS 
N-LINKED GLYCAN ANALYSIS 
Approximate time schedule 
1. SDS-PAGE 
2. Excise protein bands 
3. Wash gel pieces 
4. PNGase F digestion 
5. N-glycan extraction 
6. 2AB labelling & clean up 
7. HPLC 







3 Y2 hour column conditioning, 3 hours per sample 
overnight 
Sub-boiling point distilled water (SBP H20 water) 
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MilliQ water has been found to contain traces of polymers and organic contaminants which 
give a high background signal on mass spectrometry. Samples are therefore prepared in 
fresh MilliQ water purified by distillation at sub-boiling point. 
1. SDS-PAGE 
Sample preparation 
Reduce proteins by the addition of DTT as follows: 
14 Jll sample, 4 Jll 5x Laemli sample buffer, 2 Jll 0.5 molll DTT (7.71 mg DTT in 100 Jll 
SBPH20) 
Incubate at 70°C for 10 minutes. 
Alkylate proteins with lA as follows. 
Add 100 mmol/l lA at 10% of the final volume ( 18.5 mg in 1 ml SBP H20). 
Wrap samples in foil (lA is light sensitive) and incubate at room temperature (RT) for 30 
minutes. 
Note: Reduction and alkylation are necessary to separate disulphide bonded chains and to 
ensure optimal efficiency in digests using PNGase F. 
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Stock Solutions 




Sx Running buffer : 
Amps (10%) 
SDS (10%) 
30% acrylamide, 0.8% bisacrylamide solution 
0.5M Tris, pH 6.6 [6g Tris in 100 ml H20, use HCl to adjust pH] 
l.5M Tris pH 8.8 [18.2g Tris in 100 ml H20, use HCl to adjust pH] 
144g glycine, 30g Tris, lOg SDS in 21 H20 
lg Amps in lOml H20 
lg SDS in lOml H20 





10%SDS, 0.5ml glycerol, made up to 5 ml with H20 
1.25g Coomassie R-250 (Brilliant blue), 250 ml methanol, 50 ml 
concentrated acetic acid, 200ml H20 
50% methanol, 7% concentrated acetic acid, 43% H20 
5 % methanol, 7% concentrated acetic acid, 88% H20 
12.5 %polyacrylamide gels (2 mini gels) 
Packing gel: Stacking gel: 
Proto gel 5.0ml Protogel 0.665 ml 
Gel buffer 3.0ml Stacking buffer 1.25 ml 
SBPH20 4.0ml SBPH20 3.05 ml 
SDS (10%) 120 f..ll SDS (10%) 50 f..ll 
Amps (10%) 120 f..ll Amps (10%) 50 f..ll 
TEMED 12 f..ll TEMED 5 f..ll 
Staining and destaining 
Add Coomassie stain and leave overnight on a shaker (at low speed). 
Place in "destain 1" solution for 5 minutes followed by "destain 2" solution for several 
hours as required. 
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2. EXCISE PROTEIN BANDS 
Place the gel on a glass sheet over a light box and cut out the Coomassie-stained bands 
from the gel using a clean scalpel. Cut each band into small pieces ( -1 mm3) and transfer 
to 1.5ml eppendorf tube. Freeze the gel pieces for at least 2 hours; this helps break up the 
gel and facilitate PNGase F digestion. 
3. WASHING OF GEL PIECES 
Add 1 ml ACN to the eppendorf tube and vortex. Place the eppendorf in a 50 ml plastic 
tube on a mixer and wash for 30 minutes at RT. Discard ACN and repeat with 1 ml 
20 mmol/1 NaHC03 (0.168 gin 100 ml SBP H20, adjust to pH 7.0 with 1 mol/1 HCl). 
Repeat the washings with ACN, followed by NaHC03 and finishing with ACN. The gel 
piece should move freely in the liquid so add more liquid if necessary. This removes 
background contamination which may interfere with 2AB labelling and subsequent mass 
spectrometry. The reducing and alkylating reagents as well as residual SDS are removed. 
Dry samples in a vacuum centrifuge. 
4. PNGase F DIGESTION 
The volumes given are for 15 mm3 of gel. To the dried gel pieces add 3 J.1). PNGase F (1 
U/~ in SBP H20) and 27 ,.U of 20 mmol/1 NaHC03• Leave the samples for about 5 minutes 
until the gel pieces have re-swelled. Then cover the gel with additional buffer (a total of 
about 70- 100 Jl).) until the gel is covered, and incubate at 37 °C for 12 - 16 hours. 
S. N-GLYCANEXTRACTION 
After incubation in PNGase F, vortex the samples and centrifuge at 10 000 g for 5 minutes. 
In order to extract the glycans, remove and retain the supernatant and place it in a 1.5 ml 
eppendorf tube. Add 200 ,.U SBP H20 to the gel and sonicate for 30 minutes, remove the 
supernatant and add to the retained supernatant. Repeat the sonication with a further two 
washed of SBP H20 followed by 200 ,.U ACN (this shrinks the gel), 200 ,.U SBP H20 and 
lastly 200 ,.U ACN. Dry the combined supernatants down to a fmal volume of 400 - 500 ,.U. 
Prepare AG-50 (W activated) immediately as outlined below. Vortex the resin and water 
mixture and immediately add 50 ,.U resin to each sample. Place the eppendorf in a 50 ml 
plastic tube and mix for 5 minutes at RT to desalt. Filter the supernatant through 0.45 Jlll1 
Millipore filter using a 1 ml syringe into a 1.5 ml eppendorf tube. Add 50 f.Ll SBP H20 to 
the resin remaining in the eppendorf tube and filter as before. 
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Dry down the sample in vacuum centrifuge and when the volume has reached 
100 f..ll or less, transfer the supernatant to a 0.5 ml eppendorf, rinse the larger eppendorf out 
twice with 25 f..ll SBP H20, vortex and spin and transfer to the 0.2 ml eppendorf. Divide the 
sample in equal parts and dry. One half will be fluorescently labelled and the other will be 
retained for mass spectrometry. 
AG-50 preparation: To activate AG SOW Xl2 200-400 mesh, put about 5 ml AG-50 in a 
50 ml bottle, add 50 ml 1 molll HCl, shake, decant, repeat 3 times. Wash with 50 ml SBP 
H20 and repeat 4 times. Check that the pH is 7 and store at 4 °C. Before use take 0.5 ml of 
suspension, allow to settle, remove water from above resin and discard. Add lml SBP 
H20, vortex and allow to settle. Remove SBP H20 and discard. Repeat this process and 
remove most of the water. 
6. 2AB LABELLING AND CLEAN UP 
Add 5 f..ll of 2AB labelling mixture and vortex and spin down the sample. Incubate at 65 °C 
for 2 hours in a dry oven. After 30 minutes, remix and spin down the sample. Allow to 
cool at -20 °C for 5 minutes before applying to 3MM filter paper. Spot each labelled 
glycan sample onto a clean piece of filter paper about 1 em from the bottom and allow to 
dry for about 20 - 30 minutes or until the spot appears dry (method for cleaning is detailed 
below). Run for 90 minutes in ACN. Inspect under UV light and cut out the glycan spot. 
Roll up the paper disc and place in a 1 ml syringe fitted with a 0.45 J..lm filter. Remove the 
plunger, insert paper disc and pipette 0.5 ml SBP H 20 into the syringe. Leave for 10 
minutes and then push through the glycans into an acid washed rotary evaporator tube 
(abbreviated as "rotovap"). Add a further 0.5 ml double distilled H20, leave for 10 
minutes and repeat for a total of 4 washes. 
Evaporate the sample down to 50- 100 f..ll and transfer to a 0.5 ml eppendorf, rinse out 
the rotovap tube with 50 f..ll SBP H20, vortex and centrifuge at 150 g for 5 minutes. 
Repeat twice with 50 ~tl SBP H20 . Dry the labelled glycans in a vacuum centrifuge and 
dissolve in a final volume of 200 J..ll SBP H20. 
APPENDIXC A27 
Preparation of 3MM paper: Cut a 10 x 2.5 em piece of paper for each sample. Was 
Whatman 3MM filter paper in a large volume of MilliQ H20 for 2 washes of 15 minutes 
each, followed by a final wash of 15 minutes in SBP H20 . Allow to dry completely before 
use. 
7. HPLC 
The amount of glycan required will depend on the amount of glycoprotein, the percentage 
glycosylation and the number of different glycans present. For the first analysis, use 1 % of 
the total glycan pool (i.e. 21200 f.ll). 
NP-HPLC 
Make the glycans up to 20 f.ll with SBP H20 and then add 80 f.ll ACN before analysis. 
Include a dextran sample as a standard. For NP-HPLC, a 4.6 x 250 mm Glycosep-N 
column (Glyko, England) was fitted to a Waters Alliance Separations module and 
monitored at a fluorescence of 420 nm following excitation at 330 nm. Solvent A was 
50 mmol/1 ammonium formate (pH 4.0) and solvent B was ACN. The glycans were 
separated with the following gradient conditions: 20- 58% A (0.4 ml/minute) over 
152 minutes, 58 - 100% A for 3 minutes (0.4 ml/minute), 100% A for 5 minutes 
(1.0 ml/minute), 100-20% A for 1 minute (1.0 ml/minute), 20% A for 14 minutes 
( 1.0 ml/minute) and then decreasing the flow rate to 0.4 ml/minute over 1.5 minutes. The 
total column time per sample is 180 minutes. 
WAX-HPLC 
Make the glycans up to 100 f.ll with SBP H20 before analysis. Include a bovine serum 
fetuin sample as a standard. For W AX-HPLC, the glycans were separated according to 
charge density using a 7.5 x 50 mm Vydac 301VHP575 column (Anachem Limited, Luton, 
England). Solvent A was 0.50 mol/1 formic acid (pH 9.0) and solvent B was 10 % 
methanol in SBP H20 (v/v). The gradient conditions were as follows: 0 - 5 % A over 
12 minutes, 5 - 21 % A over 13 minutes, 21 - 50 % A over 25 minutes, 80- 100 % A over 
5 minutes, 100% A for 5 minutes (all at 1.0 ml/minute); then 100-0% A over 1 minute, 
0 % A for 11 minutes (both at 2.0 ml/minute ); then continue at 1.0 ml/minute until 
80 minutes. The fluorescence was monitored at 420 nm following excitation at 330 nm. 
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8. EXOGLYCOSIDASE DIGESTION 
Dry aliquots of the 2AB labelled glycan pool (usually 1 %) in 0.5 ml eppendorf tubes. Add 
exoglycosidases at the final concentrations indicated in Table 4.2 (page 70) and incubate 
overnight at 37 °C in a circulating water bath. Use all exoglycosidases except JBM with a 
10 times concentrated mix buffer (50 mmolll sodium acetate final concentration, pH 5.5). 
Use JBM with a separate buffer (100 mmolll sodium acetate, 2 mmolll Zn, pH 5.0). 
Table: Examples of exoglycosidase array preparations 
Volume (pi): 
Sample Abs Amf Btg GluE Jbh Bkf Jbm Nani iuffet dd 
u~o 
Control 0 0 0 0 0 1 
Abs 1 0 0 0 0 1 
Abs+Amf I 1 0 0 0 1 
Abs+Amf+Btg 1 1 2 0 0 1 
Abs+Amf+Btg+GluH 1 1 2 1 0 1 
Abs+Amf+Btg+Jbh 1 1 2 2 1 
Abs+Amf+Btg+GluH+Bkf 1 1 2 1 2 1 
• Abs+Amf+Btg+GluH+Bkf+Jbm 5 1 
Nani 1 1 
The glycan pool was incubated overnight with Abs+Amf+Btg+GluH+Bkf and "cleaned up" as described 
below. The sample was then dried down and incubated overnight with Jbm in the Jbm buffer. 
After overnight digestion, clean up samples to remove excess enzyme. Pre-wash Amicon 
Micropure-EZ enzyme removers with 200 ,U SBP H20, centrifuge at 2800 g for 10 minutes 
and discard the washings. Apply the digested glycans to the filter, centrifuge (10000 g for 
2 minutes) and wash out the digestion tube with 20 ,U SBP H20 and apply to the filter. 
Centrifuge (10000 g for 2 minutes) and apply 100 ,U SBP H20 to the membrane. 
Centrifuge again ( 10000 g for 2 minutes) and dry down the sample under vacuum. 
Redissolve in 20 ,U SBP H20 and transfer to an HPLC vial. Add 80 ,U ACN and inject 
onto the HPLC. 










0-linked glycans were released by manual hydrazinolysis. This method also releases a 
small amount of N-linked glycans but these can readily be distinguished according to the 
elution position on HPLC. 
1. Dialyse proteins overnight against 0.1 % TFA. 
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2. Transfer the dialysed samples to acid-washed hydrazinolysis tubes (do not fill the bulb 
more than half way). Put on a lid with a teflon insert which is punctured. Place the tube 
in a clean 50 ml plastic tube and freeze-dry overnight. 
3. The sample is then cryongenically frozen (by Dr Brian Matthews, Glycobiology 
Institute, Oxford University). 
4. Cut 4 7 em lengths of Whatman 1 chromatography paper with pinking shears and make 
folds at 2, 6.5 and 8.5 em. Run with SBP H20 by descending chromatography for 
24 hours and hang up the strips to dry. 
5. Hydrazinolysis (Dr Brian Matthews): 60 °C for 6 hours; heat up to 60 °C at 10 °C per 
minute 
6. Prepare an AG50 x 12(W) 200-400 mesh column from resin which has been activated 
by HCl whilst the hydraziDe is being removed under vacuum. Make a column in a 1 ml 
Biorad disposable column[- 0.4 ml resin]. Wash through the column with five column 
volumes of SBP H20. 
7. Put the sample on ice. Add 20 ,.U of 0.2 molfl sodium acetate and then add 20 ,.U acetic 
anhydride (with an acid-washed glass pipette). Leave the sample on ice for 10 minutes 
after shaking a little and then add a further 20 ,.U acetic anhydride. Leave for 
50 minutes at RT. There must be sufficient acetic anhydride so that you can see phase 
separation; otherwise, add more acetic anhydride. 
8. Desalt the sample on the AG50 and wash through with five column volumes of SBP 
H20 into rotovap tubes. 
9. The samples must be washed out of the tubes and dried down in eppendorf tubes. Add 
a drop of octanol during drying down to prevent foaming. The shaker should be on full 
speed with the temperature no greater than 28 °C during drying. Add 1 ml SBP H20 
and a drop of octanol, vortex, centrifuge (150 g for 5 minutes) and rotovap until dry. 
Repeat this process twice to remove the acetic anhydride. Add 0.5 ml SBP H20, vortex, 
centrifuge (150 g for 5 minutes) and rotovap and dry down again. Repeat with 200 J11 
and then 25 ,.U SBP H20 at a lower rotovap speed. 
10. Apply the sample to the pre-washed chromatography paper at the 8.5 em mark. Use a 
further 25 f.d SBP H20 to wash out the tube and apply to the paper as well. Allow the 
spots to dry thoroughly. 
11. Run the paper by descending chromatography in a tank with fresh solvent (-5 em deep) 
and filter paper lined walls (allow time for the tank to equilibrate). Run for 48 -72 
hours with the following solvent, butanol : ethanol : SBP H20 as 8:2: 1. 
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12. Dty the paper and cut out from -1 em to+ 3 em. Roll up this piece (containing the 
0-glycans) using waxed paper (so as not to handle sample) and place in a teflon 2.5 ml 
sytinge fitted with a 0.5 IJ.m 13mm filter on the end over an acid-washed rotovap tube. 
13. In order to wash the glycans off the paper, apply 1.5 ml SBP H20, wait for 5 minutes 
and push the sample through. Repeat this procedure three times with 1.5 ml SBP H 20 
and rotovap to dtyness. Wash down the sides of the rotovap tube 1 ml SBP H 20, 
vortex, centrifuge as before and dry on the rotovap at a moderate speed. Finally, repeat 
with 0.5 ml and then 0.25 ml SBP H20. 
14. Redissolve the glycans in 25 IJ.l SBP H20, centrifuge at 150 g for 5 minutes and 
transfer to an eppendorf tube. Wash out the rotovap tube with a further 3 x 25 IJ.l SBP 
H 20, centrifuging each time. Store the glycans at -20 °C until 2AB labelling. 
15. Now proceed from 2AB labelling as for theN-linked glycans. 
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APPENDIX C: TABLES 
Table Cl: NP-HPLC analysis of N-linked glycans on UPTFl from white control subjects 
Peak GU %AREA: 
ID WCl WC2 WC3 WC4 wcs WC6 WC7 WC8 Ave 
I 4.43 0.1 0.1 0.2 0.1 
2 4.91 0.4 0.2 0.3 1.0 0.2 0.4 0.4 
3 5.06 0.3 0.1 0.1 1.2 0.4 
4 5.31 0.1 0.4 1.2 1.4 1.0 0.8 
5 5.45 0.6 0.6 
6 5.58 0.6 0.3 0.2 0.7 1.0 0.5 2.2 0.8 
7 5.83 0.5 0.1 0.5 0.9 0.3 0.8 0.5 
8 5.90 1.3 0.6 0.5 1.7 1.7 0.6 1.3 0.9 1.1 
9 6.03 0.8 0.9 0.4 1.2 1.4 0.8 1.1 0.3 0.9 
10 6.20 0.2 0.2 
11 6.28 0.6 0.4 0.9 0.3 0.5 0.5 
12 6.37 1.8 1.5 0.8 0.8 1.6 2.1 1.2 1.4 
13 6.58 0.7 0.6 2.7 1.7 0.8 0.4 1.2 
14 6.70 1.9 l.l 0.8 2.2 1.8 1.4 2.3 1.0 1.6 
15 6.80 2.2 1.7 1.5 2.5 2.9 1.8 2.4 2.1 2.1 
16 7.07 2.2 1.0 0.6 0.9 1.8 1.0 1.9 1.2 1.3 
17 7.16 9.8 5.4 3.4 9.6 9.1 5.8 8.8 4.9 7.1 
18 7.36 1.9 1.9 1.5 2.3 0.7 1.7 
19 7.49 1.8 1.8 1.9 3.6 3.4 2.1 2.8 3.0 2.6 
20 7.77 1.6 1.5 1.1 1.5 1.4 1.6 1.8 1.4 1.5 
21 7.88 30.7 24.1 21.6 32.4 30.4 27.3 30.7 24.5 27.7 
22 8.20 
23 8.25 2.3 4.1 3.7 3.2 3.2 3.3 3.4 6.2 3.7 
24 8.40 0.7 1.3 1.8 0.6 1.0 2.1 0.9 1.0 1.2 
25 8.56 35.6 49.2 57.5 33.1 31.9 43.3 33.2 49.8 41.7 
26 8.91 1.1 1.6 1.8 1.0 0.8 1.6 1.2 1.7 1.4 
27 9.26 0.1 0.1 0.2 0.4 0.2 
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Table C2: NP-HPLC analysis of N-linked glycans on UPTFI from black control subjects 
Peak GU %AREA: 
ID BCl BC2 BC3 BC4 BC5 BC6 BC7 Ave 
1 4.43 0.8 0.8 
2 4.91 0.3 0.1 0.8 0.8 3.4 1.1 
3 5.06 0.1 0.1 0.1 
4 5.31 0.2 0.2 
5 5.45 0.5 0.9 1.4 0.9 
6 5.58 0.2 0.2 0.3 0.2 
7 5.83 0.1 0.1 0.5 0.4 0.8 0.4 
8 5.90 0.7 0.6 0.4 0.4 1.3 1.3 1.8 0.9 
9 6.03 1.0 0.7 0.6 0.2 0.6 1.0 1.6 0.8 
10 6.20 
11 6.28 0.4 0.4 
12 6.37 1.6 1.1 1.1 1.0 1.0 1.3 2.3 1.3 
13 6.58 0.7 0.6 0.2 0.5 1.0 1.2 0.7 
14 6.70 1.2 1.4 1.3 0.7 1.9 2.0 2.3 1.5 
15 6.80 1.7 1.6 1.5 1.1 2.8 3.0 3.4 2.2 
16 7.07 1.2 0.8 0.7 1.7 2.2 2.5 1.5 
17 7.16 5.7 5.5 5.2 3.2 5.0 7.1 6.0 5.4 
18 7.36 1.7 2.3 1.7 1.2 0.8 1.5 
19 7.49 2.3 1.6 1.8 1.7 2.6 3.3 3.4 2.4 
20 7.77 1.6 1.1 1.1 1.0 1.8 2.0 2.3 1.6 
21 7.88 25.3 26.8 24.4 22.7 24.6 22.0 19.1 23.6 
22 8.20 3.9 0.5 4.1 2.8 
23 8.25 2.8 4.9 4.6 5.3 5.2 4.6 
24 8.40 1.3 0.4 0.7 0.9 1.1 1.0 1.3 1.0 
25 8.56 47.8 50.3 54.3 57.8 46.0 44.4 35.8 48.1 
26 8.91 1.4 0.4 0.8 2.1 1.1 0.9 1.1 
27 9.26 0.2 0.2 0.2 
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Table C3: NP-HPLC analysis of N-linked glycans on UPTFl from white (WSF) and black 
(BSF) stone-fonners 
Peak GU %AREA: 
ID WSFl WSF2 WSF3a WSF3b• WSF4 WSFS WSF6a WSF6b* WSFAv· 
1 4.43 0.2 0.2 
2 4.91 1.1 1.6 0.7 0.2 1.3 1.0 1.0 
3 5.06 0.3 0.5 0.4 
4 5.31 
5 5.45 0.4 0.8 0.8 0.7 
6 5.58 0.8 1.0 0.5 0.9 0.8 
7 5.83 0.8 0.4 0.5 0.4 0.6 0.5 0.5 
8 5.90 1.9 1.3 0.9 1.3 1.5 1.7 0.7 1.3 
9 6.03 1.2 1.1 1.2 0.9 0.8 1.6 1.1 
10 6.20 0.8 0.8 
11 6.28 1.2 0.8 0.6 0.7 0.8 
12 6.37 1.3 4.5 2.2 1.2 0.9 0.7 1.4 0.5 1.6 
13 6.58 0.4 1.8 1.3 0.6 1.3 1.2 1.1 1.1 1.1 
14 6.70 1.5 1.9 1.4 1.5 1.1 1.6 1.9 0.9 1.5 
15 6.80 2.4 4.0 2.3 1.6 2.5 2.6 2.8 1.8 2.5 
16 7.07 1.8 1.7 1.4 1.6 1.9 3.1 1.9 
17 7.16 6.0 14.3 9.4 7.1 10.8 10.6 9.8 1.9 8.7 
18 7.36 2.3 5.0 1.0 0.8 9.7 3.8 
19 7.49 2.2 3.8 4.3 3.8 3.4 3.0 3.5 3.4 
20 7.77 2.0 3.9 2.5 2.4 1.3 1.4 1.5 1.5 2.1 
21 7.88 26.6 24.5 22.8 23.8 32.5 33.7 33.3 32.0 28.7 
22 8.20 1.8 1.8 
23 8.25 3.4 2.5 5.0 7.2 4.2 3.5 3.3 3.8 4.1 
24 8.40 1.8 0.7 1.2 0.7 1.0 0.8 0.6 1.0 
25 8.56 42.9 29.1 41.3 43.3 30.4 32.9 33.2 33.8 35.9 
26 8.91 1.5 1.1 1.1 3.2 2.1 1.3 0.7 1.6 
27 9.26 0.5 0.4 0.5 0.3 0.4 
* These samples contamed two bands correspondmg to UPTF 1 whzch were exczsed and treated separately. 
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APPENDIX D: TABLES 
Table 01: Particle number as a function of sodium oxalate concentration in synthetic urine 
[NaOx] Particle number (/500 pi): 
I (mmoVI) Experiment I I Experiment 2 Average(± SE) I 
I 15 900 332 616 ± 284 I 
I 30 984 I 370 677 ± 307 I 
I 45 * 1119 I 646 902 ± 256 
I 60 11633 15604 13539 ± 2066 
I 75 13949 12518 l 13152 ± 634 
I 90 20138 22452 I 21249 ± 1203 ' ' I I 
* NaOr concentration equimlent to metastable limit 
Table 02: Particle size (pm) of synthetic urine (SU) before and after addition of WFl and BFl at 
final concentrations of 1.25 mg/1 
Sample 1 2 3 4 5 6 7 8 9 10 Ave. I 
I 
su 16.96 16.96 15.54 16.96 16.96 18.37 18.37 17.88 18.37 17.88 17.45 1 
I SU+WFI 13.43 11.43 12.72 12.72 14.13 12.41 11.72 12.41 12.60 1 
SU+BFI 10.60 10.60 12.72 12.72 12.72 11.30 12.72 12.72 12.41 12.41 12.o9 1 
I 
Table 03: (~C)-oxalate deposition expressed as a percentage precipitated [1-tC]-oxalate of 
synthetic urine (SU) before and after addition of WFI and BFl at final concentrations of 
1.25 mg/1 
Experiment I: Experiment 2: Average: 
Time su SU+WFl SU+BFl su SU+WFl l SU+BFl su SU+WFl SU+BFl 
0 0 0 0 0 0 I 0 0 0 0 
I 
30 24.2 14.9 12.8 27.1 17.4 10.6 25.7 16.2 11.7 
60 42.4 35.0 32.1 41.5 28.8 26.0 42.0 31.9 29.0 
90 51.4 49.4 46.1 50.0 36.0 39.2 50.7 42.5 42.6 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 05.1: Particle number as a function of sodium oxalate concentration in ultrafiltered urine 
from white males 
[NaOx) Particle number (/500 pi): 
(mmol/1) Experiment 1 Experiment 2 Experiment 3 Experiment 4 Experiment 5 
15 641 394 605 1424 557 
30 741 824 428 1214 * 619 
45 253 846 * 382 * 9744 700 
60 705 * 4279 6372 17594 1078* 
75 2799 5892 10334 18408 5606 
90 4573 7332 14768 21118 16680 
105 3955 8080 17362 20284 
120 12330 
*The corresponding NaOx concentration was equivalent to the metastable limit. 
Table 05.2: Particle number as a function of sodium oxalate concentration in ultrafiltered urine 
from black males 
[NaOx] Particle nunmer (/500 pi): 
(mmol/1) Experiment 1 Experiment 2 Experiment 3 Experiment 4 Experiment 5 
15 189 417 286 896 
30 376 926 1175 457 254 
45 316 698 576 444 415 
60 474 * 403 2143 * 770 838 
75 12135 399 11192 1563 770 
90 10428 833 21827 1975 833 * 
105 6098 1468 * 16940 I 121 * 2790 
120 23648 10260 7703 8583 
135 9759 12738 13570 
150 26552 15354 15211 
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Table D7.1: Absorbance slopes (x-10'5s'1) of COM crystal slurries before and after addition of 
WF1 and BF1 at final concentrations of 1.25 mg/1 
Sample 1 2 3 4 5 6 7 Ave. ± SE 
COM 300 322 349 320 388 337 336 ± 8.52 
COM+WF I 73 52 59 78 107 68 73 ± 8.52 
COM+BFI 58 54 63 45 46 62 70 57± 8.52 
Table D7.2: Absorbance slopes (x-10'5s'1) of COD crystal slurries before and after addition of 
WF1 and BF1 at final concentrations of 1.25 mg/1 
Sample 1 2 3 4 5 6 . 7 8 9 10 11 12 Ave.± SE 
COD 98 96 99 99 79 89 89 93 I ll 95 ± 2.90 
COD+WFI 44 48 52 43 34 32 41 53 4 1 55 31 35 41 ± 2.90 
COD+BFI 55 4 1 35 40 57 42 49 62 43 39 44 ±2.90 
Table D8.1: Zeta potential (mV) of COM crystal slurries before and after addition of WFl and 
BF1 at final concentrations of 1.25 mg/1 
Sample ZP1 ZP2 ZP3 ZP4 ZP5 ZP6 Ave. 
± SE 
COM -15.5 -15.5 -17.9 -17.9 -17.4 -16.0 -16.7 ± 0.55 
COM+WF1 -33.1 -30.8 -31.5 -33.9 -32.6 -31.0 -32.2 ± 0.55 
COM+BF1 -31.9 -29.3 -30.3 -33.8 -32.1 -32.0 -31.6 ± 0.55 
Table D8.2: Zeta potential (mV) of COD crystal slurries (COD) before and after addition of WF1 
and BF1 at final concentrations of 1.25 mg/1 
Sample ZPI ZP2 ZP3 ZP4 ZP5 ZP6 Ave. 
± SE 
COD -15.2 -18.1 -17.0 -16.7 -15.7 -13.0 -16.0 ±0.62 
COD+WF1 -26.3 -27.9 -28.8 -26.4 -28.5 -25.5 -27.2 ± 0.62 
COD+BF1 -28.2 -25.9 -26.3 -24.7 -28.5 -26.2 -26.6 ±0.62 
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APPENDIX D: FIGURES 
Figure Dl: Particle size distribution in synthetic urine before and after addition of WFl and BFl 
at final concentrations of 1.25 mg/1. 
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Figure Dl.l: Particle size listribution in synthetic Figure Dl.2: Particle size distriwtion in synthetic 
urine urine after addition ofWFl (final cone. l.25mg/l) 
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Figure D2: [14C]-()xalate deposition in synthetic urine before and after addition of WFl and BFl at 











0 30 60 90 120 
Time (min) 
Fig D2.1 : [
14
C]-ox dep>Sition in synthetic urine (exp 1). 
















C]-ox dep>Sition in synthetic urine (expt 2). 
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Figure 03: MSL plots of white (3.1-3.5) and black (3.6-3.10) subjects' pooled urines 
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Figure 03.3: MSL plot of white 's pooled urine3 Figure 03.4: MSL plot of white's pooled urine 4 
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Figure D4: Particle size distributions in white (4.1- 4.4) and black (4.5- 4.7) subjects' 
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Figure 05: [14C]-oxalate deposition in ultrafiltered urine from white (5.1- 5.3) and black 
(5.4 - 5.6) subjects. 
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C]-ox deposition in WUF (experiment 1) 
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Figure 06.1: 006zo plots of COM crystal slurries 
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Figure 06.2: 00620 plots of COM crystal slurries after addition of WFl (final concentration 1.25 mg/1) 
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Figure 06.3.1: Oll62o plotfor COMtBFl 
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Figure 06.3.3: OD62o plot for COMtBFl 




















Figure 06.3.5: 01)6 2 o plot for COM±BFI 
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Egure 06.3.7: 006 20 plot for COMtBFl 
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Figure 07.1: 00620 plots of COD crystal slurries 
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Figure 07.2: 00620 plots of COD crystal slurries after addition of WFl (final cone. 1.25 mg/1) 
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Figure 07.3:00620 plots of COO crystal slurry after addition ofBFl (final cone. 1.25 mg/1) 
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APPENDIX E: TABLES 
Table El: Urine composition (mmoV24hr) and physicochemical parameters of white control 
subjects 
Variables WCl WC2 WC3 WC4 wcs WCave.±SE 
pH 6.62 6.10 6.38 6.52 6.38 6.40 ± 0.120 
Volwne (ml/24hr) 730 1270 1340 1000 1040 1076 ±359 
Calcium (mmoV24hr) 1.13 4.72 5.48 3.47 3.83 3.73 ±0.585 
Chloride (mmoV24hr) 105 152 138 105 109 122 ± 28.0 
Citrate (mmoV24hr) 1.40 2.47 2.67 1.98 2.00 2.10±0.442 
Creatinine (mmoV24hr) 10.5 16.9 15.9 13.1 15.1 14.3 ± 1.73 
Magnesium (mmoV24hr) 1.33 3.90 3.64 2.52 2.57 2.79 ±0.629 
Oxalate (mmoV24hr) 0.11 0.16 0.18 0.25 0.13 0.17 ± 0.0355 
Phosphate (mmoV24hr) 15.2 35.4 24.7 32.8 28.7 27.4 ± 6.27 
Potassium (mmoV24hr) 59.1 59.4 34.8 58.5 54.6 53.3 ± 8.84 
Sodium (mmoV24hr) 91.3 30.9 55.8 34.7 97.5 62.0± 38.2 
Sulphate (mmoV24hr) 10.2 18.6 10.9 6.83 33.6 16.0 ± 3.90 
Uric acid (mmoV24hr) 2.5 5.3 3.8 4.0 3.6 3.84 ±0.521 
RS Brushite 0.862 1.74 2.28 3.16 2.02 2.03 ±0.300 
RS Calcium oxalate 1.16 4.02 5.18 6.96 3.06 4.10±0.867 
RS Uric acid 0.646 2.39 0.930 0.961 1.10 1.10 ± 0.627 
RS: Relative supersaturation 
Table E2: Urine composition (mmoV24hr) and physicochemical parameters of black control 
subjects 
Variables BCl BC2 BC3 BC4 BCS BCave.±SE 
pH 6.12 6.48 6.35 6.20 6.30 6.29±0.120 
Volume (ml/24hr) 1380 1170 1170 1290 1220 1246 ± 359 
Calcium (mmoV24hr) 3.15 3.01 2.83 3.52 3.22 3.15 ±0.585 
Chloride (mmoV24hr) 186 98 85 260 173 160 ± 28.0 
Citrate (mmoV24hr) 2.25 1.89 2.51 2.38 2.55 2.32 ±0.442 
Creatinine (mmoV24hr) 23.0 11.9 11.7 23.0 18.7 17.7 ± 1.73 
Magnesium (mmoV24hr) 3.33 1.56 1.24 4.53 2.98 2.73 ±0.629 
Oxalate (mmoV24hr) 0.16 0.20 0.22 0.31 0.11 0.20 ± 0.0355 
Phosphate (mmoV24hr) 59.2 14.9 13.1 34.3 30.7 30.4 ± 6.27 
Potassium (mmoV24hr) 55.5 29.8 16.2 37.7 67.9 41.4 ± 8.84 
Sodium (mmoV24hr) 109 27.6 20.3 213 42.3 82.4 ± 38.2 
Sulphate (mmoV24hr) 30.4 8.3 9.09 20.9 21.6 18.0±3.90 
Uric acid (mmoV24hr) 4.8 2.8 2.4 3.9 4.0 3.6 ± 0.521 
RS Brushite 1.33 1.24 0.744 1.25 1.34 1.27 ±0.300 
RS Calcium oxalate 1.98 5.67 5.93 4.42 1.98 3.62±0.867 
RS Uric acid 1.88 0.645 0.736 1.38 1.24 1.11 ±0.627 
RS: Relative supersaturation 
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Table E3: Urine composition (mrnoV24hr) and physicochemical parameters of white 
stone-formers 
Variables WSFl WSF2 WSF3 WSF4 WSFS WSFave.±SE 
pH 6.30 5.55 5.80 5.50 6.25 5.88 ± 0.120 
Volume (ml/24hr) 4180 560 1580 1300 1765 1877 ± 359 
Calcium (mmol/24hr) 7.65 6.36 5.33 4.14 3.82 5.46±0.585 
Chloride (mmoll24hr) 188 77 175 226 97 153 ± 28.0 
Citrate (mmol/24hr) 5.11 1.36 3.80 1.86 1.71 2.77 ± 0.442 
Creatinine (mmol/24hr) 18.8 13.8 20.7 18.6 18.5 18.1 ± 1.73 
Magnesium (mmol/24hr) 5.87 4.03 4.63 2.53 1.41 3.69 ±0.629 
Oxalate (mmol/24hr) 0.34 0.10 0.13 0.11 0.11 0.16 ± 0.0355 
Phosphate (mmol/24hrJ 18.8 20.9 48.2 36.5 44.5 33.8 ±6.27 
Potassium (mmol/24hr) 43.8 91.6 50.5 21.8 49.7 51.5 ± 8.84 
Sodium (mmol/24hr) 119 368 274 352 125 248 ±38.2 
Sulphate (mmol/24hr) 21.8 10.2 22.1 20.7 21.5 19.3 ±3.90 
Uric acid (mmol/24hr) 5.8 2.0 4.5 4.8 5.2 4.5 ±0.521 
RS Brushite 0.351 2.26 0.907 0.480 1.28 1.06 ±0.300 
RS Calcium oxalate 2.77 5.62 1.88 1.86 1.57 2.74 ±0.867 
RS Uric acid 0.566 5.12 2.79 5.70 1.27 3.09 ±0.627 
RS: Relative supersaturation 
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Table E4: X-ray powder diffraction peak assignments and percentage composition of CaOx 
crystals precipitated from white control subjects' urine 
Sample d-spacing Assignment Composition: 
(..\) %COM %COD 







2.35 COM 40 60 






2.35 COD 0 100 






2.35 COD 0 100 





2.37 COD 0 100 





2.35 COD 0 100 
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Table ES: X-ray powder diffraction peak assignments and percentage composition of CaOx 
crystals precipitated from black control subjects' urine 
d·spacing Assignment Composition: 
Sample (A) %COM %COD 





2.35 COD 0 100 





2.42 30%COM, 70%COD 
2.35 COM 50 50 





2.35 COM 100 0 






2.42 30%COM, 70%COD 
2.35 COM 60 40 




2.42 30%COM, 70%COD 
2.35 COM 30 70 
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Table E6: X-ray powder diffraction peak assignments and percentage composition of CaOx 
crystals precipitated from white stone-formers' urine 
Sample I d-spacing Assignment Composition: 
<A) %COM %COD 
WSF1 6.28 COD 
6.02 COM 
4.46 COD 
3.69 95% COM. 5% COD 
2.99 COM 
2.79 COD 
2.42 30%COM. 70% COD 
2.35 COM 35 65 
WSF2 6.10 COM 
4.51 COD 




2.42 30%COM. 70% COD 
2.37 COM 70 30 





2.35 COD 0 100 





2.37 COD 0 100 






2.50 COM 65 35 
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APPENDIX E: FIGURES 
Figure El: X-ray powder diffraction patterns of CaOx crystals precipitated from white 
control subjects' urine. The subjects are WCI (Fig El.l), WC2 (Fig El.2), WC3 (Fig E1.3), WC4 
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Figure E2: X-ray powder diffraction patterns of CaOx crystals precipitated from black 
control subjects' urine. The subjects are BCl (Fig E2.1), BC2 (Fig E2.2), BC3 (Fig E2.3), BC4 
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Figure E3: X-ray powder diffraction patterns of CaOx crystals precipitated from white 
stone-formers' urine. The subjects are WSFl (Fig E3.1), WSF2 (Fig E3.2), WSF3 (Fig E3.3), 
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Figure E4: Desalting chromatograms of demineralised CaOx crystals precipitated from white 
control subjects' urine. The subjects are WCI (Fig E4.1), WC2 (Fig E4.2), WC3 (Fig E4.3), WC4 
(Fig E4.4) and WC5 (Fig E4.5). 
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Figure ES: Desalting chromatograms of demineralised CaOx crystals precipitated from black 
control subjects' urine. The subjects are BCI (Fig E5.1 ), BC2 (Fig E5.2), BC3 (Fig E5.3), BC4 
(Fig E5.4) and BCS (Fig E5.5). 
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Figure E6: Desalting chromatograms of demineralised CaOx crystals precipitated from white 
stone-formers' urine. The subjects are WSFI (Fig E6.1 ), WSF2 (Fig E6.2), WSF3 (Fig E6.3 ), 
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APPENDIX F: TABLES 
Table Fl.l: X-ray powder diffraction peak assignments and percentage composition of CaOx 
crystals precipitated from the urine of black group 1 
Ca d-spacing · Assignment Composition: 
(mmolll) (A) %cOM %COD · 




2.40 COM 100 0 




2.51 COM 100 0 





2.51 COM 55 45 
4.00 5.94 COM 




2.51 COM 75 25 







2.42 30% COM, 70% COD 30 70 
•Control urine, i.e. unadjusted Ca 
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Table F1.2: X-ray powder diffraction peak assignments and percentage composition of CaOx 
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Table F1.3: X-ray powder diffraction peak assignments and percentage composition of CaOx 
crystals precipitated from the urine of black group 3 
Ca d-spacing Assignment Composition: 
0 
(nunolll) (A) % COM % COD 
0.50 6.10 COM 
3.69 COM 
2.99 COM 
2.47 COM 100 0 







2.51 COD 60 40 





2.42 30% COM, 70% COD 
2.37 COM 45 55 





2.45 COM 35 65 
12.0 6.28 COD 
4.46 COD 
3.72 COD 
3. 11 COD 
2.80 COD 
2.42 COD 
2.37 COD 0 100 





2.35 COD 0 100 
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Table F2.1: X-ray powder diffraction peak assignments and percentage composition of CaOx 
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Table F2.2: X-ray powder diffraction peak assignments and percentage composition of CaOx 
crystals precipitated from the urine of white group 2 
Ca d-spacing Assignment Composition: 
(mmol/1) 
0 
(A) %COM %COD 




2.47 COM 100 0 





2.47 COM 100 0 







2.41 30% COM, 70% COD 40 60 





2.35 COD 0 100 






2.37 COD 0 100 
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Table F2.3: X-ray powder diffraction peak assignments and percentage composition of CaOx 











































































APPENDIX F: FIGURES 
Figure Fl: X-ray powder diffraction patterns of CaOx crystals precipitated from black males' 
urines at various calcium concentrations. The patterns are from black group 1 's urine at: 
0.50 rnmol/1 Ca (Fig Fl. I), 1.02 mmol/1 Ca (Fig F1.2), 2.00 mmol/1 Ca (Fig F1.3), 4.00 mmol/1 Ca 
(Fig F1.4) and 8.00 rnmol/1 Ca (Fig Fl.5); black group 2's urine at: 0.64 mmol/1 Ca (Fig F1.6). 
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Figure Fl: X-ray powder diffraction patterns of CaOx crystals precipitated from black males' 
urines at various calcium concentrations. The patterns are from black group 2's urine at: 
1.00 mmol/1 Ca (Fig Fl.7), 2.00 mmol/1 Ca (Fig Fl.8), 4.00 mmol/1 Ca (Fig Fl.9) and 8.00 mmol/1 
Ca (Fig F 1.1 0); black group 3 's urine at: 0.50 mmol/1 Ca (Fig F 1.11 ), 1.23 mmo1/l Ca (Fig F 1.12). 
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Figure Fl: X-ray powder diffraction patterns of CaOx crystals precipitated from 
black males' urines at various calcium concentrations. The patterns are from black 
group 3's urine at: 8.00 mmol/l Ca (Fig F1.13), 10.0 mmol/l Ca (Fig F1.14), 12.0 mmol/l Ca 
(Fig F 1.15) and 16.0 mmol/l Ca (Fig F1.16). 




12 16 20 24 28 32 36 40 12 16 20 24 28 32 36 40 
29 
Figure Fl.l5 (12.0 mmolll Ca) Figure Fl.l6 (16.0 rnrnolll Ca) 
1M ...-------------------....--------, 100.-------------------------~ 
2.80 2.79 
,... 75r-------------~----~ 1 100 f----------------jlt-------1 ·i c .. .. 
.:s .. 
.::: = .... 
" 
2.37 





12 16 20 24 28 32 36 40 
APPENDIXF A75 
Figure F2: X-ray powder diffraction patterns of CaOx crystals precipitated from white males' 
urines at various calcium concentrations. The patterns are from white group 1 's urine at: 
0.50 mmol/1 Ca (Fig F2.1), 1.02 mmol/1 Ca (Fig F2.2), 2.00 mmol/1 Ca (Fig F2.3), 4.00 mmol/1 Ca 
(Fig F2.4), 6.52 mmol/1 Ca (Fig F2.5) and 8.00 mmol/1 Ca (Fig F2.6). 
... 
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Figure F2.6 (8.00 mmol/1 Ca) 
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Figure F2: X-ray powder diffraction patterns of CaOx crystals precipitated from white 
males' urines at various calcium concentrations. The patterns are from white group 2's urine at: 
0.50 mmol/1 Ca (Fig F2. 7), 1.67 mmol/1 Ca (Fig F2.8), 8.00 mmol/1 Ca (Fig F2.9), 12.0 mmol/1 Ca 
(Fig F2.1 0) and 16.0 mmol/1 Ca (Fig F2.11 ); white group 3 's urine at: 0.50 mmol/1 Ca (Fig F2.12). 
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Figure F2.8 ( 1.67 mmol/1 Ca) 
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Figure Fl: X-ray powder diffraction patterns of CaOx crystals precipitated from 
white males' urines at various calcium concentrations. The patterns are from white 
group 3's urine at: 1.00 mmol/1 Ca (Fig F2.13), 3.96 mmol/1 Ca (Fig F2.14), 10.0 mmol/1 
Ca (Fig 2.15) and 12.0 mmol/1 Ca (Fig F2.16). 
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APPENDIX G: TABLES 
Table Gl: Urine composition (mmolll) and physicochemical parameters of white and black 
subjects' pooled urines 
~~t:f,~,''1'0lb,w\:i~,~-1;~~~~fi[~~-l~~ ~~:~~, 














5580 9385 7490 
60 135 75 
4.82 1.17 2.28 
124 76.9 %.0 
2.02 0.801 1.40 
13.9 5.70 8.90 
Magnesium (mmol/1) 1.49 3.71 1.28 2.02 
Oxalate (mmol!l) 0.112 0.142 0.199 0.116 
Phosphate (mmol/l) 12.9 27.1 10.5 12.4 
Potassium (mmol/1) 28.3 50.5 23.3 210 
Sodium (mmol/l) 59.8 42.3 58.1 79.4 
Uric acid (mmol/l) 1.91 3.58 1.69 2.10 





Add excess CaOx to a 10 mmol/l NaCl solution (ca. 10 g to 500 ml) 
and stir while heating to 90 °C for 15 min, agitate the solution at 37 °C 
and 100 rpm for 3 nights. Add Tris at a final concentration of 
12.5 mmol/l, adjust the pH and store the suspension at 37 °C. 
Add ca. 10 g CaOx to a 12.5 mmol/l Tris solution (500 ml, pH 6.0) 
and agitate at 37 °C and 100 rpm for 3 nights. Store the suspension at 
37 °C. 
* Commercially available COM crystals were used to prepare the CaOx solutions. 
** The excess CaOx was removed by filtration (0.22 fJm) at room temperature. 
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Figure 3.3: A~nge particle number of synthetic: urine as 
a function of time. Before and after addition of CME from 
white (WE) and black (BE) subjects at fmal cone. of 5mgll 
Figure 3.4: A~rage .. rtide wlume of synthetic: urine as a 
function of time. Before and after- addition of CME from 











.Figure 4.7: SDS-PAGE of crystal matrix 
extract from white control subjectWC6. 
